[go: up one dir, main page]

US20210101902A1 - Compounds and compositions as inhibitors of endosomal toll-like receptors - Google Patents

Compounds and compositions as inhibitors of endosomal toll-like receptors Download PDF

Info

Publication number
US20210101902A1
US20210101902A1 US17/124,346 US202017124346A US2021101902A1 US 20210101902 A1 US20210101902 A1 US 20210101902A1 US 202017124346 A US202017124346 A US 202017124346A US 2021101902 A1 US2021101902 A1 US 2021101902A1
Authority
US
United States
Prior art keywords
methyl
pyrazolo
pyridin
octan
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/124,346
Inventor
Phillip Alper
Jonathan DEANE
Songchun Jiang
Tao Jiang
Thomas Knoepfel
Pierre-Yves Michellys
Daniel Mutnick
Wei Pei
Peter SYKA
Guobao Zhang
Yi Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Novartis Institutes for Biomedical Research Inc
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to US17/124,346 priority Critical patent/US20210101902A1/en
Publication of US20210101902A1 publication Critical patent/US20210101902A1/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NOVARTIS PHARMA AG
Assigned to NOVARTIS PHARMA AG reassignment NOVARTIS PHARMA AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KNOEPFEL, THOMAS
Assigned to NOVARTIS AG reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.
Assigned to NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. reassignment NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MUTNICK, DANIEL
Assigned to NOVARTIS AG reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC.
Assigned to NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. reassignment NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ZHANG, YI, ZHANG, GUOBAO, ALPER, PHILLIP, DEANE, Jonathan, JIANG, SONGCHUN, JIANG, TAO, MICHELLYS, PIERRE-YVES, PEI, WEI, SYKA, Peter
Priority to US18/678,198 priority patent/US20240376099A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the invention provides 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine compounds and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine compounds, the use thereof for inhibiting an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) and any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9), the use thereof for inhibiting an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, and any combinations thereof, and methods of treating autoimmune diseases using such compounds.
  • an endosomal Toll-like receptor e.g. TLR7, TLR8 or TLR9
  • TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9 an endosomal Toll-like receptor pathway
  • TLRs Toll-like receptors
  • PRRs pattern recognition receptors
  • TLRs Toll-like receptors
  • TLR1, TLR2, TLR4, TLR5, and TLR6 respond to extracellular stimuli
  • TLR3, TLR7, TLR8, and TLR9 respond to intracytoplasmic pathogen associated molecular patterns (PAMPs), being associated with the endolysosomal compartment.
  • PAMPs pathogen associated molecular patterns
  • Toll-like receptors recognize pathogens associated molecular patterns present in molecules that are broadly shared by pathogens but are structurally distinct from host molecules.
  • the ligands for these receptors are highly conserved microbial molecules such as lipopolysaccharides (LPS) (recognized by TLR4), lipopeptides (TLR2 in combination with TLR1 or TLR6), flagellin (TLR5), single-stranded RNA (TLR7 and TLR8), double-stranded RNA (TLR3), CpG motif-containing DNA (recognized by TLR9), and profilin present on uropathogenic bacteria (TLR 11).
  • TLR dimers including TLR4-MD-2, TLR1-TLR2, and TLR6-TLR2 recognize microbial membrane lipids, whereas the endosomal Toll-like receptors TLR3, TLR7, TLR8, and TLR9 reside in intracellular organelles and recognize microbial nucleic acids.
  • TLR7, TLR8, and TLR9 belong to a subfamily of TLRs based on their genomic structure, sequence similarities, and homology. TLR7, TLR8, and TLR9 are located in intracellular endolysosomal compartments and show a unique pattern of cell type-specific expression that is thought to be responsible for different pathogen response profiles.
  • TLR7 and 9 innate immune sensors for microbial RNA or DNA, respectively, have been implicated in autoimmune diseases such as psoriasis (see Lande et al., “Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide”, Nature 449, pp 564-569, 2007), arthritis (see Asagiri et al., “Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis”, Science 319, pp 624-627, 2008), and systemic lupus erythematosus (SLE) (see Pisitkun, P. et al.
  • TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE”, J. Exp. Med. 203, pp 553-561, 2006; Deane, J. A., and Bolland S. “Nucleic acid-sensing TLRs as modifiers of autoimmunity”, J. Immunol., 117, pp 6573-8, 2006; and Marshak-Rothstein, A., and Rifkin, I. R., “Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease”, Annu. Rev. Immunol., 25, pp 419-441, 2007).
  • autoimmune diseases like SLE
  • self-RNA and self-DNA are complexed with autoantibodies against the nucleic acid or nucleoproteins, delivered into endosomal compartments via FcgRII-mediated endocytosis, leading to dendritic cell (DC) activation and production of type I interferon (IFN)
  • DC dendritic cell
  • IFN type I interferon
  • RA rheumatoid arthritis
  • TNF plays a central role in RA and the inhibition of TLR8 has been shown to inhibit TNF production (see Sandra M. Sacre et al. “Inhibitors of TLR8 Reduce TNF Production from Human Rheumatoid Synovial Membrane Cultures”, J. Immun., 81, pp 8002-8009, 2008).
  • TLR7, TLR8 and TLR9 are important therapeutic targets for the treatment of systemic lupus erythematosus, rheumatoid arthritis, psoriasis and other autoimmune diseases.
  • the invention provides compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, which may inhibit an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) and any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9). Additionally, the compounds of the invention may inhibit an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, and any combinations thereof.
  • an endosomal Toll-like receptor e.g. TLR7, TLR8 or TLR9
  • the invention further provides methods of treating, preventing, or ameliorating autoimmune diseases associated with the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9), or any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9), comprising administering to a subject in need thereof an effective amount of a compound of the invention.
  • an endosomal Toll-like receptor e.g. TLR7, TLR8 or TLR9
  • TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9 an endosomal Toll-like receptor
  • compounds having the structure of Formula (A), and the pharmaceutically acceptable salts thereof which may inhibit an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) and any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9). Additionally, the compounds of Formula (A) may inhibit an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, and any combinations thereof:
  • an 8-oxa-3-azabicyclo[3.2.1]octanyl a 5-6 membered heteroaryl having 1 to 3 ring members independently selected from N, O and S, and a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR 16 and O which is unsubstituted or is substituted with 1-2 R 7 groups;
  • compositions that includes a therapeutically effective amount of a compound of Formula (A), Formula (I) or Formula (II) or subformulae thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • Another aspect of the invention is the use of a compound of Formula (A), Formula (I) or Formula (II), or subformulae thereof, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an autoimmune disease associated with the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9), or any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9).
  • an endosomal Toll-like receptor e.g. TLR7, TLR8 or TLR9
  • TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9 an endosomal Toll-like receptor
  • Another aspect of the invention is the use of a compound of Formula (A), Formula (I) or Formula (II), or subformulae thereof, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an autoimmune disease associated with
  • Another aspect of the invention is the use of a compound of Formula (A), Formula (I) or Formula (II), or subformulae thereof, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an autoimmune disease associated with the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, and any combinations thereof.
  • an endosomal Toll-like receptor e.g. TLR7, TLR8 or TLR9
  • Another aspect of the invention is the use of a compound of Formula (A), Formula (I) or Formula (II), or subformulae thereof, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an autoimmune disease.
  • Another aspect of the invention is the use of a compound of Formula (A), Formula (I) or Formula (II), or subformulae thereof, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an autoimmune disease
  • an autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, Sjögren's syndrome or psoriasis.
  • Another aspect of the invention is a method for treating an autoimmune disease associated with the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9), or any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9), wherein the method includes administering to a subject in need of such treatment an effective amount of a compound of Formula (A), Formula (I) or Formula (II), or subformulae thereof, or pharmaceutically acceptable salt thereof, thereby treating the disease.
  • an endosomal Toll-like receptor e.g. TLR7, TLR8 or TLR9
  • the method includes administering to a subject in need of such treatment an effective amount of a compound of Formula (A), Formula (I) or Formula (II), or subformulae thereof, or pharmaceutically acceptable salt thereof, thereby treating the disease.
  • Another aspect of the invention is a method for treating an autoimmune disease associated with:
  • Another aspect of the invention is a method for treating an autoimmune disease associated with the activity of with the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, and any combinations thereof, wherein the method includes administering to a subject in need of such treatment an effective amount of a compound of Formula (A), Formula (I) or Formula (II), or subformulae thereof, or pharmaceutically acceptable salt thereof, thereby treating the disease.
  • an endosomal Toll-like receptor e.g. TLR7, TLR8 or TLR9
  • Another aspect of the invention is a method for treating an autoimmune disease associated with TLR7 activity, wherein the method includes administering to a subject in need of such treatment an effective amount of a compound of Formula (A), Formula (I) or Formula (II), or subformulae thereof, or pharmaceutically acceptable salt thereof, thereby treating the disease.
  • Another aspect of the invention is a method for treating an autoimmune disease associated with TLR7 and TLR8 activity, wherein the method includes administering to a subject in need of such treatment an effective amount of a compound of Formula (A), Formula (I) or Formula (II), or subformulae thereof, or pharmaceutically acceptable salt thereof, thereby treating the disease.
  • Another aspect of the invention is a method for treating an autoimmune disease associated with TLR7, TLR8 and TLR9 activity, wherein the method includes administering to a subject in need of such treatment an effective amount of a compound of Formula (A), Formula (I) or Formula (II), or subformulae thereof, or pharmaceutically acceptable salt thereof, thereby treating the disease.
  • the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, Sjögren's syndrome or psoriasis.
  • Another aspect of the invention is a compound of Formula (A), Formula (I) or Formula (II), or subformulae thereof, or pharmaceutically acceptable salt thereof, for use in treating an autoimmune disease
  • an autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, Sjögren's syndrome or psoriasis.
  • Another aspect of the invention is a combination comprising a therapeutically effect amount of a compound of Formula (A), Formula (I) or Formula (II), or subformulae thereof, or pharmaceutically acceptable salt thereof, and one or more additional therapeutically agents and optionally further comprising a pharmaceutically acceptable carrier, wherein the additional therapeutically agent is independently selected from anti-inflammatory agents, immunomodulatory agents, immunosuppressive agents, cytokines, nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarial compounds, anti-rheumatic compounds, inhibitors of B-cell activating factor (BAFF), inhibitors of B-lymphocyte stimulator (BLyS), and steroid hormones.
  • additional therapeutically agent is independently selected from anti-inflammatory agents, immunomodulatory agents, immunosuppressive agents, cytokines, nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarial compounds, anti-rheumatic compounds, inhibitors of B-cell activating factor (BAFF), inhibitors of B-lymphocyte stimulator (BLyS), and steroid
  • C 1 -C 6 alkyl refers to a fully saturated branched or straight chain hydrocarbon containing 1 to 6 carbon atoms.
  • Non-limiting examples of “C 1 -C 6 alkyl” groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl and hexyl.
  • C 1 -C 6 alkoxy refers to the group —O—C 1 -C 6 alkyl, wherein the “C 1 -C 6 alkyl” group is as defined herein.
  • Non-limiting examples of “C 1 -C 6 alkoxy” groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentyloxy, isopentyloxy and hexyloxy.
  • cycloalkyl refers to a saturated, monocyclic, fused bicyclic, fused tricyclic or bridged polycyclic ring system.
  • fused bicyclic or bridged polycyclic ring systems include bicyclo[1.1.1]pentane, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[3.1.1]heptane, bicyclo[3.2.1]octane, bicyclo[2.2.2]octane and adamantanyl.
  • C 3 -C 6 cycloalkyl refers to a saturated monocyclic group having at least 3, and at most 6, carbon atoms.
  • Non-limiting examples of such “C 3 -C 6 cycloalkyl” groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl groups.
  • C 1 -C 6 haloalkyl refer to the respective “C 1 -C 6 alkyl”, as defined herein, wherein at least one of the hydrogen atoms of the “C 1 -C 6 alkyl” is replaced by a halo atom.
  • the C 1 -C 6 haloalkyl groups can be monoC 1 -C 6 haloalkyl, wherein such C 1 -C 6 haloalkyl groups have one iodo, one bromo, one chloro or one fluoro.
  • the C 1 -C 6 haloalkyl groups can be diC 1 -C 6 haloalkyl wherein such C 1 -C 6 haloalkyl groups can have two halo atoms independently selected from iodo, bromo, chloro or fluoro.
  • the C 1 -C 6 haloalkyl groups can be polyC 1 -C 6 haloalkyl wherein such C 1 -C 6 haloalkyl groups can have two or more of the same halo atoms or a combination of two or more different halo atoms.
  • Such polyC 1 -C 6 haloalkyl can be perhaloC 1 -C 6 haloalkyl where all the hydrogen atoms of the respective C 1 -C 6 alkyl have been replaced with halo atoms and the halo atoms can be the same or a combination of different halo atoms.
  • Non-limiting examples of C 1 -C 6 haloalkyl groups include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, trifluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl.
  • halo or halogen as used herein, refer to fluoro, chloro, bromo and iodo.
  • 5-6 membered heteroaryl refers to a monocyclic aromatic ring structure having 5 or 6 ring members, wherein 1 to 3 ring members are independently selected from the heteroatoms N, O and S.
  • Non-limiting examples of 5-6 membered heteroaryls include 2- or 3-furyl; 2- or 3-thienyl; 1-, 2- or 3-pyrrolyl; 2-, 4-, or 5-oxazolyl; 2-, 4-, or 5-thiazolyl; 1-, 2-, 4-, or 5-imidazolyl; 1-, 3-, 4-, or 5-pyrazolyl; 3-, 4-, or 5-isoxazolyl; 3-, 4-, or 5-isothiazolyl; 4- or 5-1,2,3-oxadiazolyl; 4- or 5-1,2,3-triazolyl; 2- or 5-1,3,4-thiadiazolyl; 2-, 3-, or 4-pyridyl; 3-, 4-, 5- or 6-pyridazinyl; 2-, 4-, 5- or 6-pyrimidiny
  • heteroatoms refers to nitrogen (N), oxygen (O) or sulfur (S) atoms.
  • 4-6 membered heterocycloalkyl refers to a monocyclic ring structure having 4 to 6 ring members, wherein one to two of the ring members are independently selected from N, NH, NR 16 , O or —S—, wherein R 16 is C 1 -C 6 alkyl.
  • a 4-6 membered heterocycloalkyl is a monocyclic ring structure having 4 to 6 ring members wherein one to two of the ring members are independently selected from N, NH, NR 16 and O, wherein R 16 is C 1 -C 6 alkyl.
  • Non-limiting examples of 4-6 membered heterocycloalkyl groups include azetadinyl, azetadin-1-yl, azetadin-2-yl, azetadin-3-yl, oxetanyl, oxetan-2-yl, oxetan-3-yl, oxetan-4-yl, thietanyl, thietan-2-yl, thietan-3-yl, thietan-4-yl, pyrrolidinyl, pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, pyrrolidin-4-yl, pyrrolidin-5-yl, tetrahydrofuranyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrofuran-4-yl, tetra
  • hydroxyl refers to a —OH group.
  • oxo refers to a ⁇ O group.
  • autoimmune disease refers diseases wherein cells uncontrollably attack the body's own tissues and organs (autoimmunity), producing inflammatory reactions and other serious symptoms and diseases.
  • Non-limiting examples of autoimmune diseases include idiopathic thrombocytopenic purpura, hemolytic anemia, systemic lupus erythematosus, cutaneous lupus, discoid lupus, rheumatoid arthritis (RA), multiple sclerosis (MS), systemic sclerosis, immune-mediated or type 1 diabetes mellitus, immune mediated glomerulonephritis, scleroderma, pernicious anemia, alopecia, pemphigus, pemphigus vulgaris, myasthenia gravis, inflammatory bowel diseases, Crohn's disease, Graves' disease, psoriasis, autoimmune thyroid diseases, Hashimoto's disease, Hashimoto's thyroiditis, polymyositis
  • ком ⁇ онент or “pharmaceutical combination,” as used herein mean a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients.
  • fixed combination means that the active ingredients, by way of example, a compound of the invention and one or more additional therapeutic agent, are administered to a subject simultaneously in the form of a single entity or dosage.
  • non-fixed combination means that the active ingredients, by way of example, a compound of the invention and one or more additional therapeutic agent, are administered to a subject as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the active ingredients in the body of the subject.
  • cocktail therapy e.g. the administration of 3 or more active ingredients.
  • composition refers to a mixture of a compound of the invention with at least one and optionally more than one other pharmaceutically acceptable chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients.
  • pharmaceutically acceptable chemical components such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients.
  • the term “inhibit”, “inhibition” or “inhibiting” refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
  • an optical isomer or “a stereoisomer”, as used herein, refers to any of the various stereo isomeric configurations which may exist for a given compound of the present invention and includes geometric isomers. It is understood that a substituent may be attached at a chiral center of a carbon atom.
  • the term “chiral” refers to molecules which have the property of non-superimposability on their mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner. Therefore, the invention includes enantiomers, diastereomers or racemates of the compound. “Enantiomers” are a pair of stereoisomers that are non-superimposable mirror images of each other.
  • a 1:1 mixture of a pair of enantiomers is a “racemic” mixture.
  • the term is used to designate a racemic mixture where appropriate.
  • “Diastereoisomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other.
  • the absolute stereochemistry is specified according to the Cahn-Ingold-Prelog R-S system. When a compound is a pure enantiomer the stereochemistry at each chiral carbon may be specified by either R or S.
  • Resolved compounds whose absolute configuration is unknown can be designated (+) or ( ⁇ ) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line.
  • Certain compounds described herein contain one or more asymmetric centers or axes and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, and the like and combinations thereof, as would be known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.
  • pharmaceutically acceptable salt refers to a salt which does not abrogate the biological activity and properties of the compounds of the invention, and does not cause significant irritation to a subject to which it is administered.
  • subject encompasses mammals and non-mammals.
  • mammals include, but are not limited to, humans, chimpanzees, apes, monkeys, cattle, horses, sheep, goats, swine, rabbits, dogs, cats, rats, mice, guinea pigs, and the like.
  • non-mammals include, but are not limited to, birds, fish and the like.
  • the subject is a human, and may be a human who has been diagnosed as in need of treatment for a disease or disorder associated with the activity of an endosomal Toll-like receptor (e.g.
  • TLR7, TLR8 or TLR9 and any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9), or associated with an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, and any combinations.
  • a subject in need of such treatment refers to a subject which would benefit biologically, medically or in quality of life from such treatment.
  • a therapeutically effective amount refers to an amount of a compound of the present invention that will elicit the biological or medical response of a subject, for example, reduction or inhibition of an enzyme or a protein activity, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease, etc.
  • a therapeutically effective amount refers to the amount of the compound of the present invention that, when administered to a subject, is effective to (1) at least partially alleviate, inhibit, prevent and/or ameliorate a condition, or a disorder or a disease (i) mediated by an endosomal Toll-like receptor (e.g.
  • TLR7, TLR8 or TLR9 and any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9), or mediated by an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, and any combinations thereof or (ii) associated with an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) and any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9), or associated with an endosomal Toll-like receptor (e.g.
  • TLR7, TLR8 or TLR9 pathway, and any combinations thereof, or (iii) characterized by activity (normal or abnormal) of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) and any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9); or (2) reduce or inhibit the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) and any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9); or (3) reduce or inhibit the expression of an endosomal Toll-like receptor (e.g.
  • a therapeutically effective amount refers to the amount of the compound provided herein that, when administered to a cell, or a tissue, or a non-cellular biological material, or a medium, is effective to at least partially reducing or inhibiting the activity of an endosomal Toll-like receptor (e.g.
  • TLR7, TLR8 or TLR9 and any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9), or inhibiting the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, and any combinations thereof.
  • an endosomal Toll-like receptor e.g. TLR7, TLR8 or TLR9 pathway, and any combinations thereof.
  • TLR7 inhibitors refer to a compound of the invention which inhibits Toll-like Receptor 7 (TLR7).
  • TLR7 Toll-like Receptor 7
  • Compounds of the invention inhibit both type I Interferon and proinflammatory cytokines downstream of TLR7.
  • TLR8 inhibitors refer to a compound of the invention which inhibits Toll-like Receptor 8 (TLR8).
  • TLR7 and TLR8 inhibitors refer to a compound of the invention which inhibits Toll-like Receptor 7 (TLR7) and Toll-like Receptor 8 (TLR8).
  • TLR7 and TLR8 antagonists refer to a compound of the invention which inhibits Toll-like Receptor 7 (TLR7) and Toll-like Receptor 8 (TLR8).
  • TLR7 and TLR8 antagonists inhibit both type I Interferon downstream of TLR7 and proinflammatory cytokines downstream of NF-KB in TLR7 and TLR8 signaling.
  • TLR7/8 antagonist can also be represented by the term “TLR7/8 antagonist”.
  • TLR7, TLR8 and TLR9 inhibitors refer to a compound of the invention which inhibits Toll-like Receptor 7 (TLR7), Toll-like Receptor 8 (TLR8) and Toll-like Receptor 9 (TLR9).
  • TLR7, TLR8 and TLR9 inhibitors inhibit both type I Interferon downstream of TLR7 and proinflammatory cytokines downstream of NF-KB in TLR7 and TLR8 signaling.
  • a “TLR7 and TLR8 and TLR9 inhibitor” or “TLR7 and TLR8 and TLR9 antagonist” can also be represented by the term “TLR7/8/9 antagonist”.
  • any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof).
  • “treat”, “treating” or “treatment” refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient.
  • “treat”, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both.
  • “treat”, “treating” or “treatment” refers to preventing or delaying the onset or development or progression of the disease or disorder.
  • the term “compounds of the present invention”, “compounds of the invention” or “compounds provided herein” refers to compounds of formula (A), Formula (I), Formula (II) and subformulae thereof (such as compounds of Formula (Ia to Ip) and Formula (IIa to IIk), and pharmaceutically acceptable salts, stereoisomers (including diastereoisomers and enantiomers), rotamers, tautomers and isotopically labeled compounds (including deuterium substitutions), as well as inherently formed moieties.
  • the compounds of the invention are compounds having the structure of Formula (A), or a pharmaceutically acceptable salt thereof:
  • an 8-oxa-3-azabicyclo[3.2.1]octanyl a 5-6 membered heteroaryl having 1 to 3 ring members independently selected from N, O and S, and a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR 16 and O which is unsubstituted or is substituted with 1-2 R 7 groups;
  • Y 1 , Y 2 , Y 3 , L, R 1 , R 2 , R 3 and R 18 are as defined herein for compounds of Formula (A).
  • R 1 is as defined herein for compounds of Formula (A).
  • Y 1 , Y 2 , Y 3 , L, R 1 , R 2 , R 3 , R 4 , R 13 , R 14 and R 18 are as defined herein for compounds of Formula (A).
  • Y 1 , Y 2 , Y 3 , L, R 1 , R 2 , R 3 and R 18 are as defined herein for compounds of Formula (A).
  • a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR 16 or O which is unsubstituted or is substituted with 1-2 R 7 groups.
  • a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR 16 or O which is unsubstituted or is substituted with 1-2 R 7 groups.
  • R 1 is 8-oxa-3-azabicyclo[3.2.1]octanyl
  • a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR 16 or O substituted with 1-2 R 7 groups.
  • a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR 16 or O which is unsubstituted or is substituted with 1-2 R 7 groups;
  • a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR 16 or O which is unsubstituted or is substituted with 1-2 R 7 groups;
  • certain embodiments of the compounds of the present invention are present in the form of one of the possible isomers or as mixtures thereof, for example as pure optical isomers, or as isomer mixtures, such as racemates and diastereoisomer mixtures, depending on the number of asymmetric carbon atoms.
  • the present invention is meant to include all such possible isomers, including racemic mixtures, diasteriomeric mixtures and optically pure forms.
  • Optically active (R)- and (S)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituent may be E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans-configuration. All tautomeric forms are also intended to be included.
  • compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) are prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), with a stoichiometric amount of an appropriate pharmaceutically acceptable organic acid or inorganic acid or a suitable anion exchange reagent.
  • Certain compounds of the present invention are capable of forming acid addition salts by virtue of the presence of amino groups or groups similar thereto.
  • the salt forms of compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) are prepared using salts of the starting materials or intermediates.
  • Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids.
  • the organic acid or inorganic acids used to form certain pharmaceutically acceptable acid addition salts of compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) include, but are not limited to, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzoic acid, benzenesulfonic acid, carbonic acid, camphor sulfonic acid, capric acid, chlorotheophyllinate, citric acid, ethanedisulfonic acid, fumaric acid, D-glycero-D-gulo-Heptonicacid, galactaric aid, galactaric acid/mucic acid, gluceptic acid, glucoheptonoic acid, gluconic acid, glucuronic acid, glutamatic acid, glutaric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid,
  • Salt forms of the compounds of the invention can be converted into the free compounds by treatment with a suitable basic agent.
  • Pharmaceutically acceptable acid addition salts of compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) include, but are not limited to, a acetate, adipate, ascorbate, aspartate, benzoate, besylatye, benzenesulfonate, bicarbonate/carbonate, bisulfate/sulfate, bromide/hydrobromide, camphor sulfonate, camsylate, caprate, chloride/hydrochloride, chlorotheophyllinate, citrate, edisylate, ethanedisulfonate, fumarate, gluceptate, glucoheptonate, gluconate, glucuronate, glutamate, glutarate, glycolate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulphate, malate, maleate, mal
  • the present invention provides N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)oxetan-3-amine in an acetate, adipate, ascorbate, aspartate, benzoate, besylatye, benzenesulfonate, bicarbonate/carbonate, bisulfate/sulfate, bromide/hydrobromide, camphor sulfonate, camsylate, caprate, chloride/hydrochloride, chlortheophyllonate, citrate, edisylate, ethanedisulfonate, fumarate, gluceptate, glucoheptonate, gluconate, glucuronate
  • the present invention provides N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(dimethylamino)acetamide in an acetate, adipate, ascorbate, aspartate, benzoate, besylatye, benzenesulfonate, bicarbonate/carbonate, bisulfate/sulfate, bromide/hydrobromide, camphor sulfonate, camsylate, caprate, chloride/hydrochloride, chlortheophyllonate, citrate, edisylate, ethanedisulfonate, fumarate, gluceptate, glucoheptonate, gluconate,
  • the present invention provides (S)—N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide in an acetate, adipate, ascorbate, aspartate, benzoate, besylatye, benzenesulfonate, bicarbonate/carbonate, bisulfate/sulfate, bromide/hydrobromide, camphor sulfonate, camsylate, caprate, chloride/hydrochloride, chlortheophyllonate, citrate, edisylate, ethanedisulfonate, fumarate, gluceptate, glucoheptonate, gluconate,
  • the present invention provides (R)—N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide in an acetate, adipate, ascorbate, aspartate, benzoate, besylatye, benzenesulfonate, bicarbonate/carbonate, bisulfate/sulfate, bromide/hydrobromide, camphor sulfonate, camsylate, caprate, chloride/hydrochloride, chlortheophyllonate, citrate, edisylate, ethanedisulfonate, fumarate, gluceptate, glucoheptonate, gluconate,
  • the present invention provides 6-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-oxa-6-azaspiro[3.3]heptane in an acetate, adipate, ascorbate, aspartate, benzoate, besylatye, benzenesulfonate, bicarbonate/carbonate, bisulfate/sulfate, bromide/hydrobromide, camphor sulfonate, camsylate, caprate, chloride/hydrochloride, chlortheophyllonate, citrate, edisylate, ethanedisulfonate, fumarate, gluceptate, glucoheptonate,
  • any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds.
  • Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 18 F 31 P, 32 P, 35 S, 36 C, 123 I, 124 I, 125 I respectively.
  • the invention includes various isotopically labeled compounds as defined herein, for example those into which radioactive isotopes, such as 3 H and 14 C, or those into which non-radioactive isotopes, such as 2 H and 13 C are present.
  • isotopically labelled compounds are useful in metabolic studies (with 14 C), reaction kinetic studies (with, for example 2 H or 3 H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
  • PET positron emission tomography
  • SPECT single-photon emission computed tomography
  • an 18 F or labeled compound may be particularly desirable for PET or SPECT studies.
  • Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed.
  • isotopic enrichment factor means the ratio between the isotopic abundance and the natural abundance of a specified isotope.
  • a substituent in a compound of this invention is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
  • solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D 2 O, d 6 -acetone, d 6 -DMSO.
  • co-crystals may be capable of forming co-crystals with suitable co-crystal formers.
  • co-crystals may be prepared from compounds of the invention by known co-crystal forming procedures. Such procedures include grinding, heating, co-subliming, co-melting, or contacting in solution compounds of the invention with the co-crystal former under crystallization conditions and isolating co-crystals thereby formed.
  • Suitable co-crystal formers include those described in WO 2004/078163.
  • the invention further provides co-crystals comprising a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk).
  • any asymmetric atom (e.g., carbon or the like) of the compound(s) of the present invention can be present in racemic or enantiomerically enriched, for example the (R)-, (S)- or (R,S)-configuration.
  • each asymmetric atom has at least 50% enantiomeric excess, at least 60% enantiomeric excess, at least 70% enantiomeric excess, at least 80% enantiomeric excess, at least 90% enantiomeric excess, at least 95% enantiomeric excess, or at least 99% enantiomeric excess in the (R)- or (S)-configuration.
  • Substituents at atoms with unsaturated double bonds may, if possible, be present in cis- (Z)- or trans- (E)-form.
  • a compound of the present invention can be in the form of one of the possible isomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric (cis or trans) isomers, diastereomers, optical isomers (antipodes), racemates or mixtures thereof.
  • Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization.
  • Any resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound.
  • a basic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-O,O′-p-toluoyl tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid. Racemic products can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent.
  • HPLC high pressure liquid chromatography
  • the compounds of the present invention can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.
  • the compounds of the present invention may inherently or by design form solvates with pharmaceutically acceptable solvents (including water); therefore, it is intended that the invention embrace both solvated and unsolvated forms.
  • solvate refers to a molecular complex of a compound of the present invention (including pharmaceutically acceptable salts thereof) with one or more solvent molecules.
  • solvent molecules are those commonly used in the pharmaceutical art, which are known to be innocuous to the recipient, e.g., water, ethanol, and the like.
  • hydrate refers to the complex where the solvent molecule is water.
  • the compounds of the present invention including salts, hydrates and solvates thereof, may inherently or by design form polymorphs.
  • Scheme 1 illustrates one embodiment for making compounds of Formula (A), Formula (I) and Formula (II) using Buchwald-Hartwig Amination, where Pd catalyzed cross-coupling of protected amine intermediate (Int-A) or protected amine intermediate (Int-B) with a heteroaryl halide intermediate (Int-1) followed by deprotection gives a compound of Formula (Ia) or Formula (IIa), respectively, where R 1 is NH 2 . Further alkylation or acylation results in compounds of Formula (Ia) or Formula (IIa), where R 1 is as further defined herein.
  • compounds of Formula (A), Formula (I) and Formula (II) can be obtained by replacing intermediate (Int-1) with either intermediates Int-2, Int-3, Int-4, Int-5, Int-6, Int-7, Int-8, Int-9, Int-10 or Int-11, resulting compounds of Formula (Ic), Formula (b), Formula (If), Formula (Ig), Formula (Id), Formula (Ie), Formula (Ij), Formula (Ii), Formula (Ik), Formula (Ih), Formula (IIc), Formula (IIb), Formula (IIf), Formula (IIg), Formula (IId), Formula (IIe), Formula (IIj), Formula (IIi), Formula (IIk), and Formula (IIh), respectively.
  • Table 1 shows the alternative intermediates and the respective products
  • X 1 is Br, Cl, I or —SO 3 CF 3
  • Y 1 , Y 2 , Y 3 , L, R 1 , R 2 , R 3 , R 4 , R 13 and R 14 are as defined herein.
  • the Pd catalyst used in the coupling reactions of Scheme 1 is selected from Pd(II) catalysts, for example, bis(tri-o-tolylphosphine)palladium(II)dichloride, bis(tri-o-tolylphosphine)Pd(dba) 2 , bis(tri-o-tolylphosphine)Pd 2 (dba) 3 , PdCl 2 (dppf), (tri-o-tolylphosphine)Pd(OAc) 2 , Pd(OAc) 2 and a palladacycle.
  • Pd(II) catalysts for example, bis(tri-o-tolylphosphine)palladium(II)dichloride, bis(tri-o-tolylphosphine)Pd(dba) 2 , bis(tri-o-tolylphosphine)Pd 2 (dba) 3 , PdCl 2 (dppf), (tri-o-
  • the optional ligand of Scheme 1 is selected from diphenylphospinobinaphthyl (BINAP), diphenylphospinoferrocene (DPPF), tri-o-tolylphosphine (P(o-tol) 3 ), triphenylphosphine (PPh 3 ), tri-tert-butylphosphine (P(t-Bu) 3 ), 2-(dicyclohexylphosphino)3,6-dimethoxy-2′,4′,6′-triisopropyl-1,1′-biphenyl (BrettPhos), 2-(di-tert-butylphosphino)-2′,4′,6′-triisopropyl-3,6-dimethoxy-1,1′-biphenyl (t-BuBrettPhos), 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (XP
  • the bases used in such coupling reactions of Scheme 1 include, KOAc, NaOAc, K 2 CO 3 , Na 2 CO 3 , NaOEt, KOtBu, NaOtBu, LiHMDS, Cs 2 CO 3 , K 3 PO 4 , NaOH, KOH, tBuOH and NEt 3 .
  • Such coupling reactions are stirred at temperatures in the range of approximately 100-180° C., or are conducted in a microwave oven.
  • solvents for example benzene, toluene, 1,2-dimethoxyethane, acetonitrile, DCM, DMF, THF, dioxane and N-methyl-2-pyrrolidone are used.
  • the reaction may be carried out under an inert gas such as nitrogen or argon.
  • Scheme 2 illustrates another embodiment for making compounds of Formula (A), Formula (I) and Formula (II) using base catalyzed cross-coupling of protected amine intermediate (Int-A) or protected amine intermediate (Int-B) with a heteroaryl halide intermediate (Int-1) followed by deprotection gives a compound of Formula (Ia) or Formula (IIa), respectively, where R 1 is NH 2 . Further alkylation or acylation results in compounds of Formula (Ia) or Formula (IIa), where R 1 is as further defined herein.
  • compounds of Formula (A), Formula (I) and Formula (II) can be obtained by replacing intermediate (Int-1) with either intermediates Int-2, Int-3, Int-4, Int-5, Int-6, Int-7, Int-8, Int-9, Int-10 or Int-11, resulting compounds of Formula (Ic), Formula (Ib), Formula (If), Formula (Ig), Formula (Id), Formula (Ie), Formula (Ij), Formula (Ii), Formula (Ik), Formula (Ih), Formula (IIc), Formula (IIb), Formula (IIf), Formula (IIg), Formula (IId), Formula (IIe), Formula (IIj), Formula (IIi), Formula (IIk), and Formula (IIh), respectively.
  • Table 2 shows the alternative intermediates and the respective products
  • X 1 is Br, Cl, I or —SO 3 CF 3
  • Y 1 , Y 2 , Y 3 , L, R 1 , R 2 , R 3 , R 4 , R 13 and R 14 are as defined herein.
  • the bases used in such coupling reactions of Scheme 2 include, DIPEA, Cs 2 CO 3 , 1,8-diazabicycloundec-7-ene (DBU), NEt 3 , K 2 CO 3 , CaCO 3 , Na 2 CO 3 , K 3 PO 4 , KF, KOAc, NaOEt, KOtBu and NaOH.
  • DBU 1,8-diazabicycloundec-7-ene
  • the solvent used in such coupling reactions of Scheme (VII) and Scheme (VII), include H 2 O, 2-methyl-THE, 2-methyl-THF/H 2 O (1:1), THE, MeOH, butanol, t-butanol, EtOAc, CAN, ACN, DMSO, NMP, toluene dimethylacetamide and DMF.
  • the reaction may be carried out under an inert gas such as nitrogen or argon.
  • Scheme 3 illustrates an embodiment for making intermediates Int-A and Int-B.
  • Scheme 4 illustrates an embodiment for making intermediates Int-A and Int-B.
  • the amine protecting group (Prot) in Schemes 1 to 4 is selected from methyl carbamate, 9-Fluorenylmethyl carbamate (Fmoc), 2,2,2-Trichlorethyl carbamate (Troc), t-butyl carbamate Boc), 2-(Trimethylsilyl)ethyl carbamate (Teoc), allyl carbamate (Alloc), benzyl carbamate (Cbz), benzylideneamine, p-toluenesulfonamide, trifluoroacetamide, acetamide, phthalimide, benzylamine, 4-methoxybenzyl amine (PMB), allyl amine and tritylamine.
  • the invention further includes any variant of the present processes, in which an intermediate product obtainable at any stage thereof is used as starting material and the remaining steps are carried out, or in which the starting materials are formed in situ under the reaction conditions, or in which the reaction components are used in the form of their salts or optically pure material.
  • the compounds of the present invention can be produced as shown in the following examples.
  • the following examples are intended to illustrate the invention and are not to be construed as being limitations thereon.
  • the structure of final products, intermediates and starting materials is confirmed by standard analytical methods, e.g., microanalysis and spectroscopic characteristics, e.g., MS, IR, NMR. Abbreviations used are those conventional in the art.
  • All starting materials, building blocks, reagents, acids, bases, dehydrating agents, solvents, and catalysts utilized to synthesis the compounds of the present invention are either commercially available or can be produced by organic synthesis methods known to one of ordinary skill in the art or can be produced by organic synthesis methods as described herein.
  • Tail Group intermediates used to obtain compounds of the invention are shown below and in Table 4, with their respective synthesis also described below. Unless purchased, the synthesis of certain reagents used to obtain these intermediates is also described below.
  • Reagent No. Reagent Structure Reagent Name i-A0 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine i-A1 3-methyl-1H-pyrazolo[4,3-c]pyridine i-A2 1H-pyrazolo[4,3-c]pyridine i-A3 tert-butyl 7,7-dimethyl-1,4,6,7-tetrahydro-5H- pyrazolo[4,3-c]pyridine-5-carboxylate i-A4 3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3- c]pyridine i-A6 3-(trifluoromethyl)-1H-pyrazolo[4,3-c]pyridine i-A7 tert-butyl 3-(trifluoromethyl)-6,7-dihydro-1H- pyrazolo[4,3-c]pyridin-5(4H)-carboxylate
  • Step 1 To a solution of 4-((tert-butoxycarbonyl)amino)bicyclo[2.2.2]octane-1-carboxylic acid (4.565 g, 16.9 mmol) in THE (30 mL) was added BH 3 -DMS (5.15 mL, 3.0 eq) at 0° C. After addition, the reaction was further stirred overnight at rt. LC/MS indicated that the reaction was complete. The reaction was then treated with dropwise addition of 10% citric acid.
  • Step 2 To a mixture of tert-butyl (4-(hydroxymethyl)bicyclo[2.2.2]octan-1-yl)carbamate (1.021 g, 4.0 mmol) and 4-(trifluoromethyl)benzenesulfonyl chloride (1.566 g, 6.4 mmol, 1.6 eq) and DCM (10 mL) was added Et 3 N (1.12 mL, 2.0 eq) and DMAP (49 mg, 0.1 eq) at rt. After addition, the resulting mixture was further stirred at rt for 4 hrs.
  • Step 1 LiAlH 4 (83 mg, 2.188 mmol) was dissolved in THE (20 mL) at 0° C.
  • Starting material methyl 3-((tert-butoxycarbonyl)amino)bicyclo[1.1.1]pentane-1-carboxylate (240 mg, 0.995 mmol) was dissolved in 5 mL THF, then was added to the LiAlH 4 solution at 0° C.
  • the reaction mixture was warmed up to rt and stirred for 2 hrs. Sat. Na 2 SO 4 solution was then added to quench the reaction. After filtering the solvent was removed to obtain tert-butyl (3-(hydroxymethyl)bicyclo[1.1.1]pentan-1-yl)carbamate for use in the next step.
  • Step 2 tert-Butyl (3-(hydroxymethyl)bicyclo[1.1.1]pentan-1-yl)carbamate (180 mg, 0.844 mmol), 4-(trifluoromethyl)benzenesulfonyl chloride (206 mg, 0.844 mmol) and DIPEA (0.295 mL, 1.688 mmol) were mixed in DCM (5 mL) and the reaction mixture was stirred at 25° C. for 5 hrs.
  • Step 1 A solution of 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (i-A0) (165 mg, 0.64 mmol) in methanol (13.5 ml) was treated with DIPEA (2.91 ml, 16.66 mmol), followed by dropwise addition of benzyl chloroformate (0.837 ml, 5.95 mmol). The whole mixture was stirred for 18 hrs. LCMS showed a completed reaction and the reaction mixture was concentrated in vacuo.
  • Step 2 To a 20 mL scintillation vial containing benzyl 1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (165 mg, 0.641 mmol), was added 4-((tert-butoxycarbonyl)amino)bicyclo[2.2.2]octan-1-yl)methyl 4-(trifluoromethyl)benzenesulfonate (i-B1) (446 mg, 0.962 mmol), cesium carbonate (418 mg, 1.28 mmol) and anhydrous DMSO (3.2 mL). The mixture was heated to 110° C. for 18 hr, before diluted in ethyl acetate and water.
  • Citric acid was added as solid to neutralize pH. After partition, the aqueous layer was re-extracted with ethyl acetate three times. All the organic layers were combined, dried over magnesium sulfate and concentrated in vacuo. The residue was purified on a 40 g silica gel column using 0-10% methanol in DCM to afford a mixture of the two desired regioisomers (MS calculated for C 20 H 32 N 4 O 2 (M+H + ) 361.3, found 361.3.
  • Step 3 To a mixture of (TG1a) and (TG2a) (102 mg, 0.21 mmol), was added palladium on carbon (0.0220 g, 0.0207 mmol) and ethanol (1 ml). The mixture was stirred with hydrogen (65 psi) for 18 hr; LCMS showed ⁇ 90% conversion. The mixture was filtered, washed with methanol and concentrated in vacuo. The residue was loaded on a 40 g silica gel column using 0-80% isopropanol in DCM with 2% ammonia as modifier to afford the pure product directly used in the separation step (below).
  • Step 1 A suspension of 3-methyl-1H-pyrazolo[4,3-c]pyridine (i-A1) (2.66 g, 19.98 mmol), in DMSO (80 ml) was treated with (4-((tert-butoxycarbonyl)amino)bicyclo[2.2.2]octan-1-yl)methyl 4-(trifluoromethyl)benzenesulfonate (i-B1) (9.26 g, 19.98 mmol) and cesium carbonate (13.02 g, 40.0 mmol). The mixture was heated to 120° C. for 18 hr to complete, before being cooled to rt and diluted in ethyl acetate and water.
  • tert-butyl (4-((3-methyl-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (1.011 g, 2.73 mmol) was hydrogenated using a H-cube system. Once complete, the reaction solution was concentrated and loaded on a 24 g silica gel column using 0-100% IPA in DCM with 3% NH 3 as modifier to yield tert-butyl (4-((3-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG4).
  • Step 1 A mixture of 3-methyl-1H-pyrazolo[4,3-c]pyridine (i-A1) (133 mg, 1.0 mmol), (4-((tert-butoxycarbonyl)amino)bicyclo[2.2.1]heptan-1-yl)methyl methanesulfonate (i-B5) (351 mg, 1.1 mmol) and Cs 2 CO 3 in DMSO (2 mL) was stirred at 80° C. overnight. LC-MS showed completion of the reaction. The reaction mixture was then cooled down to rt and diluted with EtOAc/water. The layers were separated and the organic layer was dried over Na 2 SO 4 then concentrated.
  • Step 220 mg (0.617 mmol) of, tert-butyl (4-((3-methyl-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.1]heptan-1-yl)carbamate was transformed to the desired product, tert-butyl (4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.1]heptan-1-yl)carbamate (TG5) using H-Cube: 90° C., 20 bar H 2 , 10% Pd/C, 1 mL/min flow rate. RT (LCMS Method 2) 1.92 min. MS calculated for C 20 H 32 N 4 O 2 (M+H + ) 361.5, found 361.5. Note: Product 2 was not hydrogenated.
  • tert-butyl 7,7-dimethyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (120 mg, 0.477 mmol), (4-((tert-butoxycarbonyl)amino)bicyclo[2.2.2]octan-1-yl)methyl 4-(trifluoromethyl)benzenesulfonate (i-B1) (220 mg, 0.477 mmol) and Cs 2 CO 3 (156 mg, 0.477 mmol) were mixed in DMA (10 mL) and stirred at 120° C. for 1 hr.
  • Step 1 A mixture of 291 mg (1 mmol) of tert-butyl 3-(trifluoromethyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carboxylate (i-A7), 510 mg (1.1 mmol) of (4-((tert-butoxycarbonyl)amino)bicyclo[2.2.1]heptan-1-yl)methyl methanesulfo(4-((tert-butoxycarbonyl)amino)bicyclo[2.2.2]octan-1-yl)methyl methanesulfonate and cesium carbonate (652 mg, 2.0 mmol) in DMSO (5 mL) was stirred at 80° C.
  • Step 2 To a solution of 66 mg (0.125 mmol) of tert-butyl 1-((4-((tert-butoxycarbonyl)amino)bicyclo[2.2.2]octan-1-yl)methyl)-3-(trifluoromethyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carboxylate (TG8a) in dioxane/MeOH (0.5 mL/0.3 mL) was added HCl (4M solution in dioxane, 0.5 mL). The resulting mixture was stirred at rt for 2 hrs.
  • Step 1 To a solution of 1.85 g (4.0 mmol) of (4-((tert-butoxycarbonyl)amino)bicyclo[2.2.2]octan-1-yl)methyl 4-(trifluoromethyl)benzenesulfonate (i-B1) in THF was added 208 mg (5.2 mmol) of NaH at 0° C. under N 2 . The mixture was warmed up to rt and stirred for 30 min then cooled back to 0° C. before CH 3 I (2.84 g, 20.0 mmol) was added dropwise. The resulting mixture was slowly warmed up to rt and stirred overnight. LC-MS showed desired product but the reaction was not complete.
  • Step 2 A mixture of 133 mg (1.0 mmol) of 3-methyl-1H-pyrazolo[4,3-c]pyridine, 525 mg (1.1 mmol) of (4-((tert-butoxycarbonyl)(methyl)amino)bicyclo[2.2.2]octan-1-yl)methyl 4-(trifluoromethyl)benzenesulfonate and 652 mg (2.0 mmol) of Cs 2 CO 3 in DMSO was stirred at 80° C. overnight. After cooling to rt, the mixture was diluted with EtOAc/water. The layers were separated and the organic layer was dried over Na 2 SO 4 , then concentrated.
  • Step 3 tert-butyl methyl(4-((3-methyl-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (233 mg, 0.606 mmol) was transformed to the desired product, tert-butyl methyl(4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG10) using H-Cube: 100° C., 15 bar H 2 , 10% Pd/C, 1 mL/min flow rate. The product was used directly without purification. RT (method 2): 1.7 min, MS (ES+): 389.3 (M+1)+.
  • Step 1 A solution of 1-(4-methoxybenzyl)-1H-pyrazol-5-amine and ethyl acetoacetate in acetic acid was stirred at rt overnight. The reaction was concentrated in vacuo and then taken up in DOWThermA and heated in a sealed vessel to 230° C. The reaction was maintained at this temperature for 40 min and then cooled to rt. The reaction was purified by column chromatography (SiO 2 , ISCO, 0-15% MeOH in dichloromethane) to afford the desired phenol directly used in the next step.
  • Step 2 To the solution of 1-(4-methoxybenzyl)-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-ol (1.895 g, 7.04 mmol) in mix solvent of DCM (100 mL, 3.33 parts) and THF (30 mL, 1 part) at 0° C. was added triethylamine (7.36 mL, 52.8 mmol) followed by triflicAnhydride (2.97 mL, 17.59 mmol). The reaction was gradually warmed up to rt in 3 hrs. The reaction was quenched with saturated sodium bicarbonate solution and extracted with DCM. The organic phase was washed with brine and dried.
  • Step 1 A mixture of 2.5 g of 1-ethyl-1H-pyrazol-5-amine (22.5 mmol), 23.4 g (180 mmol) of ethyl 3-oxobutanoate and 1.35 g (22.5 mmol) of AcOH was reacted in flow using a Vapourtec R2C+/R4 (trip pressure set to 40 bar; SS tube reactor; solution pressure set by 250 psi BPR) in dioxane at a flow rate of 0.2 mL/min at 250° C. The reaction was quenched using MeOH (flow rate 0.25 mL/min).
  • Step 1 To a pressure flask containing tert-butyl (4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG3) (0.565 g, 42.5 mmol) was added 4-bromo-1,6-dimethyl-1H-pyrazolo[3,4-b]pyridine (HG1) (0.94 g, 2.5 mmol), cesium carbonate (1.63 g, 5.1 mmol), Pd 2 (dba) 3 (0.057 g, 0.062 mmol), RuPhos (0.14 g, 0.3 mmol) and THF (25 mL).
  • TG3 4-bromo-1,6-dimethyl-1H-pyrazolo[3,4-b]pyridine
  • the mixture was heated at 80° C. for 18 hrs to complete, then cooled to rt.
  • the mixture was diluted in ethyl acetate and water. After partition, the aqueous layer was extracted with ethyl acetate once more. Both organic layers were combined, dried over MgSO 4 , filtered and concentrated in vacuo.
  • Step 2 To a 500 mL round bottom flask containing tert-butyl (4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (1.5 g, 1.45 mmol) was added methanol (6 mL), then 4N HCl in dioxane (7.2 mL, 28.9 mmol). The mixture was stirred at rt for 18 hr then concentrated in vacuo.
  • Step 3 Ambersep 9000H (17 ml, 0.8 meq/mL, prewashed with 60 mL of MeOH) was added into a solution of 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine as HCl salt (Compound No. 1-HCl) (1.53 g, 2.7 mmol) in MeOH (100 mL).
  • Step 1 tert-butyl (4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG3) (110 mg, 0.294 mmol), 1-(4-methoxybenzyl)-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl trifluoromethanesulfonate (HG7) (118 mg, 0.294 mmol), DIPEA (0.154 mL, 0.881 mmol) and BuOH (0.05 mL) were added to a reaction vial and then stirred at 120° C. for 3 hrs.
  • DIPEA 0.154 mL, 0.881 mmol
  • BuOH 0.05 mL
  • reaction mixture was purified by HPLC to give tert-butyl (4-((5-(1-(4-methoxybenzyl)-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate.
  • RT (method 2): 2.29 min, ESIMS m/z 626.4 (M + +1)
  • Step 2 To the solution of tert-butyl (4-((5-(1-(4-methoxybenzyl)-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (110 mg, 0.176 mmol) in MeOH (1 mL) was added hydrochloric acid (0.879 mL, 5.27 mmol). The reaction was stirred for 16 hr at 25° C.
  • Step 3 To a 20 mL pressure tube was added 4-((5-(1-(4-methoxybenzyl)-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 53) (80 mg, 0.152 mmol), cysteine (36.9 mg, 0.304 mmol) and TFA (2 mL). The mixture was heated at 75° C. for 2 hr and then cooled to rt and concentrated in vacuo.
  • Step 1 To the reaction vial were added tert-butyl (4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG3) (105 mg, 0.280 mmol), 4-chloro-2-methyl-1,7-naphthyridine (HG9) (50 mg, 0.280 mmol), DIPEA (0.147 mL, 0.840 mmol) and BuOH (0.1 mL). The reaction was stirred at 120° C. for 3 hr, diluted with methanol and purified by HPLC.
  • TG3 tert-butyl (4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate
  • TG3 105
  • Step 2 To a solution of tert-butyl (4-((3-methyl-5-(2-methyl-1,7-naphthyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (124 mg, 0.240 mmol) in MeOH (1 mL) was added hydrochloric acid (1.200 mL, 7.20 mmol). The reaction was stirred for 16 hr at 25° C.
  • Step 1 To a reaction vial were added tert-butyl (4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG3) (67.0 mg, 0.179 mmol), 4-chloro-2-methyl-7H-pyrrolo[2,3-d]pyrimidine (HG14) (30 mg, 0.179 mmol), DIPEA (0.094 mL, 0.537 mmol) and BuOH (0.1 mL). The reaction was stirred at 120° C.
  • Step 2 To a solution of tert-butyl (4-((3-methyl-5-(2-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (35 mg, 0.075 mmol) in MeOH (1 mL) was added hydrochloric acid (0.445 mL, 2.67 mmol). The reaction was stirred for 16 hr at 25° C.
  • Step 1 To the reaction vial were added tert-butyl (4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG3) (62.2 mg, 0.166 mmol), 4-chloro-1,6-dimethyl-1H-pyrrolo[2,3-b]pyridine (HG15) (30 mg, 0.166 mmol), RuPhos (9.30 mg, 0.020 mmol), tris(dibenzylideneacetone)dipalladium(0) (7.60 mg, 8.30 ⁇ mol), Cs 2 CO 3 (108 mg, 0.332 mmol) and THE (2 mL). The reaction was stirred @75° C. for 18 hrs. Reaction completed. The reaction was diluted with ethyl acetate and filtered through celite to remove salt. The filtrate was dried and the crude product was directly used in the next step.
  • Step 2 To a solution of tert-butyl (4-((5-(1,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (30 mg, 0.046 mmol) in MeOH (1 mL) was added hydrochloric acid (0.231 mL, 1.388 mmol).
  • the resulting mixture was stirred at rt for 1 hr then washed with 30 mL of water.
  • the aqueous layer was extracted with DCM (100 mL ⁇ 3) and the combined organic layers were dried over Na 2 SO 4 , filtered and concentrated to give the crude product.
  • the crude product was added to a 80 g gold silica gel column and was eluted with 0-50% (over 30 min) IPA (containing 0.02 M of ammonia) in DCM.
  • Step 1 A mixture of 7-chloro-1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidine (HG4) (263 mg, 1.335 mmol), tert-butyl (4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG3) (500 mg, 1.335 mmol) and DIPEA (0.233 mL, 1.335 mmol) in 2-propanol (30 mL) was heated to 100° C. for 1 hr.
  • HG4 7-chloro-1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidine
  • TG3 tert-butyl (4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)
  • Step 3 A mixture of (60 mg, 0.138 mmol) of 4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 26), 101 mg (0.414 mmol) of 1,1-bis(bromomethyl)cyclobutane and K 2 CO 3 (95 mg, 0.690 mmol) in 2-propanol (10 mL) was heated to 120° C. for 72 hrs.
  • Step 1 4,6-dichloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine (HG16) (40 mg, 0.197 mmol), tert-butyl (4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG3) (70 mg, 0.187 mmol), Pd 2 dba 3 (10 mg, 10.92 ⁇ mol), RuPhos (10 mg, 0.021 mmol) and Cs 2 CO 3 (65 mg, 0.199 mmol) were mixed in dioxane (5 mL) and stirred at 120° C.
  • Step 2 tert-butyl (4-((5-(6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (20 mg, 0.037 mmol), (4-fluorophenyl)boronic acid (10 mg, 0.071 mmol), PdCl 2 (dppf).
  • Step 3 tert-butyl (4-((5-(6-(4-fluorophenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (10 mg, 0.017 mmol) and 4N HCl (0.152 mL, 4.99 mmol) were mixed in MeOH (1 mL) and stirred at 50° C. for 5 hrs.
  • Step 1 2-chloro-4-fluoropyridine (130 mg, 0.988 mmol), tert-butyl (4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG3) (370 mg, 0.988 mmol) and DIPEA (130 mg, 1.006 mmol) were mixed in DMA (5 mL) and stirred at 150° C. for 4 hrs.
  • TG3 tert-butyl (4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate
  • DIPEA 130 mg, 1.006 mmol
  • Step 2 tert-butyl (4-((5-(2-chloropyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (25 mg, 0.051 mmol), (4-cyanophenyl)boronic acid (15 mg, 0.102 mmol), PdCl 2 (dppf). CH 2 Cl 2 adduct (5 mg, 6.12 ⁇ mol) and K 2 CO 3 (25 mg, 0.181 mmol) were mixed in dioxane (3 mL) and stirred at 120° C. for 17 hrs.
  • Step 3 tert-Butyl (4-((5-(2-(4-cyanophenyl)pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (20 mg, 0.036 mmol) and 4N HCl (0.220 mL, 7.24 mmol) were mixed in MeOH (1 mL) and stirred at 50° C. for 3 hrs.
  • Step 1 A mixture of 4-bromo-1,6-dimethyl-1H-pyrazolo[3,4-b]pyridine (HG1) (67 mg, 0.295 mmol), tert-butyl methyl(4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG10) (115 mg, 0.295 mmol), Pd 2 dba 3 (6.8 mg, 0.074 mmol), RuPhos (17 mg, 0.035 mmol) and Cs 2 CO 3 (192 mg, 0.590 mmol) in THE was purged with argon before being heated to 75° C.
  • HG1 4-bromo-1,6-dimethyl-1H-pyrazolo[3,4-b]pyridine
  • TG10 tert-butyl methyl(4-((3-methyl-4,5,6,
  • Step 2 To a solution of 90 mg (0.169 mmol) of tert-butyl (4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)(methyl)carbamate (Compound No. 49) in dioxane/MeOH (1 mL/1 mL) was added HCl (2 mL of a 4M solution in dioxane). The resulting mixture was stirred at rt for 2 hrs. LC-MS showed completion of the reaction.
  • Step 1 To a solution of 14.2 mg (0.12 mmol) of 2-methoxy-2-methylpropanoic acid in DMF (2 mL) was added HATU (45.6 mg, 0.12 mmol) and DIPEA (0.035 mL, 25.8 mg, 0.2 mmol). The mixture was stirred at rt for 5 min before of 42.0 mg (0.1 mmol) 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 1) was added.
  • Step 2 To a stirred solution of 17 mg (0.033 mmol) of N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-methoxy-2-methylpropanamide in THE (1 mL) was added 6.5 mg (0.164 mmol) of LiAlH 4 at 0° C. The resulting mixture was then slowly warmed up to rt and stirred overnight. After cooling at 0° C. the reaction was quenched with IPA then water and concentrated.
  • Step 1 To a solution of 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 1) (121 mg, 0.246 mmol) in CPME (12.3 mL) was added tert-butyl methyl(2-oxoethyl)carbamate (63.8 mg, 0.369 mmol). The mixture was stirred at 25° C. for 30 min before sodium triacetoxyborohydride (156 mg, 0.737 mmol) was added.
  • Step 2 A mixture of 40 mg (0.069 mmol) of tert-butyl (2-((4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)ethyl)(methyl)carbamate, 35.5 mg (0.024 mL, 0.208 mmol) of ethyl 2-bromoacetate and 10.5 mg (0.076 mmol) of potassium carbonate in EtOH (1 mL) was heated under microwave irradiation at 150° C.
  • Step 3 To a mixture of 27.0 mg (0.043 mmol) of 2-((2-((tert-butoxycarbonyl)(methyl)amino)ethyl)(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)acetic acid in 1 mL of 1,4-dioxane was added 0.3 mL of MeOH to get a clear solution.
  • Step 1 To a mixture of 80 mg (0.139 mmol) of tert-butyl (2-((4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)ethyl)(methyl)carbamate (Example 27, Step 1) and 36 mg (0.048 ⁇ L, 0.277 mmol) of DIPEA in 1.0 mL of DCM was added dropwise into a solution of 2-bromoacetyl bromide (0.062 mL, 0.694 mmol) in DCM (1.0 mL) at 0° C.
  • the resulting mixture was slowly warmed up to rt and stirred for 1 hr. Then quenched the reaction by adding 0.1 mL of water and concentrated. The crude product was added to a 4 g silica gel column and was eluted with 0-30% IPA (containing 0.02 M ammnia) in DCM.
  • Step 2 To a mixture of 40.0 mg (0.057 mmol) of tert-butyl (2-(2-bromo-N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[222]octan-1-yl)acetamido)ethyl)(methyl)carbamate in 1 mL of 1,4-dioxane was added 0.5 mL of MeOH to get a clear solution.
  • Step 1 To a mixture of 16.7 mg (0.120 mmol) of 2-bromoacetic acid and 42.0 mg (0.1 mmol) of 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 1) in DCM (1 mL) were added HATU (45.6 mg, 0.12 mmol) and DIPEA (25.8 mg, 0.035 mL, 0.2 mmol). The resulting mixture was stirred at rt for 1 hr.
  • Step 2 A mixture of 27 mg (0.05 mmol) of 2-bromo-N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)acetamide, 7.3 mg (0.065 mmol) of 3-fluoroazetidine and 20.7 mg (0.15 mmol) of potassium carbonate in DMA (1 mL) was heated at 120° C. under microwave irradiation for 40 min.
  • Step 1 To a mixture of 10.1 mg (0.11 mmol) of 2-oxoacetic acid and 42 mg (0.1 mmol) of 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 1) in DCM was added HATU (41.8 mg, 0.11 mmol) and DIPEA (25.8 mg, 0.035 mL, 0.2 mmol).
  • the present invention provides a pharmaceutical composition, which comprises a compound of the invention, or pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients.
  • a pharmaceutical composition which comprises a compound of the invention, or pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients.
  • solvates and hydrates are generally considered compositions.
  • pharmaceutically acceptable carriers are sterile.
  • the pharmaceutical composition of the present invention can be in unit dosage of about 1-1000 mg of active ingredient(s) for a subject of about 50-70 kg.
  • the therapeutically effective dosage of a compound, the pharmaceutical composition, or the combinations thereof, is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated. A physician, clinician or veterinarian of ordinary skill can readily determine the effective amount of each of the active ingredients necessary to prevent, treat or inhibit the progress of the disorder or disease.
  • the above-cited dosage properties are demonstrable in vitro and in vivo tests using advantageously mammals, e.g., mice, rats, dogs, monkeys or isolated organs, tissues and preparations thereof.
  • the compounds of the present invention can be applied in vitro in the form of solutions, e.g., aqueous solutions, and in vivo either enterally, parenterally, advantageously intravenously, e.g., as a suspension or in aqueous solution.
  • the dosage in vitro may range between about 10-3 molar and 10-9 molar concentrations.
  • a therapeutically effective amount in vivo may range depending on the route of administration, between about 0.1-500 mg/kg.
  • the activity of a compound according to the present invention can be assessed by the following in vitro & in vivo methods.
  • compositions of the invention can be prepared using processes which include admixing a compound of the invention, or pharmaceutically acceptable salts thereof, with one or more pharmaceutically acceptable carriers, diluents or excipients.
  • the pharmaceutical compositions of the inventions are manufactured by mixing, granulating and/or coating methods using a compound of the invention in free form, or in a pharmaceutically acceptable salt form, in association with at least one pharmaceutically acceptable carrier, diluent or excipient.
  • the present invention further provides anhydrous pharmaceutical compositions and dosage forms comprising the compounds of the present invention as active ingredients, since water may facilitate the degradation of certain compounds.
  • Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions.
  • An anhydrous pharmaceutical composition may be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions are packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e. g., vials), blister packs, and strip packs.
  • compositions and dosage forms that comprise one or more agents that reduce the rate by which the compound of the present invention as an active ingredient will decompose.
  • agents which are referred to herein as “stabilizers,” include, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers, etc.
  • the pharmaceutical composition can be formulated for particular routes of administration such as oral administration, rectal administration, transdermal administration, parenteral, intravenous administration, intramuscular administration, pulmonary administration, inhalation administration, intranasal administration, ophthalmic administration and topical administration.
  • routes of administration such as oral administration, rectal administration, transdermal administration, parenteral, intravenous administration, intramuscular administration, pulmonary administration, inhalation administration, intranasal administration, ophthalmic administration and topical administration.
  • compositions of the invention can be administered orally as discrete dosage forms, wherein such dosage forms include, but are not limited to, capsules, gelatin capsules, caplets, tablets, chewable tablets, lozenges, dispersible powders, granules, syrups, flavored syrups, solutions or suspensions in aqueous or non-aqueous liquids, edible foams or whips, and oil-in-water liquid emulsions or water-in-oil liquid emulsions.
  • compositions of the invention comprising an effective amount of a compound of the invention can be made up in a solid form (including without limitation capsules, gelatin capsules, hard or soft capsules, tablets, chewable tablets, lozenges, caplets, pills, granules or dispersible powders), or in a liquid form (including without limitation solutions, aqueous or oily suspensions, syrups, elixirs, foams, whips or emulsions).
  • compositions can be subjected to conventional pharmaceutical operations such as sterilization and/or can contain conventional inert diluents, lubricating agents, or buffering agents, as well as adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers and buffers, etc.
  • compositions intended for oral use are prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
  • the pharmaceutical compositions are tablets or gelatin capsules comprising the active ingredient together with one or more of:
  • Tablets may contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients are, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc. Tablets may be either film coated or enteric coated according to methods known in the art.
  • the tablets are uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate can be employed.
  • Formulations for oral use can be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
  • compositions of the invention are administered parenterally by various routes including, but not limited to, subcutaneous, intravenous (including bolus injection), intramuscular, and intraarterial.
  • compositions are aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions.
  • Said compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances.
  • Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1-75%, or contain about 1-50%, of the active ingredient.
  • compositions of the invention are administered by topical application of a pharmaceutical composition containing a compound of the invention in the form of a lotion, gel, ointment, solution, emulsion, suspension or cream.
  • compositions for topical application include aqueous solutions, suspensions, ointments, creams, gels or sprayable formulations, e.g., for delivery by aerosol or the like.
  • topical delivery systems will in particular be appropriate for dermal application, e.g., for the treatment of skin cancer, e.g., for prophylactic use in sun creams, lotions, sprays and the like. They are thus particularly suited for use in topical, including cosmetic, formulations well-known in the art.
  • Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
  • a topical application may also pertain to an inhalation or to an intranasal application. They may be conveniently delivered in the form of a dry powder (either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids) from a dry powder inhaler or an aerosol spray presentation from a pressurized container, pump, spray, atomizer or nebulizer, with or without the use of a suitable propellant.
  • a dry powder either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids
  • compositions of the invention of the invention are administered rectally in the form of suppositories, enemas, ointment, creams rectal foams or rectal gels.
  • suppositories are prepared from fatty emulsions or suspensions, cocoa butter or other glycerides.
  • compositions of the invention of the invention are formulated as a depot preparation. Such formulations are administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • such formulations include polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • Compounds of the invention and pharmaceutical compositions provided herein are administered singly or in combination with one or more additional therapeutic agents.
  • the combination of the present invention can be in unit dosage of about 1-1000 mg of active ingredient(s) for a subject of about 50-70 kg.
  • the therapeutically effective dosage of the combinations is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated. A physician, clinician or veterinarian of ordinary skill can readily determine the effective amount of each of the active ingredients necessary to prevent, treat or inhibit the progress of the disorder or disease.
  • the above-cited dosage properties are demonstrable in vitro and in vivo tests using advantageously mammals, e.g., mice, rats, dogs, monkeys or isolated organs, tissues and preparations thereof.
  • the compounds of the present invention can be applied in vitro in the form of solutions, e.g., aqueous solutions, and in vivo either enterally, parenterally, advantageously intravenously, e.g., as a suspension or in aqueous solution.
  • the dosage in vitro may range between about 10-3 molar and 10-9 molar concentrations.
  • a therapeutically effective amount in vivo may range depending on the route of administration, between about 0.1-500 mg/kg.
  • the activity of a compound according to the present invention can be assessed by the following in vitro & in vivo methods.
  • the compound of the present invention may be administered either simultaneously with, or before or after, one or more other therapeutic agent.
  • the compound of the present invention may be administered separately, by the same or different route of administration, or together in the same pharmaceutical composition as the other agents.
  • a therapeutic agent is, for example, a chemical compound, peptide, antibody, antibody fragment or nucleic acid, which is therapeutically active or enhances the therapeutic activity when administered to a patient in combination with a compound of the invention.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), and another therapeutic agent(s).
  • the pharmaceutical composition may comprise a pharmaceutically acceptable carrier, as described above.
  • the invention provides a product comprising a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), and at least one other therapeutic agent as a combined preparation for simultaneous, separate or sequential use in therapy.
  • the therapy is the treatment of an autoimmune disease or condition mediated by activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9), or any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9).
  • Products provided as a combined preparation include a composition comprising the compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk) and the other therapeutic agent(s) together in the same pharmaceutical composition, or the compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk) and the other therapeutic agent(s) in separate form, e.g. in the form of a kit.
  • the invention provides a product comprising a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), and at least one other therapeutic agent as a combined preparation for simultaneous, separate or sequential use in therapy.
  • the therapy is the treatment of an autoimmune disease or condition mediated by TLR7, TLR7 and TLR8 or TLR7, TLR8 and TLR9 activity.
  • Products provided as a combined preparation include a composition comprising the compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk) and the other therapeutic agent(s) together in the same pharmaceutical composition, or the compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk) and the other therapeutic agent(s) in separate form, e.g. in the form of a kit.
  • the invention provides a product comprising a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), and at least one other therapeutic agent as a combined preparation for simultaneous, separate or sequential use in therapy.
  • the therapy is the treatment of an autoimmune disease or condition mediated by activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, or any combinations thereof.
  • an endosomal Toll-like receptor e.g. TLR7, TLR8 or TLR9
  • Products provided as a combined preparation include a composition comprising the compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk) and the other therapeutic agent(s) together in the same pharmaceutical composition, or the compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk) and the other therapeutic agent(s) in separate form, e.g. in the form of a kit.
  • the invention provides a kit comprising two or more separate pharmaceutical compositions, at least one of which contains a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk).
  • the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet.
  • An example of such a kit is a blister pack, as typically used for the packaging of tablets, capsules and the like.
  • the kit of the invention may be used for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another.
  • the kit of the invention typically comprises directions for administration.
  • the compound of the invention and the other therapeutic agent may be manufactured and/or formulated by the same or different manufacturers. Moreover, the compound of the invention and the other therapeutic may be brought together into a combination therapy: (i) prior to release of the combination product to physicians (e.g. in the case of a kit comprising the compound of the invention and the other therapeutic agent); (ii) by the physician themselves (or under the guidance of the physician) shortly before administration; (iii) in the patient themselves, e.g. during sequential administration of the compound of the invention and the other therapeutic agent.
  • the compound of the invention and the additional therapeutics agent(s) act additively. In certain embodiments of the combination therapies described herein, the compound of the invention and the additional therapeutics agent(s) act synergistically.
  • the additional therapeutic agents used in combination with a compound of the invention include, but are not limited to anti-inflammatory agents, immunomodulatory agents, immunosuppressive agents, cytokines, nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarial compounds, anti-rheumatic compounds, inhibitors of B-cell activating factor (BAFF), inhibitors of B-lymphocyte stimulator (BLyS), and steroid hormones.
  • anti-inflammatory agents include, but are not limited to anti-inflammatory agents, immunomodulatory agents, immunosuppressive agents, cytokines, nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarial compounds, anti-rheumatic compounds, inhibitors of B-cell activating factor (BAFF), inhibitors of B-lymphocyte stimulator (BLyS), and steroid hormones.
  • Nonsteroidal anti-inflammatory drugs used in combination with compounds of the invention, include, but are not limited to, salicylic acid, acetylsalicylic acid, methyl salicylate, diflunisal, salsalate, olsalazine, sulfasalazine, acetaminophen, indomethacin, sulindac, etodolac, mefenamic acid, meclofenamate sodium, tolmetin, ketorolac, dichlofenac, ibuprofen, naproxen, naproxen sodium, fenoprofen, ketoprofen, flurbinprofen, oxaprozin, piroxicam, meloxicam, ampiroxicam, droxicam, pivoxicam, tenoxicam, nabumetome, phenylbutazone, oxyphenbutazone, antipyrine, aminopyrine, apazone and nimesulide.
  • NSAIDs used
  • Anti-rheumatic compound used in combination with compounds of the invention include, but are not limited to, methotrexate.
  • Antimalarial compound used in combination with compounds of the invention include, but are not limited to, chloroquine and hydroxycloroquine.
  • Inhibitors of B-cell activating factor include, but are not limited to, belimumab (Benlysta®), Blisibimod and BR3-Fc.
  • Immunosuppressive agents used in combination with compounds of the invention include, but are not limited to, mycophenolate mofetil (MMF), mycophenolic acid, cyclophosphamide, azathioprine and Laquinimod (5-chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide).
  • MMF mycophenolate mofetil
  • azathioprine azathioprine
  • Laquinimod 5-chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide
  • DHEA dehydroepiandrosterone
  • compositions and combinations of the invention are provided in the following listing of additional, enumerated embodiments. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of the present invention.
  • Compounds of the invention are generally inhibitors of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9), or any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9), and may therefore be useful in the treatment of autoimmune diseases associated with the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9), or any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9).
  • TLR7, TLR8 or TLR9 an endosomal Toll-like receptor
  • compounds of the invention may be useful in the treatment of autoimmune diseases, including systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • autoimmune diseases including systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • Compounds of the invention are typically inhibitors of TLR7, TLR7 and TLR8, or TLR7 and TLR8 and TLR9, and may therefore useful in the treatment of autoimmune diseases associated with TLR7 activity, TLR7 and TLR8 activity, or TLR7 and TLR8 and TLR9 activity.
  • compounds of the invention may be useful in the treatment of autoimmune diseases, including systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • autoimmune diseases including systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • compounds of the invention are generally inhibitors of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, or any combinations thereof, and may therefore be useful in the treatment of autoimmune diseases associated with the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, or any combinations thereof.
  • an endosomal Toll-like receptor e.g. TLR7, TLR8 or TLR9
  • compounds of the invention may be useful in the treatment of autoimmune diseases, including systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • autoimmune diseases including systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • the compounds of the invention in free form or in pharmaceutically acceptable salt form, exhibit valuable pharmacological properties, e.g. as indicated in vitro and in vivo tests as provided herein, and are therefore indicated for therapy or for use as research chemicals, e.g. as tool compounds.
  • the present invention provides the use of a compound of the invention in therapy, wherein the therapy is the treatment of an autoimmune disease which may be treated by inhibition of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9), or any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9).
  • an endosomal Toll-like receptor e.g. TLR7, TLR8 or TLR9
  • TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9 an endosomal Toll-like receptor
  • the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • the therapy is the treatment of an autoimmune disease which may be treated by inhibition of TLR7, TLR7 and TLR8, or TLR7 and TLR8 and TLR9.
  • the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • the present invention provides the use of a compound of the invention in therapy, wherein the therapy is the treatment of an autoimmune disease which may be treated by inhibition of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, and any combinations thereof.
  • an endosomal Toll-like receptor e.g. TLR7, TLR8 or TLR9 pathway, and any combinations thereof.
  • the autoimmune disease is selected from an autoimmune disease like systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • an autoimmune disease like systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • the invention provides a method of treating an autoimmune disease which is treated by inhibition of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9), or any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9), wherein the method comprises administration of a therapeutically acceptable amount of a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk).
  • an endosomal Toll-like receptor e.g. TLR7, TLR8 or TLR9
  • the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • the invention provides a method of treating an autoimmune disease which is treated by inhibition of TLR7, TLR7 and TLR8 or TLR7 and TLR8 and TLR9, wherein the method comprises administration of a therapeutically acceptable amount of a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk).
  • the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • the invention provides a method of treating an autoimmune disease which is treated by inhibition of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, or any combinations thereof, wherein the method comprises administration of a therapeutically acceptable amount of a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk).
  • an endosomal Toll-like receptor e.g. TLR7, TLR8 or TLR9
  • the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • the present invention provides the use of a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk) in the manufacture of a medicament for the treatment of an autoimmune disease associated the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9), or any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9).
  • an endosomal Toll-like receptor e.g. TLR7, TLR8 or TLR9
  • TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9 an endosomal Toll-like receptor
  • the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • the present invention provides the use of a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk) in the manufacture of a medicament for the treatment of an autoimmune disease associated with the activity of TLR7, TLR7 and TLR8 or TLR7 and TLR8 and TLR9.
  • the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • the present invention provides the use of a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk) in the manufacture of a medicament for the treatment of an autoimmune disease associated the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, or any combinations.
  • an endosomal Toll-like receptor e.g. TLR7, TLR8 or TLR9
  • the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • PBMCs Peripheral blood mononuclear cells
  • Purified PBMCs were re-suspended in assay medium (RPMI-1640 w Glutamax (Invitrogen) supplemented with 5% HI-FBS, 10 mM HEPES, 50 uM ⁇ -mercaptoethanol, and 100 mG/L penicillin/streptomycin cocktail). Viable PBMCs were counted on a hemacytometer and kept on ice until ready for plating.
  • assay medium RPMI-1640 w Glutamax (Invitrogen) supplemented with 5% HI-FBS, 10 mM HEPES, 50 uM ⁇ -mercaptoethanol, and 100 mG/L penicillin/streptomycin cocktail.
  • a 4 ⁇ concentration (4 ug/ml or 40 ug/ml for TLR8 or TLR7 assays, respectively) of the TLR7/8 agonist ssRNA40 (IDT) was complexed with 10% DOTAP (Roche) in assay medium for 30 min prior to addition to the PBMC suspension (5 million cells/ml).
  • the final concentration of ssRNA40 in the TLR7/8 stimulated PBMC suspension was 1 ⁇ g/ml for TLR8 assay, and 10 g/mL for the TLR7 assay.
  • the final DOTAP concentration was 2.5%.
  • Diluted PBMCs (5 million cells/ml) were treated with 4 ⁇ TLR9 agonist ODN2216 (Invivogen). Final concentration of ODN2216 in TLR9 stimulated PBMC suspension was 0.3 ⁇ M.
  • Agonist stimulated PBMCs were plated on the compound treated 384 well plates at 150,000 cells/well. Un-stimulated PBMCs were plated as controls on each plate. Plating volume was 40 ⁇ L per well. DMSO concentration in each well was 0.25%.
  • a separate plate, without compounds, with titrations of ssRNA40 and ODN2216 was included in every assay to measure agonist response of each donor's PBMC prep.
  • Assay plates were placed in a tissue culture incubator (37° C., 5% CO 2 ) for 14-16 hrs. After this incubation, the plates were centrifuged and stored at ⁇ 20° C. until they were assayed.
  • Cisbio Human IL-6 kit, 20,000 tests (62TNFPEC), and GNF High-Base TC 384 well plates (cat #789163G) were used; 2) the Anti-TIL-6 Cryptate conjugate and the Anti-IL-6 XL665 conjugate were diluted 1:20 in Reconstitution Buffer; 3) a 1:1 mixture of 3 ⁇ l/well Anti-IL-6 Cryptate conjugate and 3 ⁇ l/well Anti-IL-6 XL665 conjugate was prepared; 4) 6 ⁇ l/well HTRF dilution mastermix was added to 6 ⁇ l of transferred supernatant samples in proxiplates; 5) The plates were incubated for 3 hrs at rt in the dark; and 6) the levels of IL-6 production was measured using an Envision plate reader (665 nm (emmission)/590 nm (excitation)) with HTRF settings and ratiometric read-out: (XL665 emission/Eu Cryptate emission) ⁇ 10,000.
  • THP-1 cells were cultured in RPMI 1640 with 10% FBS, 10 mM HEPES, 1 mM Sodium Pyruvate, 1% Penicillin-Streptomycin L-glutamine, and 1% Non-Essential Amino Acids; 2) 3 sets of different passages of THP-1 cells in assay media were pooled, counted, and resuspended in the same media as culture media, but with 5% FBS; 3) Cells were diluted to 100,000 cells/well (30 ⁇ l/well) and the R848 agonist was diluted to 25 ⁇ M in 10 ul/well in media; 4) The cell and agonist dilutions were combined and 40 ⁇ l/well were added to 384-well flat bottom Greiner assay plates containing test compounds in DMSO, which were Echo pre-spotted at 50 nL per well with a 8 mM top dose and 10 point 1:3 serial dilutions—10 M final top dose; 5) The plates were incubated overnight for 18
  • Various compounds of the invention in free form or in pharmaceutically acceptable salt form, exhibit pharmacological properties, for example, as indicated by the assay results presented in Table 7.
  • the IC 50 values are given as the concentration of the test compound in question that provoke a response halfway between the baseline and maximum responses. Dashes (---) in Table 7 mean that no tests were conducted.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention disclosed herein relates to 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridinyl compounds and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinyl compounds of Formula (A), pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of autoimmune diseases.
Figure US20210101902A1-20210408-C00001

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application claims the benefit of U.S. Provisional Application No. 62/385,726, filed 9 Sep. 2016, which is incorporated by reference herein in its entirety.
    • FIELD OF THE INVENTION
  • The invention provides 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine compounds and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine compounds, the use thereof for inhibiting an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) and any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9), the use thereof for inhibiting an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, and any combinations thereof, and methods of treating autoimmune diseases using such compounds.
    • BACKGROUND OF THE INVENTION
  • Early detection of specific classes of pathogens is accomplished by the innate immune system with the help of pattern recognition receptors (PRRs). Toll-like receptors (TLRs) are pattern recognition receptors which play an essential role in the innate immunity, by recognizing invasion of microbial pathogens and initiating intracellular signal transduction pathways to trigger expression of genes, the products of which can control innate immune responses. There are 10 TLRs in the human genome, where TLR1, TLR2, TLR4, TLR5, and TLR6 respond to extracellular stimuli, while TLR3, TLR7, TLR8, and TLR9 respond to intracytoplasmic pathogen associated molecular patterns (PAMPs), being associated with the endolysosomal compartment.
  • Toll-like receptors recognize pathogens associated molecular patterns present in molecules that are broadly shared by pathogens but are structurally distinct from host molecules. The ligands for these receptors are highly conserved microbial molecules such as lipopolysaccharides (LPS) (recognized by TLR4), lipopeptides (TLR2 in combination with TLR1 or TLR6), flagellin (TLR5), single-stranded RNA (TLR7 and TLR8), double-stranded RNA (TLR3), CpG motif-containing DNA (recognized by TLR9), and profilin present on uropathogenic bacteria (TLR 11). Thus cell-surface TLR dimers including TLR4-MD-2, TLR1-TLR2, and TLR6-TLR2 recognize microbial membrane lipids, whereas the endosomal Toll-like receptors TLR3, TLR7, TLR8, and TLR9 reside in intracellular organelles and recognize microbial nucleic acids.
  • TLR7, TLR8, and TLR9 belong to a subfamily of TLRs based on their genomic structure, sequence similarities, and homology. TLR7, TLR8, and TLR9 are located in intracellular endolysosomal compartments and show a unique pattern of cell type-specific expression that is thought to be responsible for different pathogen response profiles.
  • In addition to recognizing foreign material, TLRs can mistakenly respond to self products and cause autoimmune diseases. TLR7 and 9, innate immune sensors for microbial RNA or DNA, respectively, have been implicated in autoimmune diseases such as psoriasis (see Lande et al., “Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide”, Nature 449, pp 564-569, 2007), arthritis (see Asagiri et al., “Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis”, Science 319, pp 624-627, 2008), and systemic lupus erythematosus (SLE) (see Pisitkun, P. et al. “Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication”, Science 312, pp 1669-72, 2006; Deane, J. A. et al., “Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation”, Immunity, 27, pp 801-10, 2007; Christensen, S. R. et al. “Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus”, Immunity 25, pp 417-428, 2006; Ehlers, M., et al. “TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE”, J. Exp. Med. 203, pp 553-561, 2006; Deane, J. A., and Bolland S. “Nucleic acid-sensing TLRs as modifiers of autoimmunity”, J. Immunol., 117, pp 6573-8, 2006; and Marshak-Rothstein, A., and Rifkin, I. R., “Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease”, Annu. Rev. Immunol., 25, pp 419-441, 2007).
  • It has been shown that autoimmunity is exacerbated by the aberrant trafficking of self nucleic acids to endolysosomes (see Lande et al., 2007; Marshak-Rothstein and Rifkin, 2007; and Leadbetter et al., “Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors”, Nature, 416, pp 603-607, 2002). In autoimmune diseases like SLE, self-RNA and self-DNA are complexed with autoantibodies against the nucleic acid or nucleoproteins, delivered into endosomal compartments via FcgRII-mediated endocytosis, leading to dendritic cell (DC) activation and production of type I interferon (IFN) (Barrat et al., “Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus”, J. Exp. Med. 202, pp 1131-1139, 2005). While in psoriasis, self-DNA and -RNA form complexes with the cationic antimicrobial peptide LL37, gain access to TLR7 and 9 in endolysosomes of DCs, and induce aberrant production of IFN-a (Ganguly et al., “Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8”, J. Exp. Med. 206, pp 1983-1994, 2009; and Lande et al., 2007). In rheumatoid arthritis (RA) the synovial membrane is infiltrated by activated immune cells, predominantly macrophages and T cells, resulting in the chronic production of proinflammatory cytokines and matrix metalloproteinases. TNF plays a central role in RA and the inhibition of TLR8 has been shown to inhibit TNF production (see Sandra M. Sacre et al. “Inhibitors of TLR8 Reduce TNF Production from Human Rheumatoid Synovial Membrane Cultures”, J. Immun., 81, pp 8002-8009, 2008).
  • Because of their association with autoimmune diseases, it has been suggested that TLR7, TLR8 and TLR9 are important therapeutic targets for the treatment of systemic lupus erythematosus, rheumatoid arthritis, psoriasis and other autoimmune diseases.
    • SUMMARY OF THE INVENTION
  • There remains a need for new treatments and therapies for autoimmune diseases, in particular autoimmune diseases associated with TLR7, TLR8 and/or TLR9 activity. The invention provides compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, which may inhibit an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) and any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9). Additionally, the compounds of the invention may inhibit an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, and any combinations thereof. The invention further provides methods of treating, preventing, or ameliorating autoimmune diseases associated with the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9), or any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9), comprising administering to a subject in need thereof an effective amount of a compound of the invention. Various embodiments of the invention are described herein.
  • In one aspect of the invention are compounds having the structure of Formula (A), and the pharmaceutically acceptable salts thereof, which may inhibit an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) and any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9). Additionally, the compounds of Formula (A) may inhibit an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, and any combinations thereof:
  • Figure US20210101902A1-20210408-C00002
  • wherein:
    • RA is
  • Figure US20210101902A1-20210408-C00003
    • L is —CH2— or —CH2CH2—;
    • Y1 is —CH2— or —CH2CH2—;
    • Y2 is —CH2— or —CH2CH2—;
    • Y3 is —CH2—, —XCH2— or —CH2X—;
    • X is —CH2— or O;
    • R1 is —NHC(═O)R6, —NHC(═O)(CH2)nR6, —NH(CH2)nC(═O)R6, —NHC(═O)(CH2)mNHR5, —NHC(═O)(CH2)mN(R5)2, —NHC(═O)(CHR9)mNHR5, —NHC(═O)(CH2)mNH2, —NHC(═O)(CH2)nOR9, —NHC(═O)OR9, —NH(CH2)mC(═O)N(R8)2, —NH(CHR9)nC(═O)R6, NHC(═O)(CHR9)nR6, —NHC(═O)(CHR9)nN(R8)2, —NHC(═O)(CHR9)nNHR8, —NH(CHR9)nC(═O)N(R8)2, —NH(CHR9)mC(═O)R6, —NHR6, —NR5R6, —NH2, —N(R5)2, —NHR5, —NHR8, —N(R6R8), —NH(C(R9)2)nR10, —NR9C(═O)OR11, —NH(CH2)nR6, —NH(CHR9)nR6, —N(R6)2, —NHC(═O)(CH2)nN(CD3)2, —NH(CHR9)nCH2OR9, —NHCH2(CHR9)nOR9, —NH(CHR9)nOR9, —NR9(CH2)nOR9, —NHCH2(C(R9)2)nOR9, —OR9, —NR9C(═O)R5, —NR9C(═O)(CH2)nR5, —NR9C(═O)OR5, —NHS(═O)2R5, —NHC(═O)(CH2)nNR9C(═O)R5, —NHC(═O)(CH2)nNR9S(═O)2R5,
  • Figure US20210101902A1-20210408-C00004
  • an 8-oxa-3-azabicyclo[3.2.1]octanyl, a 5-6 membered heteroaryl having 1 to 3 ring members independently selected from N, O and S, and a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR16 and O which is unsubstituted or is substituted with 1-2 R7 groups;
    • R2 is H, C1-C6alkyl, C1-C6haloalkyl or C1-C6alkyl substituted with 1-2 R15 groups;
    • R3 is H, C1-C6alkyl, —CD3 or benzyl substituted with 1-2 R10 groups;
    • R4 is H, NH2, C1-C6alkyl, halo or a phenyl substituted with 0-2 R18 groups;
    • each R5 is independently selected from C1-C6alkyl, —CD3 and —(CH2)nOR9;
    • R6 is a C3-C6cycloalkyl, an oxa-3-azabicyclo[3.2.1]octane, or a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR16 and O which is unsubstituted or is substituted with 1-2 R12 groups;
    • each R7 is independently selected from C1-C6alkyl, halo, hydroxyl, oxo and a C1-C6alkyl substituted with 1 to 3 —OH;
    • each R8 is independently selected from C1-C6haloalkyl, —(C(R9)2)nOR9 and a C1-C6alkyl substituted with 1 to 3 —OH;
    • each R9 is independently selected from H and C1-C6alkyl;
    • R10 is C1-C6alkoxy or C3-C6cycloalkyl;
    • R11 is a C3-C6cycloalkyl which is unsubstituted or is substituted with 1 to 3 C1-C6alkyl groups;
    • each R12 is independently selected from C1-C6alkyl, hydroxyl, halo and a C1-C6alkyl substituted with 1 to 3 —OH;
    • R13 is H or C1-C6alkyl;
    • R14 is H or C1-C6alkyl;
    • R15 is —NHC(═O)(CH2)mNHR5, —NHC(═O)(CH2)mN(R5)2, —NHC(═O)(CH2)mNH2, —NHC(═O)(CHR9)nR6, —NHC(═O)(CHR9)nN(R8)2, —NHC(═O)(CHR9)nNHR8, —NH(CHR9)nC(═O)N(R8)2, —NH(CHR9)nC(═O)R6, —NHR6, —NH2, —N(R5)2, —NHR8, —N(R6R8), —NH(C(R9)2)nR10, —NR9C(═O)OR11, —NH(CHR9)nR6, —N(R6)2, —N(CD3)2, —NH(CHR9)nOR9 or —NHCH2(C(R9)2)nOR9;
    • each R16 is C1-C6alkyl;
    • each R17 is independently selected from H and C1-C6alkyl;
    • each R18 is independently selected from halo, —CN, C1-C6alkoxy and C1-C6alkyl;
    • m is 1, 2, 3, 4, 5 or 6, and
    • n is 1, 2, 3, 4, 5 or 6
  • In certain embodiments of such compounds of Formula (A) are compounds of Formula (I) and Formula (II):
  • Figure US20210101902A1-20210408-C00005
  • Another aspect of the invention is a pharmaceutical compositions that includes a therapeutically effective amount of a compound of Formula (A), Formula (I) or Formula (II) or subformulae thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • Another aspect of the invention is the use of a compound of Formula (A), Formula (I) or Formula (II), or subformulae thereof, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an autoimmune disease associated with the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9), or any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9).
  • Another aspect of the invention is the use of a compound of Formula (A), Formula (I) or Formula (II), or subformulae thereof, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an autoimmune disease associated with
      • i) TLR7 activity, or
      • ii) TLR7 activity and TLR8 activity, or
      • iii) TLR7 activity and TLR8 activity and TLR9 activity.
  • Another aspect of the invention is the use of a compound of Formula (A), Formula (I) or Formula (II), or subformulae thereof, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an autoimmune disease associated with the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, and any combinations thereof.
  • Another aspect of the invention is the use of a compound of Formula (A), Formula (I) or Formula (II), or subformulae thereof, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an autoimmune disease.
  • Another aspect of the invention is the use of a compound of Formula (A), Formula (I) or Formula (II), or subformulae thereof, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis. In an embodiment of this aspect the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, Sjögren's syndrome or psoriasis.
  • Another aspect of the invention is a method for treating an autoimmune disease associated with the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9), or any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9), wherein the method includes administering to a subject in need of such treatment an effective amount of a compound of Formula (A), Formula (I) or Formula (II), or subformulae thereof, or pharmaceutically acceptable salt thereof, thereby treating the disease.
  • Another aspect of the invention is a method for treating an autoimmune disease associated with:
      • i) TLR7 activity, or
      • ii) TLR7 activity and TLR8 activity, or
      • iii) TLR7 activity and TLR8 activity and TLR9 activity,
        wherein the method includes administering to a subject in need of such treatment an effective amount of a compound of Formula (A), Formula (I) or Formula (II), or subformulae thereof, or pharmaceutically acceptable salt thereof, thereby treating the disease.
  • Another aspect of the invention is a method for treating an autoimmune disease associated with the activity of with the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, and any combinations thereof, wherein the method includes administering to a subject in need of such treatment an effective amount of a compound of Formula (A), Formula (I) or Formula (II), or subformulae thereof, or pharmaceutically acceptable salt thereof, thereby treating the disease.
  • Another aspect of the invention is a method for treating an autoimmune disease associated with TLR7 activity, wherein the method includes administering to a subject in need of such treatment an effective amount of a compound of Formula (A), Formula (I) or Formula (II), or subformulae thereof, or pharmaceutically acceptable salt thereof, thereby treating the disease.
  • Another aspect of the invention is a method for treating an autoimmune disease associated with TLR7 and TLR8 activity, wherein the method includes administering to a subject in need of such treatment an effective amount of a compound of Formula (A), Formula (I) or Formula (II), or subformulae thereof, or pharmaceutically acceptable salt thereof, thereby treating the disease.
  • Another aspect of the invention is a method for treating an autoimmune disease associated with TLR7, TLR8 and TLR9 activity, wherein the method includes administering to a subject in need of such treatment an effective amount of a compound of Formula (A), Formula (I) or Formula (II), or subformulae thereof, or pharmaceutically acceptable salt thereof, thereby treating the disease.
  • In certain embodiments of such methods of treatment the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis. In another embodiment the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, Sjögren's syndrome or psoriasis.
  • Another aspect of the invention is a compound of Formula (A), Formula (I) or Formula (II), or subformulae thereof, or pharmaceutically acceptable salt thereof, for use in treating an autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis. In an embodiment of this aspect the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, Sjögren's syndrome or psoriasis.
  • Another aspect of the invention is a combination comprising a therapeutically effect amount of a compound of Formula (A), Formula (I) or Formula (II), or subformulae thereof, or pharmaceutically acceptable salt thereof, and one or more additional therapeutically agents and optionally further comprising a pharmaceutically acceptable carrier, wherein the additional therapeutically agent is independently selected from anti-inflammatory agents, immunomodulatory agents, immunosuppressive agents, cytokines, nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarial compounds, anti-rheumatic compounds, inhibitors of B-cell activating factor (BAFF), inhibitors of B-lymphocyte stimulator (BLyS), and steroid hormones.
    • DETAILED DESCRIPTION OF THE INVENTION
  • Various enumerated embodiments of the invention are described herein. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of the present invention.
    • Definitions
  • The term “C1-C6alkyl”, as used herein, refers to a fully saturated branched or straight chain hydrocarbon containing 1 to 6 carbon atoms. Non-limiting examples of “C1-C6alkyl” groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl and hexyl.
  • The term “C1-C6alkoxy”, as used herein, refers to the group —O—C1-C6alkyl, wherein the “C1-C6alkyl” group is as defined herein. Non-limiting examples of “C1-C6alkoxy” groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentyloxy, isopentyloxy and hexyloxy.
  • The term “cycloalkyl,” as used herein, refers to a saturated, monocyclic, fused bicyclic, fused tricyclic or bridged polycyclic ring system. Non-limiting examples of fused bicyclic or bridged polycyclic ring systems include bicyclo[1.1.1]pentane, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[3.1.1]heptane, bicyclo[3.2.1]octane, bicyclo[2.2.2]octane and adamantanyl. As used herein, the term “C3-C6cycloalkyl”, refers to a saturated monocyclic group having at least 3, and at most 6, carbon atoms. Non-limiting examples of such “C3-C6cycloalkyl” groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl groups.
  • The term “C1-C6haloalkyl”, as used herein, refer to the respective “C1-C6alkyl”, as defined herein, wherein at least one of the hydrogen atoms of the “C1-C6alkyl” is replaced by a halo atom. The C1-C6haloalkyl groups can be monoC1-C6haloalkyl, wherein such C1-C6haloalkyl groups have one iodo, one bromo, one chloro or one fluoro. Additionally, the C1-C6haloalkyl groups can be diC1-C6haloalkyl wherein such C1-C6haloalkyl groups can have two halo atoms independently selected from iodo, bromo, chloro or fluoro. Furthermore, the C1-C6haloalkyl groups can be polyC1-C6haloalkyl wherein such C1-C6haloalkyl groups can have two or more of the same halo atoms or a combination of two or more different halo atoms. Such polyC1-C6haloalkyl can be perhaloC1-C6haloalkyl where all the hydrogen atoms of the respective C1-C6alkyl have been replaced with halo atoms and the halo atoms can be the same or a combination of different halo atoms. Non-limiting examples of C1-C6haloalkyl groups include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, trifluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl.
  • The terms “halo” or “halogen” as used herein, refer to fluoro, chloro, bromo and iodo.
  • The term “5-6 membered heteroaryl,” as used herein, refers to a monocyclic aromatic ring structure having 5 or 6 ring members, wherein 1 to 3 ring members are independently selected from the heteroatoms N, O and S. Non-limiting examples of 5-6 membered heteroaryls include 2- or 3-furyl; 2- or 3-thienyl; 1-, 2- or 3-pyrrolyl; 2-, 4-, or 5-oxazolyl; 2-, 4-, or 5-thiazolyl; 1-, 2-, 4-, or 5-imidazolyl; 1-, 3-, 4-, or 5-pyrazolyl; 3-, 4-, or 5-isoxazolyl; 3-, 4-, or 5-isothiazolyl; 4- or 5-1,2,3-oxadiazolyl; 4- or 5-1,2,3-triazolyl; 2- or 5-1,3,4-thiadiazolyl; 2-, 3-, or 4-pyridyl; 3-, 4-, 5- or 6-pyridazinyl; 2-, 4-, 5- or 6-pyrimidinyl, and 2- or 3-pyrazinyl.
  • The term “heteroatoms” as used herein, refers to nitrogen (N), oxygen (O) or sulfur (S) atoms.
  • The term “4-6 membered heterocycloalkyl,” as used herein refers to a monocyclic ring structure having 4 to 6 ring members, wherein one to two of the ring members are independently selected from N, NH, NR16, O or —S—, wherein R16 is C1-C6alkyl. In preferred embodiments a 4-6 membered heterocycloalkyl is a monocyclic ring structure having 4 to 6 ring members wherein one to two of the ring members are independently selected from N, NH, NR16 and O, wherein R16 is C1-C6alkyl. Non-limiting examples of 4-6 membered heterocycloalkyl groups, as used herein, include azetadinyl, azetadin-1-yl, azetadin-2-yl, azetadin-3-yl, oxetanyl, oxetan-2-yl, oxetan-3-yl, oxetan-4-yl, thietanyl, thietan-2-yl, thietan-3-yl, thietan-4-yl, pyrrolidinyl, pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, pyrrolidin-4-yl, pyrrolidin-5-yl, tetrahydrofuranyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrofuran-4-yl, tetrahydrofuran-5-yl, tetrahydrothienyl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, tetrahydrothien-4-yl, tetrahydrothien-5-yl, piperidinyl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperidin-5-yl, piperidin-6-yl, tetrahydropyranyl, tetrahydropyran-2-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydropyran-5-yl, tetrahydropyran-6-yl, tetrahydrothiopyranyl, tetrahydrothiopyran-2-yl, tetrahydrothiopyran-3-yl, tetrahydrothiopyran-4-yl, tetrahydrothiopyran-5-yl, tetrahydrothiopyran-6-yl, piperazinyl, piperazin-1-yl, piperazin-2-yl, piperazin-3-yl, piperazin-4-yl, piperazin-5-yl, piperazin-6-yl, morpholinyl, morpholin-2-yl, morpholin-3-yl, morpholin-4-yl, morpholin-5-yl, morpholin-6-yl, thiomorpholinyl, thiomorpholin-2-yl, thiomorpholin-3-yl, thiomorpholin-4-yl, thiomorpholin-5-yl, thiomorpholin-6-yl, oxathianyl, oxathian-2-yl, oxathian-3-yl, oxathian-5-yl, oxathian-6-yl, dithianyl, dithian-2-yl, dithian-3-yl, dithian-5-yl, dithian-6-yl, dioxolanyl, dioxolan-2-yl, dioxolan-4-yl, dioxolan-5-yl, thioxanyl, thioxan-2-yl, thioxan-3-yl, thioxan-4-yl, thioxan-5-yl, dithiolanyl, dithiolan-2-yl, dithiolan-4-yl, dithiolan-5-yl, pyrazolidinyl, pyrazolidin-1-yl, pyrazolidin-2-yl, pyrazolidin-3-yl, pyrazolidin-4-yl and pyrazolidin-5-yl.
  • The term “hydroxyl” as used herein, refers to a —OH group.
  • The term “oxo” as used herein, refers to a ═O group.
  • The term “autoimmune disease,” or “autoimmune disorder,” as used herein, refers diseases wherein cells uncontrollably attack the body's own tissues and organs (autoimmunity), producing inflammatory reactions and other serious symptoms and diseases. Non-limiting examples of autoimmune diseases include idiopathic thrombocytopenic purpura, hemolytic anemia, systemic lupus erythematosus, cutaneous lupus, discoid lupus, rheumatoid arthritis (RA), multiple sclerosis (MS), systemic sclerosis, immune-mediated or type 1 diabetes mellitus, immune mediated glomerulonephritis, scleroderma, pernicious anemia, alopecia, pemphigus, pemphigus vulgaris, myasthenia gravis, inflammatory bowel diseases, Crohn's disease, Graves' disease, psoriasis, autoimmune thyroid diseases, Hashimoto's disease, Hashimoto's thyroiditis, polymyositis, dermatomyositis, CREST syndrome, Goodpasture's syndrome, mixed connective tissue disease myasthenia gravis pseudoparalytica, ophtalmia sympatica, phakogene uveitis, chronical aggressive hepatitis, primary billiary cirrhosis, autoimmune hemolytic anemy, Werlof disease, vitiligo vulgaris, Behcet's disease, collagen disease, uveitis, Sjögren's syndrome, autoimmune myocarditis, autoimmune hepatic diseases, autoimmune gastritis, pemphigus, Guillain-Barre syndrome, atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, idiopathic thrombocytopenia, polyarteritis nodosa, primary biliary sclerosis, sarcoidosis, sclerosing cholangitis, Takayasu's arteritis, temporal arteritis, Wegener's granulomatosis and HTLV-1-associated myelopathy.
  • The terms “combination” or “pharmaceutical combination,” as used herein mean a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients. The term “fixed combination” means that the active ingredients, by way of example, a compound of the invention and one or more additional therapeutic agent, are administered to a subject simultaneously in the form of a single entity or dosage. The term “non-fixed combination” means that the active ingredients, by way of example, a compound of the invention and one or more additional therapeutic agent, are administered to a subject as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the active ingredients in the body of the subject. The latter also applies to cocktail therapy, e.g. the administration of 3 or more active ingredients.
  • The terms “composition” or “pharmaceutical composition,” as used herein, refers to a mixture of a compound of the invention with at least one and optionally more than one other pharmaceutically acceptable chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients.
  • As used herein, the term “inhibit”, “inhibition” or “inhibiting” refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
  • The term “an optical isomer” or “a stereoisomer”, as used herein, refers to any of the various stereo isomeric configurations which may exist for a given compound of the present invention and includes geometric isomers. It is understood that a substituent may be attached at a chiral center of a carbon atom. The term “chiral” refers to molecules which have the property of non-superimposability on their mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner. Therefore, the invention includes enantiomers, diastereomers or racemates of the compound. “Enantiomers” are a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a “racemic” mixture. The term is used to designate a racemic mixture where appropriate. “Diastereoisomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other. The absolute stereochemistry is specified according to the Cahn-Ingold-Prelog R-S system. When a compound is a pure enantiomer the stereochemistry at each chiral carbon may be specified by either R or S. Resolved compounds whose absolute configuration is unknown can be designated (+) or (−) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line. Certain compounds described herein contain one or more asymmetric centers or axes and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-.
  • The term “pharmaceutically acceptable carrier”, as used herein, includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, and the like and combinations thereof, as would be known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.
  • The term “pharmaceutically acceptable salt,” as used herein, refers to a salt which does not abrogate the biological activity and properties of the compounds of the invention, and does not cause significant irritation to a subject to which it is administered.
  • The term “subject”, as used herein, encompasses mammals and non-mammals. Examples of mammals include, but are not limited to, humans, chimpanzees, apes, monkeys, cattle, horses, sheep, goats, swine, rabbits, dogs, cats, rats, mice, guinea pigs, and the like. Examples of non-mammals include, but are not limited to, birds, fish and the like. Frequently the subject is a human, and may be a human who has been diagnosed as in need of treatment for a disease or disorder associated with the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) and any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9), or associated with an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, and any combinations.
  • The term “a subject in need of such treatment”, refers to a subject which would benefit biologically, medically or in quality of life from such treatment.
  • The term “therapeutically effective amount,” as used herein, refers to an amount of a compound of the present invention that will elicit the biological or medical response of a subject, for example, reduction or inhibition of an enzyme or a protein activity, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease, etc. In one non-limiting embodiment, the term “a therapeutically effective amount” refers to the amount of the compound of the present invention that, when administered to a subject, is effective to (1) at least partially alleviate, inhibit, prevent and/or ameliorate a condition, or a disorder or a disease (i) mediated by an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) and any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9), or mediated by an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, and any combinations thereof or (ii) associated with an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) and any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9), or associated with an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, and any combinations thereof, or (iii) characterized by activity (normal or abnormal) of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) and any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9); or (2) reduce or inhibit the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) and any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9); or (3) reduce or inhibit the expression of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) and any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9). In another non-limiting embodiment, the term “a therapeutically effective amount” refers to the amount of the compound provided herein that, when administered to a cell, or a tissue, or a non-cellular biological material, or a medium, is effective to at least partially reducing or inhibiting the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) and any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9), or inhibiting the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, and any combinations thereof.
  • The terms “TLR7 inhibitors”, “TLR7 antagonist”, “inhibitor of TLR7” or “inhibitors of TLR7”, as used herein, refer to a compound of the invention which inhibits Toll-like Receptor 7 (TLR7). Compounds of the invention inhibit both type I Interferon and proinflammatory cytokines downstream of TLR7.
  • The terms “TLR8 inhibitors”, “TLR8 antagonist”, “inhibitor of TLR8” or “inhibitors of TLR8”, as used herein, refer to a compound of the invention which inhibits Toll-like Receptor 8 (TLR8).
  • The terms “TLR7 and TLR8 inhibitors”, “TLR7 and TLR8 antagonists”, “inhibitor of TLR7 and TLR8” or “inhibitors of TLR7 and TLR8”, as used herein, refer to a compound of the invention which inhibits Toll-like Receptor 7 (TLR7) and Toll-like Receptor 8 (TLR8). Compounds of the invention inhibit both type I Interferon downstream of TLR7 and proinflammatory cytokines downstream of NF-KB in TLR7 and TLR8 signaling. A “TLR7 and TLR8 inhibitor” or “TLR7 and TLR8 antagonist” can also be represented by the term “TLR7/8 antagonist”.
  • The terms “TLR7, TLR8 and TLR9 inhibitors”, “TLR7, TLR8 and TLR9 antagonists”, “inhibitor of TLR7, TLR8 and TLR9” or “inhibitors of TLR7, TLR8 and TLR9”, as used herein, refer to a compound of the invention which inhibits Toll-like Receptor 7 (TLR7), Toll-like Receptor 8 (TLR8) and Toll-like Receptor 9 (TLR9). Compounds of the invention inhibit both type I Interferon downstream of TLR7 and proinflammatory cytokines downstream of NF-KB in TLR7 and TLR8 signaling. A “TLR7 and TLR8 and TLR9 inhibitor” or “TLR7 and TLR8 and TLR9 antagonist” can also be represented by the term “TLR7/8/9 antagonist”.
  • The terms “treat”, “treating” or “treatment” of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment “treat”, “treating” or “treatment” refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient. In yet another embodiment, “treat”, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In yet another embodiment, “treat”, “treating” or “treatment” refers to preventing or delaying the onset or development or progression of the disease or disorder.
  • The compound names provided herein were obtained using ChemDraw Ultra version 12.0 (CambridgeSoft®) or JChem version 5.3.1 (ChemAxon).
  • Unless specified otherwise, the term “compounds of the present invention”, “compounds of the invention” or “compounds provided herein” refers to compounds of formula (A), Formula (I), Formula (II) and subformulae thereof (such as compounds of Formula (Ia to Ip) and Formula (IIa to IIk), and pharmaceutically acceptable salts, stereoisomers (including diastereoisomers and enantiomers), rotamers, tautomers and isotopically labeled compounds (including deuterium substitutions), as well as inherently formed moieties.
  • As used herein, the term “a,” “an,” “the” and similar terms used in the context of the present invention (especially in the context of the claims) are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context.
    • Compounds of the Invention
  • The compounds of the invention are compounds having the structure of Formula (A), or a pharmaceutically acceptable salt thereof:
  • Figure US20210101902A1-20210408-C00006
  • wherein:
    • RA is
  • Figure US20210101902A1-20210408-C00007
    • L is —CH2— or —CH2CH2—;
    • Y1 is —CH2— or —CH2CH2—;
    • Y2 is —CH2— or —CH2CH2—;
    • Y3 is —CH2—, —XCH2— or —CH2X—;
    • X is —CH2— or O;
    • R1 is —NHC(═O)R6, —NHC(═O)(CH2)nR6, —NH(CH2)nC(═O)R6, —NHC(═O)(CH2)mNHR5, —NHC(═O)(CH2)mN(R5)2, —NHC(═O)(CHR9)mNHR5, —NHC(═O)(CH2)mNH2, —NHC(═O)(CH2)nOR9, —NHC(═O)OR9, —NH(CH2)mC(═O)N(R5)2, —NH(CHR9)C(═O)R6, NHC(═O)(CHR9)nR6, —NHC(═O)(CHR9)nN(R8)2, —NHC(═O)(CHR9)nNHR8, —NH(CHR9)nC(═O)N(R8)2, —NH(CHR9)mC(═O)R6, —NHR6, —NR5R6, —NH2, —N(R5)2, —NHR5, —NHR8, —N(R6R8), —NH(C(R9)2)nR10, —NR9C(═O)OR11, —NH(CH2)nR6, —NH(CHR9)nR6, —N(R6)2, —NHC(═O)(CH2)nN(CD3)2, —NH(CHR9)nCH2OR9, —NHCH2(CHR9)nOR9, —NH(CHR9)nOR9, —NR9(CH2)nOR9, —NHCH2(C(R9)2)nOR9, —OR9, —NR9C(═O)R5, —NR9C(═O)(CH2)nR5, —NR9C(═O)OR5, —NHS(═O)2R5, —NHC(═O)(CH2)nNR9C(═O)R5, —NHC(═O)(CH2)nNR9S(═O)2R5,
  • Figure US20210101902A1-20210408-C00008
  • an 8-oxa-3-azabicyclo[3.2.1]octanyl, a 5-6 membered heteroaryl having 1 to 3 ring members independently selected from N, O and S, and a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR16 and O which is unsubstituted or is substituted with 1-2 R7 groups;
    • R2 is H, C1-C6alkyl, C1-C6haloalkyl or C1-C6alkyl substituted with 1-2 R15 groups;
    • R3 is H, C1-C6alkyl, —CD3 or benzyl substituted with 1-2 R10 groups;
    • R4 is H, NH2, C1-C6alkyl, halo or a phenyl substituted with 0-2 R18 groups;
    • each R5 is independently selected from C1-C6alkyl, —CD3 and —(CH2)nOR9;
    • R6 is a C3-C6cycloalkyl, an oxa-3-azabicyclo[3.2.1]octane or a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR16 and O which is unsubstituted or is substituted with 1-2 R12 groups;
    • each R7 is independently selected from C1-C6alkyl, halo, hydroxyl, oxo and a C1-C6alkyl substituted with 1 to 3 —OH;
    • each R8 is independently selected from C1-C6haloalkyl, —(C(R9)2)nOR9 and a C1-C6alkyl substituted with 1 to 3 —OH;
    • each R9 is independently selected from H and C1-C6alkyl;
    • R10 is C1-C6alkoxy or C3-C6cycloalkyl;
    • R11 is a C3-C6cycloalkyl which is unsubstituted or is substituted with 1 to 3 C1-C6alkyl groups;
    • each R12 is independently selected from C1-C6alkyl, hydroxyl, halo and a C1-C6alkyl substituted with 1 to 3 —OH;
    • R13 is H or C1-C6alkyl;
    • R14 is H or C1-C6alkyl;
    • R15 is —NHC(═O)(CH2)mNHR5, —NHC(═O)(CH2)mN(R5)2, —NHC(═O)(CH2)mNH2, —NHC(═O)(CHR9)nR6, —NHC(═O)(CHR9)nN(R8)2, —NHC(═O)(CHR9)nNHR8, —NH(CHR9)nC(═O)N(R8)2, —NH(CHR9)nC(═O)R6, —NHR6, —NH2, —N(R5)2, —NHR8, —N(R6R8), —NH(C(R9)2)nR10, —NR9C(═O)OR11, —NH(CHR9)nR6, —N(R6)2, —N(CD3)2, —NH(CHR9)nOR9 or —NHCH2(C(R9)2)nOR9;
    • each R16 is C1-C6alkyl;
    • each R17 is independently selected from H and C1-C6alkyl;
    • each R18 is independently selected from halo, —CN, C1-C6alkoxy and C1-C6alkyl;
    • m is 1, 2, 3, 4, 5 or 6, and
    • n is 1, 2, 3, 4, 5 or 6
  • Certain aspects and examples of the compounds of the invention are provided in the following listing of additional, enumerated embodiments. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of the present invention.
    • Embodiment 1. The compound having the structure of Formula (A) is a compound having the structure of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof:
  • Figure US20210101902A1-20210408-C00009
  • wherein Y1, Y2, Y3, L, R1, R2 and RA are as defined herein for compounds of Formula (A).
    • Embodiment 2. The compound having the structure of Formula (A) or Formula (I) is a compound having the structure of Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), Formula (If), Formula (Ig), Formula (Ih), Formula (Ii), Formula (Ij) or Formula (Ik), or a pharmaceutically acceptable salt thereof:
  • Figure US20210101902A1-20210408-C00010
    Figure US20210101902A1-20210408-C00011
    Figure US20210101902A1-20210408-C00012
      • Formula (Ie) Formula (If)
        wherein Y1, Y2, Y3, L, R1, R2, R3, R4, R13, R14 and R18 are as defined herein for compounds of Formula (A).
    • Embodiment 3. The compound having the structure of Formula (A) or Formula (I) is a compound having the structure of Formula (Ia) or Formula (Ig), or a pharmaceutically acceptable salt thereof:
  • Figure US20210101902A1-20210408-C00013
  • wherein Y1, Y2, Y3, L, R1, R2, R3, R4 and R13 are as defined herein for compounds of Formula (A)
    • Embodiment 4. The compound having the structure of Formula (A) or Formula (I) is a compound having the structure of Formula (Ib), Formula (Ic) or Formula (Id), or a pharmaceutically acceptable salt thereof:
  • Figure US20210101902A1-20210408-C00014
  • wherein Y1, Y2, Y3, L, R1, R2, R3, R4 and R13 are as defined herein for compounds of Formula (A).
    • Embodiment 5. The compound having the structure of Formula (A) or Formula (I) is a compound having the structure of Formula (Ie) or Formula (Ih), or a pharmaceutically acceptable salt thereof:
  • Figure US20210101902A1-20210408-C00015
  • wherein Y1, Y2, Y3, L, R1, R2 and R3 are as defined herein for compounds of Formula (A).
    • Embodiment 6. The compound having the structure of Formula (A) or Formula (I) is a compound having the structure of Formula (If), or a pharmaceutically acceptable salt thereof:
  • Figure US20210101902A1-20210408-C00016
  • wherein Y1, Y2, Y3, L, R1, R2, R3, R4 and R14 are as defined herein for compounds of Formula (A).
    • Embodiment 7. The compound having the structure of Formula (A) or Formula (I) is a compound having the structure of Formula (Ii), or a pharmaceutically acceptable salt thereof:
  • Figure US20210101902A1-20210408-C00017
  • wherein Y1, Y2, Y3, L, R1, R2, R4 and each R13 are as defined herein for compounds of Formula (A).
    • Embodiment 8. The compound having the structure of Formula (A) or Formula (I) is a compound having the structure of Formula (Ij) or Formula (Ik), or a pharmaceutically acceptable salt thereof:
  • Figure US20210101902A1-20210408-C00018
  • wherein Y1, Y2, Y3, L, R1, R2, R3 and R18 are as defined herein for compounds of Formula (A).
    • Embodiment 9. The compound having the structure of Formula (A) or Formula (I) is a compound having the structure of Formula (Im), or a pharmaceutically acceptable salt thereof:
  • Figure US20210101902A1-20210408-C00019
  • wherein Y1, Y2, Y3, L, R1, R2, R3 and R4 are as defined herein for compounds of Formula (A).
    • Embodiment 10. The compound having the structure of Formula (A) or Formula (I) is a compound having the structure of Formula (In), or a pharmaceutically acceptable salt thereof:
  • Figure US20210101902A1-20210408-C00020
  • wherein Y1, X, L, R1, R2, R3 and R4 are as defined herein for compounds of Formula (A).
    • Embodiment 11. The compound having the structure of Formula (A) or Formula (I) is a compound having the structure of Formula (Io), or a pharmaceutically acceptable salt thereof:
  • Figure US20210101902A1-20210408-C00021
  • wherein L, R1, R2, R3 and R4 are as defined herein for compounds of Formula (A).
    • Embodiment 12. The compound having the structure of Formula (A) or Formula (I) is a compound having the structure of Formula (Ip), or a pharmaceutically acceptable salt thereof:
  • Figure US20210101902A1-20210408-C00022
  • wherein R1 is as defined herein for compounds of Formula (A).
    • Embodiment 13. The compound having the structure of Formula (A) or Formula (II) is a compound having the structure of Formula (IIa), Formula (IIb), Formula (IIc), Formula (IId), Formula (IIe), Formula (IIf), Formula (IIg), Formula (IIh), Formula (IIi), Formula (IIj) or Formula (IIk), or a pharmaceutically acceptable salt thereof:
  • Figure US20210101902A1-20210408-C00023
    Figure US20210101902A1-20210408-C00024
    Figure US20210101902A1-20210408-C00025
  • wherein Y1, Y2, Y3, L, R1, R2, R3, R4, R13, R14 and R18 are as defined herein for compounds of Formula (A).
    • Embodiment 14. The compound having the structure of Formula (A) or Formula (II) is a compound having the structure of Formula (IIa) or Formula (IIg), or a pharmaceutically acceptable salt thereof:
  • Figure US20210101902A1-20210408-C00026
  • wherein Y1, Y2, Y3, L, R1, R2, R3, R4 and R13 are as defined herein for compounds of Formula (A).
    • Embodiment 15. The compound having the structure of Formula (A) or Formula (II) is a compound having the structure of Formula (IIb), Formula (IIc) or Formula (IId), or a pharmaceutically acceptable salt thereof:
  • Figure US20210101902A1-20210408-C00027
  • wherein Y1, Y2, Y3, L, R1, R2, R3, R4 and R13 are as defined herein for compounds of Formula (A).
    • Embodiment 16. The compound having the structure of Formula (A) or Formula (II) is a compound having the structure of Formula (IIe) or Formula (IIh), or a pharmaceutically acceptable salt thereof:
  • Figure US20210101902A1-20210408-C00028
  • wherein Y1, Y2, Y3, L, R1, R2 and R3 are as defined herein for compounds of Formula (A).
    • Embodiment 17. The compound having the structure of Formula (A) or Formula (II) is a compound having the structure of Formula (IIf), or a pharmaceutically acceptable salt thereof:
  • Figure US20210101902A1-20210408-C00029
  • wherein Y1, Y2, Y3, L, R1, R2, R3, R4 and R14 are as defined herein for compounds of Formula (A).
    • Embodiment 18. The compound having the structure of Formula (A) or Formula (II) is a compound having the structure of Formula (IIi), or a pharmaceutically acceptable salt thereof:
  • Figure US20210101902A1-20210408-C00030
  • wherein Y1, Y2, Y3, L, R1, R2, R4 and each R13 are as defined herein for compounds of Formula (A).
    • Embodiment 19. The compound having the structure of Formula (A) or Formula (II) is a compound having the structure of Formula (IIj) or Formula (IIk), or a pharmaceutically acceptable salt thereof:
  • Figure US20210101902A1-20210408-C00031
  • wherein Y1, Y2, Y3, L, R1, R2, R3 and R18 are as defined herein for compounds of Formula (A).
    • Embodiment 20. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • L is —CH2— or —CH2CH2—;
      • Y1 is —CH2— or —CH2CH2—;
      • Y2 is —CH2— or —CH2CH2—;
      • Y3 is —CH2— or —XCH2—;
      • X is —CH2— or O;
      • R1 is —NHC(═O)R6, —NHC(═O)(CH2)nR6, —NHC(═O)(CH2)mNHR5, —NHC(═O)(CH2)mN(R5)2, —NHC(═O)(CHR9)mNHR5, —NHC(═O)(CH2)mNH2, —NHC(═O)(CH2)nOR9, —NHC(═O)OR9, —NHC(═O)(CHR9)nR6, —NHC(═O)(CHR9)nN(R8)2, —NHC(═O)(CHR9)nNHR8, —NR9C(═O)OR11, —NHC(═O)(CH2)nN(CD3)2, —NR9C(═O)R5, —NR9C(═O)(CH2)nR5, —NR9C(═O)OR5, —NHS(═O)2R5, —NHC(═O)(CH2)nNR9C(═O)R5 or —NHC(═O)(CH2)nNR9S(═O)2R5;
      • R2 is H, C1-C6alkyl or C1-C6haloalkyl;
      • R3 is H, C1-C6alkyl or —CD3;
      • R4 is H, NH2, C1-C6alkyl or halo;
      • each R5 is independently selected from C1-C6alkyl, —CD3 and —(CH2)nOR9;
      • R6 is a C3-C6cycloalkyl or a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR16 and O which is unsubstituted or is substituted with 1-2 R12 groups;
      • each R8 is independently selected from C1-C6haloalkyl, —(C(R9)2)nOR9 and a C1-C6alkyl substituted with 1 to 3 —OH;
      • each R9 is independently selected from H and C1-C6alkyl;
      • R11 is a C3-C6cycloalkyl which is unsubstituted or is substituted with 1 to 3 C1-C6alkyl groups;
      • each R12 is independently selected from C1-C6alkyl, hydroxyl, halo and a C1-C6alkyl substituted with 1 to 3 —OH;
      • R13 is H or C1-C6alkyl;
      • R14 is H or C1-C6alkyl;
      • each R16 is C1-C6alkyl;
      • each R17 is independently selected from H and C1-C6alkyl;
      • each R18 is independently selected from halo, —CN, C1-C6alkoxy and C1-C6alkyl;
      • m is 1, 2, 3, 4, 5 or 6, and
      • n is 1, 2, 3, 4, 5 or 6.
    • Embodiment 21. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • L is —CH2— or —CH2CH2—;
      • Y1 is —CH2— or —CH2CH2—;
      • Y2 is —CH2— or —CH2CH2—;
      • Y3 is —CH2— or —XCH2—;
      • X is —CH2— or O;
      • R1 is —NH(CH2)nC(═O)R6, —NH(CH2)mC(═O)N(R5)2, —NH(CHR9)nC(═O)R6, —NH(CHR9)nC(═O)N(R8)2, —NH(CHR9)mC(═O)R6, —NH(C(R9)2)nR10, —NH(CH2)nR6, —NH(CHR9)nR6, —NH(CHR9)nCH2OR9, —NHCH2(CHR9)nOR9, —NH(CHR9)nOR9, —NR9(CH2)nOR9, or —NHCH2(C(R9)2)nOR9;
      • R2 is H, C1-C6alkyl or C1-C6haloalkyl;
      • R3 is H, C1-C6alkyl or —CD3;
      • R4 is H, NH2, C1-C6alkyl or halo;
      • each R5 is independently selected from C1-C6alkyl, —CD3 and —(CH2)nOR9;
      • R6 is a C3-C6cycloalkyl or a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR16 and O which is unsubstituted or is substituted with 1-2 R12 groups;
      • each R8 is independently selected from C1-C6haloalkyl, —(C(R9)2)nOR9 and a C1-C6alkyl substituted with 1 to 3 —OH;
      • each R9 is independently selected from H and C1-C6alkyl;
      • R10 is C1-C6alkoxy or C3-C6cycloalkyl;
      • each R12 is independently selected from C1-C6alkyl, hydroxyl, halo and a C1-C6alkyl substituted with 1 to 3 —OH;
      • R13 is H or C1-C6alkyl;
      • R14 is H or C1-C6alkyl;
      • each R16 is C1-C6alkyl;
      • each R17 is independently selected from H and C1-C6alkyl;
      • each R18 is independently selected from halo, —CN, C1-C6alkoxy and C1-C6alkyl;
      • m is 1, 2, 3, 4, 5 or 6, and
      • n is 1, 2, 3, 4, 5 or 6.
    • Embodiment 22. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • L is —CH2— or —CH2CH2—;
      • Y1, is —CH2— or —CH2CH2—;
      • Y2 is —CH2— or —CH2CH2—;
      • Y3 is —CH2— or —XCH2—;
      • X is —CH2— or O;
      • R1 is —NHR6, —NR5R6, —NH2, —N(R5)2, —NHR5, —NHR8, —N(R6R8) or —N(R6)2;
      • R2 is H, C1-C6alkyl or C1-C6haloalkyl;
      • R3 is H, C1-C6alkyl or —CD3;
      • R4 is H, NH2, C1-C6alkyl or halo;
      • each R5 is independently selected from C1-C6alkyl, —CD3 and —(CH2)OR9;
      • R6 is a C3-C6cycloalkyl or a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR16 and O which is unsubstituted or is substituted with 1-2 R12 groups;
      • each R8 is independently selected from C1-C6haloalkyl, —(C(R9)2)nOR9 and a C1-C6alkyl substituted with 1 to 3 —OH;
      • each R12 is independently selected from C1-C6alkyl, hydroxyl, halo and a C1-C6alkyl substituted with 1 to 3 —OH;
      • R13 is H or C1-C6alkyl;
      • R14 is H or C1-C6alkyl;
      • each R16 is C1-C6alkyl;
      • each R17 is independently selected from H and C1-C6alkyl;
      • each R18 is independently selected from halo, —CN, C1-C6alkoxy and C1-C6alkyl;
      • m is 1, 2, 3, 4, 5 or 6, and
      • n is 1, 2, 3, 4, 5 or 6.
    • Embodiment 23. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • R1 is —NHC(═O)R6, —NHC(═O)(CH2)nR6, —NH(CH2)nC(═O)R6, —NHC(═O)(CH2)mNHR5, —NHC(═O)(CH2)mN(R5)2, —NHC(═O)(CHR9)mNHR5, —NHC(═O)(CH2)mNH2, —NHC(═O)(CH2)nOR9, —NHC(═O)OR9, —NH(CH2)mC(═O)N(R5)2, —NH(CHR9)nC(═O)R6, NHC(═O)(CHR9)nR6, —NHC(═O)(CHR9)nN(R8)2, —NHC(═O)(CHR9)nNHR8, —NH(CHR9)nC(═O)N(R8)2, —NH(CHR9)mC(═O)R6, —NHR6, —NR5R6, —NH2, —N(R5)2, —NHR5, —NHR8, —N(R6R8), —NH(C(R9)2)nR10, —NR9C(═O)OR11, —NH(CH2)nR6, —NH(CHR9)nR6, —N(R6)2, —NHC(═O)(CH2)nN(CD3)2, —NH(CHR9)nCH2OR9, —NHCH2(CHR9)nOR9, —NH(CHR9)nOR9, —NR9(CH2)nOR9, —NHCH2(C(R9)2)nOR9, —OR9, —NR9C(═O)R5, —NR9C(═O)(CH2)nR5, —NR9C(═O)OR5, —NHS(═O)2R5, —NHC(═O)(CH2)nNR9C(═O)R5, or —NHC(═O)(CH2)nNR9S(═O)2R5.
    • Embodiment 24. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • R1 is —NHC(═O)R6, —NHC(═O)(CH2)nR6, —NH(CH2)nC(═O)R6, —NHC(═O)(CH2)mNHR5, —NHC(═O)(CH2)mN(R5)2, —NHC(═O)(CHR9)mNHR5, —NHC(═O)(CH2)mNH2, —NHC(═O)(CH2)nOR9, —NHC(═O)OR9, —NH(CH2)mC(═O)N(R5)2, —NH(CHR9)mC(═O)R6, —NHR6, —NR5R6, —NH2, —N(R5)2, —NHR5, —NHR8, —NR9C(═O)OR11, —NH(CH2)nR6, —N(R6)2, —NHC(═O)(CH2)nN(CD3)2, —NH(CHR9)nCH2OR9, —NHCH2(CHR9)nOR9, —NH(CHR9)nOR9, —NR9(CH2)nOR9, —NHCH2(C(R9)2)nOR9, —OR9, —NR9C(═O)R5, —NR9C(═O)OR5, —NHS(═O)2R5, —NHC(═O)(CH2)nNR9C(═O)R5, or —NHC(═O)(CH2)nNR9S(═O)2R5.
    • Embodiment 25. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • R1 is —NHC(═O)R6, —NHC(═O)(CH2)nR6, —NHC(═O)(CH2)mNHR5, —NHC(═O)(CH2)mN(R5)2, —NHC(═O)(CHR9)mNHR5, —NHC(═O)(CH2)mNH2, —NHC(═O)(CH2)nOR9, —NHC(═O)OR9, —NHC(═O)(CHR9)nR6, —NHC(═O)(CHR9)N(R8)2, —NHC(═O)(CHR9)nNHR8, —NR9C(═O)OR11, —NHC(═O)(CH2)nN(CD3)2, —NR9C(═O)R5, —NR9C(═O)(CH2)nR5, —NR9C(═O)OR5, —NHS(═O)2R5, —NHC(═O)(CH2)nNR9C(═O)R5 or —NHC(═O)(CH2)nNR9S(═O)2R5.
    • Embodiment 26. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • R1 is —NHC(═O)R6, —NHC(═O)(CH2)nR6, —NH(CH2)nC(═O)R6, —NHC(═O)(CH2)mNHR5, —NHC(═O)(CH2)mN(R5)2, —NHC(═O)(CHR9)mNHR5, —NHC(═O)(CH2)mNH2, —NH(CH2)mC(═O)N(R5)2, —NH(CHR9)nC(═O)R6, —NHR6, —NH2, —N(R5)2, —NHR5, —NHR8, —NH(CHR9)nOR9 or —NHCH2(C(R9)2)nOR9.
    • Embodiment 27. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • R1 is —NHC(═O)R6, —NHC(═O)(CH2)mN(R5)2, —NHC(═O)(CH2)mNHR5, —NHC(═O)(CH2)mNH2, —NHC(═O)(CHR9)nR6, —NHC(═O)(CHR9)nNHR8, —NH(CHR9)nC(═O)N(R8)2, —NH(CHR9)nC(═O)R6, —NHR6, —NH2, —N(R5)2, or —NHR8.
    • Embodiment 28. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • R1 is —NHC(═O)R6, —NHC(═O)(CH2)nR6, —NHC(═O)(CH2)mNHR5, —NHC(═O)(CH2)mN(R5)2, —NHC(═O)(CHR9)mNHR5, —NHC(═O)(CH2)mNH2, —NHR6, —NH2, —N(R5)2, —NHR5, or —NHR8.
    • Embodiment 29. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • R1 is —NH(CH2)nC(═O)R6, —NH(CH2)mC(═O)N(R5)2, —NH(CHR9)nC(═O)R6, —NH(CHR9)nOR9 or —NHCH2(C(R9)2)nOR9.
    • Embodiment 30. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, R1 is —NHC(═O)R6, —NHC(═O)(CH2)mN(R5) 2, —NHR6 or —NH2.
    • Embodiment 31. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, R1 is —NHC(═O)R6, —NHC(═O)(CHR9)nR6, —NH(CHR9)nC(═O)R6 or —NHR6;
    • Embodiment 32. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • R1 is —NH(CH2)nC(═O)R6, —NH(CH2)mC(═O)N(R5)2, —NH(CHR9)nC(═O)R6, —NH(CHR9)nC(═O)N(R8)2, —NH(CHR9)mC(═O)R6, —NH(C(R9)2)nR10, —NH(CH2)nR6, —NH(CHR9)nR6, —NH(CHR9)nCH2OR9, —NHCH2(CHR9)nOR9, —NH(CHR9)nOR9, —NR9(CH2)nOR9, or —NHCH2(C(R9)2)nOR9.
    • Embodiment 33. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • R1 is —NHR6, —NR5R6, —NH2, —N(R5)2, —NHR5, —NHR8, —N(R6R8) or —N(R6)2.
    • Embodiment 34. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • R1 is —NHC(═O)R6, —NHC(═O)(CH2)mN(R5)2, —NHC(═O)(CH2)mNHR5, —NHC(═O)(CH2)mNH2, —NHC(═O)(CHR9)nR6, —NHC(═O)(CHR9)nNHR8, —NH(CHR9)nC(═O)N(R8)2, —NH(CHR9)nC(═O)R6, —NHR6, —NH2, —N(R5)2, —NHR8, an 8-oxa-3-azabicyclo[3.2.1]octanyl,
  • Figure US20210101902A1-20210408-C00032
  • or a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR16 or O which is unsubstituted or is substituted with 1-2 R7 groups.
    • Embodiment 35. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • R1 is —NHC(═O)R6, —NHC(═O)(CH2)nR6, —NH(CH2)nC(═O)R6, —NHC(═O)(CH2)mNHR5, —NHC(═O)(CH2)mN(R5)2, —NHC(═O)(CHR9)mNHR5, —NHC(═O)(CH2)mNH2, —NH(CH2)mC(═O)N(R5)2, —NH(CHR9)nC(═O)R6, —NHR6, —NH2, —N(R5)2, —NHR5, —NHR8, —NH(CHR9)nOR9, —NHCH2(C(R9)2)nOR9, an 8-oxa-3-azabicyclo[3.2.1]octanyl,
  • Figure US20210101902A1-20210408-C00033
  • or a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR16 or O which is unsubstituted or is substituted with 1-2 R7 groups.
    • Embodiment 36. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • L is —CH2— or —CH2CH2—;
      • Y1 is —CH2— or —CH2CH2—;
      • Y2 is —CH2— or —CH2CH2—;
      • Y3 is —CH2— or —XCH2—;
      • X is —CH2— or O;
      • R1 is
  • Figure US20210101902A1-20210408-C00034
  • —OR9, an 8-oxa-3-azabicyclo[3.2.1]octanyl, a 5-6 membered heteroaryl having 1 to 3 ring members independently selected from N, O and S, or a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR16 or O which is unsubstituted or is substituted with 1-2 R7 groups;
      • R2 is H, C1-C6alkyl or C1-C6haloalkyl;
      • R3 is H, C1-C6alkyl or —CD3;
      • R4 is H, NH2, C1-C6alkyl or halo;
      • each R7 is independently selected from C1-C6alkyl, halo, hydroxyl, oxo and a C1-C6alkyl substituted with 1 to 3 —OH;
      • each R9 is independently selected from H and C1-C6alkyl;
      • R13 is H or C1-C6alkyl;
      • R14 is H or C1-C6alkyl;
      • each R16 is C1-C6alkyl;
      • each R17 is independently selected from H and C1-C6alkyl;
      • each R18 is independently selected from halo, —CN, C1-C6alkoxy and C1-C6alkyl;
      • m is 1, 2, 3, 4, 5 or 6, and
      • n is 1, 2, 3, 4, 5 or 6.
    • Embodiment 37. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
  • R1 is 8-oxa-3-azabicyclo[3.2.1]octanyl,
  • Figure US20210101902A1-20210408-C00035
  • an unsubstituted 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR16 and O, or a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR16 or O substituted with 1-2 R7 groups wherein each R7 is independently selected from C1-C6alkyl, hydroxyl and oxo.
    • Embodiment 38. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • R1 is an unsubstituted 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR16 and O, or a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR16 or O substituted with 1-2 R7 groups wherein each R7 is independently selected from C1-C6alkyl, hydroxyl and oxo.
    • Embodiment 39. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • R1 is azetadinyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, or imidazolyl,
      • or
      • R1 is azetadinyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl or imidazolyl substituted with 1-2 R7 groups, wherein and each R7 is independently selected from C1-C6alkyl, hydroxyl and oxo.
    • Embodiment 40. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • R1 is an unsubstituted 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR16 and O, an 8-oxa-3-azabicyclo[3.2.1]octanyl,
  • Figure US20210101902A1-20210408-C00036
  • or a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR16 or O substituted with 1-2 R7 groups.
    • Embodiment 41. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • R1 is a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR16 or O which is unsubstituted or is substituted with 1-2 R7 group.
    • Embodiment 42. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, R1 is azetadinyl, pyrrolidinyl, morpholinyl, piperidinyl or piperazinyl.
    • Embodiment 43. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, R1 is azetadinyl, pyrrolidinyl, morpholinyl, piperidinyl or piperazinyl, each of which is substituted with 1-2 R7 groups.
    • Embodiment 44. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, R1 is an 8-oxa-3-azabicyclo[3.2.1]octanyl, or
  • Figure US20210101902A1-20210408-C00037
    • Embodiment 45. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, R6 is a C3-C6cycloalkyl or an unsubstituted 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH and O.
    • Embodiment 46. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, R6 is a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH and O.
    • Embodiment 47. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, R6 is an unsubstituted 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR16 and O.
    • Embodiment 48. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • R6 is a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH and O substituted with 1-2 R12 groups, wherein each R12 is independently selected from C1-C6alkyl, hydroxyl and a C1-C6alkyl substituted with 1 to 3 —OH.
    • Embodiment 49. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • R6 is a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR16 and O substituted with 1-2 R12 groups, wherein each R12 is independently selected from C1-C6alkyl, hydroxyl and a C1-C6alkyl substituted with 1 to 3 —OH.
    • Embodiment 50. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, R6 is a C3-C6cycloalkyl.
    • Embodiment 51. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, R6 is cyclobutyl, oxetanyl, piperidinyl, pyrrolidinyl, morpholinyl or azetadinyl.
    • Embodiment 52. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • R6 is cyclobutyl, oxetanyl, piperidinyl, pyrrolidinyl, morpholinyl or azetadinyl each of which is substituted with 1-2 R12 groups, wherein each R12 is independently selected from C1-C6alkyl, hydroxyl and a C1-C6alkyl substituted with 1 to 3 —OH.
    • Embodiment 53. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, R6 is oxetanyl, piperidinyl, pyrrolidinyl, morpholinyl or azetadinyl.
    • Embodiment 54. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, R6 is cyclobutyl.
    • Embodiment 55. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • L is —CH2—; Y1 is —CH2CH2—; Y2 is —CH2CH2—; Y3 is —XCH2—; and X is —CH2— or O.
    • Embodiment 56. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • L is —CH2—; Y1 is —CH2CH2—; Y2 is —CH2CH2—; Y3 is —XCH2—; and X is —CH2—.
    • Embodiment 57. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • L is —CH2— or —CH2CH2—; Y1 is —CH2— or —CH2CH2—; Y2 is —CH2— or —CH2CH2—; Y3 is —CH2— or —XCH2—; and X is —CH2— or O.
    • Embodiment 58. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • L is —CH2—; Y1 is —CH2—; Y2 is —CH2—; Y3 is —CH2—; and X is —CH2—.
    • Embodiment 59. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • L is —CH2—; Y1 is —CH2—; Y2 is —CH2CH2—; Y3 is —XCH2—; and X is —CH2— or O.
    • Embodiment 60. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • L is —CH2—; Y1 is —CH2—; Y2 is —CH2CH2—; Y3 is —XCH2—; and X is —CH2—.
    • Embodiment 61. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, R2 is C1-C6alkyl; R3 is C1-C6alkyl, and R4 is C1-C6alkyl.
    • Embodiment 62. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, R2 is methyl; R3 is methyl, and R4 is methyl.
    • Embodiment 63. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, R2 is H, C1-C6alkyl or C1-C6haloalkyl
    • Embodiment 64. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, R2 is H or C1-C6alkyl.
    • Embodiment 65. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, R3 is H, C1-C6alkyl or —CD3.
    • Embodiment 66. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, R3 is H or C1-C6alkyl.
    • Embodiment 67. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, R4 is H, NH2, C1-C6alkyl or halo.
    • Embodiment 68. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, R4 is H, NH2 or C1-C6alkyl.
    • Embodiment 69. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, R4 is H or C1-C6alkyl.
    • Embodiment 70. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, each R5 is independently selected from C1-C6alkyl and —(CH2)nOR9.
    • Embodiment 71. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, each R5 is independently selected from C1-C6alkyl and —CD3.
    • Embodiment 72. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, each R5 is independently selected from methyl, ethyl, isopropyl, tert-butyl, —CD3, —CH2CH2OCH2CH3 and —CH2CH2OCH3.
    • Embodiment 73. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, each R7 is independently selected from methyl, ethyl and oxo.
    • Embodiment 74. The compound of Formula (I), Formula (Ia), Formula (Ib) and Formula (Ic), wherein, each R8 is independently selected from C1-C6haloalkyl, —(C(R9)2)nOR9 and a C1-C6alkyl substituted with 1 to 3 —OH.
    • Embodiment 75. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, each R8 is independently selected from —CH2CHF2, —CH2CF3, —CH(CH3)CH2OH, —CH2C(CH3)2OCH3, —CH2CH2OCH3, CH2CH2OCH2CH3 and —CH2C(CH3)2OH.
    • Embodiment 76. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, each R9 is independently selected from H and C1-C6alkyl.
    • Embodiment 77. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, each R9 is independently selected from H, methyl and ethyl.
    • Embodiment 78. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, R13 is H.
    • Embodiment 79. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, R13 is C1-C6alkyl.
    • Embodiment 80. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, R14 is H.
    • Embodiment 81. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, R13 is H and R14 is H.
    • Embodiment 82. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, m is 1, 2 or 3 and n is 1, 2, 3 or 4.
    • Embodiment 83. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, m is 1, 2 or 3.
    • Embodiment 84. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein, n is 1, 2, 3 or 4.
    • Embodiment 85. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • R1 is —NHC(═O)R6, —NHC(═O)(CH2)nR6, —NH(CH2)nC(═O)R6, —NHC(═O)(CH2)mNHR5, —NHC(═O)(CH2)mN(R5)2, —NHC(═O)(CHR9)mNHR5, —NHC(═O)(CH2)mNH2, —NH(CH2)mC(═O)N(R5)2, —NH(CHR9)nC(═O)R6, —NHR6, —NH2, —N(R5)2, —NHR5, —NHR8, —NH(CHR9)nOR9, —NHCH2(C(R9)2)nOR9, an 8-oxa-3-azabicyclo[3.2.1]octanyl,
  • Figure US20210101902A1-20210408-C00038
  • or a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR16 or O which is unsubstituted or is substituted with 1-2 R7 groups;
      • each R5 is independently selected from C1-C6alkyl and —(CH2)nOR9;
      • R6 is an unsubstituted 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH and O, or a C3-C6cycloalkyl;
      • each R7 is independently selected from C1-C6alkyl, hydroxyl and oxo;
      • each R8 is independently selected from C1-C6haloalkyl, and —(C(R9)2)nOR9;
      • each R9 is independently selected from H and C1-C6alkyl;
      • R16 is C1-C6alkyl;
      • m is 1, 2, 3, 4, 5 or 6
      • and
      • n is 1, 2, 3, 4, 5 or 6.
    • Embodiment 86. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • R1 is —NHC(═O)R6, —NHC(═O)(CH2)mN(R5)2, —NHC(═O)(CH2)mNHR5, —NHC(═O)(CH2)mNH2, —NHC(═O)(CHR9)nR6, —NHC(═O)(CHR9)nNHR8, —NH(CHR9)nC(═O)N(R8)2, —NH(CHR9)nC(═O)R6, —NHR6, —NH2, —N(R5)2, —NHR6, an 8-oxa-3-azabicyclo[3.2.1]octanyl,
  • Figure US20210101902A1-20210408-C00039
  • or a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR16 or O which is unsubstituted or is substituted with 1-2 R7 groups;
      • each R5 is independently selected from C1-C6alkyl and —(CH2)nOR9;
      • R6 is a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR16 and O, or a C3-C6cycloalkyl;
      • each R7 is independently selected from C1-C6alkyl, hydroxyl and oxo;
      • each R8 is independently selected from C1-C6alkyl, C1-C6haloalkyl, and —(C(R9)2)nOR9;
      • each R9 is independently selected from H and C1-C6alkyl;
      • m is 1, 2, 3, 4, 5 or 6, and
    • n is 1, 2, 3, 4, 5 or 6.
    • Embodiment 87. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • R1 is —NHC(═O)R6, —NHC(═O)(CH2)mN(R5)2, —NHC(═O)(CH2)mNHR5, —NHC(═O)(CH2)mNH2, —NHC(═O)(CHR9)nR6, —NHC(═O)(CHR9)nNHR8, —NH(CHR9)nC(═O)N(R8)2, —NH(CHR9)nC(═O)R6, —NHR6, —NH2, —N(R5)2, or —NHR8;
      • each R5 is independently selected from C1-C6alkyl and —(CH2)nOR9
      • R6 is an unsubstituted 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR16 and O, or a C3-C6cycloalkyl;
      • each R8 is independently selected from C1-C6alkyl, C1-C6haloalkyl, —(C(R9)2)nOR9 and a C1-C6alkyl substituted with 1 to 3 —OH;
      • each R9 is independently selected from H and C1-C6alkyl;
      • m is 1, 2, 3, 4, 5 or 6, and
      • n is 1, 2, 3, 4, 5 or 6.
    • Embodiment 88. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • R1 is —NHC(═O)(CH2)mN(R5)2, —NHC(═O)(CH2)mNHR5, —NHC(═O)(CH2)mNH2, —NHC(═O)(CHR9)nNHR8, —NH(CHR9)nC(═O)N(R8)2, —NH2, —N(R8)2, or —NHR8;
      • each R5 is independently selected from C1-C6alkyl and —(CH2)nOR9;
      • each R8 is independently selected from C1-C6alkyl, C1-C6haloalkyl, —(C(R9)2)nOR9 and a C1-C6alkyl substituted with 1 to 3 —OH;
      • each R9 is independently selected from H and C1-C6alkyl;
      • m is 1, 2, 3, 4, 5 or 6, and
      • n is 1, 2, 3, 4, 5 or 6.
    • Embodiment 89. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • R1 is —NHC(═O)R6, —NHC(═O)(CHR9)nR6, —NH(CHR9)nC(═O)R6 or —NHR6;
      • R6 is an unsubstituted 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR16 and O, or a C3-C6cycloalkyl;
      • each R9 is independently selected from H and C1-C6alkyl;
      • m is 1, 2, 3, 4, 5 or 6, and
      • n is 1, 2, 3, 4, 5 or 6.
    • Embodiment 90. The compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) wherein,
      • L is —CH2—;
      • Y1 is —CH2CH2—;
      • Y2 is —CH2CH2—;
      • Y3 is —XCH2—;
      • X is —CH2—;
      • R1 is —NHC(═O)R6;
      • R2 is C1-C6alkyl;
      • R3 is C1-C6alkyl;
      • R4 is C1-C6alkyl;
      • R6 is an unsubstituted 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, and O;
      • R13 is H;
      • R14 is H; and
      • each R17 is H.
    • Embodiment 91. The compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk), or a pharmaceutically acceptable salt thereof, selected from:
    • 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • 4-((3-methyl-5-(6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • 4-((3-methyl-5-(2-methyl-1,7-naphthyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • 4-((3-methyl-5-(2-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • 4-((5-(1,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)oxetan-3-amine;
    • N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(dimethylamino)acetamide
    • (S)—N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide;
    • (R)—N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide;
    • 6-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-oxa-6-azaspiro[3.3]heptane;
    • 4-(1-((4-aminobicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
    • 4-(2-((4-aminobicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-2H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
    • 4-(1-((4-aminobicyclo[2.2.2]octan-1-yl)methyl)-3-methyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
    • 4-(2-((4-aminobicyclo[2.2.2]octan-1-yl)methyl)-3-methyl-6,7-dihydro-2H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
    • 4-((5-(5-chloro-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • 1,6-dimethyl-4-(3-methyl-1-((4-(pyrrolidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1H-pyrazolo[3,4-d]pyrimidine;
    • 1,3,5-trimethyl-7-(3-methyl-1-((4-(pyrrolidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1H-pyrazolo[4,3-d]pyrimidine;
    • N-(2-methoxyethyl)-4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • 4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine;
    • 2-(ethylamino)-N-(4-((3-methyl-5-(6-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)acetamide;
    • 4-(4-((3-methyl-5-(6-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine;
    • 2-(ethylamino)-N-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[22.2]octan-1-yl)acetamide;
    • 4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-(oxetan-3-ylmethyl)bicyclo[2.2.2]octan-1-amine;
    • 3-(dimethylamino)-N-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[22.2]octan-1-yl)propanamide;
    • 4-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine;
    • 4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • N-cyclobutyl-4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • N,N-dicyclobutyl-4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • 6-methyl-4-(3-methyl-1-((4-(piperidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1H-pyrazolo[3,4-d]pyrimidine;
    • 6-methyl-4-(3-methyl-1-((4-(pyrrolidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1H-pyrazolo[3,4-d]pyrimidine;
    • (3-(((4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)methyl)oxetan-3-yl)methanol;
    • N-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)azetidine-3-carboxamide;
    • (S)—N-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide;
    • (S)—N-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-2-carboxamide;
    • (R)—N-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide;
    • (R)—N-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-2-carboxamide;
    • 3,6-dimethyl-4-(3-methyl-1-((4-morpholinobicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)isoxazolo[5,4-d]pyrimidine;
    • 1,3,5-trimethyl-7-(3-methyl-1-((4-(piperidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1H-pyrazolo[4,3-d]pyrimidine;
    • 1,6-dimethyl-4-(3-methyl-1-((4-(piperidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1H-pyrazolo[3,4-d]pyrimidine;
    • 4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N,N-bis(trideuteromethyl)bicyclo[2.2.2]octan-1-amine;
    • 4-((3-methyl-5-(1H-pyrazolo[3,4-b]pyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • 4-((3-methyl-5-(1H-pyrazolo[3,4-b]pyridin-4-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N,N-dimethylbicyclo[2.2.2]octan-1-amine;
    • 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.1]heptan-1-amine;
    • 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-ol;
    • N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)acetamide;
    • N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)methanesulfonamide;
    • tert-butyl (4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)(methyl)carbamate;
    • 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-methylbicyclo[2.2.2]octan-1-amine;
    • 1-methylcyclopropyl (4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate;
    • 3-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)bicyclo[1.1.1]pentan-1-amine;
    • 4-((5-(1-(4-methoxybenzyl)-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • N-cyclobutyl-4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-isopropylbicyclo[2.2.2]octan-1-amine;
    • 2-((4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)propan-1-ol;
    • 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-ethylbicyclo[2.2.2]octan-1-amine;
    • 5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-1-((4-(pyrrolidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
    • 4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine;
    • 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-7,7-dimethyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • N-(2,2-difluoroethyl)-4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • -((3-methyl-5-(2-methylquinolin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • 4-((3-methyl-5-(2-phenylpyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • 1-((4-(azetidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
    • 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-7,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • 4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)thiomorpholine 1,1-dioxide;
    • 5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-1-((4-(piperidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
    • 1-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)azetidin-3-ol;
    • 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-(2-methoxyethyl)bicyclo[2.2.2]octan-1-amine;
    • 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N,N-bis(2-methoxyethyl)bicyclo[2.2.2]octan-1-amine;
    • 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-(2-ethoxyethyl)bicyclo[2.2.2]octan-1-amine;
    • 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N,N-bis(2-ethoxyethyl)bicyclo[2.2.2]octan-1-amine;
    • 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-(2-methoxyethyl)-N-methylbicyclo[2.2.2]octan-1-amine;
    • (3S,4R)-1-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)pyrrolidine-3,4-diol;
    • (S)-1-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)pyrrolidin-3-ol;
    • 2-((4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)-N,N-dimethylacetamide;
    • N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-N-methyloxetan-3-amine;
    • 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-isopropyl-N-methylbicyclo[2.2.2]octan-1-amine;
    • N-cyclobutyl-4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-methylbicyclo[2.2.2]octan-1-amine;
    • (3S,4S)-1-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)pyrrolidine-3,4-diol;
    • 1-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-amine;
    • 5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-1-((4-(pyrrolidin-1-yl)-2-oxabicyclo[2.2.2]octan-1-yl)methyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
    • 4-((5-(6-(4-fluorophenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • 4-(4-(1-((4-aminobicyclo[2.2.2]octan-1-yl)methyl)-3-methyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)pyridin-2-yl)benzonitrile;
    • 3-methyl-5-(2-phenylpyridin-4-yl)-1-((4-(pyrrolidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
    • 2-methyl-4-(3-methyl-1-((4-(pyrrolidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1,7-naphthyridine;
    • 4-((5-(2-(4-fluorophenyl)pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • 4-((5-(2-(2-fluoro-4-methylphenyl)pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • 4-((5-(2-(4-methoxyphenyl)pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • 4-((3-methyl-5-(2-(p-tolyl)pyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • 4-(2-(5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)ethyl)bicyclo[2.2.2]octan-1-amine;
    • 4-((5-(2,8-dimethyl-1,7-naphthyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • 4-((3-methyl-5-(2-methyl-6-phenylpyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • 4-((5-([2,2′-bipyridin]-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • 5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-1-((4-(piperidin-1-yl)-2-oxabicyclo[2.2.2]octan-1-yl)methyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
    • 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-(1-methoxypropan-2-yl)bicyclo[2.2.2]octan-1-amine;
    • 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-ethyl-N-methylbicyclo[2.2.2]octan-1-amine;
    • 1-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N,N-dimethyl-2-oxabicyclo[2.2.2]octan-4-amine;
    • 2-((4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)-1-(piperidin-1-yl)ethanone;
    • N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(pyrrolidin-1-yl)acetamide;
    • 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-(2-methoxy-2-methylpropyl)bicyclo[2.2.2]octan-1-amine;
    • 1-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-(2-methoxyethyl)-2-oxabicyclo[2.2.2]octan-4-amine;
    • 4-((5-(2-chloro-5,7-dihydrofuro[3,4-d]pyrimidin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • 4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-1-methylpiperazin-2-one;
    • N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-3-(dimethylamino)propanamide;
    • 2-((4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)-1-(pyrrolidin-1-yl)ethanone;
    • (R)-4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-methylmorpholine;
    • 1-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-4-methylpiperazin-2-one;
    • (S)-4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-methylmorpholine;
    • (2S,6R)-4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2,6-dimethylmorpholine;
    • (2S,6S)-4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2,6-dimethylmorpholine;
    • N-(cyclobutylmethyl)-1-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-amine;
    • (2R,6R)-4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2,6-dimethylmorpholine;
    • N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(ethylamino)acetamide;
    • 3-amino-N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)propanamide;
    • 6-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-oxa-6-azaspiro[3.3]heptane;
    • (R)—N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(methylamino)propanamide;
    • (S)—N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(methylamino)propanamide;
    • 1-((4-(1H-imidazol-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
    • (1R,5S)-3-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-8-oxa-3-azabicyclo[3.2.1]octane;
    • N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(methylamino)acetamide;
    • N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-4-methylmorpholine-3-carboxamide;
    • 1-((4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)-2-methylpropan-2-ol;
    • 2-(ethylamino)-N-(4-((3-methyl-5-(5-methyl-1H-pyrazolo[4,3-b]pyridin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)acetamide;
    • N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-2-carboxamide;
    • N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-3-(ethylamino)propanamide;
    • N-ethyl-4-((3-methyl-5-(2-phenylpyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • (S)-4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-3-methylmorpholine;
    • (R)-4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-3-methylmorpholine;
    • N-(2-methoxyethyl)-4-((3-methyl-5-(2-phenylpyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)azetidine-3-carboxamide;
    • N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(ethyl(methyl)amino)acetamide;
    • N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(3-fluoroazetidin-1-yl)acetamide;
    • 2-(bis(trideuteromethyl)amino)-N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)acetamide;
    • N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-hydroxyacetamide;
    • N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(3-hydroxyazetidin-1-yl)acetamide;
    • (3-(((4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)methyl)oxetan-3-yl)methanol;
    • N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(N-methylmethylsulfonamido)acetamide;
    • N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(N-methylacetamido)acetamide
    • 4-((3-methyl-5-(6-methyl-1-(trideuteromethyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • (S)—N-(4-((5-(1-ethyl-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide;
    • N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-3-(methylamino)propanamide;
    • N-cyclobutyl-1-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-amine;
    • N-cyclobutyl-4-((3-methyl-5-(2-phenylpyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
    • tert-butyl (4-((5-(1-ethyl-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate;
    • tert-butyl (4-((3-methyl-5-(2-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate;
    • tert-butyl (4-((3-methyl-5-(2-methyl-1,7-naphthyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate;
    • tert-butyl (4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.1]heptan-1-yl)carbamate;
    • 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine, and
    • 4-((5-(1-ethyl-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine.
    • Embodiment 92. The compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk), or a pharmaceutically acceptable salt thereof, selected from:
    • N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)oxetan-3-amine;
    • N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(dimethylamino)acetamide;
    • (S)—N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide;
    • (R)—N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide, and
    • 6-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-oxa-6-azaspiro[3.3]heptane.
  • Depending on the choice of the starting materials and procedures, certain embodiments of the compounds of the present invention are present in the form of one of the possible isomers or as mixtures thereof, for example as pure optical isomers, or as isomer mixtures, such as racemates and diastereoisomer mixtures, depending on the number of asymmetric carbon atoms. The present invention is meant to include all such possible isomers, including racemic mixtures, diasteriomeric mixtures and optically pure forms. Optically active (R)- and (S)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituent may be E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans-configuration. All tautomeric forms are also intended to be included.
  • In certain embodiments, compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) are prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), with a stoichiometric amount of an appropriate pharmaceutically acceptable organic acid or inorganic acid or a suitable anion exchange reagent. Certain compounds of the present invention are capable of forming acid addition salts by virtue of the presence of amino groups or groups similar thereto. Alternatively, the salt forms of compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) are prepared using salts of the starting materials or intermediates.
  • Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. The organic acid or inorganic acids used to form certain pharmaceutically acceptable acid addition salts of compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) include, but are not limited to, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzoic acid, benzenesulfonic acid, carbonic acid, camphor sulfonic acid, capric acid, chlorotheophyllinate, citric acid, ethanedisulfonic acid, fumaric acid, D-glycero-D-gulo-Heptonicacid, galactaric aid, galactaric acid/mucic acid, gluceptic acid, glucoheptonoic acid, gluconic acid, glucuronic acid, glutamatic acid, glutaric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, isethionic acid, lactic acid, lactobionic acid, lauryl sulfuric acid, malic acid, maleic acid, malonic acid, mandelic acid, mesylic acid, methanesulfonic acid, mucic acid, naphthoic acid, 1-hydroxy-2-naphthoic acid, naphthalenesulfonic acid, 2-naphthalenesulfonic acid, nicotinic acid, nitric acid, octadecanoic acid, oleaic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, polygalacturonic acid, propionic acid, sebacic acid, stearic acid, succinic acid, sulfosalicylic acid, sulfuric acid, tartaric acid, p-toluenesulfonic acid, trifluoroacetic acid and triphenylacetic acid.
  • Lists of additional suitable acid addition salts can be found, e.g., in “Remington's Pharmaceutical Sciences”, 20th ed., Mack Publishing Company, Easton, Pa., (1985); and in “Handbook of Pharmaceutical Salts: Properties, Selection, and Use” by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002.
  • Salt forms of the compounds of the invention can be converted into the free compounds by treatment with a suitable basic agent.
  • Pharmaceutically acceptable acid addition salts of compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) include, but are not limited to, a acetate, adipate, ascorbate, aspartate, benzoate, besylatye, benzenesulfonate, bicarbonate/carbonate, bisulfate/sulfate, bromide/hydrobromide, camphor sulfonate, camsylate, caprate, chloride/hydrochloride, chlorotheophyllinate, citrate, edisylate, ethanedisulfonate, fumarate, gluceptate, glucoheptonate, gluconate, glucuronate, glutamate, glutarate, glycolate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulphate, malate, maleate, malonate, mandelate, mesylate, methanesulfonate, methylsulfate, mucate, naphthoate, napsylate, 2-napsylate, naphthalenesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, polygalacturonate, propionate, sebacate, stearate, succinate, sulfosalicylate, sulfate, tartrate, tosylate, p-toluenesulfonate, trifluoroacetate, trifenatate, triphenylacetete and xinafoate salt forms.
  • In one embodiment, the present invention provides N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)oxetan-3-amine in an acetate, adipate, ascorbate, aspartate, benzoate, besylatye, benzenesulfonate, bicarbonate/carbonate, bisulfate/sulfate, bromide/hydrobromide, camphor sulfonate, camsylate, caprate, chloride/hydrochloride, chlortheophyllonate, citrate, edisylate, ethanedisulfonate, fumarate, gluceptate, glucoheptonate, gluconate, glucuronate, glutamate, glutarate, glycolate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulphate, malate, maleate, malonate, mandelate, mesylate, methanesulfonate, methylsulfate, mucate, naphthoate, napsylate, 2-napsylate, naphthalenesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, polygalacturonate, propionate, sebacate, stearate, succinate, sulfosalicylate, sulfate, tartrate, tosylate, p-toluenesulfonate, trifluoroacetate, trifenatate, triphenylacetete or xinafoate salt form.
  • In one embodiment, the present invention provides N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(dimethylamino)acetamide in an acetate, adipate, ascorbate, aspartate, benzoate, besylatye, benzenesulfonate, bicarbonate/carbonate, bisulfate/sulfate, bromide/hydrobromide, camphor sulfonate, camsylate, caprate, chloride/hydrochloride, chlortheophyllonate, citrate, edisylate, ethanedisulfonate, fumarate, gluceptate, glucoheptonate, gluconate, glucuronate, glutamate, glutarate, glycolate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulphate, malate, maleate, malonate, mandelate, mesylate, methanesulfonate, methylsulfate, mucate, naphthoate, napsylate, 2-napsylate, naphthalenesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, polygalacturonate, propionate, sebacate, stearate, succinate, sulfosalicylate, sulfate, tartrate, tosylate, p-toluenesulfonate, trifluoroacetate, trifenatate, triphenylacetete or xinafoate salt form.
  • In one embodiment, the present invention provides (S)—N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide in an acetate, adipate, ascorbate, aspartate, benzoate, besylatye, benzenesulfonate, bicarbonate/carbonate, bisulfate/sulfate, bromide/hydrobromide, camphor sulfonate, camsylate, caprate, chloride/hydrochloride, chlortheophyllonate, citrate, edisylate, ethanedisulfonate, fumarate, gluceptate, glucoheptonate, gluconate, glucuronate, glutamate, glutarate, glycolate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulphate, malate, maleate, malonate, mandelate, mesylate, methanesulfonate, methylsulfate, mucate, naphthoate, napsylate, 2-napsylate, naphthalenesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, polygalacturonate, propionate, sebacate, stearate, succinate, sulfosalicylate, sulfate, tartrate, tosylate, p-toluenesulfonate, trifluoroacetate, trifenatate, triphenylacetete or xinafoate salt form.
  • In one embodiment, the present invention provides (R)—N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide in an acetate, adipate, ascorbate, aspartate, benzoate, besylatye, benzenesulfonate, bicarbonate/carbonate, bisulfate/sulfate, bromide/hydrobromide, camphor sulfonate, camsylate, caprate, chloride/hydrochloride, chlortheophyllonate, citrate, edisylate, ethanedisulfonate, fumarate, gluceptate, glucoheptonate, gluconate, glucuronate, glutamate, glutarate, glycolate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulphate, malate, maleate, malonate, mandelate, mesylate, methanesulfonate, methylsulfate, mucate, naphthoate, napsylate, 2-napsylate, naphthalenesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, polygalacturonate, propionate, sebacate, stearate, succinate, sulfosalicylate, sulfate, tartrate, tosylate, p-toluenesulfonate, trifluoroacetate, trifenatate, triphenylacetete or xinafoate salt form.
  • In one embodiment, the present invention provides 6-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-oxa-6-azaspiro[3.3]heptane in an acetate, adipate, ascorbate, aspartate, benzoate, besylatye, benzenesulfonate, bicarbonate/carbonate, bisulfate/sulfate, bromide/hydrobromide, camphor sulfonate, camsylate, caprate, chloride/hydrochloride, chlortheophyllonate, citrate, edisylate, ethanedisulfonate, fumarate, gluceptate, glucoheptonate, gluconate, glucuronate, glutamate, glutarate, glycolate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulphate, malate, maleate, malonate, mandelate, mesylate, methanesulfonate, methylsulfate, mucate, naphthoate, napsylate, 2-napsylate, naphthalenesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, polygalacturonate, propionate, sebacate, stearate, succinate, sulfosalicylate, sulfate, tartrate, tosylate, p-toluenesulfonate, trifluoroacetate, trifenatate, triphenylacetete or xinafoate salt form.
  • Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2H, 3H, 11C, 13C, 14C, 15N, 18F 31P, 32P, 35S, 36C, 123I, 124I, 125I respectively. The invention includes various isotopically labeled compounds as defined herein, for example those into which radioactive isotopes, such as 3H and 14C, or those into which non-radioactive isotopes, such as 2H and 13C are present. Such isotopically labelled compounds are useful in metabolic studies (with 14C), reaction kinetic studies (with, for example 2H or 3H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an 18F or labeled compound may be particularly desirable for PET or SPECT studies. Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed.
  • Further, substitution with heavier isotopes, particularly deuterium (i.e., 2H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index. It is understood that deuterium in this context is regarded as a substituent of a compound of the formula (I). The concentration of such a heavier isotope, specifically deuterium, may be defined by the isotopic enrichment factor. The term “isotopic enrichment factor” as used herein means the ratio between the isotopic abundance and the natural abundance of a specified isotope. If a substituent in a compound of this invention is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
  • Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D2O, d6-acetone, d6-DMSO.
  • Compounds of the invention that contain groups capable of acting as donors and/or acceptors for hydrogen bonds may be capable of forming co-crystals with suitable co-crystal formers. These co-crystals may be prepared from compounds of the invention by known co-crystal forming procedures. Such procedures include grinding, heating, co-subliming, co-melting, or contacting in solution compounds of the invention with the co-crystal former under crystallization conditions and isolating co-crystals thereby formed. Suitable co-crystal formers include those described in WO 2004/078163. Hence the invention further provides co-crystals comprising a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk).
  • All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g. “such as”) provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed.
  • Any asymmetric atom (e.g., carbon or the like) of the compound(s) of the present invention can be present in racemic or enantiomerically enriched, for example the (R)-, (S)- or (R,S)-configuration. In certain embodiments, each asymmetric atom has at least 50% enantiomeric excess, at least 60% enantiomeric excess, at least 70% enantiomeric excess, at least 80% enantiomeric excess, at least 90% enantiomeric excess, at least 95% enantiomeric excess, or at least 99% enantiomeric excess in the (R)- or (S)-configuration. Substituents at atoms with unsaturated double bonds may, if possible, be present in cis- (Z)- or trans- (E)-form.
  • Accordingly, as used herein a compound of the present invention can be in the form of one of the possible isomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric (cis or trans) isomers, diastereomers, optical isomers (antipodes), racemates or mixtures thereof.
  • Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization. Any resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound. In particular, a basic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-O,O′-p-toluoyl tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid. Racemic products can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent.
  • Furthermore, the compounds of the present invention, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization. The compounds of the present invention may inherently or by design form solvates with pharmaceutically acceptable solvents (including water); therefore, it is intended that the invention embrace both solvated and unsolvated forms. The term “solvate” refers to a molecular complex of a compound of the present invention (including pharmaceutically acceptable salts thereof) with one or more solvent molecules. Such solvent molecules are those commonly used in the pharmaceutical art, which are known to be innocuous to the recipient, e.g., water, ethanol, and the like. The term “hydrate” refers to the complex where the solvent molecule is water.
  • The compounds of the present invention, including salts, hydrates and solvates thereof, may inherently or by design form polymorphs.
    • Processes for Making Compounds of Formula (A) and Subformulae Thereof
  • General procedures for preparing compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) and Formula (IIa to IIk) are described herein. In the reactions described, reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, may be protected to avoid their unwanted participation in the reactions. Within the scope of this text, only a readily removable group that is not a constituent of the particular desired end product of the compounds of the present invention is designated a “protecting group”, unless the context indicates otherwise. The protection of functional groups by such protecting groups, the protecting groups themselves, and their cleavage reactions are described for example in standard reference works, such as J. F. W. McOmie, “Protective Groups in Organic Chemistry”, Plenum Press, London and New York 1973, in T. W. Greene and P. G. M. Wuts, “Protective Groups in Organic Synthesis”, Third edition, Wiley, New York 1999, in “The Peptides”; Volume 3 (editors: E. Gross and J. Meienhofer), Academic Press, London and New York 1981, in “Methoden der organischen Chemie” (Methods of Organic Chemistry), Houben Weyl, 4th edition, Volume 15/I, Georg Thieme Verlag, Stuttgart 1974, in H.-D. Jakubke and H. Jeschkeit, “Aminosauren, Peptide, Proteine” (Amino acids, Peptides, Proteins), Verlag Chemie, Weinheim, Deerfield Beach, and Basel 1982, and in Jochen Lehmann, “Chemie der Kohlenhydrate: Monosaccharide und Derivate” (Chemistry of Carbohydrates: Monosaccharides and Derivatives), Georg Thieme Verlag, Stuttgart 1974. A characteristic of protecting groups is that they can be removed readily (i.e. without the occurrence of undesired secondary reactions) for example by solvolysis, reduction, photolysis or alternatively under physiological conditions (e.g. by enzymatic cleavage).
  • Compounds of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk) are made by processes described herein and as illustrated in the Examples. Non-limiting examples of synthetic schemes used to make compounds of the invention are illustrated in Scheme 1 and Scheme 2.
  • Scheme 1 illustrates one embodiment for making compounds of Formula (A), Formula (I) and Formula (II) using Buchwald-Hartwig Amination, where Pd catalyzed cross-coupling of protected amine intermediate (Int-A) or protected amine intermediate (Int-B) with a heteroaryl halide intermediate (Int-1) followed by deprotection gives a compound of Formula (Ia) or Formula (IIa), respectively, where R1 is NH2. Further alkylation or acylation results in compounds of Formula (Ia) or Formula (IIa), where R1 is as further defined herein.
  • Figure US20210101902A1-20210408-C00040
  • In additional embodiments, compounds of Formula (A), Formula (I) and Formula (II) can be obtained by replacing intermediate (Int-1) with either intermediates Int-2, Int-3, Int-4, Int-5, Int-6, Int-7, Int-8, Int-9, Int-10 or Int-11, resulting compounds of Formula (Ic), Formula (b), Formula (If), Formula (Ig), Formula (Id), Formula (Ie), Formula (Ij), Formula (Ii), Formula (Ik), Formula (Ih), Formula (IIc), Formula (IIb), Formula (IIf), Formula (IIg), Formula (IId), Formula (IIe), Formula (IIj), Formula (IIi), Formula (IIk), and Formula (IIh), respectively. Table 1 shows the alternative intermediates and the respective products,
  • where TGA
  • Figure US20210101902A1-20210408-C00041
    • TGB is
  • Figure US20210101902A1-20210408-C00042
  • X1 is Br, Cl, I or —SO3CF3, and Y1, Y2, Y3, L, R1, R2, R3, R4, R13 and R14 are as defined herein.
  • TABLE 1
    Product with Int-A Product with Int-B
    after Deprotection and Optional after Deprotection and Optional
    Alternative to Int-1 Alkylation or Acylation Alkylation or Acylation
    Figure US20210101902A1-20210408-C00043
    Figure US20210101902A1-20210408-C00044
    Figure US20210101902A1-20210408-C00045
    Figure US20210101902A1-20210408-C00046
    Figure US20210101902A1-20210408-C00047
    Figure US20210101902A1-20210408-C00048
    Figure US20210101902A1-20210408-C00049
    Figure US20210101902A1-20210408-C00050
    Figure US20210101902A1-20210408-C00051
    Figure US20210101902A1-20210408-C00052
    Figure US20210101902A1-20210408-C00053
    Figure US20210101902A1-20210408-C00054
    Figure US20210101902A1-20210408-C00055
    Figure US20210101902A1-20210408-C00056
    Figure US20210101902A1-20210408-C00057
    Figure US20210101902A1-20210408-C00058
    Figure US20210101902A1-20210408-C00059
    Figure US20210101902A1-20210408-C00060
    Figure US20210101902A1-20210408-C00061
    Figure US20210101902A1-20210408-C00062
    Figure US20210101902A1-20210408-C00063
    Figure US20210101902A1-20210408-C00064
    Figure US20210101902A1-20210408-C00065
    Figure US20210101902A1-20210408-C00066
    Figure US20210101902A1-20210408-C00067
    Figure US20210101902A1-20210408-C00068
    Figure US20210101902A1-20210408-C00069
    Figure US20210101902A1-20210408-C00070
    Figure US20210101902A1-20210408-C00071
    Figure US20210101902A1-20210408-C00072
  • The Pd catalyst used in the coupling reactions of Scheme 1 is selected from Pd(II) catalysts, for example, bis(tri-o-tolylphosphine)palladium(II)dichloride, bis(tri-o-tolylphosphine)Pd(dba)2, bis(tri-o-tolylphosphine)Pd2(dba)3, PdCl2(dppf), (tri-o-tolylphosphine)Pd(OAc)2, Pd(OAc)2 and a palladacycle.
  • The optional ligand of Scheme 1 is selected from diphenylphospinobinaphthyl (BINAP), diphenylphospinoferrocene (DPPF), tri-o-tolylphosphine (P(o-tol)3), triphenylphosphine (PPh3), tri-tert-butylphosphine (P(t-Bu)3), 2-(dicyclohexylphosphino)3,6-dimethoxy-2′,4′,6′-triisopropyl-1,1′-biphenyl (BrettPhos), 2-(di-tert-butylphosphino)-2′,4′,6′-triisopropyl-3,6-dimethoxy-1,1′-biphenyl (t-BuBrettPhos), 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (XPhos), 2-di-tert-butylphosphino-2′,4′,6′-triisopropylbiphenyl (t-BuXPhos), 2-Dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (SPhos), 2-Dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (RuPhos), 2-dicyclohexylphosphino-2′-(N,N-dimethylamino)biphenyl (DavePhos), 2′-(di-tert-butylphosphino)-N,N-dimethylbiphenyl-2-amine, 2-di-tert-butylphosphino-2′-(N,N-dimethylamino)biphenyl (t-BuDavePhos), 2-diphenylphosphino-2′,6′-bis(dimethylamino)-1,1′-biphenyl (PhCPhos), 2-Di(tert-butyl)phosphino-2′,4′,6′-triisopropyl-3-methoxy-6-methylbiphenyl (RockPhos), 2-(di-adamantanylphosphino)-2′,4′,6′-triisopropyl-3,6-dimethoxy-1,1′-biphenyl (AdBrettPhos), di-tert-butyl(2′,4′,6′-tricyclohexyl-3,6-dimethoxy-[1,1′-biphenyl]-2-yl)phosphine, di-tert-butyl(2′,4′,6′-triisopropyl-3,4,5,6-tetramethyl-[1,1′-biphenyl]-2-yl)phosphine, 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos), 2-(2-dicyclohexylphosphanylphenyl)-N1,N1,N3,N3-tetramethyl-benzene-1,3-diamine (CPhos), 2′-(Diphenylphosphino)-N,N′-dimethyl-(1,1′-biphenyl)-2-amine (PhDavePhos), 2-{Bis[3,5-bis(trifluoromethyl)phenyl]phosphino}-3,6-dimethoxy-2′,4′,6′-triisopropyl-1,1′-biphenyl (JackiePhos), (2-Biphenyl)di-tert-butylphosphine (JohnPhos), (2-Biphenyl)dicyclohexylphosphine (CyJohnPhos), 2-Dicyclohexylphosphino-2′-methylbiphenyl (MePhos), 2-Di-t-butylphosphino-2′-methyl)-1,1′-biphenyl (t-BuMePhos), 2-Dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (SPhos), Sodium 2′-dicyclohexylphosphino-2,6-dimethoxy-1,1′-biphenyl-3-sulfonate hydrate (sSPhos), rac-2-(Di-tert-butylphosphino)-1,1′-binaphthyl (TrixiePhos), 2-di-tert-butylphosphino-3,4,5,6-tetramethyl-2′,4′,6′-triisopropylbiphenyl (Me4 t-BuXPhos), 2′-Dicyclohexylphosphino-2,6-di-i-propyl-4-sulfonato-1,1′-biphenyl hydrate sodium salt (XPhos-SO3Na), di-tert-butyl(2′,4′,6′-triisopropyl-4,5-dimethoxy-3,6-dimethyl-[1,1′-biphenyl]-2-yl)phosphine and 2′-(dicyclohexylphosphino)-N,N-dimethyl-[1,1′-biphenyl]-4-amine and Tricyclohexylphosphine (P(Cy)3).
  • The bases used in such coupling reactions of Scheme 1 include, KOAc, NaOAc, K2CO3, Na2CO3, NaOEt, KOtBu, NaOtBu, LiHMDS, Cs2CO3, K3PO4, NaOH, KOH, tBuOH and NEt3. Such coupling reactions are stirred at temperatures in the range of approximately 100-180° C., or are conducted in a microwave oven. In addition, solvents, for example benzene, toluene, 1,2-dimethoxyethane, acetonitrile, DCM, DMF, THF, dioxane and N-methyl-2-pyrrolidone are used. The reaction may be carried out under an inert gas such as nitrogen or argon.
  • Scheme 2 illustrates another embodiment for making compounds of Formula (A), Formula (I) and Formula (II) using base catalyzed cross-coupling of protected amine intermediate (Int-A) or protected amine intermediate (Int-B) with a heteroaryl halide intermediate (Int-1) followed by deprotection gives a compound of Formula (Ia) or Formula (IIa), respectively, where R1 is NH2. Further alkylation or acylation results in compounds of Formula (Ia) or Formula (IIa), where R1 is as further defined herein.
  • Figure US20210101902A1-20210408-C00073
  • In additional embodiments, compounds of Formula (A), Formula (I) and Formula (II) can be obtained by replacing intermediate (Int-1) with either intermediates Int-2, Int-3, Int-4, Int-5, Int-6, Int-7, Int-8, Int-9, Int-10 or Int-11, resulting compounds of Formula (Ic), Formula (Ib), Formula (If), Formula (Ig), Formula (Id), Formula (Ie), Formula (Ij), Formula (Ii), Formula (Ik), Formula (Ih), Formula (IIc), Formula (IIb), Formula (IIf), Formula (IIg), Formula (IId), Formula (IIe), Formula (IIj), Formula (IIi), Formula (IIk), and Formula (IIh), respectively. Table 2 shows the alternative intermediates and the respective products,
  • where TGA is
  • Figure US20210101902A1-20210408-C00074
    • TGB is
  • Figure US20210101902A1-20210408-C00075
  • X1 is Br, Cl, I or —SO3CF3, and Y1, Y2, Y3, L, R1, R2, R3, R4, R13 and R14 are as defined herein.
  • TABLE 2
    Product with Int-A Product with Int-B
    after Deprotection and Optional after Deprotection and Optional
    Alternative for Int-1 Alkylation or Acylation Alkylation or Acylation
    Figure US20210101902A1-20210408-C00076
    Figure US20210101902A1-20210408-C00077
    Figure US20210101902A1-20210408-C00078
    Figure US20210101902A1-20210408-C00079
    Figure US20210101902A1-20210408-C00080
    Figure US20210101902A1-20210408-C00081
    Figure US20210101902A1-20210408-C00082
    Figure US20210101902A1-20210408-C00083
    Figure US20210101902A1-20210408-C00084
    Figure US20210101902A1-20210408-C00085
    Figure US20210101902A1-20210408-C00086
    Figure US20210101902A1-20210408-C00087
    Figure US20210101902A1-20210408-C00088
    Figure US20210101902A1-20210408-C00089
    Figure US20210101902A1-20210408-C00090
    Figure US20210101902A1-20210408-C00091
    Figure US20210101902A1-20210408-C00092
    Figure US20210101902A1-20210408-C00093
    Figure US20210101902A1-20210408-C00094
    Figure US20210101902A1-20210408-C00095
    Figure US20210101902A1-20210408-C00096
    Figure US20210101902A1-20210408-C00097
    Figure US20210101902A1-20210408-C00098
    Figure US20210101902A1-20210408-C00099
    Figure US20210101902A1-20210408-C00100
    Figure US20210101902A1-20210408-C00101
    Figure US20210101902A1-20210408-C00102
    Figure US20210101902A1-20210408-C00103
    Figure US20210101902A1-20210408-C00104
    Figure US20210101902A1-20210408-C00105
  • The bases used in such coupling reactions of Scheme 2 include, DIPEA, Cs2CO3, 1,8-diazabicycloundec-7-ene (DBU), NEt3, K2CO3, CaCO3, Na2CO3, K3PO4, KF, KOAc, NaOEt, KOtBu and NaOH. Such coupling reactions are stirred at temperatures in the range of approximately 80-180, or are conducted in a microwave oven. The solvent used in such coupling reactions of Scheme (VII) and Scheme (VII), include H2O, 2-methyl-THE, 2-methyl-THF/H2O (1:1), THE, MeOH, butanol, t-butanol, EtOAc, CAN, ACN, DMSO, NMP, toluene dimethylacetamide and DMF. The reaction may be carried out under an inert gas such as nitrogen or argon.
    • Intermediates Int-A and Int-B
  • Scheme 3 illustrates an embodiment for making intermediates Int-A and Int-B.
  • Figure US20210101902A1-20210408-C00106
  • Scheme 4 illustrates an embodiment for making intermediates Int-A and Int-B.
  • Figure US20210101902A1-20210408-C00107
  • The amine protecting group (Prot) in Schemes 1 to 4 is selected from methyl carbamate, 9-Fluorenylmethyl carbamate (Fmoc), 2,2,2-Trichlorethyl carbamate (Troc), t-butyl carbamate Boc), 2-(Trimethylsilyl)ethyl carbamate (Teoc), allyl carbamate (Alloc), benzyl carbamate (Cbz), benzylideneamine, p-toluenesulfonamide, trifluoroacetamide, acetamide, phthalimide, benzylamine, 4-methoxybenzyl amine (PMB), allyl amine and tritylamine.
  • The invention further includes any variant of the present processes, in which an intermediate product obtainable at any stage thereof is used as starting material and the remaining steps are carried out, or in which the starting materials are formed in situ under the reaction conditions, or in which the reaction components are used in the form of their salts or optically pure material.
  • Compounds of the invention and intermediates can also be converted into each other according to methods generally known to those skilled in the art.
    • EXAMPLES
  • The compounds of the present invention can be produced as shown in the following examples. The following examples are intended to illustrate the invention and are not to be construed as being limitations thereon. Temperatures are given in degrees Celsius. If not mentioned otherwise, all evaporations are performed under reduced pressure, typically between about 15 mm Hg and 100 mm Hg (=20-133 mbar). The structure of final products, intermediates and starting materials is confirmed by standard analytical methods, e.g., microanalysis and spectroscopic characteristics, e.g., MS, IR, NMR. Abbreviations used are those conventional in the art.
  • All starting materials, building blocks, reagents, acids, bases, dehydrating agents, solvents, and catalysts utilized to synthesis the compounds of the present invention are either commercially available or can be produced by organic synthesis methods known to one of ordinary skill in the art or can be produced by organic synthesis methods as described herein.
    • Abbreviations:
  • BH3-DMS borane dimethyl sulfide
    brine concentrated aqueous sodium chloride solution
    CPME cyclopentyl methyl ether
    d doublet
    dd doublet of doublets
    DCM dichloromethane
    DMA dimethylacetamide
    • DMAP 4-Dimethylaminopyridine
  • DME 1,2-dimethoxyethane
    • DMF N,N-dimethylformamide
  • DMSO dimethylsulfoxide
    DIPEA diisopropylethylamine
    ESI electrospray ionization
    ESIMS electrospray ionization mass spectrometry
    EtOAc ethyl acetate
    EtOH ethanol
    eq equivalent
    HPLC high pressure liquid chromatography
    hr hour
    hrs hours
    IPA isopropyl alcohol
    LC-MS or LC/MS liquid chromatography and mass spectrometry
    MeOH methanol
    MS mass spectrometry
    m multiplet
    mg milligram
    min minutes
    mL milliliter
    mm millimeter
    mmol millimol
    m/z mass to charge ratio
    nm nanometer
    nM nanomolar
    NMR nuclear magnetic resonance
    RT retention time
    rt room temperature
    s singlet
    t triplet
    TFA trifluoroacetic acid
    THE tetrahydrofuran
    UV ultra violet
    μm micrometer
    • Instrumentation LC-MS Methods
    • Method 1: The instrument was comprised of an Agilent LC/MS system with a 1200sl HPLC pump and 6100 series single quadrupole mass spectrometer with electrospray (ESI) ionization. The sample was injected onto a Waters Acquity®HSS T3 column C18 1.8 μm 2.1×50 mm at 60° C. The gradient pump method used a flow rate of 0.9 mL/min throughout the 2.25 min run, with mobile phase A: 0.05% TFA in H2O and mobile phase B: 0.035% TFA in acetonitrile, 10% B-100% B in 1.36 min.
    • Method 2: 3.5MIN_10TO100B: The instrument was comprised of an Agilent LC/MS system with a 1200sl HPLC pump and 6100 series single quadrupole mass spectrometer with electrospray (ESI) ionization. The sample was injected onto a Waters Acquity®HSS T3 column C18 1.8 μm 2.1×50 mm at 60° C. The gradient pump method used a flow rate of 0.9 mL/min throughout the 2.25 min run, with mobile phase A: 0.05% TFA in H2O and mobile phase B: 0.035% TFA in acetonitrile, 10% B-100% B in 1.36 min.
    Tail Groups
  • The Tail Group intermediates used to obtain compounds of the invention are shown below and in Table 4, with their respective synthesis also described below. Unless purchased, the synthesis of certain reagents used to obtain these intermediates is also described below.
    • Purchased Reagents
  • Reagent No. Reagent Structure Reagent Name
    i-A0
    Figure US20210101902A1-20210408-C00108
         		4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine
    i-A1
    Figure US20210101902A1-20210408-C00109
         		3-methyl-1H-pyrazolo[4,3-c]pyridine
    i-A2
    Figure US20210101902A1-20210408-C00110
         		1H-pyrazolo[4,3-c]pyridine
    i-A3
    Figure US20210101902A1-20210408-C00111
         		tert-butyl 7,7-dimethyl-1,4,6,7-tetrahydro-5H- pyrazolo[4,3-c]pyridine-5-carboxylate
    i-A4
    Figure US20210101902A1-20210408-C00112
         		3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3- c]pyridine
    i-A6
    Figure US20210101902A1-20210408-C00113
         		3-(trifluoromethyl)-1H-pyrazolo[4,3-c]pyridine
    i-A7
    Figure US20210101902A1-20210408-C00114
         		tert-butyl 3-(trifluoromethyl)-6,7-dihydro-1H- pyrazolo[4,3-c]pyridin-5(4H)-carboxylate
    • Synthesis of Certain Intermediates Used in the Synthesis of Various Tail Groups Synthesis of 4-((tert-butylcarbonyl)amino)bicyclo[2.2.2]octan-1-yl)methyl 4-(trifluoromethyl)benzenesulfonate (i-B1)
  • Figure US20210101902A1-20210408-C00115
  • Step 1: To a solution of 4-((tert-butoxycarbonyl)amino)bicyclo[2.2.2]octane-1-carboxylic acid (4.565 g, 16.9 mmol) in THE (30 mL) was added BH3-DMS (5.15 mL, 3.0 eq) at 0° C. After addition, the reaction was further stirred overnight at rt. LC/MS indicated that the reaction was complete. The reaction was then treated with dropwise addition of 10% citric acid. Aqueous work up followed by ISCO purification (hexane/EtOAc) afforded tert-butyl (4-(hydroxymethyl)bicyclo[2.2.2]octan-1-yl)carbamate as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 6.31 (s, 1H), 4.31 (t, J=5.4 Hz, 1H), 2.99 (d, J=5.4 Hz, 2H), 1.75-1.61 (m, 6H), 1.41-1.27 (m, 15H). ESIMS (M+H+) 256.20.
  • Step 2: To a mixture of tert-butyl (4-(hydroxymethyl)bicyclo[2.2.2]octan-1-yl)carbamate (1.021 g, 4.0 mmol) and 4-(trifluoromethyl)benzenesulfonyl chloride (1.566 g, 6.4 mmol, 1.6 eq) and DCM (10 mL) was added Et3N (1.12 mL, 2.0 eq) and DMAP (49 mg, 0.1 eq) at rt. After addition, the resulting mixture was further stirred at rt for 4 hrs. LC/MS indicated the reaction was complete: mainly two peaks, product peak with m/z 408 (M+H+-56) and intermediate peak with m/z 331. Aqueous work up followed by ISCO purification (hexane/EtOAc) to get the product (i-B1) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 8.12 (d, J=8.4 Hz, 2H), 8.06 (d, J=8.4 Hz, 2H), 6.39 (s, 1H), 3.74 (s, 2H), 1.75-1.57 (m, 6H), 1.42-1.26 (m, 15H). ESIMS calcd. for C21H28F3NO5S (M+H+) 464.17, found 408.00 (M+H+-56).
    • Synthesis of (3-((tert-butoxycarbonyl)amino)bicyclo[1.1.1]pentan-1-yl)methyl 4-(trifluoromethyl)benzenesulfonate (i-B2)
  • Figure US20210101902A1-20210408-C00116
  • Step 1: LiAlH4 (83 mg, 2.188 mmol) was dissolved in THE (20 mL) at 0° C. Starting material methyl 3-((tert-butoxycarbonyl)amino)bicyclo[1.1.1]pentane-1-carboxylate (240 mg, 0.995 mmol) was dissolved in 5 mL THF, then was added to the LiAlH4 solution at 0° C. After completion of the reaction, the reaction mixture was warmed up to rt and stirred for 2 hrs. Sat. Na2SO4 solution was then added to quench the reaction. After filtering the solvent was removed to obtain tert-butyl (3-(hydroxymethyl)bicyclo[1.1.1]pentan-1-yl)carbamate for use in the next step.
  • Step 2: tert-Butyl (3-(hydroxymethyl)bicyclo[1.1.1]pentan-1-yl)carbamate (180 mg, 0.844 mmol), 4-(trifluoromethyl)benzenesulfonyl chloride (206 mg, 0.844 mmol) and DIPEA (0.295 mL, 1.688 mmol) were mixed in DCM (5 mL) and the reaction mixture was stirred at 25° C. for 5 hrs. After working-up and prep LC-MS, (3-((tert-butoxycarbonyl)amino)bicyclo[1.1.1]pentan-1-yl)methyl 4-(trifluoromethyl)benzenesulfonate (i-B2) was obtained for use in the next step. ESIMS (M+H+) 422.1.
    • Synthesis of 2-(4-((tert-butoxycarbonyl)amino)bicyclo[2.2.2]octan-1-yl)ethyl methanesulfonate (i-B3)
  • Figure US20210101902A1-20210408-C00117
  • 2-(4-((tert-butoxycarbonyl)amino)bicyclo[2.2.2]octan-1-yl)ethyl methanesulfonate (i-B3) was synthesized by mixing (287 mg, 1.065 mmol) of tert-butyl (4-(2-hydroxyethyl)bicyclo[2.2.2]octan-1-yl)carbamate and triethylamine (216 mg, 2.131 mmol) in DCM (10.700 ml). To this solution was added methanesulfonyl chloride (159 mg, 1.385 mmol) at 0° C. After addition, the resulting mixture was further stirred at 25° C. for 18 hrs. LC-MS indicated the reaction was completed. After workup (water addition and extraction in DCM), the organic layer was dried over MgSO4, filtered and concentrated in vacuo. The residue was used without further purification. 1H NMR (400 MHz, Chloroform-d) δ 4.23 (d, J=6.0 Hz, 1H), 4.15 (t, J=7.3 Hz, 2H), 2.92 (s, 3H), 1.78-1.71 (m, 6H), 1.55-1.50 (m, 2H), 1.50-1.42 (m, 6H), 1.35 (s, 9H). ESIMS (M+H+) 348.2.
    • Synthesis of (4-((tert-butoxycarbonyl)amino)bicyclo[2.2.1]heptan-1-yl)methyl 4-(trifluoromethyl)benzenesulfonate (i-B4)
  • Figure US20210101902A1-20210408-C00118
  • (4-((tert-butoxycarbonyl)amino)bicyclo[2.2.1]heptan-1-yl)methyltrifluoromethanesulfonate (i-B4) was made by following the synthetic method for 2-(4-((tert-butoxycarbonyl)amino)bicyclo[2.2.2]octan-1-yl)ethyl methanesulfonate (i-B3), except methyl 4-((tert-butoxycarbonyl)amino)bicyclo[2.2.1]heptane-1-carboxylate was used in place of tert-butyl (4-(2-hydroxyethyl)bicyclo[2.2.2]octan-1-yl)carbamate. 4-((tert-butoxycarbonyl)amino)bicyclo[2.2.1]heptan-1-yl)methyl trifluoromethanesulfonate (i-B4) was typically used as crude.
    • Synthesis of (4-((tert-butoxycarbonyl)amino)bicyclo[2.2.1]heptan-1-yl)methylmethanesulfonate (i-B5)
  • Figure US20210101902A1-20210408-C00119
  • (4-((tert-butoxycarbonyl)amino)bicyclo[2.2.1]heptan-1-yl)methylmethanesulfonate (i-B5) was made by following the synthetic method for 2-(4-((tert-butoxycarbonyl)amino)bicyclo[2.2.2]octan-1-yl)ethyl methanesulfonate (i-B3), except tert-butyl (4-(2-hydroxyethyl)bicyclo[2.2.1]heptan-1-yl)carbamate was used in place of tert-butyl (4-(2-hydroxyethyl)bicyclo[2.2.2]octan-1-yl)carbamate. (4-((tert-butoxycarbonyl)amino)bicyclo[2.2.1]heptan-1-yl)methyl methanesulfonate (i-B5) was typically used as crude.
    • Synthesis of (4-((tert-butoxycarbonyl)amino)-2-oxabicyclo[2.2.2]octan-1-yl)methyl 4-(trifluoromethyl)benzenesulfonate (i-B6)
  • Figure US20210101902A1-20210408-C00120
  • (4-((tert-butoxycarbonyl)amino)-2-oxabicyclo[2.2.2]octan-1-yl)methyl 4-(trifluoromethyl)benzenesulfonate (i-B6) was made by following the synthetic method for (3-((tert-butoxycarbonyl)amino)bicyclo[1.1.1]pentan-1-yl)methyl 4-(trifluoromethyl)benzenesulfonate (i-B2), except methyl 4-((tert-butoxycarbonyl)amino)-2-oxabicyclo[2.2.2]octane-1-carboxylate was used in place of methyl 3-((tert-butoxycarbonyl)amino)bicyclo[1.1.1]pentane-1-carboxylate. RT (method 1): 1.84 min. ESIMS calcd. for C20H26F3NO6S (M+H+) 465.5, found 488.5 (M+Na).
    • Synthesis of Tail Groups Synthesis of tert-butyl (4-((4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG1) and tert-butyl (4-((4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG2)
  • Figure US20210101902A1-20210408-C00121
  • Step 1: A solution of 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (i-A0) (165 mg, 0.64 mmol) in methanol (13.5 ml) was treated with DIPEA (2.91 ml, 16.66 mmol), followed by dropwise addition of benzyl chloroformate (0.837 ml, 5.95 mmol). The whole mixture was stirred for 18 hrs. LCMS showed a completed reaction and the reaction mixture was concentrated in vacuo. The residue was loaded on a 24 g silica gel column using 10% methanol in DCM to afford benzyl 1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (MS calculated for C14H15N3O2 (M+H+) 258.1, found 258.1).
  • Step 2: To a 20 mL scintillation vial containing benzyl 1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (165 mg, 0.641 mmol), was added 4-((tert-butoxycarbonyl)amino)bicyclo[2.2.2]octan-1-yl)methyl 4-(trifluoromethyl)benzenesulfonate (i-B1) (446 mg, 0.962 mmol), cesium carbonate (418 mg, 1.28 mmol) and anhydrous DMSO (3.2 mL). The mixture was heated to 110° C. for 18 hr, before diluted in ethyl acetate and water. Citric acid was added as solid to neutralize pH. After partition, the aqueous layer was re-extracted with ethyl acetate three times. All the organic layers were combined, dried over magnesium sulfate and concentrated in vacuo. The residue was purified on a 40 g silica gel column using 0-10% methanol in DCM to afford a mixture of the two desired regioisomers (MS calculated for C20H32N4O2 (M+H+) 361.3, found 361.3.
  • Step 3: To a mixture of (TG1a) and (TG2a) (102 mg, 0.21 mmol), was added palladium on carbon (0.0220 g, 0.0207 mmol) and ethanol (1 ml). The mixture was stirred with hydrogen (65 psi) for 18 hr; LCMS showed ˜90% conversion. The mixture was filtered, washed with methanol and concentrated in vacuo. The residue was loaded on a 40 g silica gel column using 0-80% isopropanol in DCM with 2% ammonia as modifier to afford the pure product directly used in the separation step (below).
    • Regioisomer Separation
  • 56 mg (0.16 mmol) of TG1 and TG2 from step two were separated using SFC chromatography on a 21×250 mm Cyano column (phase: 3 μM 4.6×50 mm, cyano, solvents mixture: CO2: 85%; 1/1 v/v IPA:MeOH+10 mM NH4OAc −15%; prep conditions: 80 g/min, 88/6/6 CO2/IPA/MeOH+10 mM NH40Ac, ˜115 bar, 2 min stacked injections, 5.25 min elution time) to afford tert-butyl (4-((4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG1; peak 2, RT 2.1 min., ESIMS calcd. for C21H34N4O2(M+H+) 361.3, found 361.3) and tert-butyl (4-((4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG2; peak 1, RT 1.71 min. ESIMS calcd. for C20H32N4O2(M+H+) 361.3, found 361.3.
    • Synthesis of tert-butyl(4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG3) and tert-butyl (4-((3-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG4)
  • Figure US20210101902A1-20210408-C00122
  • Step 1: A suspension of 3-methyl-1H-pyrazolo[4,3-c]pyridine (i-A1) (2.66 g, 19.98 mmol), in DMSO (80 ml) was treated with (4-((tert-butoxycarbonyl)amino)bicyclo[2.2.2]octan-1-yl)methyl 4-(trifluoromethyl)benzenesulfonate (i-B1) (9.26 g, 19.98 mmol) and cesium carbonate (13.02 g, 40.0 mmol). The mixture was heated to 120° C. for 18 hr to complete, before being cooled to rt and diluted in ethyl acetate and water. After partitioning, the organic layer was dried over magnesium sulfate and concentrated in vacuo. The residue was purified on a 120 g silica gel column using 0-80% ethyl acetate in hexane and extended to 80% ethyl acetate in hexane to afford the desired products tert-butyl (4-((3-methyl-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (product 1). The gradient was extended 100% ethyl acetate to elute the by-product tert-butyl (4-((3-methyl-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (product 2).
  • Product 1: RT (LCMS Method 1): 1.510 min (mass -M+1- 371.2), 1H NMR (400 MHz, Methanol-d4) δ 9.07 (s, 1H), 8.37 (d, J=6.1 Hz, 1H), 7.60 (d, J=6.2 Hz, 1H), 6.18 (broad s, 1H), 4.17 (s, 2H), 2.71 (s, 3H), 1.87 (dd, J=10.0, 5.9 Hz, 6H), 1.66 (dd, J=10.0, 5.9 Hz, 6H), 1.47 (s, 9H). ESIMS calcd. for C21H30N4O2 (M+H+) 371.5, found 371.5.
  • Product 2: RT (LCMS Method 1): 1.47 min. ESIMS calcd. for C21H30N4O2 (M+H+) 371.5, found 371.5.
  • Step 2: Hydrogenation of Product 1
  • tert-butyl (4-((3-methyl-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (product 1) (3.6267 g, 9.79 mmol) was hydrogenated using a H-cube system. Once complete, the reaction solution was concentrated and loaded on a 120 g silica gel column using 0-100% IPA in DCM with 1% ammonia as modifier and then extended to 100% IPA with 1% ammonia as modifier to elute tert-butyl (4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG3): 1H NMR (400 MHz, CD3OD) δ 3.73 (s, 2H), 3.65 (s, 2H), 3.04 (t, J=5.8 Hz, 2H), 2.65 (t, J=5.9 Hz, 2H), 2.12 (s, 3H), 1.87-1.74 (m, 6H), 1.61-1.47 (m, 6H), 1.39 (s, 9H); ESIMS calcd. for C21H34N4O2 (M+H+) 375.5, found 375.5.
  • Step 2: Hydrogenation of Product 2
  • tert-butyl (4-((3-methyl-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (1.011 g, 2.73 mmol) was hydrogenated using a H-cube system. Once complete, the reaction solution was concentrated and loaded on a 24 g silica gel column using 0-100% IPA in DCM with 3% NH3 as modifier to yield tert-butyl (4-((3-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG4). 1H NMR (400 MHz, Methanol-d4) δ 4.89 (d, J=1.4 Hz, 1H), 3.75 (m 4H), 3.09 (t, J=5.9 Hz, 2H), 2.72 (m, 2H), 2.15 (s, 3H), 1.79 (m, 6H), 1.54 (m, 6H), 1.40 (s, 9H). ESIMS calcd. for C21H34N4O2 (M+H+) 375.5, found 375.5.
    • Synthesis of tert-butyl (4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.1]heptan-1-yl)carbamate (TG5)
  • Figure US20210101902A1-20210408-C00123
  • Step 1. A mixture of 3-methyl-1H-pyrazolo[4,3-c]pyridine (i-A1) (133 mg, 1.0 mmol), (4-((tert-butoxycarbonyl)amino)bicyclo[2.2.1]heptan-1-yl)methyl methanesulfonate (i-B5) (351 mg, 1.1 mmol) and Cs2CO3 in DMSO (2 mL) was stirred at 80° C. overnight. LC-MS showed completion of the reaction. The reaction mixture was then cooled down to rt and diluted with EtOAc/water. The layers were separated and the organic layer was dried over Na2SO4 then concentrated. The crude product was added (solid loading) to a 40 g silica gel column and was eluted with 0-100% EtOAc in hexanes. Collected fractions and concentrated to give product 1, tert-butyl (4-((3-methyl-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.1]heptan-1-yl)carbamate, and product 2, tert-butyl (4-((3-methyl-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)bicyclo[2.2.1]heptan-1-yl)carbamate.
  • Step 2. 220 mg (0.617 mmol) of, tert-butyl (4-((3-methyl-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.1]heptan-1-yl)carbamate was transformed to the desired product, tert-butyl (4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.1]heptan-1-yl)carbamate (TG5) using H-Cube: 90° C., 20 bar H2, 10% Pd/C, 1 mL/min flow rate. RT (LCMS Method 2) 1.92 min. MS calculated for C20H32N4O2 (M+H+) 361.5, found 361.5. Note: Product 2 was not hydrogenated.
    • Synthesis of tert-butyl 1-((4-((tert-butoxycarbonyl)amino)bicyclo[2.2.2]octan-1-yl)methyl)-7,7-dimethyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carboxylate (TG6a) and tert-butyl 2-((4-((tert-butoxycarbonyl)amino)bicyclo[2.2.2]octan-1-yl)methyl)-7,7-dimethyl-6,7-dihydro-2H-pyrazolo[4,3-c]pyridine-5(4H)-carboxylate (TG7a)
  • Figure US20210101902A1-20210408-C00124
  • tert-butyl 7,7-dimethyl-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (iA3) (120 mg, 0.477 mmol), (4-((tert-butoxycarbonyl)amino)bicyclo[2.2.2]octan-1-yl)methyl 4-(trifluoromethyl)benzenesulfonate (i-B1) (220 mg, 0.477 mmol) and Cs2CO3 (156 mg, 0.477 mmol) were mixed in DMA (10 mL) and stirred at 120° C. for 1 hr. After working-up and prep LC-MS, tert-butyl 1-((4-((tert-butoxycarbonyl)amino)bicyclo[2.2.2]octan-1-yl)methyl)-7,7-dimethyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carboxylate (TG6a) and tert-butyl 2-((4-((tert-butoxycarbonyl)amino)bicyclo[2.2.2]octan-1-yl)methyl)-7,7-dimethyl-6,7-dihydro-2H-pyrazolo[4,3-c]pyridine-5(4H)-carboxylate TG7a) were obtained.
    • Synthesis of 4-((7,7-dimethyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (TG6)
  • Figure US20210101902A1-20210408-C00125
  • tert-butyl 1-((4-((tert-butoxycarbonyl)amino)bicyclo[2.2.2]octan-1-yl)methyl)-7,7-dimethyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carboxylate (TG6a) (70 mg, 0.143 mmol) and HCl in dioxane (4N) (0.433 mL, 14.27 mmol) were mixed in MeOH (1 mL) and stirred at 50° C. for 5 hrs. After working-up and prep LC-MS 4-((7,7-dimethyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (TG6) was obtained.
    • Synthesis of 4-((7,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)bicyclo[2.2.2]octan-1-amine (TG7)
  • Figure US20210101902A1-20210408-C00126
  • tert-butyl 2-((4-((tert-butoxycarbonyl)amino)bicyclo[2.2.2]octan-1-yl)methyl)-7,7-dimethyl-6,7-dihydro-2H-pyrazolo[4,3-c]pyridine-5(4H)-carboxylate (TG7a) (70 mg, 0.143 mmol) and HCl in dioxane (4N) (0.433 mL, 14.27 mmol) were mixed in MeOH (1 mL) and stirred at 50° C. for 5 hrs. After working-up and prep LC-MS 4-((7,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)bicyclo[2.2.2]octan-1-amine (TG7) was obtained.
    • Synthesis of 4-((3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (TG8)
  • Figure US20210101902A1-20210408-C00127
  • Step 1. A mixture of 291 mg (1 mmol) of tert-butyl 3-(trifluoromethyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carboxylate (i-A7), 510 mg (1.1 mmol) of (4-((tert-butoxycarbonyl)amino)bicyclo[2.2.1]heptan-1-yl)methyl methanesulfo(4-((tert-butoxycarbonyl)amino)bicyclo[2.2.2]octan-1-yl)methyl methanesulfonate and cesium carbonate (652 mg, 2.0 mmol) in DMSO (5 mL) was stirred at 80° C. overnight. After cooling to rt the mixture was diluted with EtOAc/water. The layers were separated and the aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na2SO4 then concentrated to give the crude product. The crude product was added (solid loading) to a 40 g silica gel column and was eluted with 0-50% EtOAc in hexanes. Collected fractions and concentrated to give the desired product, tert-butyl 1-((4-((tert-butoxycarbonyl)amino)bicyclo[2.2.2]octan-1-yl)methyl)-3-(trifluoromethyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carboxylate (TG8a) and a trace amount of tert-butyl 2-((4-((tert-butoxycarbonyl)amino)bicyclo[2.2.2]octan-1-yl)methyl)-3-(trifluoromethyl)-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (TG9a). TG8a: 1H NMR (500 MHz, Methylene Chloride-d2) δ 4.51-4.46 (m, 2H), 4.36 (s, 1H), 3.84 (s, 2H), 3.65 (t, J=5.8 Hz, 2H), 2.70 (t, J=5.9 Hz, 2H), 1.82-1.73 (m, 6H), 1.59-1.52 (m, 6H), 1.46 (s, 9H), 1.38 (s, 9H). MS (ES+): 529.4 (M+1)+. TG9a: Method 1 (RT: 2.07 min), MS (ES+): 529.4 (M+1)+.
  • Step 2: To a solution of 66 mg (0.125 mmol) of tert-butyl 1-((4-((tert-butoxycarbonyl)amino)bicyclo[2.2.2]octan-1-yl)methyl)-3-(trifluoromethyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-5(4H)-carboxylate (TG8a) in dioxane/MeOH (0.5 mL/0.3 mL) was added HCl (4M solution in dioxane, 0.5 mL). The resulting mixture was stirred at rt for 2 hrs. The reaction mixture was concentrated and lyophilized to give the final product, 4-((3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (TG8), as HCl salt. Method 1 (RT=0.9 min), MS (ES+): 329.2 (M+1)+.
    • Synthesis of tert-butyl methyl(4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[222]octan-1-yl)carbamate (TG10)
  • Figure US20210101902A1-20210408-C00128
    Figure US20210101902A1-20210408-C00129
  • Step 1. To a solution of 1.85 g (4.0 mmol) of (4-((tert-butoxycarbonyl)amino)bicyclo[2.2.2]octan-1-yl)methyl 4-(trifluoromethyl)benzenesulfonate (i-B1) in THF was added 208 mg (5.2 mmol) of NaH at 0° C. under N2. The mixture was warmed up to rt and stirred for 30 min then cooled back to 0° C. before CH3I (2.84 g, 20.0 mmol) was added dropwise. The resulting mixture was slowly warmed up to rt and stirred overnight. LC-MS showed desired product but the reaction was not complete. Additional NaH (1.0 eq.) and CH3I (5.0 eq.) were added and the reaction mixture was stirred at rt overnight. The reaction was quenched at 0° C. by dropwise adding 2.0 mL of 2-propanol, then 3.0 mL of cold water. The mixture was then partitioned between EtOAc and water. The layers were separated and the aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na2SO4 then concentrated. The crude product was added to a 80 g silica gel column and was eluted with 0-30% EtOAc in hexanes. Collected fractions and concentrated to give (4-((tert-butoxycarbonyl)(methyl)amino)bicyclo[2.2.2]octan-1-yl)methyl 4-(trifluoromethyl)benzenesulfonate. RT: 3.1 min (method 2). 1H NMR (400 MHz, Methanol-d4) δ 8.11 (d, J=8.2 Hz, 2H), 7.98 (d, J=8.2 Hz, 2H), 3.73 (d, J=1.9 Hz, 2H), 2.82 (s, 3H), 2.04-1.95 (m, 6H), 1.53-1.42 (m, 15H).
  • Step 2. A mixture of 133 mg (1.0 mmol) of 3-methyl-1H-pyrazolo[4,3-c]pyridine, 525 mg (1.1 mmol) of (4-((tert-butoxycarbonyl)(methyl)amino)bicyclo[2.2.2]octan-1-yl)methyl 4-(trifluoromethyl)benzenesulfonate and 652 mg (2.0 mmol) of Cs2CO3 in DMSO was stirred at 80° C. overnight. After cooling to rt, the mixture was diluted with EtOAc/water. The layers were separated and the organic layer was dried over Na2SO4, then concentrated. The crude product was added (solid loading) to a 40 g silica gel column and was eluted with 0-100% EtOAc in hexanes. Collected fractions and concentrated to give tert-butyl methyl(4-((3-methyl-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate as the major product (eluting first), and tert-butyl methyl(4-((3-methyl-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate as the minor by-product (eluting second). Major product (tert-butyl methyl(4-((3-methyl-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate): 1H NMR (400 MHz, Methanol-d4) δ 8.99 (d, J=1.1 Hz, 1H), 8.29 (d, J=6.2 Hz, 1H), 7.52 (dd, J=6.2, 1.2 Hz, 1H), 4.10-4.07 (m, 2H), 2.80 (s, 3H), 2.63 (s, 3H), 2.01-1.94 (m, 6H), 1.63-1.56 (m, 6H), 1.43 (s, 9H). MS (ES+): 385.2 (M+1)+. Minor product (tert-butyl methyl(4-((3-methyl-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate): 1H NMR (400 MHz, Methanol-d4) δ 9.08 (d, J=1.3 Hz, 1H), 8.14 (d, J=6.4 Hz, 1H), 7.48 (dd, J=6.3, 1.2 Hz, 1H), 4.19 (s, 2H), 2.81 (s, 3H), 2.77 (s, 3H), 2.07-1.97 (m, 6H), 1.70-1.62 (m, 6H), 1.43 (s, 9H). MS (ES+): 385.2 (M+1)+.
  • Step 3. tert-butyl methyl(4-((3-methyl-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (233 mg, 0.606 mmol) was transformed to the desired product, tert-butyl methyl(4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG10) using H-Cube: 100° C., 15 bar H2, 10% Pd/C, 1 mL/min flow rate. The product was used directly without purification. RT (method 2): 1.7 min, MS (ES+): 389.3 (M+1)+.
  • TABLE 4
    Additional Tail Groups
    Tail Group
    Code Tail Group Characterization Synthesis Method
    TG11
    Figure US20210101902A1-20210408-C00130
         		Method 1 (RT = 1.17 min), MS (ES+): 378.3 (M + 1) See Synthesis of TG3 Use (i-B6) in place of (i-B1)
    TG12
    Figure US20210101902A1-20210408-C00131
         		Method 1 (RT = 1.25 min.), MS (ES+): 390.2 (M + 1) See Synthesis of TG3 Use (i-B3) in place of (i-B1)
    TG13
    Figure US20210101902A1-20210408-C00132
         		Method 1 (RT = 1.09 min.), MS (ES+): 334.2 (M + 1) See Synthesis of TG4 Use (i-B2) in place of (i-B1)
    TG14
    Figure US20210101902A1-20210408-C00133
         		See synthesis of TG3. Use 4- hydroxybicyclo[2,2,2]octane-1- carboxylic acid as starting material instead of 4-((tert- butoxycarbonyl)amino)bicyclo[2.2.2] octane-1-carboxylic acid
    • Head Groups
  • The Head Group intermediates used to obtain compounds of the invention are shown in Table 5 and their synthesis is described below. Unless purchased, the synthesis of certain reagents used to obtain these intermediates is also described below.
  • TABLE 5
    Head Groups
    Head
    Group Synthesis Method or
    Code Head Group Head Group Name Purchase
    HG1
    Figure US20210101902A1-20210408-C00134
         		4-bromo-1,6-dimethyl- 1H-pyrazolo[3,4- b]pyridine Purchased
    HG2
    Figure US20210101902A1-20210408-C00135
         		4-chloro-1-methyl-1H- pyrazolo[3,4-d]pyrimidiin- 6-amine Purchased
    HG2a
    Figure US20210101902A1-20210408-C00136
         		tert-butyl (4-chloro-1- methyl-1H-pyrazolo[3,4- d]pyrimidin-6- yl)carbamate Boc Protected HG2
    HG3
    Figure US20210101902A1-20210408-C00137
         		5,7-dichloro-1-methyl- 1H-pyrazolo[4,3- d]pyrimidine Purchased
    HG4
    Figure US20210101902A1-20210408-C00138
         		7-chloro-1,3,5-trimethyl- 1H-pyrazolo[4,3- d]pyrimidine Purchased
    HG5
    Figure US20210101902A1-20210408-C00139
         		4-chloro-3,6- dimethylisoxazolo[5,4- d]pyrimidine Purchased
    HG6
    Figure US20210101902A1-20210408-C00140
         		4-chloro-1H- pyrazolo[3,4-b]pyridine Purchased
    HG7
    Figure US20210101902A1-20210408-C00141
         		1-(4-methoxybenzyl)-6- methyl-1H-pyrazolo[3,4- b]pyridin-4-yl trifluoromethanesulfonate See Below
    HG8
    Figure US20210101902A1-20210408-C00142
         		4-chloro-2- methylquinoline Purchased
    HG9
    Figure US20210101902A1-20210408-C00143
         		4-chloro-2-methyl-1,7- naphthyridine Purchased
    HG10
    Figure US20210101902A1-20210408-C00144
         		4-chloro-2,8-dimethyl- 1,7-naphthyridine See below
    HG11
    Figure US20210101902A1-20210408-C00145
         		2,4-dichloro-5,7- dihydrofuro[3,4- d]pyrimidine Purchased
    HG12
    Figure US20210101902A1-20210408-C00146
         		7-chloro-5-methyl-1H- pyrazolo[4,3-b]pyridine Purchased
    HG13
    Figure US20210101902A1-20210408-C00147
         		4-chloro-1-ethyl-6- methyl-1H-pyrazolo[3,4- b]pyridine See below
    HG14
    Figure US20210101902A1-20210408-C00148
         		4-chloro-2-methyl-7H- pyrrolo[2,3-d]pyrimidine Purchased
    HG15
    Figure US20210101902A1-20210408-C00149
         		4-chloro-1,6-dimethyl- 1H-pyrrolo[2,3-b]pyridine Purchased
    HG16
    Figure US20210101902A1-20210408-C00150
         		4,6-dichloro-1-methyl- 1H-pyrazolo[3,4- d]pyrimidine Purchased
    HG17
    Figure US20210101902A1-20210408-C00151
         		4-chloro-1,6-dimethyl- 1H-pyrazolo[3,4- d]pyrimidine Purchased
    HG18
    Figure US20210101902A1-20210408-C00152
         		4-chloro-6-methyl-1H- pyrazolo[3,4-d]pyrimidine Purchased
    • Synthesis of 1-(4-methoxybenzyl)-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl trifluoromethanesulfonate (HG7)
  • Figure US20210101902A1-20210408-C00153
  • Step 1: A solution of 1-(4-methoxybenzyl)-1H-pyrazol-5-amine and ethyl acetoacetate in acetic acid was stirred at rt overnight. The reaction was concentrated in vacuo and then taken up in DOWThermA and heated in a sealed vessel to 230° C. The reaction was maintained at this temperature for 40 min and then cooled to rt. The reaction was purified by column chromatography (SiO2, ISCO, 0-15% MeOH in dichloromethane) to afford the desired phenol directly used in the next step.
  • Step 2: To the solution of 1-(4-methoxybenzyl)-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-ol (1.895 g, 7.04 mmol) in mix solvent of DCM (100 mL, 3.33 parts) and THF (30 mL, 1 part) at 0° C. was added triethylamine (7.36 mL, 52.8 mmol) followed by triflicAnhydride (2.97 mL, 17.59 mmol). The reaction was gradually warmed up to rt in 3 hrs. The reaction was quenched with saturated sodium bicarbonate solution and extracted with DCM. The organic phase was washed with brine and dried. The crude product was purified by silica gel chromatography, eluted with 10% to 50% ethyl acetate in hexane to give 1-(4-methoxybenzyl)-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl trifluoromethanesulfonate (HG7). RT (LC/MS method 2): 2.79 min. ESIMS calcd. for C16H14F3N3O4 (M+H+) 402.9, found 402.9.
    • Synthesis of 4-chloro-2,8-dimethyl-1,7-naphthyridine (HG10)
  • Figure US20210101902A1-20210408-C00154
  • To a solution of 4-chloro-2-methyl-1,7-naphthyridine (405 mg, 2.267 mmol) in THE (10 mL) was intermittently added methylmagnesium bromide (4.53 mL, 13.60 mmol, 3M in diether ether) over 30 min at rt. The reaction changed from a light brown to a dark green suspension. After stirring overnight, the reaction was stopped and then quenched by addition of saturated NH4Cl (10 mL), extracted with EtOAc (3×25 mL). EtOAc was washed with brine (5 mL), dried over Na2SO4 and evaporated to give the crude desired product 4-chloro-2,8-dimethyl-7,8-dihydro-1,7-naphthyridine. MS 195.1 (M+1), RT (LC/MS method 1) 0.94 min. Contained byproduct MS 193.1 (M+1), RT (LC/MS method 1) 0.85 min. The crude was used w/o purification in next step.
  • The crude 4-chloro-2,8-dimethyl-7,8-dihydro-1,7-naphthyridine (440 mg, 2.260 mmol) from above was dissolved in DCM (20 mL). DDQ (513 mg, 2.260 mmol) was added. The mixture was sonicated for 2 min. LCMS showed completion of the reaction. The mixture was diluted with EtOAc (50 mL), filtered through Celite filter cake. The filter cake was washed with EtOAc (50 mL). The organic was evaporated to give a dark residue. The crude was purified by flash chromatography (EtOAc:hex/0-100%) giving 4-chloro-2,8-dimethyl-1,7-naphthyridine (HG10): MS 193.1 (M+1), RT 0.82 min. (method 1).
    • Synthesis of 4-chloro-1-ethyl-6-methyl-1H-pyrazolo[3,4-b]pyridine (HG13)
  • Figure US20210101902A1-20210408-C00155
  • Step 1. A mixture of 2.5 g of 1-ethyl-1H-pyrazol-5-amine (22.5 mmol), 23.4 g (180 mmol) of ethyl 3-oxobutanoate and 1.35 g (22.5 mmol) of AcOH was reacted in flow using a Vapourtec R2C+/R4 (trip pressure set to 40 bar; SS tube reactor; solution pressure set by 250 psi BPR) in dioxane at a flow rate of 0.2 mL/min at 250° C. The reaction was quenched using MeOH (flow rate 0.25 mL/min). The resulting solution was concentrated and triturated in EtOAc to afford 1-ethyl-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-ol as an off-white solid. RT 0.95 min (method 2). MS (M+1): 178.2
  • Step 2.
  • A sealed vessel charged with 1-ethyl-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-ol (1 g, 5.64 mmol) and POCl3 (0.631 mL, 6.77 mmol) in anisole (8 mL) was heated at 130° C. for 2 hrs. The reaction was cooled down and the solvent was removed in vacuo and dried to afford 4-chloro-1-ethyl-6-methyl-1H-pyrazolo[3,4-b]pyridine (HG13). RT 0.52 min (LC/MS method 2). MS (M+1): 196.6.
    • Synthesis of Exemplary Compounds Example 1 Synthesis of 4-((5-(1,6-dimethyl-H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 1)
  • Figure US20210101902A1-20210408-C00156
  • Step 1: To a pressure flask containing tert-butyl (4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG3) (0.565 g, 42.5 mmol) was added 4-bromo-1,6-dimethyl-1H-pyrazolo[3,4-b]pyridine (HG1) (0.94 g, 2.5 mmol), cesium carbonate (1.63 g, 5.1 mmol), Pd2(dba)3 (0.057 g, 0.062 mmol), RuPhos (0.14 g, 0.3 mmol) and THF (25 mL). The mixture was heated at 80° C. for 18 hrs to complete, then cooled to rt. The mixture was diluted in ethyl acetate and water. After partition, the aqueous layer was extracted with ethyl acetate once more. Both organic layers were combined, dried over MgSO4, filtered and concentrated in vacuo. The residue was purified via flash chromatography using 0-100% B/A (A=heptane; B=25% ethanol in ethyl acetate) to elute tert-butyl (4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate: 1H NMR (400 MHz, CDCl3) δ 7.98 (s, 1H), 6.27 (s, 1H), 4.49 (s, 2H), 4.38-4.25 (m, 1H), 4.11 (s, 3H), 3.94 (t, J=5.5 Hz, 2H), 3.70 (s, 2H), 2.87 (t, J=5.6 Hz, 2H), 2.62 (s, 3H), 2.25 (s, 3H), 1.89-1.75 (m, 6H), 1.58 (m, 6H), 1.42 (s, 9H); MS calculated for C29H72N7O2 (M+H+) 520.34, found 520.4.
  • Step 2: To a 500 mL round bottom flask containing tert-butyl (4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (1.5 g, 1.45 mmol) was added methanol (6 mL), then 4N HCl in dioxane (7.2 mL, 28.9 mmol). The mixture was stirred at rt for 18 hr then concentrated in vacuo. The residue was treated with isopropanol portionwise at 70° C. to get all solid dissolved. The solution was cooled naturally to rt and aged for 18 hrs. Then the solid was filtered and the filtrate was concentrated and the crystallization process repeated. Both batches were combined and dried under vacuum at 40° C. for 18 hrs to afford of 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine as HCl salt (Compound No. 1-HCl): 1H NMR (400 MHz, CD3D) δ 8.51 (s, 1H), 6.88 (s, 1H), 5.06-4.92 (m, 2H), 4.24 (s, 2H), 4.11 (s, 3H), 3.97 (s, 2H), 3.10 (t, J=5.6 Hz, 2H), 2.69 (s, 3H), 2.38 (s, 3H), 1.88-1.59 (m, 12H); MS (M+H+) found 420.3.
  • Step 3: Ambersep 9000H (17 ml, 0.8 meq/mL, prewashed with 60 mL of MeOH) was added into a solution of 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine as HCl salt (Compound No. 1-HCl) (1.53 g, 2.7 mmol) in MeOH (100 mL). The mixture was stirred at rt for 1 hr then filtered, washed with 50 mL of MeOH and concentrated. The crude product was added (by solid loading) to a 12 g silica gel column and was eluted with 2-9% MeOH (containing small amount of ammonia) in DCM. Collected fractions and concentrated to give the product, 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine, as the free base (Compound No. 1): 1H NMR (400 MHz, CD3OD) δ 8.15 (s, 1H), 6.45 (s, 1H), 4.54 (s, 2H), 4.00 (s, 3H), 3.97 (t, J=5.6 Hz, 2H), 3.73 (s, 2H), 2.90 (t, J=5.6 Hz, 2H), 2.55 (s, 3H), 2.23 (s, 3H), 1.55 (s, 12H); MS (M+H+) 420.3.
    • Example 2 Synthesis of 4-((3-methyl-5-(6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methy)bicyclo[2.2.2]octan-1-amine (Compound No. 2) and 4-((5-(1-(4-methoxybenzyl)-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 53)
  • Figure US20210101902A1-20210408-C00157
    Figure US20210101902A1-20210408-C00158
  • Step 1: tert-butyl (4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG3) (110 mg, 0.294 mmol), 1-(4-methoxybenzyl)-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl trifluoromethanesulfonate (HG7) (118 mg, 0.294 mmol), DIPEA (0.154 mL, 0.881 mmol) and BuOH (0.05 mL) were added to a reaction vial and then stirred at 120° C. for 3 hrs. The reaction mixture was purified by HPLC to give tert-butyl (4-((5-(1-(4-methoxybenzyl)-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate. RT (method 2): 2.29 min, ESIMS m/z 626.4 (M++1)
  • Step 2: To the solution of tert-butyl (4-((5-(1-(4-methoxybenzyl)-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (110 mg, 0.176 mmol) in MeOH (1 mL) was added hydrochloric acid (0.879 mL, 5.27 mmol). The reaction was stirred for 16 hr at 25° C. and then dried to give 4-((5-(1-(4-methoxybenzyl)-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 53) as HCl salt. RT (method 1): 1.28 min, ESIMS m/z 526.3 (M++1)
  • Step 3: To a 20 mL pressure tube was added 4-((5-(1-(4-methoxybenzyl)-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 53) (80 mg, 0.152 mmol), cysteine (36.9 mg, 0.304 mmol) and TFA (2 mL). The mixture was heated at 75° C. for 2 hr and then cooled to rt and concentrated in vacuo. The residue was purified by HPLC to give 4-((3-methyl-5-(6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 2). ESIMS m/z 406.2 (M++1); 1H NMR (400 MHz, Methanol-d4) δ 8.09 (s, 1H), 6.34 (s, 1H), 4.44 (s, 2H), 3.88 (t, J=5.6 Hz, 2H), 3.63 (s, 2H), 3.56 (s, 4H), 2.80 (t, J=5.6 Hz, 2H), 2.41 (s, 3H), 2.13 (s, 3H), 1.44 (s, 12H).
    • Example 3 Synthesis of 4-((3-methyl-5-(2-methyl-1,7-naphthyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 3) and tert-butyl (4-((3-methyl-5-(2-methyl-1,7-naphthyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (Compound No. 147)
  • Figure US20210101902A1-20210408-C00159
  • Step 1: To the reaction vial were added tert-butyl (4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG3) (105 mg, 0.280 mmol), 4-chloro-2-methyl-1,7-naphthyridine (HG9) (50 mg, 0.280 mmol), DIPEA (0.147 mL, 0.840 mmol) and BuOH (0.1 mL). The reaction was stirred at 120° C. for 3 hr, diluted with methanol and purified by HPLC. The fractions were pooled, neutralized with Na2CO3 and then extracted with ethyl acetate to give tert-butyl (4-((3-methyl-5-(2-methyl-1,7-naphthyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (Compound No. 147)1H NMR (400 MHz, DMSO-d6) δ 9.53 (s, 1H), 8.73 (d, J=5.9 Hz, 1H), 8.34-7.92 (m, 2H), 7.39 (s, 1H), 4.68 (s, 2H), 4.03 (t, J=5.2 Hz, 2H), 3.72 (s, 2H), 3.08 (s, 2H), 2.78 (s, 3H), 2.51 (s, 9H), 2.12 (s, 3H), 1.80-1.45 (m, 12H). ESIMS m/z 518.0 (M++1).
  • Step 2: To a solution of tert-butyl (4-((3-methyl-5-(2-methyl-1,7-naphthyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (124 mg, 0.240 mmol) in MeOH (1 mL) was added hydrochloric acid (1.200 mL, 7.20 mmol). The reaction was stirred for 16 hr at 25° C. The reaction was dried to give 4-((3-methyl-5-(2-methyl-1,7-naphthyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 3) as an HCl salt. ESIMS m/z 417.2 (M++1); 1H NMR (400 MHz, DMSO-d6) δ 9.53 (s, 1H), 8.73 (d, J=5.9 Hz, 1H), 8.16-8.05 (m, 4H), 7.39 (s, 1H), 4.70 (s, 2H), 4.03 (t, J=5.6 Hz, 2H), 3.72 (s, 2H), 3.13-3.03 (m, 2H), 2.78 (s, 3H), 2.12 (s, 3H), 1.75-1.63 (m, 6H), 1.60-1.49 (m, 6H).
    • Example 4 Synthesis of 4-((3-methyl-5-(2-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methy)bicyclo[2.2.2]octan-1-amine (Compound No. 4) and tert-butyl (4-((3-methyl-5-(2-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methy)bicyclo[2.2.2]octan-1-yl)carbamate (Compound No. 146)
  • Figure US20210101902A1-20210408-C00160
  • Step 1: To a reaction vial were added tert-butyl (4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG3) (67.0 mg, 0.179 mmol), 4-chloro-2-methyl-7H-pyrrolo[2,3-d]pyrimidine (HG14) (30 mg, 0.179 mmol), DIPEA (0.094 mL, 0.537 mmol) and BuOH (0.1 mL). The reaction was stirred at 120° C. for 3 hr and then diluted with methanol and purified by HPLC to give tert-butyl (4-((3-methyl-5-(2-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (Compound No. 146). RT (method 2): 2.11 min. MS (ES+): 507.3 (M+1)+.
  • Step 2: To a solution of tert-butyl (4-((3-methyl-5-(2-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (35 mg, 0.075 mmol) in MeOH (1 mL) was added hydrochloric acid (0.445 mL, 2.67 mmol). The reaction was stirred for 16 hr at 25° C. and then dried to give 4-((3-methyl-5-(2-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 4) as an HCl salt. ESIMS m/z 406.2 (M++1); 1H NMR (400 MHz, Methanol-d4) δ 7.36 (d, J=3.5 Hz, 1H), 7.08 (d, J=3.6 Hz, 1H), 5.18 (s, 2H), 4.47 (t, J=5.3 Hz, 2H), 4.17 (s, 2H), 3.16 (t, J=5.3 Hz, 2H), 2.71 (s, 3H), 2.52 (s, 3H), 1.90-1.66 (m, 12H).
    • Example 5 Synthesis of 4-((5-(1,6-dimethyl-H-pyrrolo[2,3-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methy)bicyclo[2.2.2]octan-1-amine (Compound No. 5)
  • Figure US20210101902A1-20210408-C00161
  • Step 1: To the reaction vial were added tert-butyl (4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG3) (62.2 mg, 0.166 mmol), 4-chloro-1,6-dimethyl-1H-pyrrolo[2,3-b]pyridine (HG15) (30 mg, 0.166 mmol), RuPhos (9.30 mg, 0.020 mmol), tris(dibenzylideneacetone)dipalladium(0) (7.60 mg, 8.30 μmol), Cs2CO3 (108 mg, 0.332 mmol) and THE (2 mL). The reaction was stirred @75° C. for 18 hrs. Reaction completed. The reaction was diluted with ethyl acetate and filtered through celite to remove salt. The filtrate was dried and the crude product was directly used in the next step.
  • Step 2: To a solution of tert-butyl (4-((5-(1,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (30 mg, 0.046 mmol) in MeOH (1 mL) was added hydrochloric acid (0.231 mL, 1.388 mmol). The reaction was stirred for 16 hr at 25° C., then was dried and purified by HPLC to give -((5-(1,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 5): ESIMS m/z 419.2 (M++1); 1H NMR (400 MHz, Methanol-d4) δ 7.14 (d, J=3.6 Hz, 1H), 6.80 (d, J=3.6 Hz, 1H), 6.66 (s, 1H), 4.67 (s, 2H), 4.03 (t, J=5.6 Hz, 2H), 3.79 (s, 3H), 3.69 (s, 2H), 2.86 (t, J=5.6 Hz, 2H), 2.55 (s, 3H), 2.13 (s, 3H), 1.66 (dd, J=10.9, 4.6 Hz, 6H), 1.56 (dd, J=10.8, 4.7 Hz, 6H).
    • Example 6 Synthesis of N-(4-((5-(1,6-dimethyl-H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)oxetan-3-amine (Compound No. 6)
  • Figure US20210101902A1-20210408-C00162
  • To a solution of 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 1 from Example 1, 1.68 g, 4.0 mmol) in DCE (40 mL) was added acetic acid (0.229 mL, 1.0 eq.) and oxetan-3-one (2.94 g, 10 eq.). The mixture was stirred at rt for 30 min before sodium triacetoxyhydroborate (2.62 g, 3.0 eq.) was added. The mixture was then stirred at rt overnight. More oxetan-3-one (1.47 g, 5 eq.), sodium triacetoxyhydroborate (1.3 g, 1.5 eq.) and 20 mL of DCE were added and the mixture was stirred at rt for additional 5 hrs then treated with 40 mL of 1N NaOH. The layers were separated and the aqueous layer was extracted with DCM/MeOH (5:1 v/v, 100 mL×3). The combined organic layers were dried over Na2SO4, filtered and concentrated to give the crude product. The crude product was added to a 40 g gold silica gel column and was eluted with 0-50% (over 25 min) IPA (containing 0.02 M ammonia) in DCM. Collected fractions and concentrated to give N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)oxetan-3-amine (Compound No. 6): 1H NMR (400 MHz, Methanol-d4) δ 8.05 (s, 1H), 6.35 (s, 1H), 4.60 (t, J=6.8 Hz, 2H), 4.43 (s, 2H), 4.34 (t, J=6.6 Hz, 2H), 4.04 (p, J=7.2 Hz, 1H), 3.90 (s, 3H), 3.87 (t, J=5.6 Hz, 2H), 3.61 (s, 2H), 2.79 (t, J=5.6 Hz, 2H), 2.44 (s, 3H), 2.12 (s, 3H), 1.47-1.33 (m, 12H). MS (ES+): 476.3 (M+1)+.
    • Example 7 Synthesis of N-(4-((5-(1,6-dimethyl-H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(dimethylamino)acetamide (Compound No. 7)
  • Figure US20210101902A1-20210408-C00163
  • To a mixture of 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl) -3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 1 from Example 1, 2.52 g, 6.0 mmol) and 2-(dimethylamino)acetic acid (0.742 g, 1.2 eq.) in DCM (60 mL) was added DIPEA (2.1 mL, 2.0 eq.) then HATU (2.74 g, 1.2 eq.). The resulting mixture was stirred at rt for 1 hr then washed with 30 mL of water. The aqueous layer was extracted with DCM (100 mL×3) and the combined organic layers were dried over Na2SO4, filtered and concentrated to give the crude product. The crude product was added to a 80 g gold silica gel column and was eluted with 0-50% (over 30 min) IPA (containing 0.02 M of ammonia) in DCM. Collected fractions and concentrated to give N (4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl) -3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(dimethylamino)acetamide (Compound No. 7): 1H NMR (600 MHz, Methanol-d4) δ 8.17 (s, 1H), 6.47 (s, 1H), 4.56 (s, 2H), 4.02 (s, 3H), 3.99 (dd, J=6.1, 5.1 Hz. 2H). 3.74 (s. 2H), 2.94 - 2.91 (m, 2H), 2.90 (s. 2H). 2.56 (s. 3H). 2.36 (s, 1H). 2.30 (s. 6H). 2.25 (s. 3H). 1.94 - 1.87 (m. 6H). 1.63 - 1.57 (m. 6H). MS (ES+): 505.4 (M+1)+.
    • Example 8 Synthesis of (S)-N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl) -3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide (Compound No. 8)
  • Figure US20210101902A1-20210408-C00164
  • A mixture of 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl) -3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 1 from Example 1) (42 mg, 0.1 mmol), (S)-4-(tert-butoxycarbonyl)morpholine-3-carboxylic acid (25.4 mg, 0.11 mmol) and DIPEA (0.035 mL, 0.2 mmol) in 1.0 mL of DMF was added HATU (45.6 mg, 0.12 mmol) then stirred at rt for 30 min. LC-MS confirmed completion of the reaction. The intermediate was purified by mass-triggered HPLC (10-90% ACN in H2O over 3.5 min). The collected fractions were concentrated and the residue was dissolved in MeOH/1,4-dioxane (1.5 mL, 1:2 v/v). 4M HCl in 1,4-dioxane (1.0 mL) was added and the mixture was stirred at rt for 1 hr then concentrated and lyophilized to give (S)—N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide (Compound No. 8), as an HCl salt. 1H NMR (400 MHz, Methanol-d4) δ 8.52 (s, 1H), 7.92 (s, 1H), 6.88 (s, 1H), 5.06-4.91 (m, 2H), 4.25 (s, 2H), 4.19-4.09 (m, 4H), 4.03-3.89 (m, 4H), 3.78-3.56 (m, 4H), 3.22 (ddd, J=12.9, 11.2, 3.7 Hz, 1H), 3.17-3.05 (m, 2H), 2.70 (s, 3H), 2.41 (s, 3H), 1.93 (dd, J=8.9, 5.0 Hz, 6H), 1.72-1.54 (m, 6H). MS (ES+): 533.3 (M+1)+.
    • Example 9 Synthesis of (R)—N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide (Compound No. 9)
  • Figure US20210101902A1-20210408-C00165
  • A mixture of 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 1 from Example 1) (42 mg, 0.1 mmol), (R)-4-(tert-butoxycarbonyl)morpholine-3-carboxylic acid (25.4 mg, 0.11 mmol) and DIPEA (0.035 mL, 0.2 mmol) in 1.0 mL of DMF was added HATU (45.6 mg, 0.12 mmol) then stirred at rt for 30 min. LC-MS confirmed completion of the reaction. The intermediate was purified by mass-triggered HPLC (10-90% ACN in H2O over 3.5 min). Collectioned fractions were concentrated and the residue was dissolved in MeOH/1,4-dioxane (1.5 mL, 1:2 v/v). 4M HCl in 1,4-dioxane (1.0 mL) was added and the mixture was stirred at rt for 1 hr then concentrated and lyophilized to give (R)—N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide (Compound No. 9), as HCl salt. 1H NMR (400 MHz, Methanol-d4) δ 8.51 (s, 1H), 7.92 (s, 1H), 6.88 (s, 1H), 5.03-4.92 (m, 1H), 4.32-4.18 (m, 2H), 4.20-4.09 (m, 4H), 4.03-3.89 (m, 4H), 3.78-3.54 (m, 4H), 3.22 (ddd, J=13.0, 11.2, 3.8 Hz, 1H), 3.15-3.05 (m, 2H), 2.69 (s, 3H), 2.39 (s, 3H), 1.98-1.85 (m, 6H), 1.62 (dd, J=10.3, 5.9 Hz, 6H). MS (ES+): 533.3 (M+1)+.
    • Example 10 Synthesis of 6-(4-((3-methyl-5-(1,3,5-trimethyl-H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-oxa-6-azaspiro[3.3]heptane (Compound No. 10) and 4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 26)
  • Figure US20210101902A1-20210408-C00166
  • Step 1. A mixture of 7-chloro-1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidine (HG4) (263 mg, 1.335 mmol), tert-butyl (4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG3) (500 mg, 1.335 mmol) and DIPEA (0.233 mL, 1.335 mmol) in 2-propanol (30 mL) was heated to 100° C. for 1 hr. After working-up and column chromatography (eluent: 2:1 EtOAc:hexane), tert-butyl (4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate was obtained. LC-MS: MS (ES+): 535.4; RT: 1.171 min (method 1)
  • Step 2. tert-butyl (4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate was subjected to the same conditions described in step 2 of Example 4 to yield 4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 26). 1H NMR (400 MHz, Methanol-d4) δ 4.96 (s, 2H), 4.31 (t, J=5.6 Hz, 2H), 4.24 (s, 3H), 3.77 (s, 2H), 3.04-2.98 (m, 2H), 2.71 (s, 3H), 2.53 (s. 3H), 2.21 (s. 3H), 1.80-1.62 (m. 12H). MS (ES+): 435.4 (M+1)+.
  • Step 3. A mixture of (60 mg, 0.138 mmol) of 4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 26), 101 mg (0.414 mmol) of 1,1-bis(bromomethyl)cyclobutane and K2CO3 (95 mg, 0.690 mmol) in 2-propanol (10 mL) was heated to 120° C. for 72 hrs. After cooling to rt, the 2-propanol was evaporated, water was added and the mixture was extracted with EtOAc. The organic layers were combined, dried (Na2SO3) and concentrated. The residue was purified by preparative LC-MS to give 6-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-oxa-6-azaspiro[3.3]heptane (Compound No. 10). 1H NMR (400 MHz, Methanol-d4) δ 4.70 (s, 4H), 4.52 (s, 2H), 4.11 (s, 3H), 3.86 (t, J=5.7 Hz, 2H), 3.71 (s, 2H), 3.39 (s, 4H), 2.99 (t, J=5.5 Hz, 2H), 2.59 (s, 3H), 2.50 (s, 3H), 2.18 (s, 3H), 1.58-1.40 (m, 12H). MS (ES+): 517.3 (M+1)+.
    • Example 11 Synthesis of 4-((5-(6-(4-fluorophenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 83)
  • Figure US20210101902A1-20210408-C00167
  • Step 1: 4,6-dichloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine (HG16) (40 mg, 0.197 mmol), tert-butyl (4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG3) (70 mg, 0.187 mmol), Pd2dba3 (10 mg, 10.92 μmol), RuPhos (10 mg, 0.021 mmol) and Cs2CO3 (65 mg, 0.199 mmol) were mixed in dioxane (5 mL) and stirred at 120° C. for 6 hrs. After working-up and prep LC-MS, tert-butyl (4-((5-(6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate was obtained.
  • Step 2: tert-butyl (4-((5-(6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (20 mg, 0.037 mmol), (4-fluorophenyl)boronic acid (10 mg, 0.071 mmol), PdCl2(dppf). CH2Cl2 adduct (6 mg, 7.35 μmol) and K2CO3 (20 mg, 0.145 mmol) were mixed in dioxane (3 mL and stirred at 110° C. for 6 hsr. After working-up and prep LC-MS, tert-butyl (4-((5-(6-(4-fluorophenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate was obtained.
  • Step 3: tert-butyl (4-((5-(6-(4-fluorophenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (10 mg, 0.017 mmol) and 4N HCl (0.152 mL, 4.99 mmol) were mixed in MeOH (1 mL) and stirred at 50° C. for 5 hrs. After working-up and prep LC-MS, 4-((5-(6-(4-fluorophenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 83) was obtained. 1H NMR (400 MHz, Methanol-d4) δ 8.55 (dd, J=8.7, 5.7 Hz, 2H), 8.27 (s, 1H), 7.21 (t, J=8.8 Hz, 2H), 4.97 (s, 2H), 4.38 (brs, 2H), 4.06 (s, 3H), 3.80 (s, 2H), 2.92 (t, J=5.4 Hz, 2H), 2.29 (s, 3H), 1.80-1.60 (m, 12H). MS (ES+): 501.3 (M+1)+.
    • Example 12 Synthesis of 4-(4-(1-((4-aminobicyclo[2.2.2]octan-1-yl)methy)-3-methyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)pyridin-2-yl)benzonitrile (Compound No. 84)
  • Figure US20210101902A1-20210408-C00168
  • Step 1: 2-chloro-4-fluoropyridine (130 mg, 0.988 mmol), tert-butyl (4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG3) (370 mg, 0.988 mmol) and DIPEA (130 mg, 1.006 mmol) were mixed in DMA (5 mL) and stirred at 150° C. for 4 hrs. After working-up and column chromatography (2:1 EtOAc:hexane), tert-butyl (4-((5-(2-chloropyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate was obtained.
  • Step 2: tert-butyl (4-((5-(2-chloropyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (25 mg, 0.051 mmol), (4-cyanophenyl)boronic acid (15 mg, 0.102 mmol), PdCl2(dppf). CH2Cl2 adduct (5 mg, 6.12 μmol) and K2CO3 (25 mg, 0.181 mmol) were mixed in dioxane (3 mL) and stirred at 120° C. for 17 hrs. After working-up and prep LC-MS, tert-butyl (4-((5-(2-(4-cyanophenyl)pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate was obtained.
  • Step 3: tert-Butyl (4-((5-(2-(4-cyanophenyl)pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (20 mg, 0.036 mmol) and 4N HCl (0.220 mL, 7.24 mmol) were mixed in MeOH (1 mL) and stirred at 50° C. for 3 hrs. After working-up and prep LC-MS, 4-(4-(1-((4-aminobicyclo[2.2.2]octan-1-yl)methyl)-3-methyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)pyridin-2-yl)benzonitrile (Compound No. 84) was obtained. 1H NMR (400 MHz, Methanol-d4) δ 8.25 (d, J=7.4 Hz, 1H), 8.08-7.97 (m, 4H), 7.56 (brs, 1H), 7.36 (m, 1H), 4.71 (s, 2H), 4.09 (brs, 2H), 3.79 (s, 2H), 2.93 (t, J=5.4 Hz, 2H), 2.25 (s, 3H), 1.82-1.60 (m, 12H). MS (ES+): 453.3 (M+1)+
    • Example 13 Synthesis of 5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-1-((4-(pyrrolidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (Compound No. 58)
  • Figure US20210101902A1-20210408-C00169
  • 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 1 from Example 1) (23 mg, 0.055 mmol) was treated with potassium carbonate (22.73 mg, 0.164 mmol), 1,4-dibromobutane (59.2 mg, 0.274 mmol) and ethanol (548 μl). The mixture was heated to 120° C. for 30 min by microwave irradiation. The mixture was diluted with ethyl acetate and 1N NaOH. After extraction, the aqueous layer was re-extracted with ethyl acetate twice. The organic layers were combined, dried with MgSO4 and concentrated in vacuo. The residue was loaded on a 4 g silica gel column using 0-50% IPA/DCM with 3% ammonia as modifier to obtain 5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-1-((4-(pyrrolidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (Compound 58). 1H NMR (400 MHz, Methanol-d4) δ 8.06 (s, 1H), 6.36 (s, 1H), 4.45 (s, 2H), 3.99 (s, 3H), 3.89 (m, 2H), 3.64 (s, 2H), 2.81 (m, 2H), 2.64 (s, 4H), 2.45 (s, 3H), 2.13 (s, 3H), 1.68 (s, 4H), 1.63-1.35 (m, 12H). ESIMS (M+H+) 475.2.
    • Example 14 Synthesis of 4-(4-((5-(1,6-dimethyl-H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine (Compound No. 59)
  • Figure US20210101902A1-20210408-C00170
  • 4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine was obtained using the method described in Example 13, except 1-bromo-2-(2-bromoethoxy)ethane (63.6 mg, 0.274 mmol) was used in place of 1,4-dibromobutane. 1H NMR (400 MHz, Methanol-d4) δ 8.16 (s, 1H), 6.46 (s, 1H), 4.55 (s, 2H), 3.99 (d, J=9.5 Hz, 5H), 3.73 (s, 2H), 3.68-3.51 (m, 4H), 2.91 (t, J=5.4 Hz, 2H), 2.23 (s, 3H), 1.57 (m, 12H). ESIMS (M+H+) 491.0.
    • Example 15 Synthesis of 1-((4-(1H-imidazol-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (Compound No. 119)
  • Figure US20210101902A1-20210408-C00171
  • 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 1 from Example 1) (55 mg, 0.131 mmol) was taken in water (807 μl) and 1 drop phosphorous acid was added (pH: 1). Paraformaldehyde (4.72 mg, 0.157 mmol) and glyoxal (18.04 μl. 0.157 mmol) 40% in water were added and the resulting mixture was heated to 80° C. A solution of ammonium chloride (8.41 mg, 0.157 mmol) dissolved in water (202 μl) was added dropwise over 10 min and the resulting mixture was heated to 110° C. for 18 hr, LC-MS showed still ˜50% unconverted starting material. An additional 47 mg of paraformaldehyde, glyoxal (18 mL) and NH4Cl (84 mg) were added to the mixture (to get it to go to completion). The mixture was heated at 110° C. for 18 hrs. The reaction mixture was adjusted to pH 8-9 using aqueous Na2CO3, extracted twice with DCM. The organic layers were concentrated and loaded on a 4 g silica gel column using 0-50% IPA in DCM with 3% NH3 as modifier to afford 1-((4-(1H-imidazol-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine (Compound 119). 1H NMR (400 MHz, Methanol-d4) δ 8.16 (s, 1H), 6.46 (s, 1H), 4.55 (s, 2H), 4.01 (s, 3H), 3.91 (m, 2H), 3.73 (s, 2H), 3.68-3.51 (m, 4H), 2.91 (m, 2H), 2.55 (m, 4H), 2.52 (s, 3H), 2.23 (s, 3H), 1.57 (m, 12H). ESIMS (M+H+) found 471.6.
    • Example 16 Synthesis of 4-((3-methyl-5-(6-methyl-1-(methyl-d3)-1H-pyrazolo[3,4-b]pyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 140)
  • Figure US20210101902A1-20210408-C00172
  • To a mixture of tert-butyl (4-((3-methyl-5-(6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate and K2CO3 in a 20 mL round-bottomed flask containing 3 mL of DMF was added dropwise CD3I (0.1 mL of a solution of 27.7 μL CD3I in 1 mL of DMF) at 0° C. The resulting mixture was slowly warmed up to rt and stirred overnight. The mixture was then concentrated then purified by ISCO (4 g silica gel column, 0-10% MeOH in DCM as eluent) to afford tert-butyl (4-((3-methyl-5-(6-methyl-1-(methyl-d3)-1H-pyrazolo[3,4-b]pyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate. RT=1.13 min (method 1), MS (ES+): 524.3 (M+1)+. To a solution of 11.5 mg (0.022 mmol) of tert-butyl (4-((3-methyl-5-(6-methyl-1-(methyl-d3)-1H-pyrazolo[3,4-b]pyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate in 1 mL of dioxane and 0.1 mL of MeOH was added 1 mL of 4M HCl in dioxane. The resulting mixture was stirred at rt for 1 hr then concentrated and lyophilized to give the desired product (Compound No. 140) as an HCl salt. 1H NMR (400 MHz, Methanol-d4) δ 8.51 (s, 1H), 6.88 (s, 1H), 5.04-4.94 (m, 2H), 4.25 (s, 2H), 3.98 (s, 2H), 3.78-3.56 (m, 2H), 3.11 (d, J=5.1 Hz, 2H), 2.70 (s, 3H), 2.39 (s, 3H), 1.85-1.66 (m, 12H). MS (ES+): 423.3 (M+1)+.
    • Example 17 Synthesis of 4-((5-(1,6-dimethyl-H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N,N-dimethylbicyclo[2.2.2]octan-1-aminee (Compound No. 43)
  • Figure US20210101902A1-20210408-C00173
  • To a solution of 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 1 from Example 1) in THF/MeOH (5 mL/1.5 mL) in a 100 mL round-bottomed flask was added DIPEA (0.13 mL, 97 mg, 0.75 mmol). The mixture was stirred at rt for 10 min before formaldehyde (0.037 mL, 37 wt % in water) was added. The resulting mixture was stirred at rt for 30 min before NaBH3CN (157 mg, 2.5 mmol) was added. Then the mixture was then stirred at rt overnight, quenched by adding 2.0 mL of water then extracted with DCM. The combined organic layers were then dried over Na2SO4 then concentrated. The crude product was added to a 4 g silica gel column and was eluted with 0-8% MeOH (containing very small amount of ammonia) in DCM. Collected fractions and concentrated then lyophilized to give the desired product, 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N,N-dimethylbicyclo[2.2.2]octan-1-amine. 1H NMR (600 MHz, Methanol-d4) δ 8.07 (s, 1H), 6.39 (s, 1H), 4.47 (s, 3H), 3.86 (s, 5H), 3.63 (d, J=2.5 Hz, 2H), 2.78 (t, J=5.6 Hz, 2H), 2.58 (s, 6H), 2.41 (s, 3H), 2.07 (s, 3H), 1.71-1.65 (m, 6H), 1.55-1.49 (m, 6H). MS (ES+): 448.4 (M+1)+.
    • Example 18 Synthesis of N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)methanesulfonamide (Compound No. 48)
  • Figure US20210101902A1-20210408-C00174
  • To a mixture of 57 mg (0.1 mmol) of 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 1) and 39 mg (0.052 mL, 0.3 mmol) of DIPEA in 2 mL of DCM was added 14.9 mg (10.1 μL, 0.13 mmol) of methanesulfonyl chloride at 0° C. The resulting mixture was slowly warmed up to rt and stirred for 2 hrs. The crude product was added (by solid loading) to a 4 g silica gel column and was eluted with 0-7% MeOH (containing very small amount of ammonia) in DCM, and further purified by mass-triggered HPLC. Collected fractions, 1.0 mL of 1N aqueous HCl was added then concentrated and lyophilized to give N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)methanesulfonamide (Compound No. 48), as HCl salt. 1H NMR (400 MHz, Methanol-d4) δ 8.53 (s, 1H), 6.89 (s, 1H), 5.06-4.94 (m, 2H), 4.25 (s, 2H), 4.12 (s, 3H), 3.98 (s, 2H), 3.18-3.06 (m, 2H), 2.94 (s, 3H), 2.70 (s, 3H), 2.43 (s, 3H), 1.96-1.85 (m, 6H), 1.67-1.57 (m, 6H). MS (ES+): 498.2 (M+1)+.
    • Example 19 Synthesis of 4-((5-(1,6-dimethyl-H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-methylbicyclo[2.2.2]octan-1-amine (Compound No. 50) and tert-buty (4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)(methy)carbamate (Compound 49)
  • Figure US20210101902A1-20210408-C00175
  • Step 1. A mixture of 4-bromo-1,6-dimethyl-1H-pyrazolo[3,4-b]pyridine (HG1) (67 mg, 0.295 mmol), tert-butyl methyl(4-((3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (TG10) (115 mg, 0.295 mmol), Pd2dba3 (6.8 mg, 0.074 mmol), RuPhos (17 mg, 0.035 mmol) and Cs2CO3 (192 mg, 0.590 mmol) in THE was purged with argon before being heated to 75° C. for 15 hrs. The reaction mixture was cooled down to rt then diluted in ethyl acetate and water. The layers were separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. The crude product was added to a 12 g silica gel column and was eluted with 0-5% methanol in DCM. Collected fractions and concentrated to give tert-butyl (4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)(methyl)carbamate (Compound No. 49). 1H NMR (400 MHz, Methanol-d4) δ 8.16 (s, 1H), 6.46 (s, 1H), 4.54 (s, 2H), 4.00 (s, 5H), 3.72 (s, 2H), 2.90 (t, J=5.6 Hz, 2H), 2.80 (s, 3H), 2.55 (s, 3H), 2.23 (s, 3H), 2.04-1.91 (m, 6H), 1.60-1.52 (m. 6H), 1.43 (s, 9H). MS (ES+): 534.4 (M+1)+.
  • Step 2. To a solution of 90 mg (0.169 mmol) of tert-butyl (4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)(methyl)carbamate (Compound No. 49) in dioxane/MeOH (1 mL/1 mL) was added HCl (2 mL of a 4M solution in dioxane). The resulting mixture was stirred at rt for 2 hrs. LC-MS showed completion of the reaction. The reaction mixture was concentrated and the residue was dissolved in 2.0 mL of MeOH then Ambersep 900 OH (0.8 meq/mL, 5.0 eq., prewashed with 5.0 mL of MeOH) was added and the mixture was stirred at rt for 1 hour. Filtered and washed with 10 mL of MeOH then concentrated. The crude product was added to a 4 g silica gel column and was eluted with 2-9% MeOH (containing a small amount of ammonia) in DCM. Collected fractions and concentrated then lyophilized to give 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-methylbicyclo[2.2.2]octan-1-amine (Compound No. 50). 1H NMR (400 MHz, Methanol-d4) δ 8.05 (s, 1H), 6.36 (s, 1H), 4.44 (s, 2H), 3.90 (s, 3H), 3.88 (t, J=5.8 Hz, 2H), 3.64 (s, 2H), 2.80 (t, J=5.6 Hz, 2H), 2.44 (s, 3H), 2.17 (s, 3H), 2.13 (s, 3H), 1.49 (s, 12H). MS (ES+): 434.3 (M+1)+.
    • Example 20 Synthesis of 1-methylcyclopropyl (4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (Compound No. 51)
  • Figure US20210101902A1-20210408-C00176
  • To a suspension of 57 mg (0.1 mmol) of 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 1) in 1 mL of DMA was added DIPEA (52 mg, 0.4 mmol) then 1-methylcyclopropyl (4-nitrophenyl) carbonate (24 mg, 0.1 mmol). The resulting mixture was heated under microwave irradiation at 150° C. for 2 hrs. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4 and concentrated. The crude product was added to a 4 g silica gel column and was eluted with 0-8% MeOH in DCM. Collected fractions and concentrated then lyophilized to give 1-methylcyclopropyl (4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate (Compound No. 51). 1H NMR (400 MHz, Methanol-d4) δ 8.05 (s, 1H), 6.35 (s, 1H), 4.44 (s, 2H), 3.90 (s, 3H), 3.87 (t, J=5.6 Hz, 2H), 3.61 (s, 2H), 2.80 (t, J=5.6 Hz, 2H), 2.44 (s, 3H), 2.13 (s, 3H), 1.74-1.63 (m, 6H), 1.50-1.40 (m, 6H), 1.35 (s, 3H), 0.71-0.61 (m, 2H), 0.48-0.41 (m 2H). MS (ES+): 518.3 (M+1)+.
    • Example 21 Synthesis of N-(2,2-difluoroethyl)-4-((5-(1,6-dimethyl-H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 61)
  • Figure US20210101902A1-20210408-C00177
  • To a mixture of 29.4 mg (0.07 mmol) of 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 1) and 18.1 mg (0.024 mL, 0.14 mmol) of DIPEA in 1 mL of THE was added 2,2-difluoroethyl trifluoromethanesulfonate (16.5 mg (10.3 μL, 0.077 mmol). The resulting mixture was stirred at 85° C. for 2 hrs. LC-MS showed desired product and completion of the reaction. The crude product was directly added to a 4 g silica gel column and was eluted with 2-9% MeOH (containing a small amount of ammonia) in DCM. Collected fractions and concentrated then lyophilized to give N-(2,2-difluoroethyl)-4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 61). 1H NMR (400 MHz, Methanol-d4) δ 8.05 (s, 1H), 6.36 (s, 1H), 5.79 (tt, J=55.9, 4.1 Hz, 1H), 4.44 (s, 2H), 3.89 (m, 5H), 3.64 (s, 2H), 2.94-2.75 (m, 4H), 2.44 (s, 3H), 2.13 (s, 3H), 1.49 (s, 12H). MS (ES+): 484.2 (M+1)+.
    • Example 22 Synthesis of 4-((5-(1,6-dimethyl-H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-(2-methoxyethyl)bicyclo[2.2.2]octan-1-amine (Compound No. 69) and 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N,N-bis(2-methoxyethyl)bicyclo[2.2.2]octan-1-amine (Compound No. 70)
  • Figure US20210101902A1-20210408-C00178
  • A mixture of 21 mg (0.05 mmol) of 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 1), 43 mg (0.031 mL, 0.250 mmol) of 1-bromo-2-ethoxyethane and 21 mg (0.150 mmol) of potassium carbonate in EtOH (1 mL) was heated under microwave irradiation at 120° C. for 30 min. LC-MS showed desired product 1 but the reaction was not complete. The solvent was changed to IPA and heated in an oil bath at 110° C. overnight. LC-MS showed two products. The crude product was added to a 12 g silica gel column and was eluted with 0-30% IPA (containing 1% of ammonia) in DCM. Collected fractions and concentrated then lyophilized to give 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-(2-ethoxyethyl)bicyclo[2.2.2]octan-1-amine (Compound No. 69) and 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N,N-bis(2-ethoxyethyl)bicyclo[2.2.2]octan-1-amine (Compound No. 70). Compound No. 69: 1H NMR (400 MHz, Methanol-d4) δ 8.16 (s, 1H), 8.05 (d, J=8.2 Hz, 0H), 8.04 (s, 0H), 7.54 (d, J=8.1 Hz, 0H), 6.46 (s, 1H), 4.54 (s, 2H), 4.00 (s, 3H), 3.98 (t, J=5.7 Hz, 2H), 3.73 (s, 2H), 3.35 (s, 2H), 2.98 (s, 3H), 2.94 (s, 3H), 2.90 (t, J=5.6 Hz, 2H), 2.55 (s, 3H), 2.23 (s, 3H), 1.56 (s, 12H). MS (ES+): 505.4 (M+1)+. Compound No. 70: 1H NMR (400 MHz, Methanol-d4) δ 8.15 (s, 1H), 6.45 (s, 1H), 4.54 (s, 2H), 4.00 (s, 3H), 3.97 (t, J=5.5 Hz, 2H), 3.69 (s, 2H), 3.31 (d, J=1.1 Hz, 6H), 2.90 (t, J=5.6 Hz, 2H), 2.75-2.65 (m, 4H), 2.55 (s, 3H), 2.23 (s, 3H), 1.64-1.47 (m, 12H). MS (ES+): 536.4 (M+1)+.
    • Example 23 Synthesis of 4-((5-(1,6-dimethyl-H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-(2-methoxyethyl)-N-methylbicyclo[2.2.2]octan-1-amine. (Compound No. 73)
  • Figure US20210101902A1-20210408-C00179
  • A mixture of 12 mg (0.028 mmol) of 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-methylbicyclo[2.2.2]octan-1-amine (Compound No. 50), 19 mg (0.013 mL, 0.138 mmol) of 1-bromo-2-methoxyethane and 11.5 mg (0.083 mmol) of K2CO3 in IPA was heated under microwave irradiation at 150° C. for 1 hr. The crude product was directly added to a 4 g silica gel column and was eluted with 0-30% IPA (containing 1% of ammonia) in DCM. Collected fractions and concentrated then lyophilized to give 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-(2-methoxyethyl)-N-methylbicyclo[2.2.2]octan-1-amine (Compound No. 73). 1H NMR (400 MHz, Methanol-d4) δ 8.16 (s, 1H), 6.46 (s, 1H), 4.54 (s, 2H), 4.00 (s, 3H), 3.98 (t, J=5.7 Hz, 2H), 3.72 (s, 2H), 3.43 (t, J=5.8 Hz, 2H), 2.90 (t, J=5.6 Hz, 2H), 2.63 (s, 2H), 2.55 (s, 3H), 2.23 (s, 6H), 1.67-1.49 (m, 12H). MS (ES+): 492.4 (M+1)+.
    • Example 24 Synthesis of 2-((4-((5-(1,6-dimethyl-H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)-N,N-dimethylacetamide (Compound No. 76)
  • Figure US20210101902A1-20210408-C00180
  • A mixture of 42.0 mg (0.1 mmol) of 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 1), 18.3 mg (0.11 mmol) of 2-bromo-N,N-dimethylacetamide and 65.2 mg (0.2 mmol) of cesium carbonate in 1 mL DMF was stirred at rt overnight. The crude product was added to a 4 g silica gel column and was eluted with 0-30% IPA (containing 1% of ammonia) in DCM. Collected fractions and concentrated then lyophilized to afford 2-((4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)-N,N-dimethylacetamide (Compound No. 76). 1H NMR (400 MHz, Methanol-d4) δ 8.17 (d, J=1.8 Hz, 1H), 6.47 (s, 1H), 4.56 (s, 2H), 4.02 (s, 3H), 4.00 (t, J=5.7 Hz, 2H), 3.76 (m, 2H), 3.56 (m, 2H), 3.03-2.95 (m, 6H), 2.92 (t, J=5.6 Hz, 2H), 2.56 (s, 3H), 2.25 (s, 3H), 1.73-1.56 (m, 12H). MS (ES+): 505.4 (M+1)+.
    • Example 25 Synthesis of N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-N-methyloxetan-3-amine (Compound No. 77)
  • Figure US20210101902A1-20210408-C00181
  • To a solution of 2.1 mg (4.4 μmol of N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)oxetan-3-amine (Compound No. 6) in THE (1 mL) was added acetic acid (1.33 mL (1.26 μL, 0.022 mmol) of and 10.9 mg (0.134 mmol) of formaldehyde. The mixture was stirred at rt for 1 hour before sodium cyanotrihydroborate was added. The resulting mixture was then stirred at rt overnight. The reaction was quenched by adding 0.1 mL of water then concentrated. The crude product was added to a 4 g silica gel column and was eluted with 0-50% IPA (containing 1% of ammonia) in DCM. Collected fractions and concentrated then lyophilized to afford N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-N-methyloxetan-3-amine (Compound No. 77). 1H NMR (400 MHz, Methanol-d4) δ 8.05 (s, 1H), 6.35 (s, 1H), 4.58 (t, J=6.9 Hz, 2H), 4.47 (t, J=7.0 Hz, 2H), 4.44 (s, 2H), 4.25 (q, J=7.3 Hz, 1H), 3.90 (s, 3H), 3.87 (t, J=5.5 Hz, 2H), 3.61 (s, 2H), 2.79 (t, J=5.6 Hz, 2H), 2.44 (s, 3H), 2.18 (s, 3H), 2.12 (s, 3H), 1.45 (s, 12H). MS (ES+): 490.4 (M+1)+.
    • Example 26 Synthesis of 4-((5-(1,6-dimethyl-H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-(2-methoxy-2-methylpropyl)bicyclo[2.2.2]octan-1-amine (Compound No. 101)
  • Figure US20210101902A1-20210408-C00182
  • Step 1. To a solution of 14.2 mg (0.12 mmol) of 2-methoxy-2-methylpropanoic acid in DMF (2 mL) was added HATU (45.6 mg, 0.12 mmol) and DIPEA (0.035 mL, 25.8 mg, 0.2 mmol). The mixture was stirred at rt for 5 min before of 42.0 mg (0.1 mmol) 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 1) was added. The resulting mixture was then stirred at rt for 1 hour. LC-MS showed completion of the reaction. The mixture was partitioned between EtOAc and water. The layers were separated and the aqueous layer was extracted with EtOAc. The combined organic layer was dried over Na2SO4 then concentrated. The crude product was added to a 4 g silica gel column and was eluted with 0-50% IPA (containing 1% of ammonia) in DCM. Collected fractions and concentrated then lyophilized to afford N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-methoxy-2-methylpropanamide. 1H NMR (400 MHz, Methanol-d4) δ 8.19 (s, 1H), 6.77 (s, 1H), 6.51 (s, 1H), 4.58 (s, 2H), 3.96 (t, J=5.4 Hz, 2H), 3.94 (s, 3H), 3.64 (s, 2H), 3.12 (s, 3H), 2.84 (t, J=5.6 Hz, 2H), 2.49 (s, 3H), 2.14 (s, 3H), 1.83-1.73 (m, 6H), 1.53-1.43 (m, 6H), 1.17 (s, 6H). MS (ES+): 520.3 (M+1)+.
  • Step 2. To a stirred solution of 17 mg (0.033 mmol) of N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-methoxy-2-methylpropanamide in THE (1 mL) was added 6.5 mg (0.164 mmol) of LiAlH4 at 0° C. The resulting mixture was then slowly warmed up to rt and stirred overnight. After cooling at 0° C. the reaction was quenched with IPA then water and concentrated. The crude product was added (by solid loading) to a 4 g silica gel column and was eluted with 0-30% IPA (containing 1% of ammonia) in DCM. Collected fractions and concentrated then further purified by mass-triggered HPLC to afford 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-(2-methoxy-2-methylpropyl)bicyclo[2.2.2]octan-1-amine (Compound No. 101), which was neutralized using Ambersep 900 OH (Strong Base Anion Exchanger). 1H NMR (600 MHz, Methanol-d4) δ 8.05 (d, J=1.1 Hz, 1H), 6.35 (s, 1H), 4.44 (s, 2H), 3.90 (s, 3H), 3.90-3.85 (m, 2H), 3.64 (d, J=6.3 Hz, 2H), 3.07 (s, 2H), 2.83-2.77 (m, 2H), 2.44 (s, 3H), 2.13 (s, 3H), 1.57-1.46 (m, 12H), 1.07 (s, 6H). MS (ES+): 506.4 (M+1)+.
    • Example 27 Synthesis of 4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-1-methylpiperazin-2-one (Compound No. 104)
  • Figure US20210101902A1-20210408-C00183
  • Step 1: To a solution of 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 1) (121 mg, 0.246 mmol) in CPME (12.3 mL) was added tert-butyl methyl(2-oxoethyl)carbamate (63.8 mg, 0.369 mmol). The mixture was stirred at 25° C. for 30 min before sodium triacetoxyborohydride (156 mg, 0.737 mmol) was added. Then the mixture was stirred at 25° C. for 3 hrs. The mixture was concentrated and purified on a 4 g silica gel column using 0-40% IPA in DCM with 2% NH3 as modifier to elute 88.6 mg (0.154 mmol) of tert-butyl (2-((4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)ethyl)(methyl)carbamate. RT (method 1): 1.26 min, MS (ES+): 577.4 (M+1)+.
  • Step 2: A mixture of 40 mg (0.069 mmol) of tert-butyl (2-((4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)ethyl)(methyl)carbamate, 35.5 mg (0.024 mL, 0.208 mmol) of ethyl 2-bromoacetate and 10.5 mg (0.076 mmol) of potassium carbonate in EtOH (1 mL) was heated under microwave irradiation at 150° C. for 1 hour. LC-MS showed completion of the reaction. The reaction was cooled down to rt, 1N aqueous NaOH was added and the mixture was stirred at rt for 3 hrs. The reaction mixture was then diluted with 2 mL of water and the organic solvent was removed on the rotorvap, and washed with Et2O (3 mL). The aqueous layer was then acidified carefully with 1N aqueous HCl to ˜pH 3. Extracted with EtOAc then DCM/MeOH but most product remained in the aqueous phase based on LC-MS. Both aqueous and organic phase were concentrated then purified by mass-triggered HPLC to afford 2-((2-((tert-butoxycarbonyl)(methyl)amino)ethyl)(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)acetic acid. RT (method 2): 1.72 min, MS (ES+): 634.8 (M+1)+.
  • Step 3. To a mixture of 27.0 mg (0.043 mmol) of 2-((2-((tert-butoxycarbonyl)(methyl)amino)ethyl)(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)acetic acid in 1 mL of 1,4-dioxane was added 0.3 mL of MeOH to get a clear solution. 4 M HCl in dioxane was added dropwise and the resulting mixture was stirred at rt for 1 hr. LC-MS showed completion of the reaction. The mixture was concentrated and the residue was dissolved in 2.0 mL of DMF and DIPEA (38 μL, 5 eq.) then added dropwise into a solution of HATU (21 mg, 1.3 eq.) in 3.0 mL of DMF at 0° C. The resulting mixture was stirred at 0° C. for 30 min. LC-MS showed completion of the reaction. The crude product was purified by mass-triggered HPLC (10-20% ACN in H2O over 3.5 min) then neutralized using basic resin to afford 4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-1-methylpiperazin-2-one (Compound No. 104). 1H NMR (400 MHz, Methanol-d4) δ 8.05 (s, 1H), 6.35 (s, 1H), 4.44 (s, 2H), 3.90 (s, 3H), 3.87 (t, J=5.5 Hz, 2H), 3.62 (s, 2H), 3.17 (dd, J=6.3, 4.5 Hz, 2H), 3.08 (s, 2H), 2.80 (m, 5H), 2.66 (dd, J=6.3, 4.5 Hz, 2H), 2.44 (s, 3H), 2.13 (s, 3H), 1.48 (tq, J=9.4, 6.4, 4.7 Hz, 12H). MS (ES+): 517.3 (M+1)+.
    • Example 28 Synthesis of 1-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-4-methylpiperazin-2-one (Compound No. 108)
  • Figure US20210101902A1-20210408-C00184
  • Step 1: To a mixture of 80 mg (0.139 mmol) of tert-butyl (2-((4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)ethyl)(methyl)carbamate (Example 27, Step 1) and 36 mg (0.048 μL, 0.277 mmol) of DIPEA in 1.0 mL of DCM was added dropwise into a solution of 2-bromoacetyl bromide (0.062 mL, 0.694 mmol) in DCM (1.0 mL) at 0° C. The resulting mixture was slowly warmed up to rt and stirred for 1 hr. Then quenched the reaction by adding 0.1 mL of water and concentrated. The crude product was added to a 4 g silica gel column and was eluted with 0-30% IPA (containing 0.02 M ammnia) in DCM. Collected fractions and concentrated to afford tert-butyl (2-(2-bromo-N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)acetamido)ethyl)(methyl)carbamate. RT (method 1): 1.45 min. MS (ES+): 701.2, 700.3 (M+1)+.
  • Step 2: To a mixture of 40.0 mg (0.057 mmol) of tert-butyl (2-(2-bromo-N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[222]octan-1-yl)acetamido)ethyl)(methyl)carbamate in 1 mL of 1,4-dioxane was added 0.5 mL of MeOH to get a clear solution. 4 M HCl in dioxane (0.5 mL, 2.0 mmol) was added dropwise and the resulting mixture was stirred at rt for 30 min. LC-MS showed completion of the reaction. The mixture was concentrated and to the residue were added 5.0 mL of DMF and cesium carbonate. The resulting mixture was stirred at rt for 1 hr and concentrated. The crude product was purified by mass-triggered HPLC (10-20% ACN in H2O over 3.5 min) then 1N aqueous HCl was added and lyophilized to afford 1-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-4-methylpiperazin-2-one, as HCl salt (Compound No. 108). 1H NMR (400 MHz, Methanol-d4) δ 8.05 (s, 1H), 6.35 (s, 1H), 4.44 (s, 2H), 3.90 (s, 3H), 3.87 (t, J=5.5 Hz, 2H), 3.62 (s, 2H), 2.80 (t, J=5.5 Hz, 2H), 2.45 (m, 5H), 2.17 (dd, J=7.9, 6.9 Hz, 2H), 2.14 (s, 6H), 2.13 (s, 3H), 1.80-1.73 (m, 6H), 1.50-1.43 (m, 6H). MS (ES+): 519.3 (M+1)+.
    • Example 29 Synthesis of N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(3-fluoroazetidin-1-yl)acetamide (Compound No. 133)
  • Figure US20210101902A1-20210408-C00185
  • Step 1: To a mixture of 16.7 mg (0.120 mmol) of 2-bromoacetic acid and 42.0 mg (0.1 mmol) of 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 1) in DCM (1 mL) were added HATU (45.6 mg, 0.12 mmol) and DIPEA (25.8 mg, 0.035 mL, 0.2 mmol). The resulting mixture was stirred at rt for 1 hr. LC-MS confirmed the completion of the reaction and the mixture was concentrated. The crude product was added to a 4 g silica gel column and was eluted with 0-50% IPA (containing 0.02 M of ammonia) in DCM. Collected fractions and concentrated to afford 2-bromo-N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)acetamide. RT (method 1): 1.26 min. MS (ES+): 540.2 and 542.1 (M+1)+.
  • Step 2: A mixture of 27 mg (0.05 mmol) of 2-bromo-N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)acetamide, 7.3 mg (0.065 mmol) of 3-fluoroazetidine and 20.7 mg (0.15 mmol) of potassium carbonate in DMA (1 mL) was heated at 120° C. under microwave irradiation for 40 min. After concentration, the crude product was purified by mass-triggered HPLC (10-30% ACN in H2O over 3.5 min) then 1N aqueous HCl was added and lyophilized to afford N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(3-fluoroazetidin-1-yl)acetamide (Compound No. 133), as HCl salt. RT (method 1): 1.04 min. MS (ES+): 535.3 (M+1)+.
    • Example 30 Synthesis of N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-hydroxyacetamide (Compound No. 135) and N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(3-hydroxyazetidin-1-yl)acetamide (Compound No. 136)
  • Figure US20210101902A1-20210408-C00186
  • Step 1: To a mixture of 10.1 mg (0.11 mmol) of 2-oxoacetic acid and 42 mg (0.1 mmol) of 4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine (Compound No. 1) in DCM was added HATU (41.8 mg, 0.11 mmol) and DIPEA (25.8 mg, 0.035 mL, 0.2 mmol). The resulting mixture was then stirred at rt for 1 hr then loaded to a 4 g silica gel column and was eluted with 0-50% IPA (containing 0.02 M of ammonia) in DCM. Collected fractions and concentrated. The residue was dissolved in 2 mL of DCE, azetidin-3-ol (HCl salt) was added and the mixture was stirred at rt for 30 min before sodium triacetoxyhydroborate was added. The mixture was then stirred at rt overnight. LC-MS showed some desired product 1 but mainly byproduct 2. The crude product was purified by mass-triggered HPLC (10-30% ACN in H2O over 3.5 min) then 1N aqueous HC was added and lyophilized to give N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(3-hydroxyazetidin-1-yl)acetamide (Compound No. 136) [RT (method 1): 1.05 min. MS (ES+): 478.3 (M+1)+] and N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-hydroxyacetamide (Compound No. 135) [RT (method 1): 0.98 min. MS (ES+): 533.3 (M+1)+], both as HC salt.
  • TABLE 6
    Additional Exemplary Compounds
    Compound Synthesis
    No. Structure and Name Characterization Method
    11
    Figure US20210101902A1-20210408-C00187
         		See Example 1 Replace (HG1) in step 1 with (HG2) and (TG3) with (TG1)
    12
    Figure US20210101902A1-20210408-C00188
         		See Example 1 Replace (HG1) in step 1 with (HG2) and (TG3) with (TG2)
    13
    Figure US20210101902A1-20210408-C00189
         		RT (method 2): 1.13 min. MS (ES+): 423.3 (M + 1)+. See Example 1 Replace (HG1) in step 1 with (HG2)
    14
    Figure US20210101902A1-20210408-C00190
         		RT (method 2): 1.17 min. MS (ES+): 423.3 (M + 1)+. See Example 1 Replace (HG1) in step 1 with (HG2) and (TG3) with (TG4)
    15
    Figure US20210101902A1-20210408-C00191
         		1H NMR (400 MHz, Methanol-d4) δ 8.00 (s, 1H), 4.64 (s, 2H), 4.25 (s, 3 H), 4.10-3.87 (m, 2H), 3.78 (s, 2H), 3.03 (t, J = 5.5 Hz, 2H), 2.19 (s, 3H), 1.96-1.40 (m, 12H). MS (ES+): 441.3 (M + 1)+. See Example 1 Replace (HG1) in step 1 with (HG3)
    16
    Figure US20210101902A1-20210408-C00192
         		1H NMR (400 MHz, Methanol-d4) δ 8.26 (s, 1H), 4.83 (s, 2H), 4.22 (brs, 2H), 3.91 (s, 3H), 4.10-3.87 (m, 2H), 3.69 (s, 2H), 3.09 (m, 2H), 2.82 (m, 2H), 2.52 (s, 3H), 2.15 (s, 3H), 1.98- 1.52 (m, 16H). MS (ES+): 475.4 (M + 1)+. See Example 13 Replace Compound No. 1 with Compound No. 149
    17
    Figure US20210101902A1-20210408-C00193
         		1H NMR (400 MHz, Methanol-d4) δ 4.96 (s, 2H), 4.27 (m, 2H), 4.24 (s, 3H), 3.77 (s, 2H), 3.63-3.55 (m, 2H), 3.38 (m, 2H), 3.21 (m, 2H), 3.06-2.98 (m, 2H), 2.71 (s, 3H), 2.53 (s, 3H), 2.21 (s, 3H), 2.08-1.92 (m, 4H), 1.91-1.83 (m, 6H), 1.72-1.60 (m, 6H). MS (ES+): 489.4 (M + 1)+. See Example 13 Replace Compound No. 1 with Compound No. 26
    18
    Figure US20210101902A1-20210408-C00194
         		1H NMR (400 MHz, Methanol-d4) δ 4.95 (s, 2H), 4.31 (t, J = 6.6 Hz, 2H), 4.24 (s, 3H), 3.78 (s, 2H), 3.63- 3.55 (m, 2H), 3.39 (s, 3H), 3.14-3.07 (m, 2H), 3.06-2.98 (m, 2H), 2.71 (s, 3H), 2.53 (s, 3H), 2.20 (s, 3H), 1.86-1.77 (m, 6H), 1.72-1.62 (m, 6H). MS (ES+): 493.4 (M + 1)+. See Example 17 Replace Compound No. 1 with Compound No. 26 and replace formaldehyde with 2- methoxyacetal- dehyde
    19
    Figure US20210101902A1-20210408-C00195
         		1H NMR (400 MHz, Methanol-d4) δ 8.22 (s, 1H), 4.87 (s, 2H), 4.26 (brs, 2H), 3.96 (s, 3H), 3.73 (s, 2H), 3.69 (m, 4H), 2.86 (t, J = 5.5 Hz, 2H), 2.68 (m, 4H), 2.55 (s, 3H), 2.24 (s, 3H), 1.68- 1.50 (m, 12H). MS (ES+): 491.4 (M + 1)+. See Example 14 Replace Compound No. 1 with Compound No. 149
    20
    Figure US20210101902A1-20210408-C00196
         		1H NMR (400 MHz, Methanol-d4) δ 8.98 (s, 1H), 5.02 (s, 2H), 4.55 (s, 2H), 3.73 (brs, 2H), 3.63 (s, 2H), 3.03 (q, J = 7.3 Hz, 2H), 2.93 (brs, 2H), 2.66 (s, 3H), 2.27 (s, 3H), 1.89 (dd, J = 9.8, 6.0 Hz, 6H), 1.58 (dd, J = 9.7, 6.1 Hz, 6H), 1.28 (t, J = 7.3 Hz, 3H). MS (ES+): 492.4 (M + 1)+. See Example 7 Replace Compound No. 1 with Compound No. 58 and replace 2- (dimethylamino) acetic acid with ethylglycine
    21
    Figure US20210101902A1-20210408-C00197
         		1H NMR (400 MHz, Methanol-d4) δ 8.99 (s, 1H), 5.01 (s, 2H), 4.56 (s, 2H), 4.06 (m, 2H), 3.84- 3.68 (m, 4H), 3.41 (m, 2H), 3.14-2.90 (m, 4H), 2.66 (s, 3H), 2.26 (s, 3H), 1.88 (dd, J = 9.3, 5.6 Hz, 6H), 1.69 (dd, J = 9.4, 5.4 Hz, 6H). MS (ES+): 477.4 (M + 1)+. See Example 14 and Example 1 Replace (HG1) in step 1 with (HG18)
    22
    Figure US20210101902A1-20210408-C00198
         		1H NMR (400 MHz, Methanol-d4) δ 4.98 (s, 2H), 4.32 (m, 2H), 4.25 (s, 3H), 3.75 (s, 2H), 3.67 (s, 3H), 3.64 (s, 2H), 3.08-3.00 (m, 4H), 2.72 (s, 3H), 2.48 (s, 3H), 1.93-1.87 (m, 6H), 1.61- 1.57 (m, 6H), 1.30 (m, 3H). MS (ES+): 520.4 (M + 1)+. See Example 7 Replace Compound No. 1 with Compound No. 26 and replace 2- (dimethylamino) acetic acid with ethylglycine
    23
    Figure US20210101902A1-20210408-C00199
         		1H NMR (400 MHz, Methanol-d4) δ 4.96 (s, 2H), 4.31 (t, J = 5.6 Hz, 2H), 4.24 (s, 3H), 3.78 (s, 2H), 3.72-3.45 (m, 4H), 3.12-2.98 (m, 4H), 2.71 (s, 3H), 2.53 (s, 3H), 2.21 (s, 3H), 2.06-1.97 (m, 1H), 1.88-1.72 (m, 6H), 1.72-1.63 (m, 6H). MS (ES+): 505.4 (M + 1)+. See Example 17 Replace Compound No. 1 with Compound No. 26 and replace formaldehyde with oxetane- 3- carbaldehyde
    24
    Figure US20210101902A1-20210408-C00200
         		1H NMR (400 MHz, Methanol-d4) δ 4.97 (s, 2H), 4.31 (t, J = 5.7 Hz, 2H), 4.24 (s, 3H), 3.73 (s, 2H), 3.33 (m, 2H), 3.02 (t, J = 5.5 Hz, 2H), 2.86 (s, 6H), 2.71 (s, 3H), 2.61 (t, J = 6.6 Hz, 2H), 2.53 (s, 3H), 2.22 (s, 3H), 1.94- 1.86 (m, 6H), 1.62-1.53 (m, 6H). MS (ES+): 534.4 (M + 1)+. See Example 7 Replace Compound No. 1 with Compound No. 26 and replace 2- (dimethylamino) acetic acid with 3- (dimethylamino) propanoic acid
    25
    Figure US20210101902A1-20210408-C00201
         		1H NMR (400 MHz, Methanol-d4) δ 4.53 (s, 2H), 4.11 (s, 3H), 3.87 (t, J = 5.7 Hz, 2H), 3.76-3.64 (m, 6H), 3.01 (J = 5.6 Hz, 2H), 2.65 (brs, 4H), 2.60 (s, 3H), 2.50 (s, 3H), 2.18 (s, 3H), 1.70-1.50 (m, 12H). MS (ES+): 505.4 (M + 1)+. See Example 14 Replace Compound No. 1 with Compound No. 26
    26
    Figure US20210101902A1-20210408-C00202
         		1H NMR (400 MHz, Methanol-d4) δ 4.96 (s, 2H), 4.31 (t, J = 5.6 Hz, 2H), 4.24 (s, 3H), 3.77 (s, 2H), 3.04-2.98 (m, 2H), 2.71 (s, 3H), 2.53 (s, 3H), 2.21 (s, 3H), 1.80-1.62 (m, 12H). MS (ES+): 435.4 (M + 1)+. See Example 10
    27
    Figure US20210101902A1-20210408-C00203
         		1H NMR (400 MHz, Methanol-d4) δ 4.96 (s, 2H), 4.31 (t, J = 5.6 Hz, 2H), 4.24 (s, 3H), 3.77 (s, 2H), 3.01 (t, J = 5.5 Hz, 2H), 2.79 (d, J = 7.4 Hz, 2H), 2.71 (s, 3H), 2.53 (s, 3H), 2.20 (s, 3H), 1.80- 1.60 (m, 12H), 1.16-0.96 (m, 1H), 0.74-0.65 (m, 2H), 0.41-0.31 (m, 2H). MS (ES+): 489.4 (M + 1)+. See example 6 Replace Compound No. 1 with Compound No. 26 and replace oxetan-3-one with 1- cyclobutanone
    28
    Figure US20210101902A1-20210408-C00204
         		1H NMR (400 MHz, Methanol-d4) δ 4.94 (s, 2H), 4.30 (t, J = 5.6 Hz, 2H), 4.24 (s, 3H), 3.76 (s, 2H), 3.21-2.98 (m, 6H), 2.69 (s, 3H), 2.53 (s, 3H), 2.20 (s, 3H), 1.96-1.86 (m, 6H), 1.72-1.62 (m, 6H), 1.26-1.18 (m, 2H), 0.84-0.75 (m, 4H), 0.54- 0.38 (m, 4H). MS (ES+): 543.4 (M + 1)+. See example 6 Replace Compound No. 1 with Compound No. 26 and replace oxetan-3-one with cyclobutanone
    29
    Figure US20210101902A1-20210408-C00205
         		1H NMR (400 MHz, Methanol-d4) δ 8.99 (s, 1H), 5.01 (s, 2H), 4.56 (brs, 2H), 3.81 (s, 2H), 3.58-3.50 (m, 2H), 3.06- 2.88 (m, 2H), 2.86-2.76 (m, 2H), 2.66 (s, 3H), 226 (brs, 3H), 2.00-1.62 (m, 18H). MS (ES+): 475.3 (M + 1)+. See Example 13 and Example 1 Replace (HG1) in step 1 with (HG18) and replace 1,4- dibromobutane with 1,5- dibromopentane
    30
    Figure US20210101902A1-20210408-C00206
         		1H NMR (400 MHz, Methanol-d4) δ 8.85 (s, 1H), 4.92 (s, 2H), 4.43 (brs, 2H), 3.70 (s, 2H), 3.28-3.30 (m, 2H), 3.16- 3.05 (m, 2H), 2.94-2.77 (m, 2H), 2.56 (s, 3H), 2.16 (brs, 3H), 1.98-1.52 (m, 16H). MS (ES+): 461.4 (M + 1)+. See Example 13 and Example 1 Replace (HG1) in step 1 with (HG18)
    31
    Figure US20210101902A1-20210408-C00207
         		1H NMR (400 MHz, Methanol-d4) δ 4.52 (s, 2H), 4.50 (s, 2H), 4.45- 4.35 (m, 4H), 4.11 (s, 3H), 3.87 (t, J = 5.6 Hz, 2H), 3.75 (s, 2H), 3.01 (t, J = 5.5 Hz, 2H), 2.87 (s, 2H), 2.60 (s, 3H), 2.50 (s, 3H), 2.18 (s, 3H), 1.64- 1.52 (m, 12H). MS (ES+): 535.4 (M + 1)+. See Example 17 This is a by- product from example 17
    32
    Figure US20210101902A1-20210408-C00208
         		1H NMR (400 MHz, Methanol-d4) δ 5.03 (s, 2H), 4.34 (t, J = 5.5 Hz, 2H), 4.25 (s, 3H), 4.15- 4.10 (m, 4H), 3.87 (s, 2H), 3.62-3.56 (m, 1H), 3.09 (t, J = 5.5 Hz, 2H), 2.74 (s, 3H), 2.55 (s, 3H), 2.32 (s, 3H), 1.96-1.88 (m, 6H), 1.66-1.56 (m, 6H). MS (ES+): 518.4 (M + 1)+. See Example 7 Replace Compound No. 1 with Compound No. 26 and replace 2- (dimethylamino) acetic acid with azetidine- 3-carboxylic acid
    33
    Figure US20210101902A1-20210408-C00209
         		1H NMR (400 MHz, Methanol-d4) δ 4.53 (s, 2H), 4.11 (s, 3H), 3.90- 3.78 (m, 3H), 3.72-3.66 (m, 3H), 3.50-3.38 (m, 3H), 3.00 (t, J = 5.5 Hz, 2H), 2.90-2.78 (m, 2H), 2.59 (s, 3H), 2.50 (s, 3H), 2.18 (s, 3H), 1.92-1.84 (m, 6H), 1.62-1.52 (m, 6H). MS (ES+): 548.4 (M + 1)+. See Example 7 Replace Compound No. 1 with Compound No. 26 and replace 2- (dimethylamino) acetic acid with (S)- morpholine-3- carboxylic acid
    34
    Figure US20210101902A1-20210408-C00210
         		1H NMR (400 MHz, Methanol-d4) δ 4.52 (s, 2H), 4.11 (s, 3H), 3.95- 3.76 (m, 4H), 3.72 (s, 2H), 3.66-3.56 (m, 1H), 3.15-3.09 (m, 1H), 3.00 (t, J = 5.5 Hz, 2H), 2.80-2.75 (m, 2H), 2.59 (s, 3H), 2.54 (m, 1H), 2.50 (s, 3H), 2.18 (s, 3H), 1.92- 1.84 (m, 6H), 1.62-1.52 (m, 6H). MS (ES+): 548.4 (M + 1)+. See Example 7 Replace Compound No. 1 with Compound No. 26 and replace 2- (dimethylamino) acetic acid with (S)- morpholine-2- carboxylic acid
    35
    Figure US20210101902A1-20210408-C00211
         		1H NMR (400 MHz, Methanol-d4) δ 4.53 (s, 2H), 4.11 (s, 3H), 3.90- 3.80 (m, 3H), 3.74-3.67 (m, 3H), 3.50-3.38 (m, 3H), 3.00 (t, J = 5.5 Hz, 2H), 2.90-2.78 (m, 2H), 2.60 (s, 3H), 2.50 (s, 3H), 2.18 (s, 3H), 1.92-1.84 (m, 6H), 1.62-1.52 (m, 6H). MS (ES+): 548.4 (M + 1)+. See Example 7 Replace Compound No. 1 with Compound No. 26 and replace 2- (dimethylamino) acetic acid with (R)- morpholine-3- carboxylic acid
    36
    Figure US20210101902A1-20210408-C00212
         		1H NMR (400 MHz, Methanol-d4) δ 4.53 (s, 2H), 4.12 (s, 3H), 3.96- 3.76 (m, 4H), 3.72 (s, 2H), 3.66-3.56 (m, 1H), 3.16-3.07 (m, 1H), 3.00 (t, J = 5.5 Hz, 2H), 2.82-2.75 (m, 2H), 2.59 (s, 3H), 2.54 (m, 1H), 2.50 (s, 3H), 2.18 (s, 3H), 1.92- 1.84 (m, 6H), 1.62-1.52 (m, 6H). MS (ES+): 548.4 (M + 1)+. See Example 7 Replace Compound No. 1 with Compound No. 26 and replace 2- (dimethylamino) acetic acid with (R)- morpholine-2- carboxylic acid
    37
    Figure US20210101902A1-20210408-C00213
         		1H NMR (400 MHz, Methanol-d4) δ 4.76 (s, 2H), 4.18 (t, J = 5.6 Hz, 2H), 4.10-4.02 (m, 2H), 3.81 (s, 2H), 3.78-3.68 (m, 2H), 3.46-3.38 (m, 2H), 3.16-3.06 (m, 2H), 2.96-2.90 (m, 2H), 2.73 (s, 3H), 2.56 (s, 3H), 2.23 (s, 3H), 1.92-1.84 (m, 6H), 1.72-1.60 (m, 6H). MS (ES+): 492.4 (M + 1)+. See Example 14 and See Example 1 Replace (HG1) in step 1 with (HG5)
    38
    Figure US20210101902A1-20210408-C00214
         		1H NMR (400 MHz, Methanol-d4) δ 4.96 (s, 2H), 4.31 (t, J = 5.7 Hz, 2H), 4.24 (s, 3H), 3.78 (s, 2H), 3.58- 3.52 (m, 2H), 3.02 (t, J = 5.3 Hz, 2H), 2.88-2.76 (m, 2H), 2.71 (s, 3H), 2.53 (s, 3H), 2.20 (s, 3H), 2.00-1.42 (m, 18H). MS (ES+): 503.4 (M + 1)+. See Example 13 Replace Compound No. 1 with Compound No. 26 and replace 1,4- dibromobutane with 1,5- dibromopentane
    39
    Figure US20210101902A1-20210408-C00215
         		1H NMR (400 MHz, Methanol-d4) δ 8.42 (s, 1H), 4.92 (s, 2H), 4.35 (brs, 2H), 4.04 (s, 3H), 3.82 (s, 2H), 3.58- 3.50 (m, 2H), 2.98-2.90 (m, 2H), 2.86-2.76 (m, 2H), 2.66 (s, 3H), 2.26 (s, 3H), 2.00-1.62 (m, 18H). MS (ES+): 489.4 (M + 1)+. See Example 13 Replace Compound No. 1 with Compound No. 149 and replace 1,4- dibromobutane with 1,5- dibromopentane
    40
    Figure US20210101902A1-20210408-C00216
         		1H NMR (400 MHz, Methanol-d4) δ 4.95 (s, 2H), 4.31 (t, J = 5.6 Hz, 2H), 4.24 (s, 3H), 3.78 (s, 2H), 3.01 (t, J = 5.5 Hz, 2H), 2.78 (s, 3H), 2.53 (s, 3H), 2.20 (s, 3H), 1.90-1.80 (m, 6H), 1.72-1.62 (m, 6H). MS (ES+): 469.4 (M + 1)+. See Example 17 Replace Compound No. 1 with Compound No. 26 and replace then treat with CD3I
    41
    Figure US20210101902A1-20210408-C00217
         		1H NMR (400 MHz, DMSO-d6) δ 8.23 (s, 1H), 8.03 (s, 1H), 7.70 (s, 3H), 4.44 (s, 2H), 3.85 (s, 2H), 3.62 (s, 2H), 2.07 (s, 3H), 1.69-1.29 (m, 14H). MS (ES+): 393.2 (M + 1)+. See Example 1 Replace (HG1) in step 1 with (HG6)
    42
    Figure US20210101902A1-20210408-C00218
         		1H NMR (400 MHz, DMSO-d6) δ 8.20 (s, 1H), 8.00 (d, J = 5.6 Hz, 1H), 6.39 (d, J = 5.7 Hz, 1H), 4.45 (s, 2H), 3.84 (t, J = 5.7 Hz, 2H), 3.61 (s, 2H), 2.72 (t, J = 5.7 Hz, 2H), 2.13 (s, 3H), 1.78 (s, 1H), 1.36 (q, J = 9.8 Hz, 12H). MS (ES+): 393.2 (M + 1)+. See Example 1 Replace (HG1) in step 1 with (HG6) and (TG3) with (TG2)
    43
    Figure US20210101902A1-20210408-C00219
         		1H NMR (600 MHz, Methanol-d4) δ 8.07 (s, 1H), 6.39 (s, 1H), 4.47 (s, 3H), 3.86 (s, 5H), 3.63 (d, J = 2.5 Hz, 2H), 2.78 (t, J = 5.6 Hz, 2H), 2.58 (s, 6H), 2.41 (s, 3H), 2.07 (s, 3H), 1.71-1.65 (m, 6H), 1.55-1.49 (m, 6H). MS (ES+): 448.4 (M + 1)+. See example 17
    44
    Figure US20210101902A1-20210408-C00220
         		1H NMR (600 MHz, Methanol-d4) δ 8.52 (s, 1H), 6.90 (s, 1H), 4.97 (s, 2H), 4.37 (s, 2H), 4.27 (d, J = 8.2 Hz, 2H), 4.12 (s, 3H), 3.13 (t, J = 5.5 Hz, 2H), 2.70 (s, 3H), 2.42 (s, 3H), 1.92-1.73 (m, 8H), 1.67-1.54 (m, 2H). MS (ES+): 406.3 (M + 1)+. See Example 1 Replace (TG3) in step 1 with (TG5)
    45
    Figure US20210101902A1-20210408-C00221
         		1H NMR (600 MHz, Methanol-d4) δ 8.37 (s, 1H), 6.83 (s, 1H), 5.08 (s, 2H), 4.36-4.16 (m, 2H), 4.11 (s, 3H), 4.02 (s, 2H), 3.08 (s, 2H), 2.69 (s, 3H), 1.82-1.68 (m, 12H). MS (ES+): 474.3 (M + 1)+. See Example 1 Replace (TG3) in step 1 with (TG8)
    46
    Figure US20210101902A1-20210408-C00222
         		1H NMR (400 MHz, Methanol-d4) δ 8.53 (s, 1H), 6.89 (s, 1H), 4.97 (d, J = 10.,7 Hz, 2H), 4.24 (d, J = 11.9 Hz, 2H), 4.12 (s, 3H), 3.99 (s, 2H), 3.14 (td, J = 5.1, 4.6, 2.6 Hz, 2H), 2.70 (s, 3H), 2.45 (s, 3H), 1.64 (s, 12H). MS (ES+): 421.2 (M + 1)+. See Example 1 Replace TG3 with TG14
    47
    Figure US20210101902A1-20210408-C00223
         		RT (method 1): 1.18 min. MS (ES+): 462.2 (M + 1)+. See Example 7 Replace Compound No. 1 with Compound No. 26 and replace 2- (dimethylamino) acetic acid with acetic acid
    48
    Figure US20210101902A1-20210408-C00224
         		1H NMR (400 MHz, Methanol-d4) δ 8.53 (s, 1H), 6.89 (s, 1H), 5.06- 4.94 (m, 2H), 4.25 (s, 2H), 4.12 (s, 3H), 3.98 (s, 2H), 3.18-3.06 (m, 2H), 2.94 (s, 3H), 2.70 (s, 3H), 2.43 (s, 3H), 1.96-1.85 (m, 6H), 1.67-1.57 (m, 6H). MS (ES+): 498.2 (M + 1)+. See Example 18
    49
    Figure US20210101902A1-20210408-C00225
         		1H NMR (400 MHz, Methanol-d4) δ 8.16 (s, 1H), 6.46 (s, 1H), 4.54 (s, 2H), 4.00 (s, 5H), 3.72 (s, 2H), 2.90 (t, J = 5.6 Hz, 2H), 2.80 (s, 3H), 2.55 (s, 3H), 2.23 (s, 3H), 2.04- 1.91 (m, 6H), 1.60-1.52 (m, 6H), 1.43 (s, 9H). MS (ES+): 534.4 (M + 1)+. See Example 19
    50
    Figure US20210101902A1-20210408-C00226
         		1H NMR (400 MHz, Methanol-d4) δ 8.05 (s, 1H), 6.36 (s, 1H), 4.44 (s, 2H), 3.90 (s, 3H), 3.88 (t, J = 5.8 Hz, 2H), 3.64 (s, 2H), 2.80 (t, J = 5.6 Hz, 2H), 2.44 (s, 3H), 2.17 (s, 3H), 2.13 (s, 3H), 1.49 (s, 12H). MS (ES+): 434.3 (M + 1)+. See Example 19
    51
    Figure US20210101902A1-20210408-C00227
         		1H NMR (400 MHz, Methanol-d4) δ 8.05 (s, 1H), 6.35 (s, 1H), 4.44 (s, 2H), 3.90 (s, 3H), 3.87 (t, J = 5.6 Hz, 2H), 3.61 (s, 2H), 2.80 (t, J = 5.6 Hz, 2H), 2.44 (s, 3H), 2.13 (s, 3H), 1.74-1.63 (m, 6H), 1.50-1.40 (m, 6H), 1.35 (s, 3H), 0.71-0.61 (m, 2H), 0.48-0.41 (m, 2H). MS (ES+): 518.3 (M + 1)+. See Example 20
    52
    Figure US20210101902A1-20210408-C00228
         		1H NMR (400 MHz, Methanol-d4) δ 8.47 (s, 1H), 6.81 (s, 1H), 4.32 (s, 2H), 4.25-4.18 (m, 2H), 4.10 (s, 3H), 3.02-2.97 (m, 2H), 2.66 (s, 3H), 2.28 (s, 3H), 1.99 (s, 6H). MS (ES+): 378.2 (M + 1)+. See Example 1 Replace (TG3) in step 1 with (TG13)
    53
    Figure US20210101902A1-20210408-C00229
         		RT (method 1), 1.28 min. MS (ES+): 528.4 (M + 1)+. See Example 2
    54
    Figure US20210101902A1-20210408-C00230
         		1H NMR (400 MHz, Methanol-d4) δ 8.16 (s, 1H), 6.46 (s, 1H), 4.55 (s, 2H), 4.01 (s, 3H), 3.98 (t, J = 5.6 Hz, 2H), 3.72 (s, 2H), 3.32 (m, 1H), 2.90 (t, J = 5.5 Hz, 2H), 2.55 (s, 3H), 2.23 (s, 3H), 2.19 (tt, J = 11.1, 5.3 Hz, 2H), 1.93-1.77 (m, 2H), 1.68 (dd, J = 11.1, 5.7 Hz, 2H), 1.63-1.51 (m, 12H). MS (ES+): 474.4 (M + 1)+. See example 6 Replace oxetan-3-one with cyclobutanone
    55
    Figure US20210101902A1-20210408-C00231
         		1H NMR (400 MHz, Methanol-d4) δ 8.16 (s, 1H), 6.46 (s, 1H), 4.55 (s, 2H), 4.01 (s, 3H), 3.98 (t, J = 5.7 Hz, 2H), 3.74 (s, 2H), 3.18 (m, 1H), 2.91 (t, J = 5.6 Hz, 2H), 2.55 (s, 3H), 2.23 (s, 3H), 1.66 (q, J = 5.6, 4.5 Hz, 6H), 1.63- 1.54 (m, 6H), 1.11 (d, J = 6.3 Hz, 6H). MS (ES+): 462.4 (M + 1)+. See example 6 Replace oxetan-3-one with propan-2- one
    56
    Figure US20210101902A1-20210408-C00232
         		RT (method 1): 0.21 min. MS (ES+): 478.4 (M + 1)+. See example 6 Replace oxetan-3-one with 1- hydroxypropan- 2-one
    57
    Figure US20210101902A1-20210408-C00233
         		1H NMR (400 MHz, Methanol-d4) δ 8.16 (s, 1H), 6.46 (s, 1H), 4.55 (s, 2H), 4.01 (s, 3H), 3.98 (t, J = 5.7 Hz, 2H), 3.75 (s, 2H), 2.91 (t, J = 5.5 Hz, 2H), 2.69 (q, J = 6.5, 5.9 Hz, 2H), 2.55 (s, 3H), 2.24 (s, 3H), 1.63 (H, J = 6.4, 5.8 Hz, 12H), 1.14 (t, J = 7.1 Hz, 3H). MS (ES+): 448.4 (M + 1)+. See example 6 Replace oxetan-3-one with acetaldehyde
    58
    Figure US20210101902A1-20210408-C00234
         		1H NMR (400 MHz, Methanol-d4) δ 8.06 (s, 1H), 6.36 (s, 1H), 4.45 (s, 2H), 3.99 (s, 3H), 3.89 (m, 2H), 3.64 (s, 2H), 2.81 (m, 2H), 2.64 (s, 4H), 2.45 (s, 3H), 2.13 (s, 3H), 1.68 (s, 4H), 1.63- 1.35 (m, 12H). ESIMS calcd. for C28H39N7 (M + H+) 475.2, found 475.2. See Example 13
    59
    Figure US20210101902A1-20210408-C00235
         		1H NMR (400 MHz, Methanol-d4) δ 8.16 (s, 1H), 6.46 (s, 1H), 4.55 (s, 2H), 3.99 (d, J = 9.5 Hz, 5H), 3.73 (s, 2H), 3.68- 3.51 (m, 4H), 2.91 (t, J = 5.4 Hz, 2H), 2.23 (s, 3H), 1.57 (m, 12H). ESIMS calcd. for C28H39N7O (M + H+) 491.0, found 491.0 See Example 14
    60
    Figure US20210101902A1-20210408-C00236
         		1H NMR (400 MHz, Methanol-d4) δ 8.51 (s, 1H), 7.47 (s, 1H), 6.83 (s, 1H), 5.02 (s, 2H), 4.13 (s, 3H), 3.97 (s, 2H), 3.95 (s, 2H), 2.66 (s, 3H), 1.79 (brs, 12H), 1.49 (s, 6H). MS (ES+): 434.3 (M + 1)+. See Example 1 Repalce (TG3) in step 1 with (TG6)
    61
    Figure US20210101902A1-20210408-C00237
         		1H NMR (400 MHz, Methanol-d4) δ 8.05 (s, 1H), 6.36 (s, 1H), 5.79 (tt, J = 55.9, 4.1 Hz, 1H), 4.44 (s, 2H), 3.89 (m, 5H), 3.64 (s, 2H), 2.94- 2.75 (m, 4H), 2.44 (s, 3H), 2.13 (s, 3H), 1.49 (s, 12H). MS (ES+): 484.2 (M + 1)+. See Example 21
    62
    Figure US20210101902A1-20210408-C00238
         		1H NMR of HCl salt (400 MHz, Methanol-d4) δ 8.25 (d, J = 8.6 Hz, 1H), 7.98 (ddd, J = 8.2, 6.9, 1.1 Hz, 1H), 7.94-7.89 (m, 1H), 7.75 (t, J = 7.7 Hz, 1H), 7.25 (d, J = 5.0 Hz, 1H), 4.75 (d, J = 2.9 Hz, 2H), 4.11 (t, J = 5.4 Hz, 2H), 3.92 (s, 2H), 3.20 (s, 3H), 2.80 (d, J = 1.7 Hz, 3H), 2.28 (d, J = 3.3 Hz, 2H), 1.88-1.62 (m, 12H); 416.2 (M + 1), rt = 1.18 min See Example 1 Repalce (HG1) in step 1 with (HG8)
    63
    Figure US20210101902A1-20210408-C00239
         		1H NMR (400 MHz, Chloroform-d) δ 8.38 (d, J = 5.9 Hz, 1H), 7.93 (dt, J = 6.4, 1.4 Hz, 2H), 7.51- 7.34 (m, 3H), 7.13 (d, J = 2.6 Hz, 1H), 6.71 (dd, J = 6.0, 2.6 Hz, 1H), 4.30 (s, 2H), 3.73 (t, J = 5.6 Hz, 2H), 3.67 (s, 2H), 2.76 (t, J = 5.7 Hz, 2H), 2.23 (s, 3H), 1.50 (m, 12H); MS 428.3 (M + 1), rt-1.02 min See Example 12 Repalce-4- cyanophenyl) boronic acid in step 2 with phenylboronic acid
    64
    Figure US20210101902A1-20210408-C00240
         		1H NMR (400 MHz, Methanol-d4) δ 8.03 (d, J = 0.9 Hz, 1H), 6.33 (s, 1H), 4.42 (s, 2H), 3.89 (s, 3H), 3.85 (q, J = 5.6 Hz, 2H), 3.61 (s, 2H), 3.33- 3.23 (m, 4H), 2.79 (t, J = 5.6 Hz, 2H), 2.43 (s, 3H), 2.12 (s, 3H), 1.95 (dt, J = 15.3, 7.6 Hz, 2H), 1.49- 1.36 (m, 12H). MS (ES+): 460.4 (M + 1)+. See Example 13 Replace 1,4- dibromobutane with 1,3- dibromopropane
    65
    Figure US20210101902A1-20210408-C00241
         		1H NMR (400 MHz, Methanol-d4) δ 8.49 (s, 1H), 7.47 (s, 1H), 6.83 (s, 1H), 5.08 (s, 2H), 4.09 (s, 3H), 3.95 (s, 2H), 3.92 (s, 2H), 2.66 (s, 3H), 1.80-1.70 (m, 6H), 1.68- 1.58 (m, 6H), 1.41 (s, 6H). MS (ES+): 434.3 (M + 1)+. See Example 1 Replace (TG3) in step 1 with (TG7)
    66
    Figure US20210101902A1-20210408-C00242
         		1H NMR (400 MHz, Methanol-d4) δ 8.39 (s, 1H), 6.75 (s, 1H), 4.12 (s, 2H), 4.00 (s, 4H), 3.79 (s, 3H), 3.74-3.32 (m, 7H), 2.95 (s, 2H), 2.58 (s, 3H), 2.20 (s, 3H), 1.89 (dd, J = 9.8, 5.0 Hz, 6H), 1.78- 1.50 (m, 6H). MS (ES+): 538.4 (M + 1)+. See Example 13 Replace 1,4- dibromobutane with 1- bromo-2-((2- bromoethyl)sul- fonyl)ethane
    67
    Figure US20210101902A1-20210408-C00243
         		1H NMR (400 MHz, Methaol-d4) δ 8.40 (s, 1H), 6.76 (s, 1H), 4.13 (s, 2H), 4.01 (s, 3H), 3.82 (s, 2H), 3.45 (d, J = 11.6 Hz, 2H), 2.97 (s, 2H), 2.73 (t, J = 12.3 Hz, 2H), 2.58 (s, 3H), 2.23 (s, 3H), 1.99- 1.49 (m, 18H), 1.38 (dd, J = 14.9, 5.7 Hz, 2H). MS (ES+): 488.3 (M + 1)+. See Example 13 Replace 1,4- dibromobutane- with 1,5- dibromopentane
    68
    Figure US20210101902A1-20210408-C00244
         		1H NMR (400 MHz, Methanol-d4) δ 8.50 (s, 1H), 6.87 (s, 1H), 4.61- 4.34 (m, 2H), 4.24 (s, 1H), 4.06 (d, J = 6.9 Hz, 1H), 3.94 (d, J = 10.1 Hz, 3H), 3.92-3.71 (m, 2H), 3.34 (m, 2H), 3.11 (m, 2H), 2.69 (s, 3H), 2.34 (s, 3H), 1.74 (m, 12H). MS (ES+): 476.9 (M + 1)+. See Example 13 Replace 1,4- dibromobutane with 1,3- dibromopropan- 2-ol
    69
    Figure US20210101902A1-20210408-C00245
         		1H NMR (400 MHz, Methanol-d4) δ 8.16 (s, 1H), 8.05 (d, J = 8.2 Hz, 0H), 8.04 (s, 0H), 7.54 (d, J = 8.1 Hz, 0H), 6.46 (s, 1H), 4.54 (s, 2H), 4.00 (s, 3H), 3.98 (t, J = 5.7 Hz, 2H), 3.73 (s, 2H), 3.35 (s, 2H), 2.98 (s, 3H), 2.94 (s, 3H), 2.90 (t, J = 5.6 Hz, 2H), 2.55 (s, 3H), 2.23 (s, 3H), 1.56 (s, 12H). MS (ES+): 505.4 (M + 1)+. See Example 22
    70
    Figure US20210101902A1-20210408-C00246
         		1H NMR (400 MHz, Methanol-d4) δ 8.15 (s, 1H), 6.45 (s, 1H), 4.54 (s, 2H), 4.00 (s, 3H), 3.97 (t, J = 5.5 Hz, 2H), 3.69 (s, 2H), 3.31 (d, J = 1.1 Hz, 6H), 2.90 (t, J = 5.6 Hz, 2H), 2.75-2.65 (m, 4H), 2.55 (s, 3H), 2.23 (s, 3H), 1.64-1.47 (m, 12H). MS (ES+): 536.4 (M + 1)+. See Example 22
    71
    Figure US20210101902A1-20210408-C00247
         		1H NMR (400 MHz, Methanol-d4) δ 8.15 (s, 1H), 6.45 (s, 1H), 4.54 (s, 2H), 4.00 (s, 3H), 3.97 (dd, J = 7.4, 4.1 Hz, 2H), 3.73 (s, 2H), 3.52-3.46 (m, 4H), 2.90 (t, J = 5.6 Hz, 2H), 2.67 (t, J = 5.5 Hz, 2H), 2.54 (s, 3H), 2.23 (s, 3H), 1.57 (s, 12H), 1.19-1.15 (m, 3H). MS (ES+): 492.4 (M + 1)+. See Example 22 Replace 1- bromo-2- methoxyethane with 1- bromo-2- ethoxyethane
    72
    Figure US20210101902A1-20210408-C00248
         		1H NMR (400 MHz, Methanol-d4) δ 8.16 (s, 1H), 6.45 (s, 1H), 4.54 (s, 2H), 4.00 (s, 3H), 3.99- 3.95 (m, 2H), 3.70 (s, 2H), 3.47 (q, J = 7.0 Hz, 4H), 3.38 (t, J = 6.8 Hz, 4H), 2.90 (t, J = 5.6 Hz, 2H), 2.71 (d, J = 7.3 Hz, 4H, 2.55 (s, 3H), 2.23 (s, 3H), 1.65-1.49 (m, 12H), 1.16 (t, J = 7.0 Hz, 6H). MS (ES+): 564.4 (M + 1)+. See Example 22 Replace 1- bromo-2- methoxyethane with 1- bromo-2- ethoxyethane
    73
    Figure US20210101902A1-20210408-C00249
         		1H NMR (400 MHz, Methanol-d4) δ 8.16 (s, 1H), 6.46 (s, 1H), 4.54 (s, 2H), 4.00 (s, 3H), 3.98 (t, J = 5.7 Hz, 2H), 3.72 (s, 2H), 3.43 (t, J = 5.8 Hz, 2H), 2.90 (t, J = 5.6 Hz, 2H), 2.63 (s, 2H), 2.55 (s, 3H), 2.23 (s, 6H), 1.67- 1.49 (m, 12H). MS (ES+): 492.4 (M + 1)+. See Example 23
    74
    Figure US20210101902A1-20210408-C00250
         		1H NMR (400 MHz, Methanol-d4) δ 8.50 (s, 1H), 6.87 (s, 1H), 4.95 (m, 2H), 4.21 (m, 4H), 4.11 (s, 3H), 3.95 (d, J = 6.5 Hz, 2H), 3.66-3.35 (m, 2H), 3.32 (m, 2H), 3.18 (m, 1H), 3.08 (s, 2H), 2.69 (s, 3H), 2.36 (d, J = 6.4 Hz, 3H), 1.88 (m, 6H), 1.79-1.57 (m, 6H). MS (ES+): 507.4 (M + 1)+. See Example 13 Replace 1,4- dibromobutane with (2R,3S)-1,4- dichlorobutane- 2,3-diol
    75
    Figure US20210101902A1-20210408-C00251
         		1H NMR (400 MHz, Methanol-d4) δ 8.51 (s, 1H), 6.88 (s, 1H), 4.50 (m, 1H), 4.25 (s, 2H), 4.11 (s, 3H), 3.97 (d, J = 5.3 Hz, 2H), 3.52-3.36 (m, 4H), 3.27 (s, 2H), 3.10 (s, 2H), 2.69 (s, 3H), 2.38 (d, J = 4.8 Hz, 3H), 2.21-1.95 (m, 2H), 1.96- 1.80 (m, 6H), 1.80- 1.63 (m, 6H). MS (ES+): 491.3 (M + 1)+. See Example 13 Replace 1,4- dibromobutane with (S)-1,4- dibromobutane- 2-ol
    76
    Figure US20210101902A1-20210408-C00252
         		1H NMR (400 MHz, Methanol-d4) δ 8.17 (d, J = 1.8 Hz, 1H), 6.47 (s, 1H), 4.56 (s, 2H), 4.02 (s, 3H), 4.00 (t, J = 5.7 Hz, 2H), 3.76 (m, 2H), 3.56 (m, 2H), 3.03-2.95 (m, 6H), 2.92 (t, J = 5.6 Hz, 2H), 2.56 (s, 3H), 2.25 (s, 3H), 1.73-1.56 (m, 12H). MS (ES+): 505.4 (M + 1)+. See Example 24
    77
    Figure US20210101902A1-20210408-C00253
         		1H NMR (400 MHz, Methanol-d4) δ 8.05 (s, 1H), 6.35 (s, 1H), 4.58 (t, J = 6.9 Hz, 2H), 4.47 (t, J = 7.0 Hz, 2H), 4.44 (s, 2H), 4.25 (q, J = 7.3 Hz, 1H), 3.90 (s, 3H), 3.87 (t, J = 5.5 Hz, 2H), 3.61 (s, 2H), 2.79 (t, J = 5.6 Hz, 2H), 2.44 (s, 3H), 2.18 (s, 3H), 2.12 (s, 3H), 1.45 (s, 12H). MS (ES+): 490.4 (M + 1)+. See Example 25
    78
    Figure US20210101902A1-20210408-C00254
         		1H NMR (400 MHz, Methanol-d4) δ 8.05 (s, 1H), 6.35 (s, 1H), 4.44 (s, 2H), 3.90 (s, 3H), 3.87 (t, J = 5.6 Hz, 2H), 3.61 (s, 2H), 3.38-3.27 (m, 1H), 2.80 (t, J = 5.6 Hz, 2H), 2.44 (s, 3H), 2.13 (s, 3H), 2.05 (s, 3H), 1.58 (dd, J = 10.0, 5.4 Hz, 6H), 1.49- 1.40 (m, 6H), 0.92 (d, J = 6.5 Hz, 6H). MS (ES+): 476.4 (M + 1)+. See Example 25 Replace Compound No. 6 with Compound No. 55
    79
    Figure US20210101902A1-20210408-C00255
         		1H NMR (400 MHz, Methanol-d4) δ 8.00 (s, 1H), 6.30 (s, 1H), 4.39 (s, 2H), 3.85 (s, 3H), 3.82 (t, J = 5.6 Hz, 2H), 3.56 (s, 2H), 3.41-3.27 (m, 1H), 2.75 (t, J = 5.6 Hz, 2H), 2.40 (s, 3H), 2.08 (s, 3H), 1.99 (s, 3H), 1.91 (td, J = 9.8, 2.4 Hz, 2H), 1.85- 1.76 (m, 2H), 1.53-1.34 (m, 14H). MS (ES+) 48.4 (M + 1)+. See Example 25 Replace Compound No. 6 with Compound No. 54
    80
    Figure US20210101902A1-20210408-C00256
         		RT (method 1): 0.97 min. MS (ES+): 507.3 (M + 1)+. See Example 13 Replace 1,4- dibromobutane with (2S,3S)-2,3- dihydroxybutane- 1,4-diyl bis(4- methylbenzene- sulfonate)
    81
    Figure US20210101902A1-20210408-C00257
         		RT (method 2): 1.21 min. MS (ES+): 423.3 (M + 1)+. See Example 1 Replace (TG3) in step 1 with (TG11)
    82
    Figure US20210101902A1-20210408-C00258
         		RT (method 2): 1.23 min. MS (ES+): 477.4 (M + 1)+. See Example 13 Replace Compound No. 1 with Compound No. 81
    83
    Figure US20210101902A1-20210408-C00259
         		1H NMR (400 MHz, Methanol-d4) δ 8.55 (dd, J = 8.7, 5.7 Hz, 2H), 8.27 (s, 1H), 7.21 (t, J = 8.8 Hz, 2H), 4.97 (s, 2H), 4.38 (brs, 2H), 4.06 (s, 3H), 3.80 (s, 2H), 2.92 (t, J = 5.4 Hz, 2H), 2.29 (s, 3H), 1.80-1.60 (m, 12H). MS (ES+): 501.3 (M + 1)+. See Example 11
    84
    Figure US20210101902A1-20210408-C00260
         		1H NMR (400 MHz, Methanol-d4) δ 8.25 (d, J = 7.4 Hz, 1H), 8.08-7.97 (m, 4H), 7.56 (brs, 1H), 7.36 (m, 1H), 4.71 (s, 2H), 4.09 (brs, 2H), 3.79 (s, 2H), 2.93 (t, J = 5.4 Hz, 2H), 2.25 (s, 3H), 1.82-1.60 (m, 12H). MS (ES+): 453.3 (M + 1)+. See Example 12
    85
    Figure US20210101902A1-20210408-C00261
         		1H NMR (400 MHz, Chloroform-d) δ 8.27 (d, J = 6.0 Hz, 1H), 7.86-7.79 (m, 2H), 7.42 (m, 2H), 7.41-7.34 (m, 1H), 7.05 (d, J = 2.6 Hz, 1H), 6.69 (dd, J = 6.1, 2.6 Hz, 1H), 4.27 (s, 2H), 3.71 (t, J = 5.6 Hz, 2H), 3.62 (s, 2H), 2.73 (t, J = 5.7 Hz, 2H), 2.53 (m, 4H), 2.19 (s, 3H), 1.68 (s, 4H), 1.63- 1.38 (m, 12H); MS 482.3 (M + 1), rt = 1.13 min See Example 13 Replace Compound No. 1 with Compound No. 63
    86
    Figure US20210101902A1-20210408-C00262
         		1H NMR (400 MHz, Chloroform-d) δ 9.31 (d, J = 0.8 Hz, 1H), 8.47 (d, J = 5.8 Hz, 1H), 7.70 (dd, J = 5.8, 0.9 Hz, 1H), 6.93 (s, 1H), 4.17 (s, 2H), 3.68 (s, 2H), 3.58 (t, J = 5.6 Hz, 2H), 2.90 (t, J = 5.7 Hz, 2H), 2.70 (s, 3H), 2.62- 2.50 (m, 4H), 2.20 (s, 3H), 1.71 (t, J = 3.2 Hz, 4H), 1.67-1.47 (m, 12H); MS 471.3 (M + 1), rt = 0.77 min See Example 13 Replace Compound No. 1 with Compound No. 3
    87
    Figure US20210101902A1-20210408-C00263
         		1H NMR (400 MHz, Methanol-d4) δ 8.25-8.16 (m, 1H), 7.96- 7.88 (m, 2H), 7.48-7.29 (m, 4H), 4.70 (s, 2H), 4.07 (brs, 2H), 3.79 (s, 2H), 2.92 (t, J = 5.4 Hz, 2H), 2.25 (s, 3H), 1.86- 1.60 (m, 12H). MS (ES+): 446.3 (M + 1)+. See Example 12 Replace (4- cyanophenyl) boronic acid in step 2 with (4- fluorophenyl) boronic acid
    88
    Figure US20210101902A1-20210408-C00264
         		1H NMR (400 MHz, Methanol-d4) δ 8.22 (d, J = 7.4 Hz, 1H), 7.59-7.41 (m, 3H), 7.36- 7.22 (m, 2H), 4.68 (s, 2H), 4.06 (t, J = 5.6 Hz, 2H), 3.79 (s, 2H), 2.91 (t, J = 5.3 Hz, 2H), 2.45 (s, 3H), 2.24 (s, 3H), 1.86- 1.56 (m, 12H). MS (ES+): 460.3 (M + 1)+. See Example 12 Replace (4- cyanophenyl) boronic acid in step 2 with (2-fluoro-4- methylphenyl) boronic acid
    89
    Figure US20210101902A1-20210408-C00265
         		1H NMR (400 MHz, Methanol-d4) δ 8.14 (d, J = 7.4 Hz, 1H), 7.86-7.80 (m, 2H), 7.41 (brs, 1H), 7.29-7.14 (m, 3H), 4.68 (s, 2H), 4.06 (brs, 2H), 3.91 (s, 3H), 3.79 (s, 2H), 2.92 (t, J = 5.4 Hz, 2H), 2.25 (s, 3H), 1.82-1.60 (m, 12H). MS (ES+): 458.3 (M + 1)+. See Example 12 Replace (4- cyanophenyl) boronic acid in step 2 with (4- methoxyphenyl) boronic acid
    90
    Figure US20210101902A1-20210408-C00266
         		1H NMR (400 MHz, Methanol-d4) δ 8.16 (d, J = 7.4 Hz, 1H), 7.76 (d, J = 8.2 Hz, 2H), 7.52-7.40 (m, 3H), 7.32- 7.26 (m, 1H), 4.69 (s, 2H), 4.07 (brs, 2H), 3.79 (s, 2H), 2.92 (t, J = 5.4 Hz, 2H), 2.47 (s, 3H), 2.25 (s, 3H), 1.84-1.54 (m, 12H). MS (ES+): 442.4 (M + 1)+. See Example 12 Replace (4- cyanophenyl) boronic acid in step 2 with p-tolylboronic acid
    91
    Figure US20210101902A1-20210408-C00267
         		RT (method 2): 1.33 min. MS (ES+): 435.3 (M + 1)+. See Example 1 Replace (TG3) in step 1 with (TG12)
    92
    Figure US20210101902A1-20210408-C00268
         		1H NMR (400 MHz, Methanol-d4) δ 8.48 (d, J = 6.3 Hz, 1H), 8.11 (d, J = 6.3 Hz, 1H), 7.42 (s, 1H), 4.56 (s, 2H), 3.92 (t, J = 5.3 Hz, 2H), 3.82 (s, 2H), 3.11 (d, J = 11.5 Hz, 8H), 2.22 (s, 3H), 1.75 (dd, J = 30.1, 8.1 Hz, 12H). MS (ES+): 431.3 (M + 1)+. See Example 1 Replace (HG1) in step 1 with (HG10)
    93
    Figure US20210101902A1-20210408-C00269
         		1H NMR (400 MHz, Methanol-d4) δ 7.86- 7.76 (m, 2H), 7.50-7.40 (m, 3H), 7.04 (d, J = 2.4 Hz, 1H), 6.80 (d, J = 2.3 Hz, 1H), 4.36 (s, 2H), 3.79 (t, J = 5.6 Hz, 2H), 3.72 (s, 2H), 2.80 (t, J = 5.6 Hz, 2H), 2.49 (s, 3H), 2.22 (s, 3H), 1.57 (s, 12H); MS 442.2 (M + 1), rt = 1.00 min See Example 12 Replace 2- chloro-4- fluoropyridine in step 1 with 2-chloro-4- fluoro-6- methylpyridine Repalce 4- cyanophenyl) boronic acid in step 2 with phenylboronic acid
    94
    Figure US20210101902A1-20210408-C00270
         		1H NMR (400 MHz, Chloroform-d) δ 8.60 (ddd, J = 4.8, 1.9, 0.9 Hz, 1H), 8.34-8.25 (m, 2H), 7.85 (d, J = 2.7 Hz, 1H), 7.73 (td, J = 7.7, 1.8 Hz, 1H), 7.26-7.19 (m, 1H), 6.68 (dd, J = 5.9, 2.7 Hz, 1H), 4.27 (s, 2H), 3.71 (t, J = 5.6 Hz, 2H), 3.59 (s, 2H), 2.69 (t, J = 5.7 Hz, 2H), 2.16 (s, 3H), 1.51- 1.37 (m, 12H); MS 429.2 (M + 1), rt = 0.95 min See Example 12 Repalce 4- cyanophenyl) boronic acid in step 2 with pyridin-2- ylboronic acid
    95
    Figure US20210101902A1-20210408-C00271
         		1H NMR (400 MHz, Methanol-d4) δ 8.39 (s, 1H), 6.76 (s, 1H), 4.12 (s, 2H), 4.01 (m, 5H), 3.88 (s, 2H), 3.39 (m, 3H), 3.02 (m, 2H), 2.81 (m, 2H), 2.58 (s, 3H), 2.23 (s, 3H), 2.13-1.50 (m, 14H), 1.38 (m, 1H). RT (method 2): 1.39 min. MS (ES+): 491.4 (M + 1)+. See Example 13 Replace Compound No. 1 with Compound No. 81 and replace 1,4- dibromobutane with 1,5- dibromopentane
    96
    Figure US20210101902A1-20210408-C00272
         		1H NMR (400 MHz, Methanol-d4) δ 8.05 (s, 1H), 6.35 (s, 1H), 4.44 (s, 2H), 3.90 (s, 3H), 3.87 (t, J = 5.7 Hz, 2H), 3.62 (s, 2H), 3.06 (dq, J = 7.7, 3.4 Hz, 2H), 3.01-2.91 (m, 1H), 2.80 (t, J = 5.6 Hz, 2H), 2.44 (s, 3H), 2.13 (s, 3H), 1.51-1.42 (m, 12H), 0.91 (d, J = 6.3 Hz, 3H). MS (ES+): 492.4 (M + 1)+. See Example 17 Replace Compound No. 1 with Compound No. 26 and replace formaldehyde with 2- 1- methoxypropan- 2-one
    97
    Figure US20210101902A1-20210408-C00273
         		1H NMR (400 MHz, Methanol-d4) δ 8.05 (s, 1H), 6.35 (s, 1H), 4.44 (s, 2H), 3.90 (s, 3H), 3.89- 3.85 (m, 2H), 3.63 (s, 2H), 2.80 (t, J = 5.6 Hz, 2H), 2.48 (d, J = 7.9 Hz, 2H), 2.44 (s, 3H), 2.14 (d, J = 6.6 Hz, 6H), 1.60- 1.41 (m, 12H), 0.99 (t, J = 7.1 Hz, 3H). MS (ES+): 462.4 (M + 1)+. See Example 25 Replace Compound No. 6 with Compound No. 57
    98
    Figure US20210101902A1-20210408-C00274
         		RT (method 2): 1.27 min. MS (ES+): 451.3 (M + 1)+. See Example 17 Replace Compound No. 1 with Compound No. 81
    99
    Figure US20210101902A1-20210408-C00275
         		1H NMR (600 MHz, Methanol-d4) δ 8.16 (s, 1H), 6.46 (s, 1H), 4.55 (s, 2H), 4.01 (s, 3H), 4.00- 3.95 (m, 2H), 3.74 (s, 2H), 3.54 (dd, J = 6.7, 4.5 Hz, 2H), 3.41-3.38 (m, 2H), 3.36 (d, J = 0.8 Hz, 2H), 2.91 (t, J = 5.6 Hz, 2H), 2.55 (s, 3H), 2.24 (s, 3H), 1.67 (ddd, J = 12.5, 7.2, 4.0 Hz, 2H), 1.57 (m, 16H). MS (ES+): 545.4 (M + 1)+. See Example 24 Replace 2- bromo-N,N- dimethylaceta- mide with 2- bromo-1- (piperidin-1- yl)ethan-1-one
    100
    Figure US20210101902A1-20210408-C00276
         		1H NMR (600 MHz, Methanol-d4) δ 8.05 (s, 1H), 6.36 (s, 1H), 4.44 (s, 2H), 3.90 (s, 3H), 3.90- 3.86 (m, 2H), 3.63 (s, 2H), 3.03 (s, 2H), 2.83- 2.77 (m, 2H), 2.62-2.53 (m, 4H), 2.45 (s, 3H), 2.14 (s, 3H), 1.81-1.76 (m, 6H), 1.75-1.71 (m, 4H), 1.51-1.46 (m, 6H). MS (ES+): 531.4 (M + 1)+. See Example 24 Replace 2- bromo-N,N- dimethylaceta- mide with 2- bromo-1- (pyrrolidin-1- yl)ethan-1-one
    101
    Figure US20210101902A1-20210408-C00277
         		1H NMR (600 MHz, Methanol-d4) δ 8.05 (d, J = 1.1 Hz, 1H), 6.35 (s, 1H), 4.44 (s, 2H), 3.90 (s, 3H), 3.90-3.85 (m, 2H), 3.64 (d, J = 6.3 Hz, 2H), 3.07 (s, 2H), 2.83-2.77 (m, 2H), 2.44 (s, 3H), 2.13 (s, 3H), 1.57-1.46 (m, 12H), 1.07 (s, 6H). MS (ES+): 506.4 (M + 1)+. See Example 26
    102
    Figure US20210101902A1-20210408-C00278
         		RT (method 2): 0.18 min. MS (ES+): 502.1 (M + Na)+. See Example 21 Replace Compound No. 1 with Compound No. 81 and Replace 2,2- difluoroethyl trifluromethane- sulfonate with 2- bromomethoxy- ethane
    103
    Figure US20210101902A1-20210408-C00279
         		1H NMR (400 MHz, Methanol-d4) δ 5.34 (t, J = 2.6 Hz, 2H), 4.84 (t, J = 2.5 Hz, 2H), 4.60 (s, 2H), 3.89 (brs, 2H), 3.76 (s, 2H), 2.79 (t, J = 5.5 Hz, 2H), 2.20 (s, 3H), 1.82-1.58 (m, 12H). MS (ES+): 429.3 (M + 1)+. See Example 1 Replace (HG1) in step 1 with (HG11)
    104
    Figure US20210101902A1-20210408-C00280
         		1H NMR (400 MHz, Methanol-d4) δ 8.05 (s, 1H), 6.35 (s, 1H), 4.44 (s, 2H), 3.90 (s, 3H), 3.87 (t, J = 5.5 Hz, 2H), 3.62 (s, 2H), 3.17 (dd, J = 6.3, 4.5 Hz, 2H), 3.08 (s, 2H), 2.80 (m, 5H), 2.66 (dd, J = 6.3, 4.5 Hz, 2H), 2.44 (s, 3H), 2.13 (s, 3H), 1.48 (tq, J = 9.4, 6.4, 4.7 Hz, 12H). MS (ES+): 517.3 (M + 1)+. See Example 27
    105
    Figure US20210101902A1-20210408-C00281
         		1H NMR (400 MHz, Methanol-d4) δ 8.05 (s, 1H), 6.35 (s, 1H), 4.44 (s, 2H), 3.90 (s, 3H), 3.87 (t, J = 5.5 Hz, 2H), 3.62 (s, 2H), 2.80 (t, J = 5.5 Hz, 2H), 2.45 (m, 5H), 2.17 (dd, J = 7.9, 6.9 Hz, 2H), 2.14 (s, 6H), 2.13 (s, 3H), 1.80-1.73 (m, 6H), 1.50- 1.43 (m, 6H). MS (ES+): 519.3 (M + 1)+. See Example 7 Replace 2- (dimethylamino) acetic acid with 3- (dimethylamino) propanoic acid
    106
    Figure US20210101902A1-20210408-C00282
         		1H NMR (400 MHz, Methanol-d4) δ 8.47 (s, 1H), 6.82 (s, 1H), 4.87 (s, 2H), 4.20 (t, J = 5.5 Hz, 2H), 4.10 (s, 3H), 3.84 (s, 2H), 3.81 (s, 2H), 3.46 (t, J = 6.8 Hz, 4H), 3.00 (t, J = 5.6 Hz, 2H), 2.67 (s, 3H), 2.25 (s, 3H), 2.01 (p, J = 6.6 Hz, 2H), 1.92 (q, J = 6.7 Hz, 2H), 1.87-1.78 (m, 6H), 1.68 (dt, J = 8.1, 5.9 Hz, 6H). MS (ES+): 531.3 (M + 1)+ See Example 21. Replace 2,2- difluoroethyl trifluoromethane- sulfonate with 2-bromo- 1-(pyrrolidin-1- yl)ethan-1-one
    107
    Figure US20210101902A1-20210408-C00283
         		RT (method 1): 0.14 min. MS (ES+): 505.3 (M + 1)+. See Example 14 Replace 1- bromo-2-(2- bromoethoxy) ethane with (R)-1-bromo- 2-(2- bromoethoxy) propane
    108
    Figure US20210101902A1-20210408-C00284
         		1H NMR (400 MHz, Methanol-d4) δ 8.53 (s, 1H), 6.90 (s, 1H), 4.99 (s, 2H), 4.27 (s, 2H), 4.12 (s, 3H), 4.02 (s, 2H), 3.92 (d, J = 12.1 Hz, 1H), 3.75 (dd, J = 35.3, 18.9 Hz, 5H), 3.20-3.11 (m, 2H), 2.94 (s, 3H), 2.71 (s, 3H), 2.46 (s, 3H), 2.16 (d, J = 7.8 Hz, 6H), 1.67 (d, J = 6.7 Hz, 6H). MS (ES+): 517.3 (M + 1)+. See Example 29
    109
    Figure US20210101902A1-20210408-C00285
         		RT (method 1): 1.09 min. MS (ES+): 505.4 (M + 1)+. See Example 14 Replace 1- bromo-2-(2- bromoethoxy) ethane with (S)-2-(2- (tosyloxy)eth- oxy)propyl 4- methylbenzene- sulfonate
    110
    Figure US20210101902A1-20210408-C00286
         		1H NMR (400 MHz, Methanol-d4) δ 8.06 (s, 1H), 6.36 (s, 1H), 4.45 (s, 2H), 3.89 (d, J = 9.6 Hz, 5H), 3.63 (s, 2H), 3.56- 3.41 (m, 2H), 2.81 (t, J = 5.5 Hz, 2H), 2.71 (m, 2H), 2.45 (s, 3H), 2.13 (s, 3H), 1.81 (m, 2H), 1.60-1.30 (m, 12H), 1.01 (d, J = 6.2 Hz, 6H). MS (ES+): 518.4 (M + 1)+. See Example 14 Replace 1- bromo-2-(2- bromoethoxy) ethane with (S)-2-(((R)-1- tosyloxypropan- 2- yl)oxy)propyl 4- methylbenzene- sulfonate
    111
    Figure US20210101902A1-20210408-C00287
         		RT (method 1): 1.12 min. MS (ES+): 518.4 (M + 1)+. See Example 14 Replace 1- bromo-2-(2- bromoethoxy) ethane with (S)-2-(((S)-1- tosyloxypropan- 2- yl)oxy)propyl 4- methylbenzene- sulfonate
    112
    Figure US20210101902A1-20210408-C00288
         		RT (method 1): 1.13 min. MS (ES+): 490.4 (M + 1)+. See Example 13 Replace Compound No. 1 with Compound No. 81 and replace 1,4- dibromobutane with (bromomethyl) cyclobutane
    113
    Figure US20210101902A1-20210408-C00289
         		RT (method 1): 1.12 min. MS (ES+): 518.4 (M + 1)+. See Example 14 Replace 1- bromo-2-(2- bromoethoxy) ethane with (R)-2-(((R)-1- tosyloxypropan- 2- yl)oxy)propyl 4- methylbenzene- sulfonate
    114
    Figure US20210101902A1-20210408-C00290
         		1H NMR (400 MHz, Methanol-d4) δ 8.51 (s, 1H), 6.88 (s, 1H), 5.03- 4.91 (m, 2H), 4.24 (s, 2H), 4.11 (s, 3H), 3.93 (s, 2H), 3.65 (s, 2H), 3.15- 3.07 (m, 2H), 3.04 (q, J = 7.3 Hz, 2H), 2.69 (s, 3H), 2.39 (s, 3H), 2.00-1.88 (m, 6H), 1.68-1.56 (m, 6H), 1.29 (t, J = 7.3 Hz, 3H). MS (ES+): 505.3 (M + 1)+ See Example 7 Replace dimethylglycine with ethylglycine
    115
    Figure US20210101902A1-20210408-C00291
         		1H NMR (400 MHz, Methanol-d4) δ 8.52 (s, 1H), 6.89 (s, 1H), 5.08- 4.91 (m, 2H), 4.25 (s, 2H), 4.12 (s, 3H), 3.98 (s, 2H), 3.18-3.05 (m, 4H), 2.70 (s, 3H), 2.52 (t, J = 6.5 Hz, 2H), 2.43 (s, 3H), 1.99-1.87 (m, 6H), 1.67- 1.54 (m, 6H). MS (ES+): 491.3 (M + 1)+. See example 7. Replace dimethylglycine with 3-((tert- butoxycarbonyl) amino)propa- noic acid
    116
    Figure US20210101902A1-20210408-C00292
         		1H NMR (400 MHz, Methanol-d4) δ 8.05 (s, 1H), 6.35 (s, 1H), 4.59 (s, 4H), 4.44 (s, 2H), 3.88 (d, J = 10.9 Hz, 5H), 3.62 (s, 2H), 3.40 (s, 4H), 2.79 (t, J = 5.4 Hz, 2H), 2.44 (s, 3H), 2.12 (s, 3H), 1.60- 1.27 (m, 12H). MS (ES+): 503.1 (M + 1)+. See Example 10 Replace Compound No. 26 with Compound No. 1
    117
    Figure US20210101902A1-20210408-C00293
         		1H NMR (400 MHz, Methanol-d4) δ 8.52 (s, 1H), 6.89 (s, 1H), 5.06- 4.92 (m, 2H), 4.25 (s, 2H), 4.12 (s, 3H), 3.98 (s, 2H), 3.69 (q, J = 6.2, 5.6 Hz, 1H), 3.20-3.06 (m, 2H), 2.70 (s, 3H), 2.62 (s, 3H), 2.42 (s, 3H), 2.00- 1.88 (m, 6H), 1.69-1.57 (m, 6H), 1.44 (d, J = 6.9 Hz, 3H). MS (ES+): 505.3 (M + 1)+. See example 7. Replace dimethylglycine with N-(tert- butoxycarbonyl)- N-methyl-D- alanine
    118
    Figure US20210101902A1-20210408-C00294
         		1H NMR (400 MHz, Methanol-d4) δ 8.53 (s, 1H), 6.90 (s, 1H), 5.10- 4.92 (m, 2H), 4.26 (s, 2H), 4.12 (s, 3H), 4.02 (s, 2H), 3.73-3.66 (m, 1H), 3.19-3.09 (m, 2H), 2.70 (s, 3H), 2.62 (s, 3H), 2.45 (s, 3H), 2.00-1.90 (m, 6H), 1.70-1.57 (m, 6H), 1.44 (d, J = 6.9 Hz, 3H). MS (ES+): 505.3 (M + 1)+ See example 7. Replace dimethylglycine with N-(tert- butoxycarbonyl)- N-methyl-L- alanine
    119
    Figure US20210101902A1-20210408-C00295
         		1H NMR (400 MHz, Methanol-d4) δ 8.06 (s, 1H), 7.66 (s, 1H), 7.13 (s, 1H), 6.85 (s, 1H), 6.36 (s, 1H), 4.45 (s, 2H), 3.90 (s, 5H), 3.71 (s, 2H), 2.83 (s, 2H), 2.45 (s, 3H), 2.14 (s, 3H), 1.93 (dd, J = 9.7, 6.0 Hz, 6H), 1.63 (dd, J = 9.7, 6.0 Hz, 6H). MS (ES+): 472.3 (M + 1)+ See Example 15
    120
    Figure US20210101902A1-20210408-C00296
         		1H NMR (400 MHz, Methanol-d4) δ 8.05 (s, 1H), 6.35 (s, 1H), 4.44 (s, 2H), 4.11 (s, 2H), 4.0 (s, 3H), 3.81 (m, 2H), 3.60 (s, 2H), 2.80 (dd, J = 10.6, 5.2 Hz, 2H), 2.44 (s, 5H), 2.29 (d, J = 10.7 Hz, 2H), 2.13 (s, 3H), 1.74 (d, J = 6.4 Hz, 2H), 1.41 (s, 12H). MS (ES+): 517.0 (M + 1)+ See Example 13 Replace 1,4- dibromobutane with ((2R,5S)- tetrahydrofuran- 2,5- diyl)bis(methyl- ene)bis(4- methylbenzene- sulfonate)
    121
    Figure US20210101902A1-20210408-C00297
         		1H NMR (400 MHz, Methanol-d4) δ 8.52 (s, 1H), 6.89 (s, 1H), 5.07- 4.93 (m, 2H), 4.25 (s, 2H), 4.12 (s, 3H), 3.98 (s, 2H), 3.66 (s, 2H), 3.13 (dt, J = 8.1, 3.2 Hz, 1H), 2.70 (s, 3H), 2.68 (s, 3H), 2.42 (s, 3H), 2.00-1.87 (m, 6H), 1.69-1.57 (m, 6H). MS (ES+): 491.3 (M + 1)+. See example 7. Replace dimethylglycine with N-(tert- butoxycarbonyl)- N- methylglycine
    122
    Figure US20210101902A1-20210408-C00298
         		1H NMR (400 MHz, Methanol-d4) δ 8.07 (s, 1H), 6.37 (s, 1H), 4.45 (s, 2H), 3.89 (d, J = 7.9 Hz, 5H), 3.72 (dd, J = 11.7, 3.2 Hz, 2H), 3.62 (s, 2H), 3.50 (td, J = 11.6, 2.4 Hz, 1H), 3.29 (dd, J = 11.6, 10.2 Hz, 1H), 2.80 (t, J = 5.6 Hz, 2H), 2.74 (d, J = 12.0 Hz, 1H), 2.68 (s, 1H), 2.45 (s, 3H), 2.30 (d, J = 10.0 Hz, 1H), 2.19 (s, 3H), 2.13 (s, 3H), 1.83- 1.72 (m, 6H), 1.53-1.42 (m, 6H). MS (ES+): 547.3 (M + 1)+. See example 7. Replace dimethylglycine with 4- methyl- morpholine-3- carboxylic acid
    123
    Figure US20210101902A1-20210408-C00299
         		1H NMR (400 MHz, Methanol-d4) δ 8.52 (s, 1H), 6.89 (s, 1H), 5.06- 4.92 (m, 2H), 4.25 (s, 2H), 4.12 (s, 3H), 3.98 (s, 2H), 3.12 (q, J = 5.7, 3.9 Hz, 2H), 2.90 (s, 2H), 2.70 (s, 3H), 2.39 (s, 3H), 1.96-1.81 (m, 6H), 1.79- 1.63 (m, 6H), 1.29 (s, 6H). MS (ES+): 492.3 (M + 1)+ See Example 14 Replace 1- bromo-2-(2- bromoethoxy) ethane with 2,2- dimethyloxirane
    124
    Figure US20210101902A1-20210408-C00300
         		1H NMR (400 MHz, Methanol-d4) δ 8.20 (s, 1H), 6.65 (s, 1H), 4.83 (m, 4H), 3.63 (s, 2H), 3.53 (s, 2H), 3.01- 2.84 (m, 4H), 2.54 (s, 3H), 2.15 (s, 3H), 1.84- 1.74 (m, 6H), 1.52-1.42 (m, 6H), 1.17 (t, J = 7.3 Hz, 3H). MS (ES+): 491.4 (M + 1)+. See Example 6 Replace HG1 with HG12
    125
    Figure US20210101902A1-20210408-C00301
         		1H NMR (400 MHz, Methanol-d4) δ 8.15 (s, 1H), 6.45 (s, 1H), 4.53 (s, 2H), 4.00 (s, 3H), 3.97 (t, J = 5.6 Hz, 2H), 3.90 (dt, J = 11.5, 2.4 Hz, 1H), 3.78 (dd, J = 10.7, 2.8 Hz, 1H), 3.72 (s, 2H), 3.63-3.54 (m, 1H), 3.10 (dd, J = 12.7, 2.8 Hz, 1H), 2.90 (t, J = 5.6 Hz, 2H), 2.78-2.72 (m, 2H), 2.54 (s, 4H), 2.23 (s, 3H), 1.92- 1.84 (m, 6H), 1.61- 1.54 (m, 6H). MS (ES+): 533.3 (M + 1)+. See Example 7 Replace dimethylglycine with 4-(tert- butoxycarbonyl) morpholine- 2-carboxylic acid
    126
    Figure US20210101902A1-20210408-C00302
         		1H NMR (400 MHz, Methanol-d4) δ 8.51 (s, 1H), 6.87 (s, 1H), 5.04- 4.93 (m, 1H), 5.03-4.95 (m, 0H), 4.95 (dddd, J = 5.4, 2.7, 2.1, 1.3 Hz, 1H), 4.24 (s, 2H), 4.11 (s, 3H), 3.91 (s, 2H), 3.17 (t, J = 6.6 Hz, 2H), 3.07 (p, J = 7.3, 6.7 Hz, 4H), 2.69 (s, 3H), 2.56 (t, J = 6.6 Hz, 2H), 2.37 (s, 3H), 1.97- 1.86 (m, 6H), 1.66-1.53 (m, 6H), 1.30 (t, J = 7.3 Hz, 3H). MS (ES+): 591.3 (M + 1)+. See Example 7 Replace dimethylglycine with 3- (ethylamino)pro- panoic acid
    127
    Figure US20210101902A1-20210408-C00303
         		1H NMR (400 MHz, Methanol-d4) δ 8.19 (d, J = 7.4 Hz, 1H), 7.90-7.83 (m, 2H), 7.72- 7.59 (m, 3H), 7.48 (s, 1H), 7.32 (d, J = 4.8 Hz, 1H), 4.70 (s, 2H), 4.08 (s, 2H), 3.79 (s, 2H), 3.03- 2.88 (m, 4H), 2.25 (s, 3H), 1.84-1.62 (m, 12H), 1.26 (t, J = 7.3 Hz, 3H). MS (ES+): 456.3 (M + 1)+. See example 6 Replace Compound No. 1 with Compound No. 63 and replace oxetan-3-one with acetaldehyde
    128
    Figure US20210101902A1-20210408-C00304
         		RT (method 1): 1.27 min. MS (ES+): 505.3 (M + 1)+. See Example 14 Replace 1- bromo-2-(2- bromoethoxy) ethane with (S)-1-chloro-3- (2- chloroethoxy)- 2- methylpropane
    129
    Figure US20210101902A1-20210408-C00305
         		NMR (DMSO-D6, 400 MHz, 1H) δ 8.72 (d, J = 5.2, 1H), 8.16 (d, J = 1.2, 1H), 8.00 (d, J = 2.3, 1H), 7.97 (dd, J = 1.8, 5.2, 1H), 7.93 (s, 3H), 7.84 (dd, J = 2.3, 8.7, 1H), 7.50 (s, 2H), 7.29 (d, J = 8.8, 1H), 3.81 (s, 2H), 1.82-1.55 (m, 12H); ESIMS MS (ES+): 505.3 (M + 1)+. See Example 14 Replace 1- bromo-2-(2- bromoethoxy) ethane with (R)-1-chloro-3- (2- chloroethoxy)- 2- methylpropane
    130
    Figure US20210101902A1-20210408-C00306
         		1H NMR (400 MHz, Methanol-d4) δ 8.19 (d, J = 7.4 Hz, 1H), 7.88-7.83 (m, 2H), 7.68- 7.62 (m, 3H), 7.48 (s, 1H), 7.32 (brs, 1H), 4.70 (s, 2H), 4.08 (brs, 2H), 3.79 (s, 2H), 3.58 (t, J = 5.0 Hz, 2H), 3.39 (s, 3H), 3.10 (t, J = 5.5 Hz, 2H), 2.92 (t, J = 5.4 Hz, 2H), 2.25 (s, 3H), 1.86-1.78 (m, 6H), 1.72-1.62 (m, 6H). MS (ES+): 486.4 (M + 1)+. See example 6 Replace Compound No. 1 with Compound No. 63 and replace oxetan-3-one with 2- methoxyacetal- dehyde
    131
    Figure US20210101902A1-20210408-C00307
         		1H NMR (400 MHz, Methanol-d4) δ 8.47 (s, 1H), 6.82 (s, 1H), 4.88 (s, 2H), 4.19 (t, J = 4.8 Hz, 2H), 4.15-4.06 (m, 7H), 3.76 (s, 2H), 3.60-3.50 (m, 1H), 3.00 (t, J = 5.4 Hz, 2H), 2.69 (s, 3H), 2.26 (s, 3H), 1.93- 1.84 (m, 6H), 1.63-1.53 (m, 6H). MS (ES+): 503.4 (M + 1)+. See Example 7 Replace dimethylglycine with 1-(tert- butoxycarbonyl) azetidine-3- carboxylic acid
    132
    Figure US20210101902A1-20210408-C00308
         		1H NMR (400 MHz, Methanol-d4) δ 8.16 (s, 1H), 6.46 (s, 1H), 4.55 (s, 2H), 4.00 (s, 3H), 3.98 (t, J = 5.5 Hz, 2H), 3.73 (s, 2H), 2.91 (t, J = 5.6 Hz, 2H), 2.88 (s, 2H), 2.55 (s, 3H), 2.47 (q, J = 7.2 Hz, 2H), 2.26 (s, 3H), 2.24 (s, 3H), 1.93-1.85 (m, 6H), 1.63-1.55 (m, 6H), 1.05 (t, J = 7.2 Hz, 3H). MS (ES+): 519.3 (M + 1)+. See Example 7 Replace dimethylglycine with N-ethyl- N- methylglycine
    133
    Figure US20210101902A1-20210408-C00309
         		RT (method 10: 1.04 min. MS (ES+): 535.3 (M + 1)+. See Example 29
    134
    Figure US20210101902A1-20210408-C00310
         		1H NMR (400 MHz, Methanol-d4) δ 8.05 (s, 1H), 6.35 (s, 1H), 4.44 (s, 2H), 3.90 (s, 3H), 3.87 (t, J = 5.6 Hz, 2H), 3.62 (s, 2H), 2.80 (t, J = 5.6 Hz, 2H), 2.73 (s, 2H), 2.44 (s, 3H), 2.13 (s, 3H), 1.82- 1.73 (m, 6H), 1.51-1.45 (m, 6H). MS (ES+): 511.3 (M + 1+. See Example 7 Replace dimethylglycine with N,N- Dimethyl-d6- glycine HCl salt
    135
    Figure US20210101902A1-20210408-C00311
         		RT (method 1): 1.05 min. MS (ES+): 478.3 (M + 1)+. See Example 30
    136
    Figure US20210101902A1-20210408-C00312
         		RT (method 10: 0.98 min. MS (ES+): 533.3 (M + 1)+. See Example 30
    137
    Figure US20210101902A1-20210408-C00313
         		1H NMR (400 MHz, Methanol-d4) δ 8.15 (s, 1H), 6.45 (s, 1H), 4.54 (s, 2H), 4.50-4.34 (m, 4H), 4.03-3.94 (m, 5H), 3.76 (s, 2H), 3.73 (s, 2H), 2.96-2.81 (m, 4H), 2.55 (s, 3H), 2.23 (s, 3H), 1.57 (m, 12H). MS (ES+): 520.4 (M + 1)+. See Example 14 Replace 1- bromo-2-(2- bromoethoxy) ethane with (3- (bromomethyl) oxetan-3- yl)methanol
    138
    Figure US20210101902A1-20210408-C00314
         		1H NMR (400 MHz, Methanol-d4) δ 8.53 (s, 1H), 6.90 (s, 1H), 4.97 (d, J = 15.5 Hz, 2H), 4.26 (s, 2H), 4.12 (s, 3H), 4.01 (s, 2H), 3.77 (s, 2H), 3.20- 3.09 (m, 2H), 2.95 (s, 3H), 2.88 (s, 3H), 2.70 (s, 3H), 2.45 (s, 3H), 1.98- 1.88 (m, 6H), 1.62 (dd, J = 10.1, 5.8 Hz, 6H). MS (ES+): 569.2 (M + 1)+. See Example 18 Replace Compound No. 1 with Compound No. 126
    139
    Figure US20210101902A1-20210408-C00315
         		1H NMR (400 MHz, Methanol-d4) δ 8.54 (s, 1H), 6.91 (s, 1H), 5.07- 4.95 (m, 2H), 4.27 (s, 2H), 4.12 (s, 3H), 4.03 (s, 2H), 3.94 (d, J = 14.3 Hz, 2H), 3.16 (q, J = 4.1, 2.9 Hz, 2H), 3.05 (s, 2H), 2.87 (s, 1H), 2.71 (s, 3H), 2.47 (s, 3H), 2.12 (s, 2H), 2.01 (s, 1H), 1.93 (ddd, J = 9.2, 5.5, 2.9 Hz, 6H), 1.62 (dt, J = 11.0, 5.3 Hz, 6H). MS (ES+): 533.3 (M + 1)+. See Example 7 Replace Compound No. 1 with Compound No. 126 and replace 2- (dimethylamino) acetic acid with acetic acid
    140
    Figure US20210101902A1-20210408-C00316
         		1H NMR (400 MHz, Methanol-d4) δ 8.51 (s, 1H), 6.88 (s, 1H), 5.04- 4.94 (m, 2H), 4.25 (s, 2H), 3.98 (s, 2H), 3.78- 3.56 (m, 2H), 3.11 (d, J = 5.1 Hz, 2H), 2.70 (s, 3H), 2.39 (s, 3H), 1.85-1.66 (m, 12H). MS (ES+): 423.3 (M + 1)+. See Example 16
    141
    Figure US20210101902A1-20210408-C00317
         		1H NMR (400 MHz, Methanol-d4) δ 8.49 (s, 1H), 6.82 (s, 1H), 4.87 (s, 2H), 4.47 (q, J = 7.2 Hz, 2H), 4.22-4.10 (m, 3H), 4.02-3.86 (m, 2H), 3.77-3.53 (m, 4H), 3.31-3.16 (m, 2H), 2.99 (t, J = 5.2 Hz, 2H), 2.67 (s, 3H), 2.25 (s, 3H), 1.93- 1.82 (m, 6H), 1.64-1.46 (m, 9H). MS (ES+): 547.4 (M + 1)+. See Example 8 Replace HG1 with HG13
    142
    Figure US20210101902A1-20210408-C00318
         		1H NMR (400 MHz, Methanol-d4) δ 8.53 (s, 1H), 6.90 (s, 1H), 5.06- 4.93 (m, 2H), 4.26 (s, 2H), 4.12 (s, 3H), 3.99 (s, 2H), 3.15 (dt, J = 10.7, 5.8 Hz, 4H), 2.69 (d, J = 5.5 Hz, 6H), 2.56 (t, J = 6.4 Hz, 2H), 2.44 (s, 3H), 1.99-1.88 (m, 6H), 1.67- 1.56 (m, 6H). MS (ES+): 505.3 (M + 1)+. See Example 7 Replace dimethylglycine with 3- (methylamino) propanoic acid
    143
    Figure US20210101902A1-20210408-C00319
         		1H NMR (400 MHz, Methanol-d4) δ 7.96 (s, 1H), 6.27 (s, 1H), 4.36 (s, 2H), 3.84 (s, 3H), 3.72 (m, 2H), 3.64 (m, 2H), 3.41 (s, 2H), 3.14 (m, 1H), 2.80 (m, 2H), 2.36 (s, 3H), 2.04 (s, 3H), 1.69- 1.26 (m, 11H). MS (ES+): 476.4 (M + 1)+. See example 6 Replace Compound No. 1 with Compound No. 81 and replace oxetan-3-one with cyclobutanone
    144
    Figure US20210101902A1-20210408-C00320
         		1H NMR (400 MHz, Methanol-d4) δ 8.22 (d, J = 6.1 Hz, 1H), 7.55 (d, J = 7.0 Hz, 2H), 7.46 (m, 3H), 7.25 (d, J = 2.4 Hz, 1H), 6.92 (dd, J = 6.1, 2.5 Hz, 1H), 4.39 (s, 2H), 3.82 (t, J = 5.5 Hz, 2H), 3.70 (s, 2H), 3.43 (m, 1H), 2.81 (t, J = 5.4 Hz, 2H), 2.23 (s, 3H), 2.11-2.01 (m, 2H), 1.78-1.64 (m, 2H), 1.62- 1.51 (m, 2H), 1.54 (m, 12H); MS 482.3 (M + 1), rt = 1.05 min See example 6 Replace Compound No. 1 with Compound No. 63 and replace oxetan-3-one with cyclobutanone
    145
    Figure US20210101902A1-20210408-C00321
         		RT (method 2): 2.24 min. MS 535.1 (M + 1) See Compound No. 157 Product of Step 1
    146
    Figure US20210101902A1-20210408-C00322
         		MS (ES+): 507.3 (M + 1)+ See Example 4
    147
    Figure US20210101902A1-20210408-C00323
         		1H NMR (400 MHz, DMSO-d6) δ 9.53 (s, 1H), 8.73 (d, J = 5.9 Hz, 1H), 8.34-7.92 (m, 2H), 7.39 (s, 1H), 4.68 (s, 2H), 4.03 (t, J = 5.2 Hz, 2H), 3.72 (s, 2H), 3.08 (s, 2H), 2.78 (s, 3H), 2.51 (s, 9H), 2.12 (s, 3H), 1.80-1.45 (m, 12H). ESIMS m/z 518.0 (M+ + 1) See Exmaple 3
    148
    Figure US20210101902A1-20210408-C00324
         		1H NMR (600 MHz, Methanol-d4) δ 8.16 (s, 1H), 6.47 (s, 1H), 4.56 (s, 2H), 4.08 (s, 2H), 4.00 (d, J = 4.9 Hz, 5H), 2.92 (t, J = 5.7 Hz, 2H), 2.55 (s, 3H), 2.24 (s, 3H), 1.80 (s, 2H), 1.7-1.59 (m, 7H), 1.40 (s, 10H). MS (ES+): 506.3 (M + 1)+. See Compound No. 44 Product of Step 1
    149
    Figure US20210101902A1-20210408-C00325
         		RT (method 1): 1.78 min. MS (ES+): 421.4 (M + 1)+ See Example 1 Replace (HG1) in step 1 with (HG17)
    150
    Figure US20210101902A1-20210408-C00326
         		1H NMR (400 MHz, Methanol-d4) δ 8.39 (s, 1H), 6.71 (s, 1H), 4.37 (q, J = 7.2 Hz, 2H), 4.09 (t, J = 5.1 Hz, 2H), 3.70 (s, 2H), 3.25 (m, 2H), 2.89 (t, J = 5.3 Hz, 2H), 2.56 (s, 3H), 2.15 (s, 3H), 1.78- 1.28 (m, 15H). MS (ES+): 434.6 (M + 1)+. See Example 1 Replace (HG1) in step 1 with (HG14)
    • Administration and Pharmaceutical Compositions
  • For the therapeutic uses of compounds of the invention, such compounds are administered in therapeutically effective amounts either alone or as part of a pharmaceutical composition. Accordingly, the present invention provides a pharmaceutical composition, which comprises a compound of the invention, or pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients. For purposes of the present invention, unless designated otherwise, solvates and hydrates are generally considered compositions. Preferably, pharmaceutically acceptable carriers are sterile.
  • The pharmaceutical composition of the present invention can be in unit dosage of about 1-1000 mg of active ingredient(s) for a subject of about 50-70 kg. The therapeutically effective dosage of a compound, the pharmaceutical composition, or the combinations thereof, is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated. A physician, clinician or veterinarian of ordinary skill can readily determine the effective amount of each of the active ingredients necessary to prevent, treat or inhibit the progress of the disorder or disease.
  • The above-cited dosage properties are demonstrable in vitro and in vivo tests using advantageously mammals, e.g., mice, rats, dogs, monkeys or isolated organs, tissues and preparations thereof. The compounds of the present invention can be applied in vitro in the form of solutions, e.g., aqueous solutions, and in vivo either enterally, parenterally, advantageously intravenously, e.g., as a suspension or in aqueous solution. The dosage in vitro may range between about 10-3 molar and 10-9 molar concentrations. A therapeutically effective amount in vivo may range depending on the route of administration, between about 0.1-500 mg/kg. The activity of a compound according to the present invention can be assessed by the following in vitro & in vivo methods.
  • The pharmaceutical compositions of the invention can be prepared using processes which include admixing a compound of the invention, or pharmaceutically acceptable salts thereof, with one or more pharmaceutically acceptable carriers, diluents or excipients. By way of example, the pharmaceutical compositions of the inventions are manufactured by mixing, granulating and/or coating methods using a compound of the invention in free form, or in a pharmaceutically acceptable salt form, in association with at least one pharmaceutically acceptable carrier, diluent or excipient.
  • The present invention further provides anhydrous pharmaceutical compositions and dosage forms comprising the compounds of the present invention as active ingredients, since water may facilitate the degradation of certain compounds.
  • Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions. An anhydrous pharmaceutical composition may be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions are packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e. g., vials), blister packs, and strip packs.
  • The invention further provides pharmaceutical compositions and dosage forms that comprise one or more agents that reduce the rate by which the compound of the present invention as an active ingredient will decompose. Such agents, which are referred to herein as “stabilizers,” include, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers, etc.
  • The pharmaceutical composition can be formulated for particular routes of administration such as oral administration, rectal administration, transdermal administration, parenteral, intravenous administration, intramuscular administration, pulmonary administration, inhalation administration, intranasal administration, ophthalmic administration and topical administration.
    • Oral Administration Dosage Forms
  • The pharmaceutical compositions of the invention can be administered orally as discrete dosage forms, wherein such dosage forms include, but are not limited to, capsules, gelatin capsules, caplets, tablets, chewable tablets, lozenges, dispersible powders, granules, syrups, flavored syrups, solutions or suspensions in aqueous or non-aqueous liquids, edible foams or whips, and oil-in-water liquid emulsions or water-in-oil liquid emulsions.
  • Accordingly, for oral administration the pharmaceutical compositions of the invention comprising an effective amount of a compound of the invention can be made up in a solid form (including without limitation capsules, gelatin capsules, hard or soft capsules, tablets, chewable tablets, lozenges, caplets, pills, granules or dispersible powders), or in a liquid form (including without limitation solutions, aqueous or oily suspensions, syrups, elixirs, foams, whips or emulsions). The pharmaceutical compositions can be subjected to conventional pharmaceutical operations such as sterilization and/or can contain conventional inert diluents, lubricating agents, or buffering agents, as well as adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers and buffers, etc.
  • Compositions intended for oral use are prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
  • Typically, the pharmaceutical compositions are tablets or gelatin capsules comprising the active ingredient together with one or more of:
      • a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine;
      • b) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also
      • c) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone; if desired
      • d) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and
      • e) absorbents, colorants, flavors and sweeteners.
  • Tablets may contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients are, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc. Tablets may be either film coated or enteric coated according to methods known in the art. The tablets are uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed. Formulations for oral use can be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
    • Parenteral Dosage Forms
  • In certain embodiments pharmaceutical compositions of the invention are administered parenterally by various routes including, but not limited to, subcutaneous, intravenous (including bolus injection), intramuscular, and intraarterial.
  • Certain injectable compositions are aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions. Said compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances. Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1-75%, or contain about 1-50%, of the active ingredient.
    • Topical Dosage Forms
  • In certain embodiments pharmaceutical compositions of the invention are administered by topical application of a pharmaceutical composition containing a compound of the invention in the form of a lotion, gel, ointment, solution, emulsion, suspension or cream.
  • Suitable compositions for topical application, e.g., to the skin and eyes, include aqueous solutions, suspensions, ointments, creams, gels or sprayable formulations, e.g., for delivery by aerosol or the like. Such topical delivery systems will in particular be appropriate for dermal application, e.g., for the treatment of skin cancer, e.g., for prophylactic use in sun creams, lotions, sprays and the like. They are thus particularly suited for use in topical, including cosmetic, formulations well-known in the art. Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
  • As used herein a topical application may also pertain to an inhalation or to an intranasal application. They may be conveniently delivered in the form of a dry powder (either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids) from a dry powder inhaler or an aerosol spray presentation from a pressurized container, pump, spray, atomizer or nebulizer, with or without the use of a suitable propellant.
    • Rectal Administration
  • In certain embodiments pharmaceutical compositions of the invention of the invention are administered rectally in the form of suppositories, enemas, ointment, creams rectal foams or rectal gels. In certain embodiments such suppositories are prepared from fatty emulsions or suspensions, cocoa butter or other glycerides.
    • Depot Administration
  • In certain embodiments pharmaceutical compositions of the invention of the invention are formulated as a depot preparation. Such formulations are administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. In certain embodiments, such formulations include polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
    • Combination Treatment
  • Compounds of the invention and pharmaceutical compositions provided herein are administered singly or in combination with one or more additional therapeutic agents.
  • The combination of the present invention can be in unit dosage of about 1-1000 mg of active ingredient(s) for a subject of about 50-70 kg. The therapeutically effective dosage of the combinations is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated. A physician, clinician or veterinarian of ordinary skill can readily determine the effective amount of each of the active ingredients necessary to prevent, treat or inhibit the progress of the disorder or disease.
  • The above-cited dosage properties are demonstrable in vitro and in vivo tests using advantageously mammals, e.g., mice, rats, dogs, monkeys or isolated organs, tissues and preparations thereof. The compounds of the present invention can be applied in vitro in the form of solutions, e.g., aqueous solutions, and in vivo either enterally, parenterally, advantageously intravenously, e.g., as a suspension or in aqueous solution. The dosage in vitro may range between about 10-3 molar and 10-9 molar concentrations. A therapeutically effective amount in vivo may range depending on the route of administration, between about 0.1-500 mg/kg. The activity of a compound according to the present invention can be assessed by the following in vitro & in vivo methods.
  • The compound of the present invention may be administered either simultaneously with, or before or after, one or more other therapeutic agent. The compound of the present invention may be administered separately, by the same or different route of administration, or together in the same pharmaceutical composition as the other agents. A therapeutic agent is, for example, a chemical compound, peptide, antibody, antibody fragment or nucleic acid, which is therapeutically active or enhances the therapeutic activity when administered to a patient in combination with a compound of the invention.
  • The invention provides a pharmaceutical composition comprising a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), and another therapeutic agent(s). Optionally, the pharmaceutical composition may comprise a pharmaceutically acceptable carrier, as described above.
  • The invention provides a product comprising a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), and at least one other therapeutic agent as a combined preparation for simultaneous, separate or sequential use in therapy. In one embodiment, the therapy is the treatment of an autoimmune disease or condition mediated by activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9), or any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9). Products provided as a combined preparation include a composition comprising the compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk) and the other therapeutic agent(s) together in the same pharmaceutical composition, or the compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk) and the other therapeutic agent(s) in separate form, e.g. in the form of a kit.
  • In an embodiment, the invention provides a product comprising a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), and at least one other therapeutic agent as a combined preparation for simultaneous, separate or sequential use in therapy. In one embodiment, the therapy is the treatment of an autoimmune disease or condition mediated by TLR7, TLR7 and TLR8 or TLR7, TLR8 and TLR9 activity. Products provided as a combined preparation include a composition comprising the compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk) and the other therapeutic agent(s) together in the same pharmaceutical composition, or the compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk) and the other therapeutic agent(s) in separate form, e.g. in the form of a kit.
  • The invention provides a product comprising a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), and at least one other therapeutic agent as a combined preparation for simultaneous, separate or sequential use in therapy. In one embodiment, the therapy is the treatment of an autoimmune disease or condition mediated by activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, or any combinations thereof. Products provided as a combined preparation include a composition comprising the compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk) and the other therapeutic agent(s) together in the same pharmaceutical composition, or the compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk) and the other therapeutic agent(s) in separate form, e.g. in the form of a kit.
  • In one embodiment, the invention provides a kit comprising two or more separate pharmaceutical compositions, at least one of which contains a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk). In one embodiment, the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is a blister pack, as typically used for the packaging of tablets, capsules and the like.
  • The kit of the invention may be used for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another. To assist compliance, the kit of the invention typically comprises directions for administration.
  • In the combination therapies of the invention, the compound of the invention and the other therapeutic agent may be manufactured and/or formulated by the same or different manufacturers. Moreover, the compound of the invention and the other therapeutic may be brought together into a combination therapy: (i) prior to release of the combination product to physicians (e.g. in the case of a kit comprising the compound of the invention and the other therapeutic agent); (ii) by the physician themselves (or under the guidance of the physician) shortly before administration; (iii) in the patient themselves, e.g. during sequential administration of the compound of the invention and the other therapeutic agent.
  • In certain embodiments of the combination therapies described herein, the compound of the invention and the additional therapeutics agent(s) act additively. In certain embodiments of the combination therapies described herein, the compound of the invention and the additional therapeutics agent(s) act synergistically.
  • The additional therapeutic agents used in combination with a compound of the invention, include, but are not limited to anti-inflammatory agents, immunomodulatory agents, immunosuppressive agents, cytokines, nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarial compounds, anti-rheumatic compounds, inhibitors of B-cell activating factor (BAFF), inhibitors of B-lymphocyte stimulator (BLyS), and steroid hormones.
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) used in combination with compounds of the invention, include, but are not limited to, salicylic acid, acetylsalicylic acid, methyl salicylate, diflunisal, salsalate, olsalazine, sulfasalazine, acetaminophen, indomethacin, sulindac, etodolac, mefenamic acid, meclofenamate sodium, tolmetin, ketorolac, dichlofenac, ibuprofen, naproxen, naproxen sodium, fenoprofen, ketoprofen, flurbinprofen, oxaprozin, piroxicam, meloxicam, ampiroxicam, droxicam, pivoxicam, tenoxicam, nabumetome, phenylbutazone, oxyphenbutazone, antipyrine, aminopyrine, apazone and nimesulide.
  • Anti-rheumatic compound used in combination with compounds of the invention, include, but are not limited to, methotrexate.
  • Antimalarial compound used in combination with compounds of the invention, include, but are not limited to, chloroquine and hydroxycloroquine.
  • Inhibitors of B-cell activating factor (BAFF), also known as inhibitors of B-lymphocyte stimulator (BLyS), used in combination with compounds of the invention, include, but are not limited to, belimumab (Benlysta®), Blisibimod and BR3-Fc.
  • Immunosuppressive agents used in combination with compounds of the invention, include, but are not limited to, mycophenolate mofetil (MMF), mycophenolic acid, cyclophosphamide, azathioprine and Laquinimod (5-chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide).
  • Steroid hormones used in combination with compounds of the invention, include, but are not limited to, dehydroepiandrosterone (DHEA).
  • Certain aspects of the pharmaceutical compositions and combinations of the invention are provided in the following listing of additional, enumerated embodiments. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of the present invention.
    • Embodiment 93. A pharmaceutical composition comprising a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
    • Embodiment 94. A pharmaceutical composition comprising a compound of Formula (I) or Formula (Ia to Ip), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
    • Embodiment 95. A pharmaceutical composition comprising a compound of Formula (II) or Formula (IIa to IIk), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
    • Embodiment 96. A pharmaceutical composition comprising a compound of Formula (A), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
    • Embodiment 97. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
    • Embodiment 98. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I) or Formula (Ia to Ip), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
    • Embodiment 99. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (II) or Formula (IIa to IIk), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
    • Embodiment 100. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (A), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
    • Embodiment 101. The pharmaceutical composition of the invention further comprising one or more additional therapeutically agents independently selected from anti-inflammatory agents, immunomodulatory agents, immunosuppressive agents, cytokines, nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarial compounds, anti-rheumatic compounds, inhibitors of B-cell activating factor (BAFF), inhibitors of B-lymphocyte stimulator (BLyS), and steroid hormones.
    • Embodiment 102. A combination comprising a therapeutically effect amount of a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), or a pharmaceutically acceptable salt thereof, and one or more additional therapeutically agents and optionally further comprising a pharmaceutically acceptable carrier, wherein the additional therapeutically agent is independently selected from anti-inflammatory agents, immunomodulatory agents, immunosuppressive agents, cytokines, nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarial compounds, anti-rheumatic compounds, inhibitors of B-cell activating factor (BAFF), inhibitors of B-lymphocyte stimulator (BLyS), and steroid hormones.
    Pharmacology and Utility
  • Compounds of the invention are generally inhibitors of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9), or any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9), and may therefore be useful in the treatment of autoimmune diseases associated with the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9), or any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9). Accordingly, compounds of the invention may be useful in the treatment of autoimmune diseases, including systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • Compounds of the invention are typically inhibitors of TLR7, TLR7 and TLR8, or TLR7 and TLR8 and TLR9, and may therefore useful in the treatment of autoimmune diseases associated with TLR7 activity, TLR7 and TLR8 activity, or TLR7 and TLR8 and TLR9 activity. Accordingly, compounds of the invention may be useful in the treatment of autoimmune diseases, including systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • In addition, compounds of the invention are generally inhibitors of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, or any combinations thereof, and may therefore be useful in the treatment of autoimmune diseases associated with the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, or any combinations thereof. Accordingly, compounds of the invention may be useful in the treatment of autoimmune diseases, including systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • The compounds of the invention, in free form or in pharmaceutically acceptable salt form, exhibit valuable pharmacological properties, e.g. as indicated in vitro and in vivo tests as provided herein, and are therefore indicated for therapy or for use as research chemicals, e.g. as tool compounds.
  • Thus, as a further embodiment, the present invention provides the use of a compound of the invention in therapy, wherein the therapy is the treatment of an autoimmune disease which may be treated by inhibition of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9), or any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9). In another embodiment, the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • In a further embodiment, the therapy is the treatment of an autoimmune disease which may be treated by inhibition of TLR7, TLR7 and TLR8, or TLR7 and TLR8 and TLR9. In another embodiment, the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • A further embodiment, the present invention provides the use of a compound of the invention in therapy, wherein the therapy is the treatment of an autoimmune disease which may be treated by inhibition of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, and any combinations thereof. In another embodiment, the autoimmune disease is selected from an autoimmune disease like systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • In another embodiment, the invention provides a method of treating an autoimmune disease which is treated by inhibition of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9), or any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9), wherein the method comprises administration of a therapeutically acceptable amount of a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk). In a further embodiment, the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • In another embodiment, the invention provides a method of treating an autoimmune disease which is treated by inhibition of TLR7, TLR7 and TLR8 or TLR7 and TLR8 and TLR9, wherein the method comprises administration of a therapeutically acceptable amount of a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk). In a further embodiment, the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • In another embodiment, the invention provides a method of treating an autoimmune disease which is treated by inhibition of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, or any combinations thereof, wherein the method comprises administration of a therapeutically acceptable amount of a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk). In a further embodiment, the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • Thus, as a further embodiment, the present invention provides the use of a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk) in the manufacture of a medicament for the treatment of an autoimmune disease associated the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9), or any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9). In another embodiment, the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • In a further embodiment, the present invention provides the use of a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk) in the manufacture of a medicament for the treatment of an autoimmune disease associated with the activity of TLR7, TLR7 and TLR8 or TLR7 and TLR8 and TLR9. In another embodiment, the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • As a further embodiment, the present invention provides the use of a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk) in the manufacture of a medicament for the treatment of an autoimmune disease associated the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, or any combinations. In another embodiment, the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
  • Certain aspects of the uses of the compounds of the invention and of the methods of treatment of the invention are provided in the following listing of additional, enumerated embodiments. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of the present invention.
    • Embodiment 103. A method for treating an autoimmune disease associated with the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9), or any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9), wherein the method includes administering to a subject in need of such treatment an effective amount of a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), or pharmaceutically acceptable salt thereof, thereby treating the disease.
    • Embodiment 104. A method for treating an autoimmune associated with the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9), or any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9), wherein the method includes administering to a subject in need of such treatment an effective amount of a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), or pharmaceutically acceptable salt thereof and wherein the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
    • Embodiment 105. A method for treating an autoimmune disease associated with the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, or any combinations thereof, wherein the method includes administering to a subject in need of such treatment an effective amount of a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), or pharmaceutically acceptable salt thereof, thereby treating the disease.
    • Embodiment 106. A method for treating an autoimmune disease associated with the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, or any combinations thereof, wherein the method includes administering to a subject in need of such treatment an effective amount of a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), or pharmaceutically acceptable salt thereof and wherein the autoimmune is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
    • Embodiment 107. A method for treating an autoimmune disease associated with
      • i) TLR7 activity, or
      • ii) TLR7 activity and TLR8 activity, or
      • iii) TLR7 activity and TLR8 activity and TLR9 activity,
        wherein the method includes administering to a subject in need of such treatment an effective amount of a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), or pharmaceutically acceptable salt thereof, thereby treating the disease.
    • Embodiment 108. A method for treating an autoimmune disease associated with
      • i) TLR7 activity, or
      • ii) TLR7 activity and TLR8 activity, or
      • iii) TLR7 activity and TLR8 activity and TLR9 activity,
    • wherein the method includes administering to a subject in need of such treatment an effective amount of a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), or pharmaceutically acceptable salt thereof, and wherein the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
    • Embodiment 109. A compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), or pharmaceutically acceptable salt thereof, for treating an autoimmune disease associated with the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9), or any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9.
    • Embodiment 110. A compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), or pharmaceutically acceptable salt thereof, for treating an autoimmune disease associated with the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9), or any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9), wherein the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
    • Embodiment 111. A compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), or pharmaceutically acceptable salt thereof, for treating an autoimmune disease associated with the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, or any combinations thereof.
    • Embodiment 112. A compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), or pharmaceutically acceptable salt thereof, for treating an autoimmune disease associated with the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, or any combinations thereof, wherein the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
    • Embodiment 113. A compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), or pharmaceutically acceptable salt thereof, for treating an autoimmune disease associated with
      • i) TLR7 activity, or
      • ii) TLR7 activity and TLR8 activity, or
      • iii) TLR7 activity and TLR8 activity and TLR9 activity,
        wherein the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
    • Embodiment 114. A compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), or pharmaceutically acceptable salt thereof, for use in treating an autoimmune disease associated with the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9), or any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9.
    • Embodiment 115. A compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), or pharmaceutically acceptable salt thereof, for use in treating an autoimmune disease associated with the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9), or any combinations thereof (including, but not limited to, TLR7/8, TLR7/8/9, TLR7/9, and TLR8/9), wherein the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
    • Embodiment 116. A compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), or pharmaceutically acceptable salt thereof, for use in treating an autoimmune disease associated with the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, or any combinations thereof.
    • Embodiment 117. A compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), or pharmaceutically acceptable salt thereof, for use in treating an autoimmune disease associated with the activity of an endosomal Toll-like receptor (e.g. TLR7, TLR8 or TLR9) pathway, or any combinations thereof, wherein the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
    • Embodiment 114. A compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), or pharmaceutically acceptable salt thereof, for use in treating a disease associated with
      • i) TLR7 activity, or
      • ii) TLR7 activity and TLR8 activity, or
      • iii) TLR7 activity and TLR8 activity and TLR9 activity,
        wherein the disease is an autoimmune disease.
    • Embodiment 115. Use of a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an autoimmune disease where TLR7 activity, TLR7 and TLR8 activity, or TLR7 and TLR8 and TLR9 activity, are implicated.
    • Embodiment 116. Use of a compound of Formula (A), Formula (I), Formula (II), Formula (Ia to Ip) or Formula (IIa to IIk), or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an autoimmune disease, wherein the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
    Assays
  • Compounds of the invention were assayed in the assays described in the following paragraphs.
    • Test Compound Preparation
  • Compounds were generally serially diluted (⅓) in DMSO and plated on sterile 384 well tissue culture plates and stored until ready for use. Each ten-point dilution was typically plated in triplicate in parallel rows.
    • TLR7, TLR8 and TLR9 Antagonist Assays in Human PBMC's PBMC Isolation
  • Fresh blood was collected from normal human donors under written informed consent in heparinized syringes on the morning of the assay. The blood was diluted in RPMI-1640 medium and the white blood cells were separated from red blood cells by centrifugation (800 g 15′0 acceleration, 0 brake) on a Ficoll cushion. Peripheral blood mononuclear cells (PBMCs) were separated from platelets by a series of low-speed centrifugations (1000 RPM 10′) in PBS+5% HI-FBS and 1 mM EDTA. Purified PBMCs were re-suspended in assay medium (RPMI-1640 w Glutamax (Invitrogen) supplemented with 5% HI-FBS, 10 mM HEPES, 50 uM β-mercaptoethanol, and 100 mG/L penicillin/streptomycin cocktail). Viable PBMCs were counted on a hemacytometer and kept on ice until ready for plating.
    • Agonist Treatment Bulk Transfection
  • A 4× concentration (4 ug/ml or 40 ug/ml for TLR8 or TLR7 assays, respectively) of the TLR7/8 agonist ssRNA40 (IDT) was complexed with 10% DOTAP (Roche) in assay medium for 30 min prior to addition to the PBMC suspension (5 million cells/ml). After addition, the final concentration of ssRNA40 in the TLR7/8 stimulated PBMC suspension was 1 μg/ml for TLR8 assay, and 10 g/mL for the TLR7 assay. The final DOTAP concentration was 2.5%. Diluted PBMCs (5 million cells/ml) were treated with 4×TLR9 agonist ODN2216 (Invivogen). Final concentration of ODN2216 in TLR9 stimulated PBMC suspension was 0.3 μM.
    • PBMC Plating and Compound Treatment
  • Agonist stimulated PBMCs were plated on the compound treated 384 well plates at 150,000 cells/well. Un-stimulated PBMCs were plated as controls on each plate. Plating volume was 40 μL per well. DMSO concentration in each well was 0.25%.
  • A separate plate, without compounds, with titrations of ssRNA40 and ODN2216 was included in every assay to measure agonist response of each donor's PBMC prep. Assay plates were placed in a tissue culture incubator (37° C., 5% CO2) for 14-16 hrs. After this incubation, the plates were centrifuged and stored at −20° C. until they were assayed.
    • IL-6 TR-FRET Assay for TLR8 Activity:
  • 1) Cisbio Human IL-6 kit, 20,000 tests (62TNFPEC), and GNF High-Base TC 384 well plates (cat #789163G) were used;
    2) the Anti-TIL-6 Cryptate conjugate and the Anti-IL-6 XL665 conjugate were diluted 1:20 in Reconstitution Buffer;
    3) a 1:1 mixture of 3 μl/well Anti-IL-6 Cryptate conjugate and 3 μl/well Anti-IL-6 XL665 conjugate was prepared;
    4) 6 μl/well HTRF dilution mastermix was added to 6 μl of transferred supernatant samples in proxiplates;
    5) The plates were incubated for 3 hrs at rt in the dark; and
    6) the levels of IL-6 production was measured using an Envision plate reader (665 nm (emmission)/590 nm (excitation)) with HTRF settings and ratiometric read-out: (XL665 emission/Eu Cryptate emission)×10,000.
    • IFNα2b AlghaLISA Assay for TLR7 or TLR9 Activity
  • After thawing the assay plates, 6 μL of supernatant samples were transferred to a low-volume AlphaPlate 384SW (Perkin-Elmer). The concentration of IFNα in supernatants was measured using the IFNα2b AlphaLISA Assay (Perkin-Elmer: AL297F). 3 μL of IFNα acceptor beads/biotinylated antibody solution was added first, using laboratory automation. After an hour incubation, 3 μL of streptavidin acceptor bead solution was added. The plates containing this mixture were incubated in the dark for an hour and read on an appropriate plate reader at reading parameters set by the manufacturer. (Envision, EnSpire: Perkin-Elmer).
    • THP-1 TLR8 Antagonist TNFalpha TR-FRET Assay Cell-Based Assay:
  • 1) THP-1 cells were cultured in RPMI 1640 with 10% FBS, 10 mM HEPES, 1 mM Sodium Pyruvate, 1% Penicillin-Streptomycin L-glutamine, and 1% Non-Essential Amino Acids;
    2) 3 sets of different passages of THP-1 cells in assay media were pooled, counted, and resuspended in the same media as culture media, but with 5% FBS;
    3) Cells were diluted to 100,000 cells/well (30 μl/well) and the R848 agonist was diluted to 25 μM in 10 ul/well in media;
    4) The cell and agonist dilutions were combined and 40 μl/well were added to 384-well flat bottom Greiner assay plates containing test compounds in DMSO, which were Echo pre-spotted at 50 nL per well with a 8 mM top dose and 10 point 1:3 serial dilutions—10 M final top dose;
    5) The plates were incubated overnight for 18-20 hrs at 37 degrees with 5% CO2;
    6) The plates were then centrifuged at 1000 rpm for 2 min at rt;
    7) 10 g/well of supernatants were transferred to 384-well low volume white Greiner proxiplates; and
    8) TNFα levels were measured using the TR-FRET assay described below.
    • TNFalpha TR-FRET Assay:
  • 1) Cisbio Human TNFalpha kit, 20,000 tests (62TNFPEC), and Greiner Bio-One LIA-white TC 384 well small volume plates (cat #784080) were used;
    2) the Anti-TNFalpha Cryptate conjugate and the Anti-TNFalpha XL665 conjugate were diluted 1:20 in Reconstitution Buffer;
    3) a 1:1 mixture of 5 μl/well Anti-TNFalpha Cryptate conjugate and 5 μl/well Anti-TNFalpha XL665 conjugate was prepared;
    4) 10 μl/well HTRF dilution mastermix were added to 10 g of transferred supernatant samples in proxiplates;
    5) The plates were incubated for 3 hrs at rt in the dark; and
    6) the levels of TNFalpha production was measured using an Envision plate reader (665 nm (emmission)/590 nm (excitation)).
  • Various compounds of the invention, in free form or in pharmaceutically acceptable salt form, exhibit pharmacological properties, for example, as indicated by the assay results presented in Table 7. The IC50 values are given as the concentration of the test compound in question that provoke a response halfway between the baseline and maximum responses. Dashes (---) in Table 7 mean that no tests were conducted.
  • TABLE 7
    Assay Results
    huPBMC TLR7 huPBMC TLR8 huPBMC TLR9
    Antagonist Antagonist Antagonist
    Compound IFNα Assay IL-6 TR-FRET Assay IFNα Assay
    No. IC50 (μM) IC50 (μM) IC50 (μM)
    1 0.025 0.236 1.519
    2 0.038 >10 3.134
    3 0.054 0.055 1.934
    4 — 0.511 —
    5 0.397 0.433 —
    6 0.019 0.135 1.386
    7 — 0.061 —
    8 0.004 0.166 4.28
    9 0.015 0.201 5.1
    10 0.056 0.048 >10
    11 0.318 — >6.58
    12 0.841 — >4.96
    13 0.042 1.348 7.75
    14 0.241 — >9.09
    15 0.288 0.203 1.27
    16 0.025 0.443 >10
    17 0.258 0.199 >10
    18 0.245 0.077 >10
    19 0.055 0.186 >10
    20 0.025 0.031 >9.38
    21 0.024 0.036 >10
    22 0.033 0.014 >10
    23 0.666 0.373 >10
    24 0.201 0.01 >7.38
    25 0.565 0.017 >8.08
    26 0.644 0.289 >10
    27 0.015 0.014 >10
    28 0.84 0.641 >10
    29 0.073 0.016 >10
    30 0.01 0.324 >10
    31 0.013 0.027 2.34
    32 0.124 0.125 —
    33 0.055 0.072 >10
    34 0.013 0.029 5.7
    35 0.014 >10 >10
    36 0.007 0.08 4.97
    37 0.159 0.079 >10
    38 0.042 0.031 >10
    39 0.06 0.119 >10
    40 0.07 0.314 2.517
    41 0.006 4.59 0.817
    42 0.017 >10 0.472
    43 0.016 0.051 0.511
    44 0.038 0.861 1.214
    45 0.038 0.63 2.056
    46 0.056 >10 >10
    47 0.004 >10 >10
    48 0.013 >10 >10
    49 0.02 >10 3.95
    50 0.006 0.308 0.376
    51 0.007 >10 7.55
    52 0.304 >10 4.86
    53 0.843 1.14 1.73
    54 0.004 0.074 0.489
    55 0.005 0.42 1.054
    56 0.007 0.292 0.68
    57 0.007 0.11 0.497
    58 0.003 0.053 0.639
    59 0.004 0.052 2.168
    60 1.028 0.277 —
    61 0.012 0.129
    62 — 0.699 —
    63 0.034 0.568 —
    64 0.004 0.115 0.443
    65 — 2.356 —
    66 — 1.13 —
    67 0.005 0.011 —
    68 — 0.155 —
    69 0.009 0.031 0.442
    70 — 0.379 —
    71 0.005 0.014 0.488
    72 0.037 0.102 0.815
    73 — 0.139 —
    74 0.007 0.158 1.542
    75 0.011 0.134 0.963
    76 — 0.201 —
    77 0.01 0.316 0.179
    78 — 0.474 —
    79 0.004 0.136 0.064
    80 0.002 0.466 0.249
    81 — 0.395 —
    82 — 0.486 —
    83 — 0.865 —
    84 0.302 0.831 1.836
    85 0.046 0.224 0.569
    86 0.081 0.048 2.741
    87 — 1.095 —
    88 — 0.715 —
    89 — 0.622 —
    90 — 1.007 —
    91 0.022 0.377 0.215
    92 0.16 0.04 0.094
    93 — 0.983 —
    94 — 1.106 —
    95 — 0.085 —
    96 — 0.775 —
    97 — 0.089 —
    98 — 0.718 —
    99 0.04 0.13 2.841
    100 0.005 0.015 1.365
    101 0.039 0.071 2.642
    102 0.022 0.366 1.239
    103 — 1.421 —
    104 0.061 0.389 >10
    105 0.014 0.027 1.63
    106 0.063 0.168 2.661
    107 0.011 0.006 1.71
    108 0.021 0.044 8.64
    109 0.012 0.016 0.515
    110 0.007 0.016 1.901
    111 0.028 0.039 1.409
    112 0.024 0.056 1.186
    113 0.053 0.016 1.407
    114 0.01 0.015 1.554
    115 0.01 0.245 >10
    116 0.009 0.068 1.574
    117 0.002 0.236 0.954
    118 0.002 0.197 0.775
    119 0.006 1.182 0.608
    120 0.004 0.02 —
    121 0.005 0.039 1.438
    122 — 0.922 —
    123 0.024 0.121 2.226
    124 1.038 >10 >10
    125 0.004 0.043 0.909
    126 0.02 0.153 9.53
    127 0.259 1.428 0.545
    128 0.006 0.013 0.792
    129 0.008 0.012 1.055
    130 1.327 2.832 0.672
    131 0.003 0.361 >10
    132 <0.000508 0.008 0.26
    133 0.012 0.806 1.14
    134 0.001 0.093 0.299
    135 0.01 8.44 >10
    136 0.006 0.178 1.169
    137 0.072 0.068 1.279
    138 0.006 2.792 —
    139 0.067 3.54 —
    140 0.027 0.331 1.803
    141 0.032 2.289 5.17
    142 0.047 0.932 >6.59
    143 0.041 0.687 0.841
    144 0.073 0.105 0.139
    145 0.061 >10 —
    146 0.236 — —
    147 0.033 >10 6.24
    148 0.054 >10 >10
    149 — 0.695 —
    150 — 4.203 —
  • TABLE 8
    Assay Results
    THP-1 TLR8
    Antagonist
    Compound TR-FRET Assay
    No. IC50 (μM)
    11 8.23
    12 >10
    14 >10
  • It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims.

Claims (24)

We claim:
1. A compound having the structure of Formula (A) or a pharmaceutically acceptable salt thereof:
Figure US20210101902A1-20210408-C00327
wherein:
RA is
Figure US20210101902A1-20210408-C00328
L is —CH2— or —CH2CH2—;
Y1 is —CH2— or —CH2CH2—;
Y2 is —CH2— or —CH2CH2—;
Y3 is —CH2—, —XCH2— or —CH2X—;
X is —CH2— or O;
R1 is —NHC(═O)R6, —NHC(═O)(CH2)nR6, —NH(CH2)nC(═O)R6, —NHC(═O)(CH2)mNHR5, —NHC(═O)(CH2)mN(R5)2, —NHC(═O)(CHR9)mNHR5, —NHC(═O)(CH2)mNH2, —NHC(═O)(CH2)nOR9, —NHC(═O)OR9, —NH(CH2)mC(═O)N(R5)2, —NH(CHR9)nC(═O)R6, NHC(═O)(CHR9)nR6, —NHC(═O)(CHR9)nN(R8)2, —NHC(═O)(CHR9)nNHR8, —NH(CHR9)nC(═O)N(R8)2, —NH(CHR9)mC(═O)R6, —NHR6, —NR5R6, —NH2, —N(R5)2, —NHR5, —NHR8, —N(R6R8), —NH(C(R9)2)nR10, —NR9C(═O)OR11, —NH(CH2)nR6, —NH(CHR9)nR6, —N(R6)2, —NHC(═O)(CH2)nN(CD3)2, —NH(CHR9)nCH2OR9, —NHCH2(CHR9)nOR9, —NH(CHR9)nOR9, —NR9(CH2)nOR9, —NHCH2(C(R9)2)nOR9, —OR9, —NR9C(═O)R5, —NR9C(═O)(CH2)nR5, —NR9C(═O)OR5, —NHS(═O)2R5, —NHC(═O)(CH2)nNR9C(═O)R5, —NHC(═O)(CH2)nNR9S(═O)2R5,
Figure US20210101902A1-20210408-C00329
an 8-oxa-3-azabicyclo[3.2.1]octanyl, a 5-6 membered heteroaryl having 1 to 3 ring members independently selected from N, O and S, or a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR16 and O which is unsubstituted or is substituted with 1-2 R7 groups;
R2 is H, C1-C6alkyl, C1-C6haloalkyl or C1-C6alkyl substituted with 1-2 R15 groups;
R3 is H, C1-C6alkyl, —CD3 or benzyl substituted with 1-2 R10 groups;
R4 is H, NH2, C1-C6alkyl, halo or a phenyl substituted with 0-2 R18 groups;
each R5 is independently selected from C1-C6alkyl, —CD3 and —(CH2)nOR9;
R6 is a C3-C6cycloalkyl, an oxa-3-azabicyclo[3.2.1]octane or a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR16 and O which is unsubstituted or is substituted with 1-2 R12 groups;
each R7 is independently selected from C1-C6alkyl, halo, hydroxyl, oxo and a C1-C6alkyl substituted with 1 to 3 —OH;
each R8 is independently selected from C1-C6haloalkyl, —(C(R9)2)nOR9 and a C1-C6alkyl substituted with 1 to 3 —OH;
each R9 is independently selected from H and C1-C6alkyl;
R10 is C1-C6alkoxy or C3-C6cycloalkyl;
R11 is a C3-C6cycloalkyl which is unsubstituted or is substituted with 1 to 3 C1-C6alkyl groups;
each R12 is independently selected from C1-C6alkyl, hydroxyl, halo and a C1-C6alkyl substituted with 1 to 3 —OH;
R13 is H or C1-C6alkyl;
R14 is H or C1-C6alkyl;
R15 is —NHC(═O)(CH2)mNHR5, —NHC(═O)(CH2)mN(R5)2, —NHC(═O)(CH2)mNH2, —NHC(═O)(CHR9)nR6, —NHC(═O)(CHR9)nN(R8)2, —NHC(═O)(CHR9)nNHR8, —NH(CHR9)nC(═O)N(R8)2, —NH(CHR9)nC(═O)R6, —NHR6, —NH2, —N(R5)2, —NHR8, —N(R6R8), —NH(C(R9)2)nR10, —NR9C(═O)OR11, —NH(CHR9)nR6, —N(R6)2, —N(CD3)2, —NH(CHR9)nOR9 or —NHCH2(C(R9)2)nOR9;
each R16 is C1-C6alkyl;
each R7 is independently selected from H and C1-C6alkyl;
each R18 is independently selected from halo, —CN, C1-C6alkoxy and C1-C6alkyl;
m is 1, 2, 3, 4, 5 or 6, and
n is 1, 2, 3, 4, 5 or 6.
2. The compound of claim 1 having the structure of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof:
Figure US20210101902A1-20210408-C00330
wherein Y1, Y2, Y3, L, R1, R2 and RA are as defined in claim 1.
3. The compound of claim 1 or claim 2, wherein the compound of Formula (A) or compound of Formula (I) has the structure of Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), Formula (If), Formula (Ig), Formula (Ih), Formula (Ii), Formula (Ij) or Formula (Ik), or a pharmaceutically acceptable salt thereof:
Figure US20210101902A1-20210408-C00331
Figure US20210101902A1-20210408-C00332
Figure US20210101902A1-20210408-C00333
wherein Y1, Y2, Y3, L, R1, R2, R3, R4, R13 and R14 are as defined in claim 1.
4. The compound of claim 1 or claim 2, wherein the compound of Formula (A) or compound of Formula (II) has the structure of Formula (IIa), Formula (IIb), Formula (IIc), Formula (IId), Formula (IIe), Formula (IIf), Formula (IIg), Formula (IIh), Formula (IIi), Formula (IIj) or Formula (IIk), or a pharmaceutically acceptable salt thereof:
Figure US20210101902A1-20210408-C00334
Figure US20210101902A1-20210408-C00335
Figure US20210101902A1-20210408-C00336
wherein Y1, Y2, Y3, L, R1, R2, R3, R4, R13 and R14 are as defined in claim 1.
5. The compound of any one of claims 1 to 4, wherein:
R1 is —NHC(═O)R6, —NHC(═O)(CH2)nR6, —NH(CH2)nC(═O)R6, —NHC(═O)(CH2)mNHR5, —NHC(═O)(CH2)mN(R5)2, —NHC(═O)(CHR9)mNHR5, —NHC(═O)(CH2)mNH2, —NHC(═O)(CH2)nOR9, —NHC(═O)OR9, —NH(CH2)mC(═O)N(R5)2, —NH(CHR9)mC(═O)R6, —NHR6, —NR5R6, —NH2, —N(R5)2, —NHR5, —NHR8, —NR9C(═O)OR11, —NH(CH2)nR6, —N(R6)2, —NHC(═O)(CH2)nN(CD3)2, —NH(CHR9)nCH2OR9, —NHCH2(CHR9)nOR9, —NH(CHR9)nOR9, —NR9(CH2)nOR9, —NHCH2(C(R9)2)nOR9, —OR9, —NR9C(═O)R5, —NR9C(═O)OR5, —NHS(═O)2R5, —NHC(═O)(CH2)nNR9C(═O)R5, or —NHC(═O)(CH2)nNR9S(═O)2R5.
6. The compound of any one of claims 1 to 4, wherein:
R1 is —NHC(═O)R6, —NHC(═O)(CH2)nR6, —NH(CH2)nC(═O)R6, —NHC(═O)(CH2)mNHR5, —NHC(═O)(CH2)mN(R5)2, —NHC(═O)(CHR9)mNHR5, —NHC(═O)(CH2)mNH2, —NH(CH2)mC(═O)N(R5)2, —NH(CHR9)nC(═O)R6, —NHR6, —NH2, —N(R5)2, —NHR5, —NHR8, —NH(CHR9)nOR9 or —NHCH2(C(R9)2)nOR9.
7. The compound of any one of claims 1 to 4, wherein:
R1 is —NHC(═O)R6, —NHC(═O)(CHR9)nR6, —NH(CHR9)nC(═O)R6 or —NHR6.
8. The compound of any one of claims 1 to 4, wherein:
L is —CH2— or —CH2CH2—;
Y1 is —CH2— or —CH2CH2—;
Y2 is —CH2— or —CH2CH2—;
Y3 is —CH2— or —XCH2—;
X is —CH2— or O;
R1 is —NH(CH2)nC(═O)R6, —NH(CH2)mC(═O)N(R5)2, —NH(CHR9)nC(═O)R6, —NH(CHR9)nC(═O)N(R8)2, —NH(CHR9)mC(═O)R6, —NH(C(R9)2)nR10, —NH(CH2)nR6, —NH(CHR9)nR6, —NH(CHR9)nCH2OR9, —NHCH2(CHR9)nOR9, —NH(CHR9)nOR9, —NR9(CH2)nOR9, or —NHCH2(C(R9)2)nOR9;
R2 is H, C1-C6alkyl or C1-C6haloalkyl;
R3 is H, C1-C6alkyl or —CD3;
R4 is H, NH2, C1-C6alkyl or halo;
each R5 is independently C1-C6alkyl, —CD3 or —(CH2)nOR9;
R6 is a C3-C6cycloalkyl or a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR16 and O which is unsubstituted or is substituted with 1-2 R12 groups;
each R8 is independently selected from C1-C6haloalkyl, —(C(R9)2)nOR9 and a C1-C6alkyl substituted with 1 to 3 —OH;
each R9 is independently selected from H and C1-C6alkyl;
R10 is C1-C6alkoxy or C3-C6cycloalkyl;
each R12 is independently selected from C1-C6alkyl, hydroxyl, halo and a C1-C6alkyl substituted with 1 to 3 —OH;
R13 is H or C1-C6alkyl;
R14 is H or C1-C6alkyl;
each R16 is C1-C6alkyl;
each R17 is independently H or C1-C6alkyl;
each R18 is independently halo, —CN, C1-C6alkoxy or C1-C6alkyl;
m is 1, 2, 3, 4, 5 or 6, and
n is 1, 2, 3, 4, 5 or 6.
9. The compound of any one of claims 1 to 4, wherein:
L is —CH2— or —CH2CH2—;
Y1 is —CH2— or —CH2CH2—;
Y2 is —CH2— or —CH2CH2—;
Y3 is —CH2— or —XCH2—;
X is —CH2— or O;
R1 is —NHR6, —NR5R6, —NH2, —N(R5)2, —NHR5, —NHR8, —N(R6R8) or —N(R6)2;
R2 is H, C1-C6alkyl or C1-C6haloalkyl;
R3 is H, C1-C6alkyl or —CD3;
R4 is H, NH2, C1-C6alkyl or halo;
each R5 is independently C1-C6alkyl, —CD3 or —(CH2)nOR9;
R6 is a C3-C6cycloalkyl or a 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH, NR16 and O which is unsubstituted or is substituted with 1-2 R12 groups;
each R8 is independently selected from C1-C6haloalkyl, —(C(R9)2)nOR9 and a C1-C6alkyl substituted with 1 to 3 —OH;
each R12 is independently selected from C1-C6alkyl, hydroxyl, halo and a C1-C6alkyl substituted with 1 to 3 —OH;
R13 is H or C1-C6alkyl;
R14 is H or C1-C6alkyl;
each R16 is C1-C6alkyl;
each R17 is independently H or C1-C6alkyl;
each R18 is independently halo, —CN, C1-C6alkoxy or C1-C6alkyl;
m is 1, 2, 3, 4, 5 or 6, and
n is 1, 2, 3, 4, 5 or 6.
10. The compound of any one of claims 1 to 9, wherein
R6 is a unsubstituted 4-6 membered heterocycloalkyl having 1 to 2 ring members independently selected from N, NH and O.
11. The compound of any one of claims 1 to 9, wherein
R6 is cyclobutyl, oxetanyl, piperidinyl, pyrrolidinyl, morpholinyl or azetadinyl.
12. The compound of claim 1 selected from:
4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
4-((3-methyl-5-(6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
4-((3-methyl-5-(2-methyl-1,7-naphthyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
4-((3-methyl-5-(2-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
4-((5-(1,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)oxetan-3-amine;
N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(dimethylamino)acetamide
(S)—N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide;
(R)—N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide;
6-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-oxa-6-azaspiro[3.3]heptane;
4-(1-((4-aminobicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
4-(2-((4-aminobicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-2H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
4-(1-((4-aminobicyclo[2.2.2]octan-1-yl)methyl)-3-methyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
4-(2-((4-aminobicyclo[2.2.2]octan-1-yl)methyl)-3-methyl-6,7-dihydro-2H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine;
4-((5-(5-chloro-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
1,6-dimethyl-4-(3-methyl-1-((4-(pyrrolidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1H-pyrazolo[3,4-d]pyrimidine;
1,3,5-trimethyl-7-(3-methyl-1-((4-(pyrrolidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1H-pyrazolo[4,3-d]pyrimidine;
N-(2-methoxyethyl)-4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine;
2-(ethylamino)-N-(4-((3-methyl-5-(6-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)acetamide;
4-(4-((3-methyl-5-(6-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine;
2-(ethylamino)-N-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)acetamide;
4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-(oxetan-3-ylmethyl)bicyclo[2.2.2]octan-1-amine;
3-(dimethylamino)-N-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)propanamide;
4-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine;
4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
N-cyclobutyl-4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
N,N-dicyclobutyl-4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
6-methyl-4-(3-methyl-1-((4-(piperidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1H-pyrazolo[3,4-d]pyrimidine;
6-methyl-4-(3-methyl-1-((4-(pyrrolidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1H-pyrazolo[3,4-d]pyrimidine;
(3-(((4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)methyl)oxetan-3-yl)methanol;
N-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)azetidine-3-carboxamide;
(S)—N-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide;
(S)—N-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-2-carboxamide;
(R)—N-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide;
(R)—N-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-2-carboxamide;
3,6-dimethyl-4-(3-methyl-1-((4-morpholinobicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)isoxazolo[5,4-d]pyrimidine;
1,3,5-trimethyl-7-(3-methyl-1-((4-(piperidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1H-pyrazolo[4,3-d]pyrimidine;
1,6-dimethyl-4-(3-methyl-1-((4-(piperidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1H-pyrazolo[3,4-d]pyrimidine;
4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N,N-bis(trideuteromethyl)bicyclo[22.2]octan-1-amine;
4-((3-methyl-5-(1H-pyrazolo[3,4-b]pyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
4-((3-methyl-5-(1H-pyrazolo[3,4-b]pyridin-4-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)bicyclo[2.2.2]octan-1-amine;
4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N,N-dimethylbicyclo[2.2.2]octan-1-amine;
4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.1]heptan-1-amine;
4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-ol;
N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)acetamide;
N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)methanesulfonamide;
tert-butyl (4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)(methyl)carbamate;
4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-methylbicyclo[2.2.2]octan-1-amine;
1-methylcyclopropyl (4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate;
3-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)bicyclo[1.1.1]pentan-1-amine;
4-((5-(1-(4-methoxybenzyl)-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
N-cyclobutyl-4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-isopropylbicyclo[2.2.2]octan-1-amine;
2-((4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)propan-1-ol;
4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-ethylbicyclo[2.2.2]octan-1-amine;
5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-1-((4-(pyrrolidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine;
4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-7,7-dimethyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
N-(2,2-difluoroethyl)-4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
-((3-methyl-5-(2-methylquinolin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
4-((3-methyl-5-(2-phenylpyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
1-((4-(azetidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-7,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl)methyl)bicyclo[2.2.2]octan-1-amine;
4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)thiomorpholine 1,1-dioxide;
5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-1-((4-(piperidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
1-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)azetidin-3-ol;
4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-(2-methoxyethyl)bicyclo[2.2.2]octan-1-amine;
4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N,N-bis(2-methoxyethyl)bicyclo[2.2.2]octan-1-amine;
4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-(2-ethoxyethyl)bicyclo[2.2.2]octan-1-amine;
4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N,N-bis(2-ethoxyethyl)bicyclo[2.2.2]octan-1-amine;
4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-(2-methoxyethyl)-N-methylbicyclo[2.2.2]octan-1-amine;
(3S,4R)-1-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)pyrrolidine-3,4-diol;
(S)-1-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)pyrrolidin-3-ol;
2-((4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)-N,N-dimethylacetamide;
N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-N-methyloxetan-3-amine;
4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-isopropyl-N-methylbicyclo[2.2.2]octan-1-amine;
N-cyclobutyl-4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-methylbicyclo[2.2.2]octan-1-amine;
(3S,4S)-1-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)pyrrolidine-3,4-diol;
1-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-amine;
5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-1-((4-(pyrrolidin-1-yl)-2-oxabicyclo[2.2.2]octan-1-yl)methyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
4-((5-(6-(4-fluorophenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
4-(4-(1-((4-aminobicyclo[2.2.2]octan-1-yl)methyl)-3-methyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)pyridin-2-yl)benzonitrile;
3-methyl-5-(2-phenylpyridin-4-yl)-1-((4-(pyrrolidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
2-methyl-4-(3-methyl-1-((4-(pyrrolidin-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-6,7-dihydro-1H-pyrazolo[4,3-c]pyridin-5(4H)-yl)-1,7-naphthyridine;
4-((5-(2-(4-fluorophenyl)pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
4-((5-(2-(2-fluoro-4-methylphenyl)pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
4-((5-(2-(4-methoxyphenyl)pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
4-((3-methyl-5-(2-(p-tolyl)pyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
4-(2-(5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)ethyl)bicyclo[2.2.2]octan-1-amine;
4-((5-(2,8-dimethyl-1,7-naphthyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
4-((3-methyl-5-(2-methyl-6-phenylpyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
4-((5-([2,2′-bipyridin]-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-1-((4-(piperidin-1-yl)-2-oxabicyclo[2.2.2]octan-1-yl)methyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-(1-methoxypropan-2-yl)bicyclo[2.2.2]octan-1-amine;
4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-ethyl-N-methylbicyclo[2.2.2]octan-1-amine;
1-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N,N-dimethyl-2-oxabicyclo[2.2.2]octan-4-amine;
2-((4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)-1-(piperidin-1-yl)ethanone;
N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(pyrrolidin-1-yl)acetamide;
4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-(2-methoxy-2-methylpropyl)bicyclo[2.2.2]octan-1-amine;
1-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-N-(2-methoxyethyl)-2-oxabicyclo[2.2.2]octan-4-amine;
4-((5-(2-chloro-5,7-dihydrofuro[3,4-d]pyrimidin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-1-methylpiperazin-2-one;
N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-3-(dimethylamino)propanamide;
2-((4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)-1-(pyrrolidin-1-yl)ethanone;
(R)-4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-methylmorpholine;
1-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-4-methylpiperazin-2-one;
(S)-4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-methylmorpholine;
(2S,6R)-4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2,6-dimethylmorpholine;
(2S,6S)-4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2,6-dimethylmorpholine;
N-(cyclobutylmethyl)-1-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-amine;
(2R,6R)-4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2,6-dimethylmorpholine;
N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(ethylamino)acetamide;
3-amino-N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)propanamide;
6-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-oxa-6-azaspiro[3.3]heptane;
(R)—N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(methylamino)propanamide;
(S)—N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(methylamino)propanamide;
1-((4-(1H-imidazol-1-yl)bicyclo[2.2.2]octan-1-yl)methyl)-5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine;
(1R,5S)-3-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-8-oxa-3-azabicyclo[3.2.1]octane;
N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(methylamino)acetamide;
N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-4-methylmorpholine-3-carboxamide;
1-((4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)-2-methylpropan-2-ol;
2-(ethylamino)-N-(4-((3-methyl-5-(5-methyl-1H-pyrazolo[4,3-b]pyridin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)acetamide;
N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-2-carboxamide;
N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-3-(ethylamino)propanamide;
N-ethyl-4-((3-methyl-5-(2-phenylpyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
(S)-4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-3-methylmorpholine;
(R)-4-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-3-methylmorpholine;
N-(2-methoxyethyl)-4-((3-methyl-5-(2-phenylpyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)azetidine-3-carboxamide;
N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(ethyl(methyl)amino)acetamide;
N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(3-fluoroazetidin-1-yl)acetamide;
2-(bis(trideuteromethyl)amino)-N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)acetamide;
N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-hydroxyacetamide;
N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(3-hydroxyazetidin-1-yl)acetamide;
(3-(((4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)amino)methyl)oxetan-3-yl)methanol;
N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(N-methylmethylsulfonamido)acetamide;
N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(N-methylacetamido)acetamide 4-((3-methyl-5-(6-methyl-1-(trideuteromethyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
(S)—N-(4-((5-(1-ethyl-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide;
N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-3-(methylamino)propanamide;
N-cyclobutyl-1-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)-2-oxabicyclo[2.2.2]octan-4-amine;
N-cyclobutyl-4-((3-methyl-5-(2-phenylpyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine;
tert-butyl (4-((5-(1-ethyl-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate;
tert-butyl (4-((3-methyl-5-(2-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate;
tert-butyl (4-((3-methyl-5-(2-methyl-1,7-naphthyridin-4-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)carbamate;
tert-butyl (4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.1]heptan-1-yl)carbamate;
4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine, and
4-((5-(1-ethyl-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-amine.
13. The compound of claim 1 selected from:
N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)oxetan-3-amine;
N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-(dimethylamino)acetamide;
(S)—N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide;
(R)—N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide, and
6-(4-((3-methyl-5-(1,3,5-trimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)-2-oxa-6-azaspiro[3.3]heptane.
14. A pharmaceutical composition comprising a therapeutically effective amount a compound of any one of claims 1 to 13 and a pharmaceutically acceptable carrier.
15. Use of a compound of any one of claims 1 to 13 in the manufacture of a medicament for treating an autoimmune disease associated with the activity of an endosomal Toll-Like Receptor selected from TLR7, TLR8 and TLR9, or a combination thereof.
16. Use of a compound of any one of claims 1 to 13 in the manufacture of a medicament for treating an autoimmune disease associated with the activity of an endosomal Toll-Like Receptor pathway selected from TLR7 pathway, TLR8 pathway and TLR9 pathway, or a combination thereof.
17. Use of a compound of any one of claims 1 to 13 in the manufacture of a medicament for treating an autoimmune disease associated with
i) TLR7 activity, or
ii) TLR7 activity and TLR8 activity, or
iii) TLR7 activity and TLR8 activity and TLR9 activity.
18. A method for treating an autoimmune disease associated with the activity of an endosomal Toll-Like Receptor selected from TLR7, TLR8 and TLR9, or a combination thereof, wherein the method comprises administering to a subject in need of such treatment a therapeutically effective amount of a compound of any one of claims 1 to 13.
19. A method for treating an autoimmune disease associated with the activity of an endosomal Toll-Like Receptor pathway selected from TLR7 pathway, TLR8 pathway and TLR9 pathway, or a combination thereof, wherein the method comprises administering to a subject in need of such treatment a therapeutically effective amount of a compound of any one of claims 1 to 13.
20. A method for treating an autoimmune disease associated with
i) TLR7 activity, or
ii) TLR7 activity and TLR8 activity, or
iii) TLR7 activity and TLR8 activity and TLR9 activity,
wherein the method comprises administering to a subject in need of such treatment a therapeutically effective amount of a compound of any one of claims 1 to 13.
21. The use of any one of claims 15 to 17 or the method of any one of claim 18 to 20, wherein the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
22. A compound of any one of claims 1 to 13 for use in treating an autoimmune disease.
23. The compound of claim 22, wherein the autoimmune disease is systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis or psoriasis.
24. A combination comprising a therapeutically effect amount of a compound of any one of claims 1 to 13 and one or more additional therapeutic agents, wherein the additional therapeutic agent is independently selected from anti-inflammatory agents, immunomodulatory agents, immunosuppressive agents, cytokines, nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarial compounds, anti-rheumatic compounds, inhibitors of B-cell activating factor (BAFF), inhibitors of B-lymphocyte stimulator (BLyS), and steroid hormones.
US17/124,346 2016-09-09 2020-12-16 Compounds and compositions as inhibitors of endosomal toll-like receptors Abandoned US20210101902A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US17/124,346 US20210101902A1 (en) 2016-09-09 2020-12-16 Compounds and compositions as inhibitors of endosomal toll-like receptors
US18/678,198 US20240376099A1 (en) 2016-09-09 2024-05-30 Compounds and compositions as inhibitors of endosomal toll-like receptors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662385726P 2016-09-09 2016-09-09
PCT/IB2017/055375 WO2018047081A1 (en) 2016-09-09 2017-09-06 Compounds and compositions as inhibitors of endosomal toll-like receptors
US201916330820A 2019-03-06 2019-03-06
US17/124,346 US20210101902A1 (en) 2016-09-09 2020-12-16 Compounds and compositions as inhibitors of endosomal toll-like receptors

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2017/055375 Continuation WO2018047081A1 (en) 2016-09-09 2017-09-06 Compounds and compositions as inhibitors of endosomal toll-like receptors
US16/330,820 Continuation US10954233B2 (en) 2016-09-09 2017-09-06 Compounds and compositions as inhibitors of endosomal toll-like receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/678,198 Continuation US20240376099A1 (en) 2016-09-09 2024-05-30 Compounds and compositions as inhibitors of endosomal toll-like receptors

Publications (1)

Publication Number Publication Date
US20210101902A1 true US20210101902A1 (en) 2021-04-08

Family

ID=60001955

Family Applications (3)

Application Number Title Priority Date Filing Date
US16/330,820 Active US10954233B2 (en) 2016-09-09 2017-09-06 Compounds and compositions as inhibitors of endosomal toll-like receptors
US17/124,346 Abandoned US20210101902A1 (en) 2016-09-09 2020-12-16 Compounds and compositions as inhibitors of endosomal toll-like receptors
US18/678,198 Abandoned US20240376099A1 (en) 2016-09-09 2024-05-30 Compounds and compositions as inhibitors of endosomal toll-like receptors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US16/330,820 Active US10954233B2 (en) 2016-09-09 2017-09-06 Compounds and compositions as inhibitors of endosomal toll-like receptors

Family Applications After (1)

Application Number Title Priority Date Filing Date
US18/678,198 Abandoned US20240376099A1 (en) 2016-09-09 2024-05-30 Compounds and compositions as inhibitors of endosomal toll-like receptors

Country Status (36)

Country Link
US (3) US10954233B2 (en)
EP (2) EP4059934A1 (en)
JP (1) JP6779371B2 (en)
KR (2) KR20190039809A (en)
CN (2) CN115215886B (en)
AU (1) AU2017323584C1 (en)
CA (1) CA3031585A1 (en)
CL (1) CL2019000588A1 (en)
CO (1) CO2019003397A2 (en)
CR (1) CR20190119A (en)
CU (1) CU24526B1 (en)
CY (1) CY1125007T1 (en)
DK (1) DK3510033T3 (en)
DO (1) DOP2019000055A (en)
EA (1) EA036880B1 (en)
EC (1) ECSP19024046A (en)
ES (1) ES2905981T3 (en)
HR (1) HRP20220144T1 (en)
HU (1) HUE057254T2 (en)
IL (1) IL265159B (en)
JO (1) JOP20190041B1 (en)
LT (1) LT3510033T (en)
MA (1) MA46196A (en)
MX (1) MX382383B (en)
MY (1) MY194813A (en)
NZ (1) NZ750781A (en)
PE (1) PE20190732A1 (en)
PH (1) PH12019500161A1 (en)
PL (1) PL3510033T3 (en)
PT (1) PT3510033T (en)
RS (1) RS62913B1 (en)
RU (1) RU2759678C2 (en)
SG (1) SG11201900482SA (en)
SI (1) SI3510033T1 (en)
WO (1) WO2018047081A1 (en)
ZA (1) ZA201900227B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400164B2 (en) 2019-03-15 2022-08-02 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
US11547761B1 (en) 2016-07-07 2023-01-10 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3929196T3 (en) 2013-09-24 2023-10-02 Fujifilm Corp Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof
WO2018047081A1 (en) 2016-09-09 2018-03-15 Novartis Ag Compounds and compositions as inhibitors of endosomal toll-like receptors
KR20230010826A (en) 2016-10-14 2023-01-19 프리시젼 바이오사이언시스 인코포레이티드 Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN111511754B (en) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 2’3’ cyclic dinucleotide with phosphonate bond that activates STING adapter protein
WO2019123294A2 (en) 2017-12-22 2019-06-27 Novartis Ag Novel uses of pyrazolo piperidine derivatives
EP3752505B1 (en) 2018-02-12 2023-01-11 F. Hoffmann-La Roche AG Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection
CA3091142C (en) 2018-02-26 2023-04-11 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
CN112423759A (en) 2018-03-30 2021-02-26 因赛特公司 Treatment of hidradenitis suppurativa with JAK inhibitors
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
TW202005654A (en) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2'2'-cyclic dinucleotides
TWI833744B (en) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-cyclic dinucleotides
TWI818007B (en) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-cyclic dinucleotides
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
MX2020012259A (en) * 2018-05-18 2021-01-29 Novartis Ag Crystalline forms of a tlr7/tlr8 inhibitor.
AU2019280728A1 (en) 2018-06-05 2020-11-12 F. Hoffmann-La Roche Ag Tetrahydro-1 H-pyrazino[2,1 -ajisoindolylquinoline compounds for the treatment of autoimmune disease
TW202016105A (en) 2018-06-12 2020-05-01 瑞士商赫孚孟拉羅股份公司 Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune disease
EP3826724B1 (en) 2018-07-23 2022-10-05 F. Hoffmann-La Roche AG Novel piperazine compounds for the treatment of autoimmune disease
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
EP3847169A1 (en) 2018-09-04 2021-07-14 F. Hoffmann-La Roche AG Benzothiazole compounds for the treatment of autoimmune diseases
EP3847173B1 (en) 2018-09-06 2023-04-12 F. Hoffmann-La Roche AG Novel pyrazolopyridine compounds for the treatment of autoimmune disease
JP2022502353A (en) 2018-09-06 2022-01-11 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft A novel cyclic amidine compound for the treatment of autoimmune disorders
JP2022501326A (en) * 2018-09-07 2022-01-06 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft A novel pyrrolidineamine compound for the treatment of autoimmune diseases
CN117105933A (en) 2018-10-31 2023-11-24 吉利德科学公司 Substituted 6-azabenzimidazole compounds with HPK1 inhibitory activity
MX2021005047A (en) 2018-10-31 2021-09-08 Gilead Sciences Inc SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS.
AU2020231115B2 (en) 2019-03-07 2025-02-20 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
DK3934757T3 (en) 2019-03-07 2023-04-17 Inst Of Organic Chemistry And Biochemistry Ascr V V I 2'3'-CYCLIC DINUCLEOTIDES AND THEIR PRODUCTS
TW202212339A (en) 2019-04-17 2022-04-01 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
TWI751516B (en) 2019-04-17 2022-01-01 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
TWI826690B (en) 2019-05-23 2023-12-21 美商基利科學股份有限公司 Substituted eneoxindoles and uses thereof
WO2020240272A1 (en) * 2019-05-31 2020-12-03 Dr.Reddy's Institute Of Life Sciences Preparation of novel 1 h-pyrazolo[4,3-d]pyrimidines, their compositions, synthesis and methods of using them for treating tuberculosis
US20220296619A1 (en) 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
EP4458975A3 (en) 2019-09-30 2025-02-12 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
WO2021084022A1 (en) 2019-10-31 2021-05-06 F. Hoffmann-La Roche Ag Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
CN114728976B (en) 2019-11-19 2024-08-16 豪夫迈·罗氏有限公司 Hydrogen-1H-pyrrolo [1,2-a ] pyrazine compounds for the treatment of autoimmune diseases
US12421252B2 (en) 2019-11-20 2025-09-23 Hoffmann-La Roche Inc. Spiro (isobenzofuranazetidine) compounds for the treatment of autoimmune disease
EP4069729B1 (en) 2019-12-06 2025-01-22 Precision BioSciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
US20230131192A1 (en) * 2020-01-27 2023-04-27 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
KR20220132590A (en) * 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists
AR121620A1 (en) 2020-03-20 2022-06-22 Gilead Sciences Inc 4-C-SUBSTITUTED-2-HALO-2-DEOXIADENOSINE NUCLEOSIDE PRODRUGS AND METHODS OF PREPARATION AND USE THEREOF
US20240317735A1 (en) * 2020-07-14 2024-09-26 Hoffmann-La Roche Inc. Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease
KR102513463B1 (en) * 2020-11-26 2023-03-29 주식회사 에스앤케이테라퓨틱스 New Small Molecule Compounds that Control Endosomal Toll-like receptors and Autoimmune Disease Treatment Using the same
US11661431B2 (en) 2021-04-16 2023-05-30 Gilead Sciences, Inc. Thienopyrrole compounds
AU2022274607A1 (en) 2021-05-13 2023-11-16 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP7686086B2 (en) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド DIACYLGLYERCOL KINASE MODULATORY COMPOUNDS
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240005901A (en) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 Diacylglycerol Kinase Modulating Compounds
CN117957234A (en) 2021-09-10 2024-04-30 吉利德科学公司 Thienopyrrole compounds
CR20240134A (en) 2021-09-24 2024-05-07 Hoffmann La Roche Pyrazolo[3,4-b]pyridine compounds for the treatment of autoimmune disease
AU2023207313A1 (en) 2022-01-11 2024-06-13 Novartis Ag Tlr7/8-antagonist for treating sjögren's syndrome or mixed connective tissue disease
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
WO2025240243A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416527C (en) 2000-08-10 2009-12-22 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
MXPA05009719A (en) 2003-03-11 2005-10-18 Pharmacia Italia Spa Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
BRPI0517378A (en) 2004-10-27 2008-10-07 Janssen Pharmaceutica Nv cannabinoid tetrahydro pyridinyl pyrazole modulators
MX2008002207A (en) * 2005-08-16 2008-03-27 Memory Pharm Corp Phosphodiesterase 10 inhibitors.
JPWO2007034817A1 (en) * 2005-09-22 2009-03-26 大日本住友製薬株式会社 New adenine compounds
WO2007123953A2 (en) 2006-04-19 2007-11-01 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
JP2010526146A (en) 2007-05-04 2010-07-29 ブリストル−マイヤーズ スクイブ カンパニー [6,5] -bicyclic GPR119G protein-coupled receptor agonist
EP2215089B1 (en) * 2007-11-02 2012-06-27 Vertex Pharmaceuticals Incorporated [1h- pyrazolo [3, 4-b]pyridine-4-yl]-phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
CN102781933B (en) * 2009-08-18 2016-01-20 文蒂雷克斯药品公司 Substituted benzazepines as TOLL-like receptor modulators*
CA2777824C (en) * 2009-10-22 2016-11-29 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CN103415515B (en) 2010-11-19 2015-08-26 因塞特公司 Cyclobutyl-substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
WO2012154608A1 (en) 2011-05-06 2012-11-15 Intellikine, Llc Reactive mtor and pi3 kinase inhibitors and uses thereof
WO2013003383A1 (en) 2011-06-27 2013-01-03 Kyorin Pharmaceutical Co., Ltd. Bridged bicyclic compounds for the treatment of bacterial infections
SG11201404743TA (en) * 2012-02-08 2014-09-26 Janssen R & D Ireland Piperidino-pyrimidine derivatives for the treatment of viral infections
JO3407B1 (en) * 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd Tetrahydropyrazolopyrimidines
WO2014034719A1 (en) 2012-08-29 2014-03-06 興和株式会社 Quinoline derivative having tlr inhibitory activity
MX365114B (en) 2012-10-10 2019-05-23 Janssen Sciences Ireland Uc Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases.
CN104918934B (en) 2013-01-18 2017-12-22 霍夫曼-拉罗奇有限公司 3‑Substituted pyrazoles and their use as DLK inhibitors
JP2016516708A (en) 2013-03-14 2016-06-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ GPR120 modulator of bicyclo [2.2.2] acid
NZ712949A (en) 2013-05-02 2017-04-28 Pfizer Imidazo-triazine derivatives as pde10 inhibitors
WO2015023958A1 (en) 2013-08-15 2015-02-19 The University Of Kansas Toll-like receptor agonists
US10189786B2 (en) 2013-08-16 2019-01-29 Duke University Antibacterial compounds
WO2015024120A1 (en) 2013-08-19 2015-02-26 Queen's University At Kingston Carbene functionalized composite materials
RU2016110016A (en) 2013-08-22 2017-09-27 Ф. Хоффманн-Ля Рош Аг ALKINYL ALCOHOLS AND WAYS OF THEIR APPLICATION
WO2015036044A1 (en) 2013-09-13 2015-03-19 Telormedix Sa Cationic lipid vehicles for delivery of tlr7 agonists for specific targeting of human cd14+ monocytes in whole blood
CA2920791C (en) 2013-10-14 2021-11-16 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
RS59911B1 (en) * 2013-10-14 2020-03-31 Eisai R&D Man Co Ltd Selectively substituted quinoline compounds
WO2016004305A2 (en) * 2014-07-02 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
PL3190113T3 (en) 2014-08-15 2021-10-25 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pyrrolopyrimidine compounds used as tlr7 agonist
WO2016097918A1 (en) * 2014-12-18 2016-06-23 Pfizer Inc. Pyrimidine and triazine derivatives and their use as axl inhibitors
MX383929B (en) 2014-12-30 2025-03-14 Novira Therapeutics Inc DERIVATIVES AND METHODS OF TREATMENT OF HEPATITIS B INFECTIONS.
WO2016128908A1 (en) 2015-02-12 2016-08-18 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
US10308628B2 (en) 2015-03-12 2019-06-04 Novartis Ag Heterocyclic compounds and methods for their use
EP3429591B1 (en) 2016-03-16 2023-03-15 Kura Oncology, Inc. Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use
WO2018047081A1 (en) 2016-09-09 2018-03-15 Novartis Ag Compounds and compositions as inhibitors of endosomal toll-like receptors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11547761B1 (en) 2016-07-07 2023-01-10 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
US11400164B2 (en) 2019-03-15 2022-08-02 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2

Also Published As

Publication number Publication date
SI3510033T1 (en) 2022-04-29
JP6779371B2 (en) 2020-11-04
HRP20220144T1 (en) 2022-04-15
AU2017323584B2 (en) 2020-03-05
PE20190732A1 (en) 2019-05-23
CN115215886A (en) 2022-10-21
IL265159A (en) 2019-05-30
RS62913B1 (en) 2022-03-31
KR102411532B1 (en) 2022-06-22
MX2019002797A (en) 2019-05-09
US10954233B2 (en) 2021-03-23
RU2019110157A (en) 2020-10-09
JP2019531280A (en) 2019-10-31
HUE057254T2 (en) 2022-04-28
US20190211009A1 (en) 2019-07-11
BR112019004597A2 (en) 2019-06-11
CO2019003397A2 (en) 2019-06-19
EP4059934A1 (en) 2022-09-21
ZA201900227B (en) 2019-10-30
JOP20190041B1 (en) 2023-03-28
CU20190018A7 (en) 2019-10-04
ES2905981T3 (en) 2022-04-12
CR20190119A (en) 2019-06-03
CN109641899B (en) 2022-07-22
CA3031585A1 (en) 2018-03-15
LT3510033T (en) 2022-02-25
EP3510033A1 (en) 2019-07-17
MX382383B (en) 2025-03-13
WO2018047081A1 (en) 2018-03-15
RU2019110157A3 (en) 2020-10-30
AU2017323584A1 (en) 2019-01-31
KR20190039809A (en) 2019-04-15
AU2017323584C1 (en) 2020-09-17
RU2759678C2 (en) 2021-11-16
CY1125007T1 (en) 2023-01-05
ECSP19024046A (en) 2019-04-30
DK3510033T3 (en) 2022-02-28
NZ750781A (en) 2025-06-27
PL3510033T3 (en) 2022-03-07
PT3510033T (en) 2022-02-18
PH12019500161A1 (en) 2019-10-28
EA036880B1 (en) 2020-12-30
IL265159B (en) 2021-08-31
DOP2019000055A (en) 2019-05-31
CN115215886B (en) 2024-10-11
CN109641899A (en) 2019-04-16
EA201990657A1 (en) 2019-07-31
JOP20190041A1 (en) 2019-03-10
CL2019000588A1 (en) 2019-05-10
US20240376099A1 (en) 2024-11-14
EP3510033B1 (en) 2021-11-24
KR20210077014A (en) 2021-06-24
SG11201900482SA (en) 2019-03-28
MY194813A (en) 2022-12-16
CU24526B1 (en) 2021-06-08
MA46196A (en) 2021-05-19

Similar Documents

Publication Publication Date Title
US10954233B2 (en) Compounds and compositions as inhibitors of endosomal toll-like receptors
US11999751B2 (en) Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
CA2945151C (en) Treatment of b-cell malignancies by a combination jak and pi3k inhibitors
TWI866258B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US20240287076A1 (en) Compounds for targeting degradation of bruton&#39;s tyrosine kinase
US20240374606A1 (en) Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer
AU2021395816B2 (en) N-(imidazo[1,2-b]pyridazin-3-yl)-1-cyclohexyl-2h-indazole-5-carboxamide and n-(pyrazolo[1,5-a]pyrimidin-3-yl)-1-cyclohexyl-2h-indazole-5-carboxamide derivatives as irak4 inhibitors for the treatment of asthma
US20230014742A1 (en) Bicyclic nitrogen containing heterocycles as inhibitors of salt-induced kinase sik2
HK40076897A (en) Compounds and compositions as inhibitors of endosomal toll-like receptors
TWI772370B (en) Compounds and compositions as inhibitors of endosomal toll-like receptors
HK40003568B (en) Compounds and compositions as inhibitors of endosomal toll-like receptors
RU2785126C2 (en) New compounds and their pharmaceutical compositions for treatment of inflammatory diseases
BR112019004597B1 (en) TOLL-TYPE ENDOSOMAL RECEPTOR INHIBITORS, THEIR USES, AND PHARMACEUTICAL COMPOSITION

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

AS Assignment

Owner name: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MUTNICK, DANIEL;REEL/FRAME:056070/0337

Effective date: 20170619

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS PHARMA AG;REEL/FRAME:056070/0926

Effective date: 20170626

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC.;REEL/FRAME:056070/0231

Effective date: 20170627

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.;REEL/FRAME:056070/0589

Effective date: 20170619

Owner name: NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ALPER, PHILLIP;DEANE, JONATHAN;JIANG, SONGCHUN;AND OTHERS;SIGNING DATES FROM 20170615 TO 20170622;REEL/FRAME:056070/0118

Owner name: NOVARTIS PHARMA AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KNOEPFEL, THOMAS;REEL/FRAME:056070/0813

Effective date: 20170622

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNOR'S INTEREST;ASSIGNOR:NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.;REEL/FRAME:056070/0589

Effective date: 20170619

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNOR'S INTEREST;ASSIGNOR:NOVARTIS PHARMA AG;REEL/FRAME:056070/0926

Effective date: 20170626

Owner name: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNOR'S INTEREST;ASSIGNOR:MUTNICK, DANIEL;REEL/FRAME:056070/0337

Effective date: 20170619

Owner name: NOVARTIS PHARMA AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNOR'S INTEREST;ASSIGNOR:KNOEPFEL, THOMAS;REEL/FRAME:056070/0813

Effective date: 20170622

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNOR'S INTEREST;ASSIGNOR:NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC.;REEL/FRAME:056070/0231

Effective date: 20170627

Owner name: NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNOR'S INTEREST;ASSIGNORS:ALPER, PHILLIP;DEANE, JONATHAN;JIANG, SONGCHUN;AND OTHERS;SIGNING DATES FROM 20170615 TO 20170622;REEL/FRAME:056070/0118

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION